<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Interrupted versus uninterrupted anticoagulation therapy for catheter ablation in adults with arrhythmias - Bawazeer, GA - 2021 | Cochrane Library</title> <meta content="Interrupted versus uninterrupted anticoagulation therapy for catheter ablation in adults with arrhythmias - Bawazeer, GA - 2021 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD013504.pub2/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Interrupted versus uninterrupted anticoagulation therapy for catheter ablation in adults with arrhythmias - Bawazeer, GA - 2021 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD013504.pub2/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD013504.pub2" name="dc.identifier" scheme="DOI"/> <meta content="Interrupted versus uninterrupted anticoagulation therapy for catheter ablation in adults with arrhythmias" name="citation_title"/> <meta content="Ghada A Bawazeer" name="citation_author"/> <meta content="King Saud University" name="citation_author_institution"/> <meta content="gbawazeer@ksu.edu.sa" name="citation_author_email"/> <meta content="Hadeel A Alkofide" name="citation_author"/> <meta content="King Saud University" name="citation_author_institution"/> <meta content="Aya A Alsharafi" name="citation_author"/> <meta content="King Saud University" name="citation_author_institution"/> <meta content="Nada O Babakr" name="citation_author"/> <meta content="King Saud University" name="citation_author_institution"/> <meta content="Arwa M Altorkistani" name="citation_author"/> <meta content="King Saud University" name="citation_author_institution"/> <meta content="Tarek S Kashour" name="citation_author"/> <meta content="King Saud University" name="citation_author_institution"/> <meta content="Michael Miligkos" name="citation_author"/> <meta content="Medical School, University of Thessaly" name="citation_author_institution"/> <meta content="Khalid M AlFaleh" name="citation_author"/> <meta content="King Saud University" name="citation_author_institution"/> <meta content="Lubna A Al-Ansary" name="citation_author"/> <meta content="King Saud University" name="citation_author_institution"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="10" name="citation_issue"/> <meta content="10.1002/14651858.CD013504.pub2" name="citation_doi"/> <meta content="2021" name="citation_date"/> <meta content="2021/10/21" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD013504.pub2/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD013504.pub2/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD013504.pub2/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Anticoagulants [adverse effects]; Arrhythmias, Cardiac; *Catheter Ablation; Heparin [adverse effects]; *Quality of Life" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013504.pub2&amp;doi=10.1002/14651858.CD013504.pub2&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013504.pub2&amp;doi=10.1002/14651858.CD013504.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013504.pub2&amp;doi=10.1002/14651858.CD013504.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013504.pub2&amp;doi=10.1002/14651858.CD013504.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013504.pub2&amp;doi=10.1002/14651858.CD013504.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013504.pub2&amp;doi=10.1002/14651858.CD013504.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013504.pub2&amp;doi=10.1002/14651858.CD013504.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013504.pub2&amp;doi=10.1002/14651858.CD013504.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013504.pub2&amp;doi=10.1002/14651858.CD013504.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013504.pub2&amp;doi=10.1002/14651858.CD013504.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013504.pub2&amp;doi=10.1002/14651858.CD013504.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013504.pub2&amp;doi=10.1002/14651858.CD013504.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013504.pub2&amp;doi=10.1002/14651858.CD013504.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013504.pub2&amp;doi=10.1002/14651858.CD013504.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013504.pub2&amp;doi=10.1002/14651858.CD013504.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013504.pub2&amp;doi=10.1002/14651858.CD013504.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013504.pub2&amp;doi=10.1002/14651858.CD013504.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013504.pub2&amp;doi=10.1002/14651858.CD013504.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013504.pub2&amp;doi=10.1002/14651858.CD013504.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013504.pub2&amp;doi=10.1002/14651858.CD013504.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013504.pub2&amp;doi=10.1002/14651858.CD013504.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013504.pub2&amp;doi=10.1002/14651858.CD013504.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013504.pub2&amp;doi=10.1002/14651858.CD013504.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773519000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773548000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000"}};Liferay.authToken="0TJL4CWK";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD013504\x2epub2\x26doi\x3d10\x2e1002\x2f14651858\x2eCD013504\x2epub2\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013504\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD013504\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513680837000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","zh_HANS","de","zh_HANT","ms","hr","fa","fr"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD013504.pub2",title:"Interrupted versus uninterrupted anticoagulation therapy for catheter ablation in adults with arrhythmias",firstPublishedDate:"Oct 21, 2021 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Heart Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734739000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=0TJL4CWK&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD013504.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD013504.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD013504.pub2/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD013504.pub2/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD013504.pub2%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD013504.pub2/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD013504.pub2/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD013504.pub2/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD013504.pub2/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD013504.PUB2" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;摘要&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;de&quot;,&quot;title&quot;:&quot;Zusammenfassung in einfacher Sprache&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;},{&quot;language&quot;:&quot;hr&quot;,&quot;title&quot;:&quot;Laički sažetak&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;简语概要&quot;},{&quot;language&quot;:&quot;zh_HANT&quot;,&quot;title&quot;:&quot;淺顯易懂的口語結論&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD013504.pub2/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD013504.PUB2" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD013504.pub2/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD013504.pub2/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>2154 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD013504.pub2" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013504.pub2/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013504.pub2/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013504.pub2/full#CD013504-abs-0002"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013504.pub2/full#CD013504-sec-0096"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013504.pub2/full#CD013504-sec-0008"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013504.pub2/full#CD013504-sec-0009"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013504.pub2/full#CD013504-sec-0014"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013504.pub2/full#CD013504-sec-0015"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013504.pub2/full#CD013504-sec-0039"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013504.pub2/full#CD013504-sec-0086"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD013504.pub2/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013504.pub2/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013504.pub2/appendices#CD013504-sec-0101"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013504.pub2/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013504.pub2/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD013504.pub2/media/CDSR/CD013504/table_n/CD013504StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD013504.pub2/media/CDSR/CD013504/table_n/CD013504StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013504.pub2/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013504.pub2/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013504.pub2/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD013504.pub2/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD013504.pub2/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD013504.pub2/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2021 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD013504.pub2/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Interrupted versus uninterrupted anticoagulation therapy for catheter ablation in adults with arrhythmias </h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD013504.pub2/information#CD013504-cr-0004"><i class="icon corresponding-author fa fa-envelope"></i>Ghada A Bawazeer</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD013504.pub2/information#CD013504-cr-0005">Hadeel A Alkofide</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD013504.pub2/information#CD013504-cr-0006">Aya A Alsharafi</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD013504.pub2/information#CD013504-cr-0007">Nada O Babakr</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD013504.pub2/information#CD013504-cr-0008">Arwa M Altorkistani</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD013504.pub2/information#CD013504-cr-0009">Tarek S Kashour</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD013504.pub2/information#CD013504-cr-0010">Michael Miligkos</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD013504.pub2/information#CD013504-cr-0011">Khalid M AlFaleh</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD013504.pub2/information#CD013504-cr-0012">Lubna A Al-Ansary</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD013504.pub2/information/en#CD013504-sec-0113">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 21 October 2021 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD013504.pub2/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD013504.pub2">https://doi.org/10.1002/14651858.CD013504.pub2</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD013504-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD013504-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD013504-abs-0013">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD013504-abs-0009">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD013504-abs-0011">Français</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD013504-abs-0003">简体中文</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD013504-abs-0001" lang="en"> <section id="CD013504-sec-0001"> <h3 class="title" id="CD013504-sec-0001">Background</h3> <p>The management of anticoagulation therapy around the time of catheter ablation (CA) procedure for adults with arrhythmia is critical and yet is variable in clinical practice. The ideal approach for safe and effective perioperative management should balance the risk of bleeding during uninterrupted anticoagulation while minimising the risk of thromboembolic events with interrupted therapy. </p> </section> <section id="CD013504-sec-0002"> <h3 class="title" id="CD013504-sec-0002">Objectives</h3> <p>To compare the efficacy and harms of interrupted versus uninterrupted anticoagulation therapy for catheter ablation (CA) in adults with arrhythmias. </p> </section> <section id="CD013504-sec-0003"> <h3 class="title" id="CD013504-sec-0003">Search methods</h3> <p>We searched CENTRAL, MEDLINE, Embase, and SCI‐Expanded on the Web of Science for randomised controlled trials on 5 January 2021. We also searched three registers on 29 May 2021 to identify ongoing or unpublished trials. We performed backward and forward searches on reference lists of included trials and other systematic reviews and contacted experts in the field. We applied no restrictions on language or publication status. </p> </section> <section id="CD013504-sec-0004"> <h3 class="title" id="CD013504-sec-0004">Selection criteria</h3> <p>We included randomised controlled trials comparing uninterrupted anticoagulation with any modality of interruption with or without heparin bridging for CA in adults aged 18 years or older with arrhythmia. </p> </section> <section id="CD013504-sec-0005"> <h3 class="title" id="CD013504-sec-0005">Data collection and analysis</h3> <p>Two review authors conducted independent screening, data extraction, and assessment of risk of bias. A third review author resolved disagreements. We extracted data on study population, interruption strategy, ablation procedure, thromboembolic events (stroke or systemic embolism), major and minor bleeding, asymptomatic thromboembolic events, cardiovascular and all‐cause mortality, quality of life (QoL), length of hospital stay, cost, and source of funding. We used GRADE to assess the certainty of the evidence.  </p> </section> <section id="CD013504-sec-0006"> <h3 class="title" id="CD013504-sec-0006">Main results</h3> <p>We identified 12 studies (4714 participants) that compared uninterrupted periprocedural anticoagulation with interrupted anticoagulation. Studies performed an interruption strategy by either a complete interruption (one study) or by a minimal interruption (11 studies), of which a single‐dose skipped strategy was used (nine studies) or two‐dose skipped strategy (two studies), with or without heparin bridging. </p> <p>Studies included participants with a mean age of 65 years or greater, with only two studies conducted in relatively younger individuals (mean age less than 60 years). Paroxysmal atrial fibrillation (AF) was the primary type of AF in all studies, and seven studies included other types of AF (persistent and long‐standing persistent). Most participants had CHADS2 or<i> </i> CHADS2‐VASc<i> </i>demonstrating a low–moderate risk of stroke, with almost all participants having normal or mildly reduced renal function. Ablation source using radiofrequency energy was the most common (seven studies). </p> <p>Ten studies (2835 participants) were conducted in East Asian countries (Japan, China, and South Korea), while the remaining two studies were conducted in the USA. Eight studies were conducted in a single centre. Postablation follow‐up was variable among studies at less than 30 days (three studies), 30 days (six studies), and more than 30 days postablation (three studies). </p> <p>Overall, the meta‐analysis showed high uncertainty of the effect between the interrupted strategy compared to uninterrupted strategy on the primary outcomes of thromboembolic events (risk ratio (RR) 1.76, 95% confidence interval (CI) 0.33 to 9.46; I<sup>2</sup> = 59%; 6 studies, 3468 participants; very low‐certainty evidence). However, subgroup analysis showed that uninterrupted vitamin K antagonist (VKA) is associated with a lower risk of thromboembolic events without increasing the risk of bleeding. There is also uncertainty on the outcome of major bleeding events (RR 1.10, 95% CI 0.59 to 2.05; I<sup>2 </sup>= 6%; 10 studies, 4584 participants; low‐certainty evidence). The uncertainty was also evident for the secondary outcomes of minor bleeding (RR 1.01, 95% CI 0.46 to 2.22; I<sup>2</sup> = 87%; 9 studies, 3843 participants; very low‐certainty evidence), all‐cause mortality (RR 0.34, 95% CI 0.01 to 8.21; 442 participants; low‐certainty evidence) and asymptomatic thromboembolic events (RR 1.45, 95% CI 0.85 to 2.47; I<sup>2</sup> = 56%; 6 studies, 1268 participants; very low‐certainty evidence). There was a lower risk of the composite endpoint of thromboembolic events (stroke, systemic embolism, major bleeding, and all‐cause mortality) in the interrupted compared to uninterrupted arm (RR 0.23, 95% CI 0.07 to 0.81; 1 study, 442 participants; low‐certainty evidence). </p> <p>In general, the low event rates, different comparator anticoagulants, and use of different ablation procedures may be the cause of imprecision and heterogeneity observed. </p> </section> <section id="CD013504-sec-0007"> <h3 class="title" id="CD013504-sec-0007">Authors' conclusions</h3> <p>This meta‐analysis showed that the evidence is uncertain to inform the decision to either interrupt or continue anticoagulation therapy around CA procedure in adults with arrhythmia on outcomes of thromboembolic events, major and minor bleeding, all‐cause mortality, asymptomatic thromboembolic events, and a composite endpoint of thromboembolic events (stroke, systemic embolism, major bleeding, and all‐cause mortality).  </p> <p>Most studies in the review adopted a minimal interruption strategy which has the advantage of reducing the risk of bleeding while maintaining a lower level of anticoagulation to prevent periprocedural thromboembolism, hence low event rates on the primary outcomes of thromboembolism and bleeding. The one study that adopted a complete interruption of VKA showed that uninterrupted VKA reduces the risk of thromboembolism without increasing the risk of bleeding. Hence, future trials with larger samples, tailored to a more generalisable population and using homogeneous periprocedural anticoagulant therapy and ablation source are required to address the safety and efficacy of the optimal management of anticoagulant therapy prior to ablation.  </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD013504-abs-0002" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD013504-abs-0002">English</a> </li> <li class="section-language"> <a class="" href="full/de#CD013504-abs-0005">Deutsch</a> </li> <li class="section-language"> <a class="" href="full/es#CD013504-abs-0014">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD013504-abs-0010">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD013504-abs-0012">Français</a> </li> <li class="section-language"> <a class="" href="full/hr#CD013504-abs-0008">Hrvatski</a> </li> <li class="section-language"> <a class="" href="full/ms#CD013504-abs-0007">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD013504-abs-0004">简体中文</a> </li> <li class="section-language"> <a class="" href="full/zh_HANT#CD013504-abs-0006">繁體中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD013504-abs-0002" lang="en"> <h3>The continuation or discontinuation of oral anticoagulants for people with arrhythmia and undergoing catheter ablation </h3> <p><b>Review question</b> </p> <p>Should doctors continue or stop blood thinner medicine before catheter ablation procedures in people with arrhythmia? </p> <p><b>Background</b> </p> <p>Irregular heartbeats (also known as arrhythmia) come in different types; the most common type of which is uncoordinated irregular beats (also known as atrial fibrillation). People with irregular heartbeats are at risk of stroke and hence they require long‐term use of blood thinner medicines to prevent blood clots. Many of these patients may need to undergo a procedure called 'ablation' where doctors use surgery or a catheter (a thin flexible tube) to restore the normal rhythm of the heart. Before this procedure, the doctor may decide to continue the blood thinner or stop it temporarily. Such a decision should consider two things. First, the risk of a blood clot developing at the time of the ablation if the blood thinner is stopped. Second, the risk of bleeding during the procedure if the blood thinner is continued. There is no clear evidence that one decision is better than the other in terms of safety. Due to this uncertainty, we undertook this review to investigate the benefit and harms of continuing versus stopping the blood thinner at the time of the ablation procedure. </p> <p><b>Study characteristics</b> </p> <p>We searched scientific databases and identified 12 clinical trials involving 4714 participants aged 18 years and older with atrial fibrillation. The participants were randomly (like a flip of a coin) put into one of two or more groups. The groups were: continuing the blood thinner at the time of the procedure or stopping the blood thinner either for several days or by one or two doses before the procedure with or without giving additional heparin.  </p> <p>The trials reported on the risks of stroke, major bleeding, and minor bleeding after a follow‐up period of about 30 days after the procedure. The included trials examined different ablation procedures as well as different blood thinners, including Coumadin and the new oral blood thinners such as apixaban, rivaroxaban, edoxaban, and dabigatran. Ten trials were conducted in East Asian populations (Japan, China, and South Korea). Drug companies funded two trials. The evidence is current to 5 January 2021. </p> <p><b>Key results</b> </p> <p>Due to the uncertainty of the evidence, after combining the results from the 12 clinical trials in this review, we are unsure about advising one strategy over another with the current evidence. The decision to continue, completely stop or withhold one or two doses of the blood thinner before the procedure should be individualised based on the patient's risks of stroke and bleeding until more well‐designed clinical trials are available to inform a conclusive decision. </p> <p><b>Quality of the evidence</b> </p> <p>The evidence should be interpreted with caution. The review results are limited by variations in most trial comparisons, low numbers of events, trials being conducted in only one medical setting, and mostly described the intervention in East Asian populations. Further high‐quality trials are needed to find the ideal strategy for handling blood thinners at the time of the ablation procedure without increasing harm. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD013504-sec-0096" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD013504-sec-0096"></div> <h3 class="title" id="CD013504-sec-0097">Implications for practice</h3> <section id="CD013504-sec-0097"> <p>In adults with atrial fibrillation undergoing catheter ablation, we found uncertain evidence to support one strategy over another. This uncertainty precluded us from providing a strong recommendation for the medical community. Nonetheless, reflecting on the types of anticoagulants used and how these drugs were interrupted is worth a close inspection. For completely interrupted strategy, the single largest study using vitamin K antagonists, which contributed the most events in this review, concluded that uninterrupted strategy was associated with a lower risk of preprocedural thromboembolism without increasing the risk of major bleeding, particularly in people with long‐standing persistent atrial fibrillation. For studies that utilised minimal interruption, skipping one or two doses of the direct oral anticoagulants or using low‐intensity international normalised ratios for vitamin K antagonists, the low event rate in outcomes of thromboembolism and major bleeding can be attributed to the nature of the strategy. Minimal interruption implies that the anticoagulant effect may still be persistent to prevent thromboembolism without increasing bleeding risks, which in general terms is similar to the uninterrupted approach (<a href="./references#CD013504-bbs2-0077" title="DeLougheryTG . Practical aspects of the oral new anticoagulants. American Journal of Hematology2011;86:586-90. [DOI: 10.1002/ajh.22021]">DeLoughery 2011</a>). At this time, we advise clinicians and patients to select either strategy while considering each patient's characteristics before embarking on either one. </p> </section> <h3 class="title" id="CD013504-sec-0098">Implications for research</h3> <section id="CD013504-sec-0098"> <p>Based on the 12 studies included in this review, the evidence is insufficient to inform the decision about the safety and harms of one strategy over the other (interrupted versus uninterrupted). The certainty of the evidence was very low for the thromboembolic risk and low for the major bleeding risk because of the low event rates observed in the available trials; therefore, there is a need for large well‐powered and well‐designed clinical trials to overcome this issue. Furthermore, future trials should consider including patients with comorbidities and higher risks and most importantly compare the same anticoagulant in standard doses. Moreover, trials investigating the optimal length of interruption before the procedure, especially for DOAC, 24 versus 48 hours, and the needs for heparin bridging are still needed. Furthermore, our findings cannot be extrapolated to other invasive cardiac and non‐cardiac procedures such as percutaneous coronary and non‐coronary interventions, invasive gastrointestinal and urological procedures, and others. These need to be addressed individually through well‐designed clinical trials and systematic reviews. Additionally, studying other important factors such as cost‐effectiveness and patient convenience and preferences deserve consideration by future clinical trials.  </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD013504-sec-0008" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD013504-sec-0008"></div> <div class="table" id="CD013504-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Interrupted versus uninterrupted anticoagulation therapy for catheter ablation in adults with arrhythmias</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Interrupted versus uninterrupted anticoagulation therapy for catheter ablation in adults with arrhythmias</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> adults with arrhythmias undergoing catheter ablation </p> <p><b>Setting:</b> hospital </p> <p><b>Intervention:</b> interrupted anticoagulation </p> <p><b>Comparison:</b> uninterrupted anticoagulation </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> <p><b>and follow‐up</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> </b> (95% CI)<b> </b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect</b> <b>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>№ of participants (studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Certainty of the evidence (GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with uninterrupted anticoagulation</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with interrupted</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Thromboembolic events</b> </p> <p>Follow‐up: 48 hours to 1 year</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>3 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>6 per 1000<br/>(1 to 33) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.76</b> </p> <p>(0.33 to 9.46) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3468 (6 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>㊉◯◯◯</p> <p><b>Very low</b><sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>In addition, 6 studies reported no thromboembolic events occurred in either the interrupted or uninterrupted arms. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Major bleeding</b> </p> <p>Follow‐up: 1 month to 1 year</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>10 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>12 per 1000 (6 to 21)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.10</b> </p> <p>(0.59 to 2.05)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4584 (10 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>㊉㊉◯◯</p> <p><b>Low</b><sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>In addition, 1 study reported no major bleeding events occurred in either arm (<a href="./references#CD013504-bbs2-0008" title="XingY , XuB , XuC , PengF , YangB , QiuY , et al. Efficacy and safety of uninterrupted low-intensity warfarin for radiofrequency catheter ablation of atrial fibrillation in the elderly. Annals of Pharmacotherapy2017;51(9):735-42. [DOI: 10.1177/1060028017712532]">Xing 2017</a>). <a href="./references#CD013504-bbs2-0007" title="TabishH , ShahzadK . Anticoagulation safety window among elderly Chinese patients with atrial fibrillation catheter ablation. Journal of the Saudi Heart Association2010;22(2):99-100. [DOI: 10.1016/j.jsha.2010.02.325]">Tabish 2010</a> did not report on this outcome. </p> <p>Follow‐up was unclear for <a href="./references#CD013504-bbs2-0002" title='Di BiaseL , BurkhardtJD , SantangeliP , MohantyP , SanchezJ , BaiR , et al. Periprocedural strokes and anticoagulation management during AF ablation: results from the "Compare" randomized multicenter trial. Circulation2013;128:A14307. Di BiaseL , BurkhardtJD , SantangeliP , MohantyP , SanchezJ , BaiR , et al. Silent thromboembolic lesions following catheter ablation for atrial fibrillation using radiofrequency energy: results from a sub-study of the "compare" randomized trial. Circulation2013;128(22 Suppl 1):A14293. Di BiaseL , BurkhardtJD , SantangeliP , MohantyP , SanchezJ , HortonR , et al. Periprocedural stroke and bleeding complications in patients undergoing catheter ablation of atrial fibrillation with different anticoagulation management: results from the "compare" randomized trial. Heart Rhythm2013;10(9):1411. Di BiaseL , BurkhardtJD , SantangeliP , MohantyP , SanchezJE , HortonR , et al. Periprocedural stroke and bleeding complications in patients undergoing catheter ablation of atrial fibrillation with different anticoagulation management: results from the role of coumadin in preventing thromboembolism in atrial fibrillation (AF) patients undergoing catheter ablation (COMPARE) randomized trial. Circulation2014;129(25):2638-44. [DOI: 10.1161/circulationaha.113.006426]NCT01006876. Role of coumadin in preventing thromboembolism in atrial fibrillation (AF) patients undergoing catheter ablation. clinicaltrials.gov/ct2/show/NCT01006876 (first received 3 November 2009). '>Di Biase 2014</a> and  <a href="./references#CD013504-bbs2-0011" title="IrikiY , IchikiH , OketaniN , YoshimuraA , OkuiH , MaenosonoR , et al. Evaluation of safety and efficacy of perioperative use of rivaroxaban and apixaban in catheter ablation for atrial fibrillation. European Heart Journal2015;36:687. [DOI: 10.1093/eurheartj/ehv400]YoshimuraA , IrikiY , IchikiH , OketaniN , OkuiH , MaenosonoR , et al. Evaluation of safety and efficacy of periprocedural use of rivaroxaban and apixaban in catheter ablation for atrial fibrillation. Journal of Cardiology2017;69(1):228-35. [DOI: 10.1016/j.jjcc.2016.03.014]">Yoshimura 2017</a> for this outcome. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Composite endpoint of thromboembolic events (stroke or systemic embolism), major bleeding events, and all‐cause mortality</b> </p> <p>Follow‐up: 3 months</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>59 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>13 per 1000</p> <p>(4 to 47)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.23</b> </p> <p>(0.07 to 0.81)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>442 (1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>㊉㊉◯◯</p> <p><b>Low</b><sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Minor bleeding</b> </p> <p>Follow‐up: 1 month to 6 months</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>56 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>57 per 1000<br/>(26 to 125) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.01</b> </p> <p>(0.46 to 2.22)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3843 (9 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>㊉◯◯◯</p> <p><b>Very low</b><sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013504-bbs2-0005" title="AonumaK . A prospective, multi-center, parallel-group comparison study to evaluate safety and efficacy of dabigatran during the perioperative period in patients with non-valvular atrial fibrillation who undergo the catheter ablation compared to warfarin. upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000015311 (first received 14 February 2014. GoyaM , NogamiA , HiraoK , AonumaK . Ablation perioperative dabigatran in use envisioning in Japan: the ABRIDGE-J study design. Journal of Cardiology2016;68(3):236-40. [DOI: 10.1016/j.jjcc.2015.10.003]]NogamiA , HaradaT , Sekiguchi Y, Otani R, YoshidaY , Yoshida K, et al. Safety and efficacy of minimally interrupted dabigatran vs uninterrupted warfarin therapy in adults undergoing atrial fibrillation catheter ablation: a randomized clinical trial. JAMA Network Open2019;2(4):15. [DOI: 10.1001/jamanetworkopen.2019.1994]NogamiA , HaradaT , YoshidaY , NakanoY , GoyaM , OrigasaH , et al. Clinical benefit of minimally-interrupted dabigatran versus uninterrupted warfarin for catheter ablation of atrial fibrillation: a prospective randomized multicenter trial. Circulation2017;136:e450. NogamiA , HaradaT , YoshidaY , NakanoY , GoyaM , OrigasaH , et al. Clinical benefit of minimally-interrupted dabigatran versus uninterrupted warfarin for catheter ablation of atrial fibrillation: a prospective randomized multicenter trial. Circulation2017;136(24):E450. [DOI: 10.1161/CIR.0000000000000546]UMIN000013129. A prospective, multi-center, parallel-group comparison study to evaluate safety and efficacy of dabigatran during the perioperative period in patients with non-valvular atrial fibrillation who undergo the catheter ablation compared to warfarin. www.who.int/trialsearch/Trial2.aspx?TrialID=JPRN-UMIN000013129 (first received 1 March 2014). ">Nogami 2019</a> did not report minor bleeding as a separate outcome but within a composite endpoint. </p> <p>Follow‐up was unclear for <a href="./references#CD013504-bbs2-0002" title='Di BiaseL , BurkhardtJD , SantangeliP , MohantyP , SanchezJ , BaiR , et al. Periprocedural strokes and anticoagulation management during AF ablation: results from the "Compare" randomized multicenter trial. Circulation2013;128:A14307. Di BiaseL , BurkhardtJD , SantangeliP , MohantyP , SanchezJ , BaiR , et al. Silent thromboembolic lesions following catheter ablation for atrial fibrillation using radiofrequency energy: results from a sub-study of the "compare" randomized trial. Circulation2013;128(22 Suppl 1):A14293. Di BiaseL , BurkhardtJD , SantangeliP , MohantyP , SanchezJ , HortonR , et al. Periprocedural stroke and bleeding complications in patients undergoing catheter ablation of atrial fibrillation with different anticoagulation management: results from the "compare" randomized trial. Heart Rhythm2013;10(9):1411. Di BiaseL , BurkhardtJD , SantangeliP , MohantyP , SanchezJE , HortonR , et al. Periprocedural stroke and bleeding complications in patients undergoing catheter ablation of atrial fibrillation with different anticoagulation management: results from the role of coumadin in preventing thromboembolism in atrial fibrillation (AF) patients undergoing catheter ablation (COMPARE) randomized trial. Circulation2014;129(25):2638-44. [DOI: 10.1161/circulationaha.113.006426]NCT01006876. Role of coumadin in preventing thromboembolism in atrial fibrillation (AF) patients undergoing catheter ablation. clinicaltrials.gov/ct2/show/NCT01006876 (first received 3 November 2009). '>Di Biase 2014</a>. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>All‐cause mortality</b> </p> <p>Follow‐up: 3 months</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>0/220 in the interrupted group vs 1/222 in the uninterrupted group died from any cause</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.34</b><br/>(0.01 to 8.21) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>442 (1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>㊉㊉◯◯</p> <p><b>Low</b><sup>d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>There was only 1 death in the uninterrupted arm in <a href="./references#CD013504-bbs2-0005" title="AonumaK . A prospective, multi-center, parallel-group comparison study to evaluate safety and efficacy of dabigatran during the perioperative period in patients with non-valvular atrial fibrillation who undergo the catheter ablation compared to warfarin. upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000015311 (first received 14 February 2014. GoyaM , NogamiA , HiraoK , AonumaK . Ablation perioperative dabigatran in use envisioning in Japan: the ABRIDGE-J study design. Journal of Cardiology2016;68(3):236-40. [DOI: 10.1016/j.jjcc.2015.10.003]]NogamiA , HaradaT , Sekiguchi Y, Otani R, YoshidaY , Yoshida K, et al. Safety and efficacy of minimally interrupted dabigatran vs uninterrupted warfarin therapy in adults undergoing atrial fibrillation catheter ablation: a randomized clinical trial. JAMA Network Open2019;2(4):15. [DOI: 10.1001/jamanetworkopen.2019.1994]NogamiA , HaradaT , YoshidaY , NakanoY , GoyaM , OrigasaH , et al. Clinical benefit of minimally-interrupted dabigatran versus uninterrupted warfarin for catheter ablation of atrial fibrillation: a prospective randomized multicenter trial. Circulation2017;136:e450. NogamiA , HaradaT , YoshidaY , NakanoY , GoyaM , OrigasaH , et al. Clinical benefit of minimally-interrupted dabigatran versus uninterrupted warfarin for catheter ablation of atrial fibrillation: a prospective randomized multicenter trial. Circulation2017;136(24):E450. [DOI: 10.1161/CIR.0000000000000546]UMIN000013129. A prospective, multi-center, parallel-group comparison study to evaluate safety and efficacy of dabigatran during the perioperative period in patients with non-valvular atrial fibrillation who undergo the catheter ablation compared to warfarin. www.who.int/trialsearch/Trial2.aspx?TrialID=JPRN-UMIN000013129 (first received 1 March 2014). ">Nogami 2019</a>, and this was used to calculate the RR. In addition, <a href="./references#CD013504-bbs2-0006" title="ReynoldsMR , AllisonJS , NataleA , WeisbergIL , EllenbogenKA , RichardsM , et al. Apixaban evaluation of interrupted or uninterrupted anticoagulation for ablation of atrial fibrillation. clinicaltrials.gov/show/NCT02608099 (first received 18 November 2015). ReynoldsMR , AllisonJS , NataleA , WeisbergIL , EllenbogenKA , RichardsM , et al. A prospective randomized trial of apixaban dosing during atrial fibrillation ablation: the AEIOU trial. JACC Clinical Electrophysiology2018;4(5):580-8. [DOI: 10.1016/j.jacep.2017.11.005]">Reynolds 2018</a> reported that there were 0 mortality events in either arm. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Asymptomatic thromboembolic events</b> </p> <p>Follow‐up: 1 hour to 1 month</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>148 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>215 per 1000<br/>(126 to 366) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.45</b> </p> <p>(0.85 to 2.47)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1268 (6 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>㊉◯◯◯</p> <p><b>Very low</b><sup>e</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Follow‐up was unclear for <a href="./references#CD013504-bbs2-0002" title='Di BiaseL , BurkhardtJD , SantangeliP , MohantyP , SanchezJ , BaiR , et al. Periprocedural strokes and anticoagulation management during AF ablation: results from the "Compare" randomized multicenter trial. Circulation2013;128:A14307. Di BiaseL , BurkhardtJD , SantangeliP , MohantyP , SanchezJ , BaiR , et al. Silent thromboembolic lesions following catheter ablation for atrial fibrillation using radiofrequency energy: results from a sub-study of the "compare" randomized trial. Circulation2013;128(22 Suppl 1):A14293. Di BiaseL , BurkhardtJD , SantangeliP , MohantyP , SanchezJ , HortonR , et al. Periprocedural stroke and bleeding complications in patients undergoing catheter ablation of atrial fibrillation with different anticoagulation management: results from the "compare" randomized trial. Heart Rhythm2013;10(9):1411. Di BiaseL , BurkhardtJD , SantangeliP , MohantyP , SanchezJE , HortonR , et al. Periprocedural stroke and bleeding complications in patients undergoing catheter ablation of atrial fibrillation with different anticoagulation management: results from the role of coumadin in preventing thromboembolism in atrial fibrillation (AF) patients undergoing catheter ablation (COMPARE) randomized trial. Circulation2014;129(25):2638-44. [DOI: 10.1161/circulationaha.113.006426]NCT01006876. Role of coumadin in preventing thromboembolism in atrial fibrillation (AF) patients undergoing catheter ablation. clinicaltrials.gov/ct2/show/NCT01006876 (first received 3 November 2009). '>Di Biase 2014</a> and <a href="./references#CD013504-bbs2-0008" title="XingY , XuB , XuC , PengF , YangB , QiuY , et al. Efficacy and safety of uninterrupted low-intensity warfarin for radiofrequency catheter ablation of atrial fibrillation in the elderly. Annals of Pharmacotherapy2017;51(9):735-42. [DOI: 10.1177/1060028017712532]">Xing 2017</a>. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI). </p> <p><b>CI:</b> confidence interval; <b>RR:</b> risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> </p> <p><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect. </p> <p><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different. </p> <p><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect. </p> <p><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded three levels. Once for risk of bias in included studies, specifically in the domains of randomisation and allocation concealment; once level for inconsistency owing to a moderate level of statistical heterogeneity, and once for imprecision due to wide confidence intervals in the effect estimate that could be explained by the low event rates in included trials.<br/><sup>b</sup>Downgraded two levels. Once for risk of bias in included studies, specifically in the domains of randomisation and allocation concealment; and once for imprecision due to wide confidence intervals in the effect estimate that could be explained by the low event rates in included trials.<br/><sup>c</sup>Downgraded two levels. Once for risk of bias in the included study, specifically in the domains of blinding; and once for imprecision as only one study with a low event rate reported this outcome.<br/><sup>d</sup>Downgraded two levels. Once for risk of bias in the included study, specifically in the domains of blinding; and once for imprecision caused by low event rate and wide confidence interval.<br/><sup>e</sup>Downgraded three levels. Once for risk of bias in included studies, specifically in the domains of randomisation and allocation concealment; once for inconsistency owing to a moderate level of statistical heterogeneity; and once for imprecision due to wide confidence intervals in the effect estimate that could be explained by the variability in assessing this outcome in the included study. </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD013504-sec-0009" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD013504-sec-0009"></div> <section id="CD013504-sec-0010"> <h3 class="title" id="CD013504-sec-0010">Description of the condition</h3> <p>Arrhythmia is a problem with the rate or rhythm of the heartbeat, causing the heart to beat in a slow, rapid, or irregular fashion (<a href="./references#CD013504-bbs2-0120" title="RakelD . Arrhythmias. In: Integrative Medicine. 4th edition. Philadelphia (PA): Elsevier, 2017:276.">Rakel 2017</a>). Some of the cardiac arrhythmias can be serious and life‐threatening, while others may not be symptomatic or significant (<a href="./references#CD013504-bbs2-0120" title="RakelD . Arrhythmias. In: Integrative Medicine. 4th edition. Philadelphia (PA): Elsevier, 2017:276.">Rakel 2017</a>). Supraventricular arrhythmias are generated above the ventricles in the atrial or atrioventricular nodal tissues; they include atrial fibrillation (AF), atrial flutter, paroxysmal supraventricular tachycardia, and automatic atrial tachycardias (<a href="./references#CD013504-bbs2-0120" title="RakelD . Arrhythmias. In: Integrative Medicine. 4th edition. Philadelphia (PA): Elsevier, 2017:276.">Rakel 2017</a>). In contrast, ventricular arrhythmias are mostly due to secondary cardiac causes (such as structural heart diseases) and they are associated with high mortality if not treated immediately (<a href="./references#CD013504-bbs2-0058" title="Al-KhatibSM , StevensonWG , AckermanMJ , BryantWJ , CallansDJ , CurtisAB , et al. 2017 AHA/ACC/HRS guideline for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: executive. Circulation2018;138(13):e210-71.">Al‐Khatib 2018</a>). Ventricular arrhythmias encompass premature ventricular complexes, ventricular tachycardia, and ventricular fibrillation (<a href="./references#CD013504-bbs2-0106" title="LudhwaniD , GoyalA , JagtapM . Ventricular fibrillation. In: StatPearls. Treasure Island (FL): StatPearls Publishing, 2019.">Ludhwani 2019</a>). Treatment modalities for arrhythmias vary according to the type, presence of symptoms, risk stratification, and the impact of abnormal automaticity on patient outcomes (e.g. stroke, sudden death). </p> <p>In clinical practice, AF is the most common arrhythmia and its incidence increases with age (<a href="./references#CD013504-bbs2-0140" title="ZimetbaumP . Atrial fibrillation. Annals of Internal Medicine2017;166(5):ITC33-48.">Zimetbaum 2017</a>). People with AF are five times more likely to experience a stroke than the rest of the population (<a href="./references#CD013504-bbs2-0118" title="PistersR , LaneD , NieuwlaatR , deVosC , CrijnsH , LipG . A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest2010;138:1093-100.">Pisters 2010</a>; <a href="./references#CD013504-bbs2-0134" title="WolfP , AbbottR , KannelW . Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke1991;22(8):983-8.">Wolf 1991</a>); the risk is higher in the presence (and severity) of underlying heart disease, as well as the comorbid existence of diabetes, hypertension, chronic kidney disease, and progressive ageing. The Global Anticoagulant Registry in the FIELD‐Atrial Fibrillation (GARFIELD‐AF) showed that in newly diagnosed people with AF at two‐year follow‐up the rate of stroke was 1.25 (95% confidence interval (CI) 1.13 to 1.38), bleeding was 0.70 (95% CI 0.62 to 0.81), and all‐cause mortality was 3.83 (95% CI 3.62 to 4.05) per 100 person‐years (<a href="./references#CD013504-bbs2-0063" title="BassandJP , AccettaG , CammAJ , CoolsF , FitzmauriceDA , FoxKA , et al. Two-year outcomes of patients with newly diagnosed atrial fibrillation: results from GARFIELD-AF. European Heart Journal2016;37(38):2882-9.">Bassand 2016</a>). Stroke is also costly due to increased healthcare resource utilisation for the management of AF and its complications (<a href="./references#CD013504-bbs2-0066" title="BlomstromLC , LipGY , KirchhofP . What are the costs of atrial fibrillation?Europace2011;13(Suppl 2):ii9-12.">Blomstrom 2011</a>; <a href="./references#CD013504-bbs2-0109" title="MurrayCJ , VosT , LozanoR , NaghaviM , FlaxmanAD , MichaudC , et al. Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet2012;380(9859):2197-223.">Murray 2012</a>). </p> <p>The management of AF focuses on three clinical approaches. First is the use of oral anticoagulants (OACs) for stroke prevention (<a href="./references#CD013504-bbs2-0096" title="JanuaryCT , WannLS , CalkinsH , ChenLY , CigarroaJE , ClevelandJC , et al. 2019 AHA/ACC/HRS focused update of the 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation. Circulation2019;139:e000.">January 2019</a>; <a href="./references#CD013504-bbs2-0099" title="KirchhofP , BenussiS , KotechaD , AhlssonA , AtarD , CasadeiB , et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. European Heart Journal2016;37(38):2893-962.">Kirchhof 2016</a>; <a href="./references#CD013504-bbs2-0105" title="LipGY , BanerjeeA , BorianiG , ChiangCE , FargoR , FreedmanB , et al. Antithrombotic therapy for atrial fibrillation: CHEST guideline and expert panel report. Chest2018;154(5):1121-201.">Lip 2018</a>). Most guidelines recommend chronic anticoagulation for people identified to be at high risk of stroke using the CHA2DS2‐VASc score (<a href="./references#CD013504-bbs2-0096" title="JanuaryCT , WannLS , CalkinsH , ChenLY , CigarroaJE , ClevelandJC , et al. 2019 AHA/ACC/HRS focused update of the 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation. Circulation2019;139:e000.">January 2019</a>; <a href="./references#CD013504-bbs2-0099" title="KirchhofP , BenussiS , KotechaD , AhlssonA , AtarD , CasadeiB , et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. European Heart Journal2016;37(38):2893-962.">Kirchhof 2016</a>; <a href="./references#CD013504-bbs2-0105" title="LipGY , BanerjeeA , BorianiG , ChiangCE , FargoR , FreedmanB , et al. Antithrombotic therapy for atrial fibrillation: CHEST guideline and expert panel report. Chest2018;154(5):1121-201.">Lip 2018</a>). Until recently, vitamin K antagonists (VKAs) were the main OAC recommended. However, novel direct oral anticoagulants (DOACs) – dabigatran, rivaroxaban, apixaban, and edoxaban – are now the preferred agents for stroke prevention in eligible people with AF (<a href="./references#CD013504-bbs2-0127" title="SteffelJ , VerhammeP , PotparaTS , AlbaladejoP , AntzM , DestegheL , et al. The 2018 European Heart Rhythm Association practical guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. European Heart Journal2018;39(16):1330-93.">Steffel 2018</a>). The second approach in the management of AF is the use of rate‐control drugs to regulate the ventricular rate. The third approach can include rhythm‐control interventions (cardioversion, medications, or ablation) for restoration and maintenance of normal sinus rhythm in selected patients (<a href="./references#CD013504-bbs2-0059" title="AndradeJG , VermaA , MitchellLB , ParkashR , LeblancK , AtzemaC , et al. 2018 focused update of the Canadian Cardiovascular Society guidelines for the management of atrial fibrillation. Canadian Journal of Cardiology2018;34(11):1371-92.">Andrade 2018</a>; <a href="./references#CD013504-bbs2-0096" title="JanuaryCT , WannLS , CalkinsH , ChenLY , CigarroaJE , ClevelandJC , et al. 2019 AHA/ACC/HRS focused update of the 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation. Circulation2019;139:e000.">January 2019</a>; <a href="./references#CD013504-bbs2-0097" title="JonesC , PollitcV , FitzmauriceD , CowanC . The management of atrial fibrillation: summary of updated NICE guidance. BMJ2014;348:g3655.">Jones 2014</a>; <a href="./references#CD013504-bbs2-0105" title="LipGY , BanerjeeA , BorianiG , ChiangCE , FargoR , FreedmanB , et al. Antithrombotic therapy for atrial fibrillation: CHEST guideline and expert panel report. Chest2018;154(5):1121-201.">Lip 2018</a>). Evidence is accumulating in support of catheter ablation (CA) as first‐line therapy for AF, especially in people with symptoms. Guidelines give a strong recommendation (class I, level A) for offering ablation therapy to people who failed treatment with antiarrhythmic drugs, have no structural heart disease, and are still symptomatic (<a href="./references#CD013504-bbs2-0068" title="CalkinsH , HindricksG , CappatoR , KimYH , SaadEB , AguinagaL , et al. 2017 HRS/EHRA/ECAS/APHRS/SOLAECE expert consensus statement on catheter and surgical ablation of atrial fibrillation. Europace2018;20(1):e1-e160.">Calkins 2018a</a>; <a href="./references#CD013504-bbs2-0096" title="JanuaryCT , WannLS , CalkinsH , ChenLY , CigarroaJE , ClevelandJC , et al. 2019 AHA/ACC/HRS focused update of the 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation. Circulation2019;139:e000.">January 2019</a>). </p> <p>Atrial flutter shares a significant clinical resemblance to AF and it commonly coexists in the same patient. CA is the most effective and first‐line therapy in atrial flutter (<a href="./references#CD013504-bbs2-0067" title="BrugadaJ , KatritsisDG , ArbeloE , ArribasF , BaxJJ , Blomstrom-LundqvistC , et al. 2019 ESC guidelines for the management of patients with supraventricular tachycardia: the Task Force for the management of patients with supraventricular tachycardia of the European Society of Cardiology (ESC). European Heart Journal2019;00:1-65.">Brugada 2019</a>; <a href="./references#CD013504-bbs2-0069" title="CalkinsH , HindricksG , CappatoR , KimYH , SaadEB , AguinagaL , et al. 2017 HRS/EHRA/ECAS/APHRS/SOLAECE expert consensus statement on catheter and surgical ablation of atrial fibrillation: executive summary. Europace2018;20(1):157-208.">Calkins 2018b</a>; <a href="./references#CD013504-bbs2-0116" title="PageRL , JoglarJA , CaldwellMA , CalkinsH , ContiJB , DealBJ , et al. 2015 ACC/AHA/HRS guideline for the management of adult patients with supraventricular tachycardia: executive summary. Circulation2016;67(13):e27-e115.">Page 2016</a>). Antithrombotic therapy is also recommended based on stroke risk assessment, similar to AF (<a href="./references#CD013504-bbs2-0099" title="KirchhofP , BenussiS , KotechaD , AhlssonA , AtarD , CasadeiB , et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. European Heart Journal2016;37(38):2893-962.">Kirchhof 2016</a>; <a href="./references#CD013504-bbs2-0105" title="LipGY , BanerjeeA , BorianiG , ChiangCE , FargoR , FreedmanB , et al. Antithrombotic therapy for atrial fibrillation: CHEST guideline and expert panel report. Chest2018;154(5):1121-201.">Lip 2018</a>). </p> <p>In people with ventricular arrhythmias, treatment approaches mainly focus on treating the underlying cardiac pathology and preventing sudden cardiac arrest and cardiac death (<a href="./references#CD013504-bbs2-0126" title="ShivkumarK . Catheter ablation of ventricular arrhythmias. New England Journal of Medicine2019;380(16):1555-64.">Shivkumar 2019</a>). CA is also one of the main strategies of management in people with sustained ventricular tachycardia (<a href="./references#CD013504-bbs2-0072" title="CroninEM , BogunFM , MauryP , PeichlP , ChenM , NamboodiriN , et al. 2019 HRS/EHRA/APHRS/LAHRS expert consensus statement on catheter ablation of ventricular arrhythmias. Europace2019;21(8):1143-4.">Cronin 2019</a>; <a href="./references#CD013504-bbs2-0126" title="ShivkumarK . Catheter ablation of ventricular arrhythmias. New England Journal of Medicine2019;380(16):1555-64.">Shivkumar 2019</a>). Although anticoagulants are not the main therapy for people with ventricular tachycardia, they could be used for people with a non‐urgent indication for ablation, especially if a mobile thrombus is present (<a href="./references#CD013504-bbs2-0072" title="CroninEM , BogunFM , MauryP , PeichlP , ChenM , NamboodiriN , et al. 2019 HRS/EHRA/APHRS/LAHRS expert consensus statement on catheter ablation of ventricular arrhythmias. Europace2019;21(8):1143-4.">Cronin 2019</a>). In such cases, treatment with OACs for a limited period of time after extensive endocardial ventricular tachycardia ablation may be considered (<a href="./references#CD013504-bbs2-0072" title="CroninEM , BogunFM , MauryP , PeichlP , ChenM , NamboodiriN , et al. 2019 HRS/EHRA/APHRS/LAHRS expert consensus statement on catheter ablation of ventricular arrhythmias. Europace2019;21(8):1143-4.">Cronin 2019</a>). Furthermore, device therapy such as implantable defibrillators, pacemakers and re‐synchronisation therapy defibrillator had become routine therapy for primary and secondary prevention in people with ventricular arrhythmia (<a href="./references#CD013504-bbs2-0096" title="JanuaryCT , WannLS , CalkinsH , ChenLY , CigarroaJE , ClevelandJC , et al. 2019 AHA/ACC/HRS focused update of the 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation. Circulation2019;139:e000.">January 2019</a>; <a href="./references#CD013504-bbs2-0102" title="LauDH , ThiyagarajahA , WillemsS , RostockT , LinzD , StilesMK , et al. Device therapy for rate control: pacing, resynchronisation and AV node ablation. Heart, Lung and Circulation2017;26(9):934-40.">Lau 2017</a>). CA procedures are carried out percutaneously through vascular access (venous or arterial, or both) and they carry the risk of thromboembolism due to interruption of anticoagulant therapy and the introduction of foreign materials to the circulation (<a href="./references#CD013504-bbs2-0133" title="WidimskyP , KockaV , RohacF , OsmancikP . Periprocedural antithrombotic therapy during various types of percutaneous cardiovascular interventions. European Heart Journal Cardiovascular Pharmacotherapy2016;2(2):131-40.">Widimsky 2016</a>). </p> </section> <section id="CD013504-sec-0011"> <h3 class="title" id="CD013504-sec-0011">Description of the intervention</h3> <p>During CA procedures, the continuation of OAC therapy presents a clinical decision that should take into account the procedure as well as the patient's risks of bleeding and thromboembolic events (<a href="./references#CD013504-bbs2-0071" title="ClarkNP , DouketisJD , HasselbladV , SchulmanS , KindzelskiAL , OrtelTL . Predictors of perioperative major bleeding in patients who interrupt warfarin for an elective surgery or procedure: analysis of the BRIDGE trial. American Heart Journal2018;195:108-14.">Clark 2018</a>; <a href="./references#CD013504-bbs2-0081" title="DohertyJU , GluckmanTJ , HuckerWJ , JanuzziJL , OrtelTL , SaxonhouseSJ , et al. 2017 ACC expert consensus decision pathway for periprocedural management of anticoagulation in patients with nonvalvular atrial fibrillation: a report of the American College of Cardiology Clinical Expert Consensus Document Task Force. Journal of the American College of Cardiology2017;69:7.">Doherty 2017</a>). Therefore, periprocedural management of OACs is paramount to improve clinical outcomes and reduce risks of bleeding and thrombosis in people with AF undergoing CA (<a href="./references#CD013504-bbs2-0057" title="AbedHS , ChenV , KilbornMJ , SyRW . Periprocedural management of novel oral anticoagulants during atrial fibrillation ablation: controversies and review of the current evidence. Heart, Lung and Circulation2016;25(12):1164-76.">Abed 2016</a>; <a href="./references#CD013504-bbs2-0068" title="CalkinsH , HindricksG , CappatoR , KimYH , SaadEB , AguinagaL , et al. 2017 HRS/EHRA/ECAS/APHRS/SOLAECE expert consensus statement on catheter and surgical ablation of atrial fibrillation. Europace2018;20(1):e1-e160.">Calkins 2018a</a>). Two major strategies are frequently used in current clinical practice (<a href="./references#CD013504-bbs2-0061" title="BalouchM , Gucuk IpekE , ChrispinJ , BajwaRJ , ZghaibT , BergerRD , et al. Trends in transesophageal echocardiography use, findings, and clinical outcomes in the era of minimally interrupted anticoagulation for atrial fibrillation ablation. JACC: Clinical Electrophysiology2017;3(4):329-36.">Balouch 2017</a>; <a href="./references#CD013504-bbs2-0076" title="De HeideJ , VroeghCJ , BhagwandienRE , WijchersSA , Szili-TorokT , ZijlstraF , et al. Minimally interrupted novel oral anticoagulant versus uninterrupted vitamin K antagonist during atrial fibrillation ablation. Journal of Interventional Cardiac Electrophysiology2018;53(3):341-6.">De Heide 2018</a>; <a href="./references#CD013504-bbs2-0080" title="Di BiaseL , KirchhofP , RomeroJ . Safety and efficacy of uninterrupted vs. minimally interrupted periprocedural direct oral anticoagulants for catheter ablation of atrial fibrillation: two sides of the same coin?Europace2019;21(2):181-3.">Di Biase 2019</a>; <a href="./references#CD013504-bbs2-0082" title="EfremidisM , VlachosK , LetsasKP , GiannopoulosG , LioniL , GeorgopoulosS , et al. Low dose dabigatran versus uninterrupted acenocoumarol for peri-procedural anticoagulation in atrial fibrillation catheter ablation. Journal of Electrocardiology2015;48(5):840-4.">Efremidis 2015</a>; <a href="./references#CD013504-bbs2-0091" title="HaFJ , BarraS , BrownAJ , BegleyDA , GraceAA , AgarwalS . Continuous and minimally-interrupted direct oral anticoagulant are both safe compared with vitamin K antagonist for atrial fibrillation ablation: an updated meta-analysis. International Journal of Cardiology2018;262:51-6.">Ha 2018</a>; <a href="./references#CD013504-bbs2-0110" title="NagaoT , SuzukiH , MatsunagaS , NishikawaY , HaradaK , MamiyaK , et al. Impact of periprocedural anticoagulation therapy on the incidence of silent stroke after atrial fibrillation ablation in patients receiving direct oral anticoagulants: uninterrupted vs. interrupted by one dose strategy. Europace2018;21(4):590-7.">Nagao 2018</a>; <a href="./references#CD013504-bbs2-0005" title="AonumaK . A prospective, multi-center, parallel-group comparison study to evaluate safety and efficacy of dabigatran during the perioperative period in patients with non-valvular atrial fibrillation who undergo the catheter ablation compared to warfarin. upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000015311 (first received 14 February 2014. GoyaM , NogamiA , HiraoK , AonumaK . Ablation perioperative dabigatran in use envisioning in Japan: the ABRIDGE-J study design. Journal of Cardiology2016;68(3):236-40. [DOI: 10.1016/j.jjcc.2015.10.003]]NogamiA , HaradaT , Sekiguchi Y, Otani R, YoshidaY , Yoshida K, et al. Safety and efficacy of minimally interrupted dabigatran vs uninterrupted warfarin therapy in adults undergoing atrial fibrillation catheter ablation: a randomized clinical trial. JAMA Network Open2019;2(4):15. [DOI: 10.1001/jamanetworkopen.2019.1994]NogamiA , HaradaT , YoshidaY , NakanoY , GoyaM , OrigasaH , et al. Clinical benefit of minimally-interrupted dabigatran versus uninterrupted warfarin for catheter ablation of atrial fibrillation: a prospective randomized multicenter trial. Circulation2017;136:e450. NogamiA , HaradaT , YoshidaY , NakanoY , GoyaM , OrigasaH , et al. Clinical benefit of minimally-interrupted dabigatran versus uninterrupted warfarin for catheter ablation of atrial fibrillation: a prospective randomized multicenter trial. Circulation2017;136(24):E450. [DOI: 10.1161/CIR.0000000000000546]UMIN000013129. A prospective, multi-center, parallel-group comparison study to evaluate safety and efficacy of dabigatran during the perioperative period in patients with non-valvular atrial fibrillation who undergo the catheter ablation compared to warfarin. www.who.int/trialsearch/Trial2.aspx?TrialID=JPRN-UMIN000013129 (first received 1 March 2014). ">Nogami 2019</a>; <a href="./references#CD013504-bbs2-0008" title="XingY , XuB , XuC , PengF , YangB , QiuY , et al. Efficacy and safety of uninterrupted low-intensity warfarin for radiofrequency catheter ablation of atrial fibrillation in the elderly. Annals of Pharmacotherapy2017;51(9):735-42. [DOI: 10.1177/1060028017712532]">Xing 2017</a>; <a href="./references#CD013504-bbs2-0053" title="XingY , XuB , ShengX , XuC , PengF , SunY , et al. Efficacy and safety of uninterrupted low-intensity warfarin for cryoballoon ablation of atrial fibrillation in the elderly: a pilot study. Journal of Clinical Pharmacy and Therapeutics2018;43(3):401-7. [DOI: 10.1111/jcpt.12671]">Xing 2018</a>). In the first strategy, OAC therapy is interrupted or minimally interrupted (defined as withholding up to two doses of the anticoagulant) before the start of the procedure, with or without the use of bridging therapy with intravenous heparin or subcutaneous low molecular weight heparin (LMWH) (<a href="./references#CD013504-bbs2-0061" title="BalouchM , Gucuk IpekE , ChrispinJ , BajwaRJ , ZghaibT , BergerRD , et al. Trends in transesophageal echocardiography use, findings, and clinical outcomes in the era of minimally interrupted anticoagulation for atrial fibrillation ablation. JACC: Clinical Electrophysiology2017;3(4):329-36.">Balouch 2017</a>; <a href="./references#CD013504-bbs2-0076" title="De HeideJ , VroeghCJ , BhagwandienRE , WijchersSA , Szili-TorokT , ZijlstraF , et al. Minimally interrupted novel oral anticoagulant versus uninterrupted vitamin K antagonist during atrial fibrillation ablation. Journal of Interventional Cardiac Electrophysiology2018;53(3):341-6.">De Heide 2018</a>; <a href="./references#CD013504-bbs2-0080" title="Di BiaseL , KirchhofP , RomeroJ . Safety and efficacy of uninterrupted vs. minimally interrupted periprocedural direct oral anticoagulants for catheter ablation of atrial fibrillation: two sides of the same coin?Europace2019;21(2):181-3.">Di Biase 2019</a>; <a href="./references#CD013504-bbs2-0091" title="HaFJ , BarraS , BrownAJ , BegleyDA , GraceAA , AgarwalS . Continuous and minimally-interrupted direct oral anticoagulant are both safe compared with vitamin K antagonist for atrial fibrillation ablation: an updated meta-analysis. International Journal of Cardiology2018;262:51-6.">Ha 2018</a>). Following the procedure, an OAC is resumed once haemostasis is achieved (<a href="./references#CD013504-bbs2-0069" title="CalkinsH , HindricksG , CappatoR , KimYH , SaadEB , AguinagaL , et al. 2017 HRS/EHRA/ECAS/APHRS/SOLAECE expert consensus statement on catheter and surgical ablation of atrial fibrillation: executive summary. Europace2018;20(1):157-208.">Calkins 2018b</a>; <a href="./references#CD013504-bbs2-0081" title="DohertyJU , GluckmanTJ , HuckerWJ , JanuzziJL , OrtelTL , SaxonhouseSJ , et al. 2017 ACC expert consensus decision pathway for periprocedural management of anticoagulation in patients with nonvalvular atrial fibrillation: a report of the American College of Cardiology Clinical Expert Consensus Document Task Force. Journal of the American College of Cardiology2017;69:7.">Doherty 2017</a>). In the second strategy, the procedure is performed without interruption or reduction of OAC therapy (<a href="./references#CD013504-bbs2-0098" title="KaiserDW , StreurMM , NagarakantiR , WhalenSP , EllisCR . Continuous warfarin versus periprocedural dabigatran to reduce stroke and systemic embolism in patients undergoing catheter ablation for atrial fibrillation or left atrial flutter. Journal of Interventional Cardiac Electrophysiology2013;37(3):241-7.">Kaiser 2013</a>; <a href="./references#CD013504-bbs2-0128" title="TapanainenJM , BraunschweigF , SchwielerJ , InsulanderP , BastaniH , DrcaN , et al. Continuous warfarin therapy is safe and feasible in catheter ablation of atrial fibrillation. Scandinavian Cardiovascular Journal2013;47(2):109-13.">Tapanainen 2013</a>). </p> <p>There are major differences between VKAs and DOACs that should be considered in preprocedural planning (<a href="./references#CD013504-bbs2-0062" title="BarnesGD , MoulandE . Peri-procedural management of oral anticoagulants in the DOAC era. Progress in Cardiovascular Diseases2018;60(6):600-6.">Barnes 2018</a>). The half‐life of clotting factors determines the antithrombotic effect of VKAs. More specifically, the reduction in the level of factor II/prothrombin, which has the longest half‐life of about 96 hours, is required for the complete antithrombotic effect of VKAs. Standard interruption for VKAs is usually five days to reverse the anticoagulant effect of warfarin and achieve normal haemostasis (<a href="./references#CD013504-bbs2-0062" title="BarnesGD , MoulandE . Peri-procedural management of oral anticoagulants in the DOAC era. Progress in Cardiovascular Diseases2018;60(6):600-6.">Barnes 2018</a>). The American College of Cardiology (ACC) 2017 consensus statement recommends using individualised international normalised ratios (INRs) to plan preprocedure warfarin interruption (<a href="./references#CD013504-bbs2-0081" title="DohertyJU , GluckmanTJ , HuckerWJ , JanuzziJL , OrtelTL , SaxonhouseSJ , et al. 2017 ACC expert consensus decision pathway for periprocedural management of anticoagulation in patients with nonvalvular atrial fibrillation: a report of the American College of Cardiology Clinical Expert Consensus Document Task Force. Journal of the American College of Cardiology2017;69:7.">Doherty 2017</a>). Bridging therapy with LMWH or heparin has previously been used and recommended when interrupting VKAs during the preoperative period; however, recent studies have argued against this approach (<a href="./references#CD013504-bbs2-0087" title="GarwoodCL , HwangJM , MoserLR . Striking a balance between the risks and benefits of anticoagulation bridge therapy in patients with atrial fibrillation: clinical updates and remaining controversies. Pharmacotherapy2011;31(12):1208-20.">Garwood 2011</a>). </p> <p>Unlike VKAs, DOACs have different pharmacokinetic properties – including having a short time to peak effect, somewhat short half‐lives (around 12 hours) – and are renally eliminated (<a href="./references#CD013504-bbs2-0127" title="SteffelJ , VerhammeP , PotparaTS , AlbaladejoP , AntzM , DestegheL , et al. The 2018 European Heart Rhythm Association practical guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. European Heart Journal2018;39(16):1330-93.">Steffel 2018</a>). Since the extent of renal clearance varies between DOACs, calculating the patient's creatinine clearance is important when developing a preprocedural plan (<a href="./references#CD013504-bbs2-0062" title="BarnesGD , MoulandE . Peri-procedural management of oral anticoagulants in the DOAC era. Progress in Cardiovascular Diseases2018;60(6):600-6.">Barnes 2018</a>). Generally, bridging therapy with either heparin or LMWH is not recommended when interrupting DOACs before CA procedures. The timing of interrupting DOACs differs depending on the agent. For dabigatran, it is currently recommended to discontinue therapy one to two days prior to CA procedures when creatinine clearance is more than 50 mL/minute, and three to five days prior to CA procedures when creatinine clearance is less than 50 mL/minute (<a href="./references#CD013504-bbs2-0062" title="BarnesGD , MoulandE . Peri-procedural management of oral anticoagulants in the DOAC era. Progress in Cardiovascular Diseases2018;60(6):600-6.">Barnes 2018</a>). For rivaroxaban, apixaban, and edoxaban, if the interruption is planned, the treatment should be stopped for at least 24 hours prior to CA and once there is adequate haemostasis, the treatment can be resumed (<a href="./references#CD013504-bbs2-0121" title="RavalAN , CigarroaJE , ChungMK , Diaz-SandovalLJ , DiercksD , PicciniJP , et al. Management of patients on non-vitamin K antagonist oral anticoagulants in the acute care and periprocedural setting: a scientific statement from the American Heart Association. Circulation2017;135(10):e604-33.">Raval 2017</a>). </p> </section> <section id="CD013504-sec-0012"> <h3 class="title" id="CD013504-sec-0012">How the intervention might work</h3> <p>Physicians face a dilemma when deciding to withhold or continue OACs for people with AF having CA procedures (<a href="./references#CD013504-bbs2-0075" title="DeharoJC , SciaraffiaE , LeclercqC , AmaraW , DoeringM , BongiorniMG , et al. Perioperative management of antithrombotic treatment during implantation or revision of cardiac implantable electronic devices: the European Snapshot Survey on Procedural Routines for Electronic Device Implantation (ESS-PREDI). Europace2016;18(5):778-84.">Deharo 2016</a>; <a href="./references#CD013504-bbs2-0114" title="NascimentoT , BirnieDH , HealeyJS , VermaA , JozaJ , BernierML , et al. Managing novel oral anticoagulants in patients with atrial fibrillation undergoing device surgery: Canadian survey. Canadian Journal of Cardiology2014;30(2):231-6.">Nascimento 2014</a>). Interruption of OACs, although recommended by various practice guidelines, has been associated with negative outcomes (which include an increased risk of thromboembolism and device‐pocket haematoma), especially when bridging with heparin is used (<a href="./references#CD013504-bbs2-0088" title="GarwoodCL , KorkisB , GrandeD , HanniC , MorinA , MoserLR , et al. Anticoagulation bridge therapy in patients with atrial fibrillation: recent updates providing a rebalance of risk and benefit. Pharmacotherapy2017;37(6):712-24.">Garwood 2017</a>; <a href="./references#CD013504-bbs2-0095" title="HiraoK , AonumaK , KumagaiK , InoueK , KimuraM , MiyauchiY , et al. Effects and risks of heparin bridging and different modes of interruption/resumption of rivaroxaban on perioperative complications of catheter ablation for atrial fibrillation: another analysis of the JACRE-R registry. Circulation Journal2018;82(2):346-52.">Hirao 2018</a>). These complications can lead to a prolonged cessation of OACs, an increase in hospital stay, the need for surgery, and an increased risk of infection (<a href="./references#CD013504-bbs2-0084" title="EssebagV , VermaA , HealeyJS , KrahnAD , KalfonE , CoutuB , et al. Clinically significant pocket hematoma increases long-term risk of device infection: BRUISE CONTROL INFECTION Study. Journal of the American College of Cardiology2016;67(11):1300-8.">Essebag 2016</a>; <a href="./references#CD013504-bbs2-0100" title="KojimaT , FujiuK , FukumaN , MatsunagaH , OshimaT , MatsudaJ , et al. Periprocedural complications in patients undergoing catheter ablation of atrial fibrillation without discontinuation of a vitamin K antagonist and direct oral anticoagulants. Circulation Journal2018;82(6):1552-7.">Kojima 2018</a>; <a href="./references#CD013504-bbs2-0119" title="ProiettiR , PortoI , LeviM , LeoA , RussoV , KalfonE , et al. Risk of pocket hematoma in patients on chronic anticoagulation with warfarin undergoing electrophysiological device implantation: a comparison of different peri-operative management strategies. European Review for Medical and Pharmacological Sciences2015;19(8):1461-79.">Proietti 2015</a>). Therefore, uninterrupted OAC therapy has been recommended with evidence suggesting this to be a safe and feasible option (<a href="./references#CD013504-bbs2-0091" title="HaFJ , BarraS , BrownAJ , BegleyDA , GraceAA , AgarwalS . Continuous and minimally-interrupted direct oral anticoagulant are both safe compared with vitamin K antagonist for atrial fibrillation ablation: an updated meta-analysis. International Journal of Cardiology2018;262:51-6.">Ha 2018</a>; <a href="./references#CD013504-bbs2-0098" title="KaiserDW , StreurMM , NagarakantiR , WhalenSP , EllisCR . Continuous warfarin versus periprocedural dabigatran to reduce stroke and systemic embolism in patients undergoing catheter ablation for atrial fibrillation or left atrial flutter. Journal of Interventional Cardiac Electrophysiology2013;37(3):241-7.">Kaiser 2013</a>; <a href="./references#CD013504-bbs2-0101" title="KwakJJ , PakHN , JangJK , KimSK , ParkJH , ChoiJI , et al. Safety and convenience of continuous warfarin strategy during the periprocedural period in patients who underwent catheter ablation of atrial fibrillation. Journal of Cardiovascular Electrophysiology2010;21(6):620-5.">Kwak 2010</a>; <a href="./references#CD013504-bbs2-0139" title="ZhaoY , LuY , QinY . A meta-analysis of randomized controlled trials of uninterrupted periprocedural anticoagulation strategy in patients undergoing atrial fibrillation catheter ablation. International Journal of Cardiology2018;270:167-71.">Zhao 2018</a>). However, the risk of bleeding remains a concern when continuing OACs in people with AF going through CA procedures. </p> </section> <section id="CD013504-sec-0013"> <h3 class="title" id="CD013504-sec-0013">Why it is important to do this review</h3> <p>Anticoagulation management around procedures such as CA is of critical importance and must be dealt with carefully to minimise the risk of thromboembolic and bleeding complications. Recommendations from international guidelines concerning whether to interrupt or continue OAC therapy for people undergoing surgical procedures diverge. The 2017 Heart Rhythm Society/European Heart Rhythm Association/European Cardiac Arrhythmia Society/Asia Pacific Heart Rhythm Society/Latin American Society of Electrophysiology and Cardiac Stimulation (HRS/EHRA/ECAS/APHRS/SOLAECE) guideline stated a class I recommendation and a level A of evidence for performing the ablation procedure under uninterrupted anticoagulant therapy for people with AF on therapeutic doses of warfarin or dabigatran (<a href="./references#CD013504-bbs2-0069" title="CalkinsH , HindricksG , CappatoR , KimYH , SaadEB , AguinagaL , et al. 2017 HRS/EHRA/ECAS/APHRS/SOLAECE expert consensus statement on catheter and surgical ablation of atrial fibrillation: executive summary. Europace2018;20(1):157-208.">Calkins 2018b</a>). However, the American College of Chest Physicians (CHEST) guideline in 2018 provided a weak recommendation and low quality evidence on continuing VKAs, dabigatran, or rivaroxaban in people with AF who are planned for CA (<a href="./references#CD013504-bbs2-0105" title="LipGY , BanerjeeA , BorianiG , ChiangCE , FargoR , FreedmanB , et al. Antithrombotic therapy for atrial fibrillation: CHEST guideline and expert panel report. Chest2018;154(5):1121-201.">Lip 2018</a>). Moreover, several meta‐analyses and systematic reviews have explored the safety and efficacy of a single strategy (uninterrupted OAC therapy) around CA procedures, with most reviews including randomised controlled trials (RCTs) as well as controlled prospective studies (<a href="./references#CD013504-bbs2-0065" title="Bin AbdulhakAA , KhanAR , TleyjehIM , SpertusJA , SandersSU , SteigerwaltKE , et al. Safety and efficacy of interrupted dabigatran for peri-procedural anticoagulation in catheter ablation of atrial fibrillation: a systematic review and meta-analysis. Europace2013;15(10):1412-20.">Bin Abdulhak 2013</a>; <a href="./references#CD013504-bbs2-0070" title="CardosoR , KnijnikL , BhonsaleA , MillerJ , NasiG , RiveraM , et al. An updated meta-analysis of novel oral anticoagulants versus vitamin K antagonists for uninterrupted anticoagulation in atrial fibrillation catheter ablation. Heart Rhythm2018;15(1):107-15.">Cardoso 2018</a>; <a href="./references#CD013504-bbs2-0083" title="ElgendyAY , MahttaD , BarakatAF , AbuzaidA , MahmoudA , MentiasA , et al. Meta-analysis of safety and efficacy of uninterrupted non-vitamin K antagonist oral anticoagulants versus vitamin K antagonists for catheter ablation of atrial fibrillation. American Journal of Cardiology2017;120(10):1830-6.">Elgendy 2017</a>; <a href="./references#CD013504-bbs2-0086" title="GargJ , ChaudharyR , KrishnamoorthyP , ShahN , BozorgniaB , NataleA , et al. Safety and efficacy of uninterrupted periprocedural apixaban in patients undergoing atrial fibrillation catheter ablation: a metaanalysis of 1,057 patients. Journal of Atrial Fibrillation2016;8(6):1368.">Garg 2016</a>; <a href="./references#CD013504-bbs2-0123" title="RomeroJ , Cerrud-RodriguezRC , DiazJC , MichaudGF , TaverasJ , AlvizI , et al. Uninterrupted direct oral anticoagulants vs. uninterrupted vitamin K antagonists during catheter ablation of non-valvular atrial fibrillation: a systematic review and meta-analysis of randomized controlled trials. Europace2018;20(10):1612-20.">Romero 2018</a>; <a href="./references#CD013504-bbs2-0129" title="UkaigweA , ShresthaP , KarmacharyaP , HussainSK , SamiiS , GonzalezMD , et al. Meta-analysis of efficacy and safety of apixaban and uninterrupted apixaban therapy compared to vitamin K antagonists in patients undergoing catheter ablation for atrial fibrillation. Journal of Interventional Cardiac Electrophysiology2017;48(2):223-33.">Ukaigwe 2017</a>; <a href="./references#CD013504-bbs2-0130" title="VallakatiA , SharmaA , MadmaniM , ReddyM , KanmanthareddyA , GundaS , et al. Efficacy and safety of novel oral anticoagulants for atrial fibrillation ablation: an updated meta-analysis. Cardiology Therapy2016;5(1):85-100.">Vallakati 2016</a>; <a href="./references#CD013504-bbs2-0131" title="VamosM , CappatoR , MarchlinskiFE , NataleA , HohnloserSH . Efficacy and safety of rivaroxaban compared with vitamin K antagonists for peri-procedural anticoagulation in catheter ablation of atrial fibrillation: a systematic review and meta-analysis. Europace2016;17(12):1787-94.">Vamos 2016</a>; <a href="./references#CD013504-bbs2-0135" title="WuS , YangYM , ZhuJ , WanHB , WangJ , ZhangH , et al. Meta-analysis of efficacy and safety of new oral anticoagulants compared with uninterrupted vitamin K antagonists in patients undergoing catheter ablation for atrial fibrillation. American Journal of Cardiology2016;117(6):926-34.">Wu 2016</a>; <a href="./references#CD013504-bbs2-0138" title="ZhaoY , YangY , TangX , YuX , ZhangL , XiaoH , et al. New oral anticoagulants compared to warfarin for perioperative anticoagulation in patients undergoing atrial fibrillation catheter ablation: a meta-analysis of continuous or interrupted new oral anticoagulants during ablation compared to interrupted or continuous warfarin. Journal of Interventional Cardica Electrophysiology2017;48(3):267-82.">Zhao 2017</a>; <a href="./references#CD013504-bbs2-0139" title="ZhaoY , LuY , QinY . A meta-analysis of randomized controlled trials of uninterrupted periprocedural anticoagulation strategy in patients undergoing atrial fibrillation catheter ablation. International Journal of Cardiology2018;270:167-71.">Zhao 2018</a>). </p> <p>In recent years, several RCTs have explored the safety and efficacy of interrupted versus uninterrupted OAC therapy around procedures such as CA (<a href="./references#CD013504-bbs2-0110" title="NagaoT , SuzukiH , MatsunagaS , NishikawaY , HaradaK , MamiyaK , et al. Impact of periprocedural anticoagulation therapy on the incidence of silent stroke after atrial fibrillation ablation in patients receiving direct oral anticoagulants: uninterrupted vs. interrupted by one dose strategy. Europace2018;21(4):590-7.">Nagao 2018</a>; <a href="./references#CD013504-bbs2-0005" title="AonumaK . A prospective, multi-center, parallel-group comparison study to evaluate safety and efficacy of dabigatran during the perioperative period in patients with non-valvular atrial fibrillation who undergo the catheter ablation compared to warfarin. upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000015311 (first received 14 February 2014. GoyaM , NogamiA , HiraoK , AonumaK . Ablation perioperative dabigatran in use envisioning in Japan: the ABRIDGE-J study design. Journal of Cardiology2016;68(3):236-40. [DOI: 10.1016/j.jjcc.2015.10.003]]NogamiA , HaradaT , Sekiguchi Y, Otani R, YoshidaY , Yoshida K, et al. Safety and efficacy of minimally interrupted dabigatran vs uninterrupted warfarin therapy in adults undergoing atrial fibrillation catheter ablation: a randomized clinical trial. JAMA Network Open2019;2(4):15. [DOI: 10.1001/jamanetworkopen.2019.1994]NogamiA , HaradaT , YoshidaY , NakanoY , GoyaM , OrigasaH , et al. Clinical benefit of minimally-interrupted dabigatran versus uninterrupted warfarin for catheter ablation of atrial fibrillation: a prospective randomized multicenter trial. Circulation2017;136:e450. NogamiA , HaradaT , YoshidaY , NakanoY , GoyaM , OrigasaH , et al. Clinical benefit of minimally-interrupted dabigatran versus uninterrupted warfarin for catheter ablation of atrial fibrillation: a prospective randomized multicenter trial. Circulation2017;136(24):E450. [DOI: 10.1161/CIR.0000000000000546]UMIN000013129. A prospective, multi-center, parallel-group comparison study to evaluate safety and efficacy of dabigatran during the perioperative period in patients with non-valvular atrial fibrillation who undergo the catheter ablation compared to warfarin. www.who.int/trialsearch/Trial2.aspx?TrialID=JPRN-UMIN000013129 (first received 1 March 2014). ">Nogami 2019</a>; <a href="./references#CD013504-bbs2-0006" title="ReynoldsMR , AllisonJS , NataleA , WeisbergIL , EllenbogenKA , RichardsM , et al. Apixaban evaluation of interrupted or uninterrupted anticoagulation for ablation of atrial fibrillation. clinicaltrials.gov/show/NCT02608099 (first received 18 November 2015). ReynoldsMR , AllisonJS , NataleA , WeisbergIL , EllenbogenKA , RichardsM , et al. A prospective randomized trial of apixaban dosing during atrial fibrillation ablation: the AEIOU trial. JACC Clinical Electrophysiology2018;4(5):580-8. [DOI: 10.1016/j.jacep.2017.11.005]">Reynolds 2018</a>; <a href="./references#CD013504-bbs2-0111" title="NakamuraK , NaitoS , SasakiT , TakeY , MinamiK , KitagawaY , et al. Uninterrupted vs. interrupted periprocedural direct oral anticoagulants for catheter ablation of atrial fibrillation: a prospective randomized single-centre study on post-ablation thrombo-embolic and haemorrhagic events. Europace2018;21(2):259-67.">Nakamura 2018</a>). The COMPARE trial showed a significantly lower risk of periprocedural symptomatic thromboembolic events in the uninterrupted VKA group compared to the interrupted group  (<a href="./references#CD013504-bbs2-0079" title="Di BiaseL , BurkhardtJD , SantangeliP , MohantyP , SanchezJE , HortonR , et al. Periprocedural stroke and bleeding complications in patients undergoing catheter ablation of atrial fibrillation with different anticoagulation management: results from the Role of Coumadin in Preventing Thromboembolism in Atrial Fibrillation (AF) Patients Undergoing Catheter Ablation (COMPARE) randomized trial. Circulation2014;129(25):2638-44.">Di Biase 2014</a>). The  uninterrupted VKA group was also associated with a higher risk of bleeding possibly due to bridge therapy. The evidence on DOACs is still emerging; so far, studies have shown a decreased risk of thromboembolic events when DOACs were uninterrupted (<a href="./references#CD013504-bbs2-0111" title="NakamuraK , NaitoS , SasakiT , TakeY , MinamiK , KitagawaY , et al. Uninterrupted vs. interrupted periprocedural direct oral anticoagulants for catheter ablation of atrial fibrillation: a prospective randomized single-centre study on post-ablation thrombo-embolic and haemorrhagic events. Europace2018;21(2):259-67.">Nakamura 2018</a>; <a href="./references#CD013504-bbs2-0112" title="NakamuraR , OkishigeK , ShigetaT , NishimuraT , KurabayashiM , YamauchiY , et al. Clinical comparative study regarding interrupted and uninterrupted dabigatran therapy during perioperative periods of cryoballoon ablation for paroxysmal atrial fibrillation. Journal of Cardiology2019;74(2):150-5.">Nakamura 2019a</a>; <a href="./references#CD013504-bbs2-0113" title="NakamuraK , NaitoS , SasakiT , TakeY , MinamiK , KitagawaY , et al. Uninterrupted vs. interrupted periprocedural direct oral anticoagulants for catheter ablation of atrial fibrillation: a prospective randomized single-centre study on post-ablation thrombo-embolic and haemorrhagic events. Europace2019;21(2):259-67.">Nakamura 2019b</a>), or minimally interrupted (<a href="./references#CD013504-bbs2-0110" title="NagaoT , SuzukiH , MatsunagaS , NishikawaY , HaradaK , MamiyaK , et al. Impact of periprocedural anticoagulation therapy on the incidence of silent stroke after atrial fibrillation ablation in patients receiving direct oral anticoagulants: uninterrupted vs. interrupted by one dose strategy. Europace2018;21(4):590-7.">Nagao 2018</a>; <a href="./references#CD013504-bbs2-0005" title="AonumaK . A prospective, multi-center, parallel-group comparison study to evaluate safety and efficacy of dabigatran during the perioperative period in patients with non-valvular atrial fibrillation who undergo the catheter ablation compared to warfarin. upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000015311 (first received 14 February 2014. GoyaM , NogamiA , HiraoK , AonumaK . Ablation perioperative dabigatran in use envisioning in Japan: the ABRIDGE-J study design. Journal of Cardiology2016;68(3):236-40. [DOI: 10.1016/j.jjcc.2015.10.003]]NogamiA , HaradaT , Sekiguchi Y, Otani R, YoshidaY , Yoshida K, et al. Safety and efficacy of minimally interrupted dabigatran vs uninterrupted warfarin therapy in adults undergoing atrial fibrillation catheter ablation: a randomized clinical trial. JAMA Network Open2019;2(4):15. [DOI: 10.1001/jamanetworkopen.2019.1994]NogamiA , HaradaT , YoshidaY , NakanoY , GoyaM , OrigasaH , et al. Clinical benefit of minimally-interrupted dabigatran versus uninterrupted warfarin for catheter ablation of atrial fibrillation: a prospective randomized multicenter trial. Circulation2017;136:e450. NogamiA , HaradaT , YoshidaY , NakanoY , GoyaM , OrigasaH , et al. Clinical benefit of minimally-interrupted dabigatran versus uninterrupted warfarin for catheter ablation of atrial fibrillation: a prospective randomized multicenter trial. Circulation2017;136(24):E450. [DOI: 10.1161/CIR.0000000000000546]UMIN000013129. A prospective, multi-center, parallel-group comparison study to evaluate safety and efficacy of dabigatran during the perioperative period in patients with non-valvular atrial fibrillation who undergo the catheter ablation compared to warfarin. www.who.int/trialsearch/Trial2.aspx?TrialID=JPRN-UMIN000013129 (first received 1 March 2014). ">Nogami 2019</a>; <a href="./references#CD013504-bbs2-0006" title="ReynoldsMR , AllisonJS , NataleA , WeisbergIL , EllenbogenKA , RichardsM , et al. Apixaban evaluation of interrupted or uninterrupted anticoagulation for ablation of atrial fibrillation. clinicaltrials.gov/show/NCT02608099 (first received 18 November 2015). ReynoldsMR , AllisonJS , NataleA , WeisbergIL , EllenbogenKA , RichardsM , et al. A prospective randomized trial of apixaban dosing during atrial fibrillation ablation: the AEIOU trial. JACC Clinical Electrophysiology2018;4(5):580-8. [DOI: 10.1016/j.jacep.2017.11.005]">Reynolds 2018</a>; <a href="./references#CD013504-bbs2-0012" title="YuHT , ShimJ , ParkJ , KimTH , UhmJS , KimJY , et al. When is it appropriate to stop non-vitamin K antagonist oral anticoagulants before catheter ablation of atrial fibrillation? A multi-center prospective randomized study. Europace2019;21:ii804. YuHT , ShimJ , ParkJ , KimTH , UhmJS , KimJY , et al. When is it appropriate to stop non-vitamin K antagonist oral anticoagulants before catheter ablation of atrial fibrillation? A multicentre prospective randomized study. European Heart Journal2019;40(19):1531-7. [DOI: 10.1093/eurheartj/ehy870]">Yu 2019</a>), with no significant increase in the risk of major bleeding. </p> <p>Since the current uncertain status of the evidence along with the publication of several new studies merits a systematic review and meta‐analysis, we planned to undertake this review to investigate the efficacy and safety of interrupted versus uninterrupted preprocedural anticoagulant therapy. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD013504-sec-0014" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD013504-sec-0014"></div> <p>To systematically compare the efficacy and harms of interrupted versus uninterrupted anticoagulation therapy for catheter ablation (CA) in adults with arrhythmias. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD013504-sec-0015" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD013504-sec-0015"></div> <section id="CD013504-sec-0016"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD013504-sec-0017"> <h4 class="title">Types of studies</h4> <p>We included RCTs that compared the efficacy and harms of uninterrupted anticoagulation with any modality of interruption with or without heparin bridging for CA in adults aged 18 years or older with arrhythmia. We included studies published as full‐text, abstract only, and those that were not published. We planned to include cluster‐randomised trials; however, we did not identify any such trials. We did not consider cross‐over trials for inclusion due to the nature of the intervention of our review. </p> </section> <section id="CD013504-sec-0018"> <h4 class="title">Types of participants</h4> <p>We included trials of people aged 18 years and older with arrhythmia – including AF, atrial flutter, or ventricular tachycardia – who were receiving long‐term treatment with OACs (VKAs or DOACs) and were undergoing CA. In the protocol, we planned to contact study authors if only a subset of eligible participants was presented in a trial and if authors were unwilling or unable to provide additional information, we planned to include studies in which at least 70% of included participants were eligible in our review (<a href="./references#CD013504-bbs2-0141" title="Bawazeer GA, Alkofide H, Alsharafi A, Babakr N, Altorkistani A, Kashour T, et al. Interrupted versus uninterrupted anticoagulation therapy for catheter ablation in adults with arrhythmias. Cochrane Database of Systematic Reviews2019, Issue 12. Art. No: CD013504. [DOI: 10.1002/14651858.CD013504]">Bawazeer 2019</a>). We planned to perform a sensitivity analysis in which such trials were removed from the primary analysis. However, we did not encounter any such trials. </p> </section> <section id="CD013504-sec-0019"> <h4 class="title">Types of interventions</h4> <p>We included all comparisons of interrupted and uninterrupted oral anticoagulation (VKAs or DOACs), including any modalities of interruption (complete interruption with or without bridge therapy, minimal interruption of anticoagulants, or any other modality). </p> </section> <section id="CD013504-sec-0020"> <h4 class="title">Types of outcome measures</h4> <p>We extracted definitions and measurement of clinical events (e.g. stroke, thromboembolic events, bleeding) according to the individual trials. We excluded studies that did not meet inclusion criteria. We contacted the authors for further information on study outcomes and characteristics. We did not encounter any trials that measured the outcomes but did not report it. We encountered one study that reported one of the outcomes (minor bleeding) in an unusable format within a composite point but not separately (<a href="./references#CD013504-bbs2-0005" title="AonumaK . A prospective, multi-center, parallel-group comparison study to evaluate safety and efficacy of dabigatran during the perioperative period in patients with non-valvular atrial fibrillation who undergo the catheter ablation compared to warfarin. upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000015311 (first received 14 February 2014. GoyaM , NogamiA , HiraoK , AonumaK . Ablation perioperative dabigatran in use envisioning in Japan: the ABRIDGE-J study design. Journal of Cardiology2016;68(3):236-40. [DOI: 10.1016/j.jjcc.2015.10.003]]NogamiA , HaradaT , Sekiguchi Y, Otani R, YoshidaY , Yoshida K, et al. Safety and efficacy of minimally interrupted dabigatran vs uninterrupted warfarin therapy in adults undergoing atrial fibrillation catheter ablation: a randomized clinical trial. JAMA Network Open2019;2(4):15. [DOI: 10.1001/jamanetworkopen.2019.1994]NogamiA , HaradaT , YoshidaY , NakanoY , GoyaM , OrigasaH , et al. Clinical benefit of minimally-interrupted dabigatran versus uninterrupted warfarin for catheter ablation of atrial fibrillation: a prospective randomized multicenter trial. Circulation2017;136:e450. NogamiA , HaradaT , YoshidaY , NakanoY , GoyaM , OrigasaH , et al. Clinical benefit of minimally-interrupted dabigatran versus uninterrupted warfarin for catheter ablation of atrial fibrillation: a prospective randomized multicenter trial. Circulation2017;136(24):E450. [DOI: 10.1161/CIR.0000000000000546]UMIN000013129. A prospective, multi-center, parallel-group comparison study to evaluate safety and efficacy of dabigatran during the perioperative period in patients with non-valvular atrial fibrillation who undergo the catheter ablation compared to warfarin. www.who.int/trialsearch/Trial2.aspx?TrialID=JPRN-UMIN000013129 (first received 1 March 2014). ">Nogami 2019</a>). We contacted the author for the results of minor bleeding. All studies were included in the final analysis in one or more of the outcomes. We assessed study outcomes at the longest follow‐up point. </p> <section id="CD013504-sec-0021"> <h5 class="title">Primary outcomes</h5> <p> <ul id="CD013504-list-0001"> <li> <p>Thromboembolic events (stroke or systemic embolism).</p> </li> <li> <p>Major bleeding, defined as bleeding requiring intervention (or as reported in included trials). </p> </li> </ul> </p> </section> <section id="CD013504-sec-0022"> <h5 class="title">Secondary outcomes</h5> <p> <ul id="CD013504-list-0002"> <li> <p>Composite endpoint of thromboembolic events (stroke or systemic embolism), major bleeding events, and all‐cause mortality. </p> </li> <li> <p>Minor bleeding, defined as bleeding not requiring intervention.</p> </li> <li> <p>Cardiovascular mortality.</p> </li> <li> <p>All‐cause mortality.</p> </li> <li> <p>Asymptomatic thromboembolism as described by studies.</p> </li> <li> <p>Patient QoL as measured by any validated health‐related QoL instruments (e.g. Seattle Angina Questionnaire (<a href="./references#CD013504-bbs2-0136" title="WyrwichKW , SpertusJA , KroenkeK , TierneyWM , BabuAN , WolinskyFD , et al. Clinically important differences in health status for patients with heart disease: an expert consensus panel report. American Heart Journal2014;147(4):615-22.">Wyrwich 2014</a>), 36‐item Short Form Health Survey (SF‐36) (<a href="./references#CD013504-bbs2-0132" title="WareJE , SherbourneCD . The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Medical Care1992;30(6):473-83.">Ware 1992</a>), EuroQOL/EQ‐5D (<a href="./references#CD013504-bbs2-0060" title="BalestroniG , BertolottiG . EuroQol-5D (EQ-5D): an instrument for measuring quality of life. Monaldi Archives for Chest Disease2012;78(3):155-9.">Balestroni 2012</a>), or participant's subjective perception of improvement (yes or no) as reported by the study authors). If we are unable to pool data on QoL due to use of different measurements, we included them in a narrative form. </p> </li> <li> <p>Economic costs (if data on economic cost could not be pooled, we included them in a narrative form). </p> </li> <li> <p>Length of hospital stay.</p> </li> </ul> </p> </section> </section> </section> <section id="CD013504-sec-0023"> <h3 class="title">Search methods for identification of studies</h3> <section id="CD013504-sec-0024"> <h4 class="title">Electronic searches</h4> <p>We searched the following electronic databases on 5 January 2021: </p> <p> <ul id="CD013504-list-0003"> <li> <p>Cochrane Central Register of Controlled Trials (CENTRAL) (Cochrane Library 2020, Issue 1); </p> </li> <li> <p>Epub Ahead of Print, In‐Process &amp; Other Non‐Indexed Citations, MEDLINE Daily and MEDLINE (Ovid, 1946 to 4 January 2021); </p> </li> <li> <p>Embase (Ovid, 1980 to week 53, 2021);</p> </li> <li> <p>Science Citation Index Expanded (SCI‐E) on the Web of Science (Clarivate Analytics, 1900 to 5 January 2021). </p> </li> </ul> </p> <p>The search strategies are presented in <a href="http://Appendix 1" target="_blank">Appendix 1</a>. We applied the Cochrane sensitivity‐maximising RCT filter (<a href="./references#CD013504-bbs2-0103" title="LefebvreC , ManheimerE , GlanvilleJ . Chapter 6: Searching for studies. In: Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from training.cochrane.org/handbook/archive/v5.1/.">Lefebvre 2011</a>) to MEDLINE (Ovid) and adaptations of it to the other databases, except CENTRAL. We imposed no restrictions on language or publication status. </p> <p>To identify ongoing or unpublished trials, we searched the following clinical trials registers on 29 May 2021:  </p> <p> <ul id="CD013504-list-0004"> <li> <p>World Health Organization (WHO) International Clinical Trials Registry Platform (<a href="http://www.who.int/ictrp/en" target="_blank">www.who.int/ictrp/en</a>); </p> </li> <li> <p>ClinicalTrials.gov (<a href="http://clinicaltrials.gov" target="_blank">clinicaltrials.gov</a>); </p> </li> <li> <p>Clinical Trials Register EU (<a href="http://www.clinicaltrialsregister.eu" target="_blank">www.clinicaltrialsregister.eu</a>). </p> </li> </ul> </p> </section> <section id="CD013504-sec-0025"> <h4 class="title">Searching other resources</h4> <p>We handsearched reference lists of included trials and reviews on the topic of management of OACs around ablation in arrhythmia. We performed backwards and forwards citation analysis on all included studies to identify other potentially relevant studies. As we did not encounter any ongoing clinical trials through searching trials registries, we did not contact researchers and<b> </b>pharmaceutical companies who produced anticoagulant drugs to request information on any unpublished trials. We will consider this in the update of this review. We planned to examine any relevant retraction statements and errata for included studies; however, we identified neither.  </p> </section> </section> <section id="CD013504-sec-0026"> <h3 class="title" id="CD013504-sec-0026">Data collection and analysis</h3> <p>We performed the review and meta‐analysis according to the recommendations in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD013504-bbs2-0092" title="HigginsJP , DeeksJJ . Chapter 7: Selecting studies and collecting data. In: Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from training.cochrane.org/handbook/archive/v5.1/.">Higgins 2011</a>). We included all eligible trials in the analysis, regardless of publication status. </p> <section id="CD013504-sec-0027"> <h4 class="title">Selection of studies</h4> <p>Three review authors (AAA, NOB, AMA) independently screened titles and abstracts of all the potential studies and coded them as 'retrieve' (eligible or potentially eligible/unclear) or 'do not retrieve'. We retrieved the full‐text publications and three review authors (AAA, NOB, AMA) independently screened these studies for inclusion, and identified and recorded reasons for exclusion of the ineligible studies. We resolved any disagreements through discussion or a fourth review author (GB or HK) arbitrated any disagreement. <a href="#CD013504-fig-0001">Figure 1</a> summarises studies flow and search processes. We excluded duplicates and collated multiple reports of the same study, so that each study, rather than each report, was the unit of interest in the review. We used a standardised process using COVIDENCE to extract information. We recorded the selection process in sufficient detail to complete a PRISMA flow diagram and <a href="./references#CD013504-sec-0120" title="">Characteristics of excluded studies</a> table (<a href="./references#CD013504-bbs2-0104" title="LiberatiA , AltmanDG , TetzlaffJ , MulrowC , GotzschePC , IoannidisJP , et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. PLoS Medicine2009;6(7):e1000100.">Liberati 2009</a>). </p> <div class="figure" id="CD013504-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="original image" data-id="CD013504-fig-0001" src="/cdsr/doi/10.1002/14651858.CD013504.pub2/media/CDSR/CD013504/image_n/nCD013504-FIG-01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"></div> </div> </section> <section id="CD013504-sec-0028"> <h4 class="title">Data extraction and management</h4> <p>Three review authors (AAA, NOB, AMA)  independently extracted study characteristics twice for each trial and recorded the information using a data collection form for study characteristics and outcome data that had been piloted on one study in the review. We extracted the following study characteristics. </p> <p> <ul id="CD013504-list-0005"> <li> <p>Methods: study design, total duration of study, number of centres and location, study setting, and study date. </p> </li> <li> <p>Participants: number of participants in each treatment group, number randomised, number lost to follow‐up/withdrawn, number analysed, mean age, age range, gender, the type of arrhythmia, comorbidities, CHADS2 or CHA2DS2VASc score, bleeding risk (e.g. HAS‐BLED (Hypertension. Abnormal renal and liver function. Stroke. Bleeding) score or as reported in individual trials), inclusion criteria, and exclusion criteria. </p> </li> <li> <p>Interventions: generic name and dose(s) of OAC for both the intervention and comparison, concomitant medications, excluded medications, duration of anticoagulant therapy in the trial, intensity of anticoagulation dose‐adjusted using the prothrombin time ratio (PTR) or INR and adherence to anticoagulant treatment, time of interruption of the anticoagulants prior to the procedure, procedure type, device type, heparin therapy (intraprocedural or as bridge therapy), time and strategy of resumption of OAC after the procedure, and duration of follow‐up. </p> </li> <li> <p>Outcomes: we collected data on planned and reported outcomes in each trial.</p> </li> <li> <p>Funding and notable conflicts of interest of trial authors.</p> </li> </ul> </p> <p>Three review authors (AAA, NOB, AMA) independently extracted outcome data from the included studies. We resolved disagreements by consensus or by involving a fourth review author (GAB or HAK). One review author (AAA)  transferred the data into Review Manager 5 (<a href="./references#CD013504-bbs2-0122" title="Nordic Cochrane Centre, The Cochrane CollaborationReview Manager (RevMan). Version 5.3. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2014.">Review Manager 2014</a>). The other two review authors (NOB, AMA)  double‐checked entered data by comparing the data presented in the systematic review with the data extraction form. We contacted the lead authors for three included trials for further clarification on study outcomes and definitions (<a href="./references#CD013504-bbs2-0002" title='Di BiaseL , BurkhardtJD , SantangeliP , MohantyP , SanchezJ , BaiR , et al. Periprocedural strokes and anticoagulation management during AF ablation: results from the "Compare" randomized multicenter trial. Circulation2013;128:A14307. Di BiaseL , BurkhardtJD , SantangeliP , MohantyP , SanchezJ , BaiR , et al. Silent thromboembolic lesions following catheter ablation for atrial fibrillation using radiofrequency energy: results from a sub-study of the "compare" randomized trial. Circulation2013;128(22 Suppl 1):A14293. Di BiaseL , BurkhardtJD , SantangeliP , MohantyP , SanchezJ , HortonR , et al. Periprocedural stroke and bleeding complications in patients undergoing catheter ablation of atrial fibrillation with different anticoagulation management: results from the "compare" randomized trial. Heart Rhythm2013;10(9):1411. Di BiaseL , BurkhardtJD , SantangeliP , MohantyP , SanchezJE , HortonR , et al. Periprocedural stroke and bleeding complications in patients undergoing catheter ablation of atrial fibrillation with different anticoagulation management: results from the role of coumadin in preventing thromboembolism in atrial fibrillation (AF) patients undergoing catheter ablation (COMPARE) randomized trial. Circulation2014;129(25):2638-44. [DOI: 10.1161/circulationaha.113.006426]NCT01006876. Role of coumadin in preventing thromboembolism in atrial fibrillation (AF) patients undergoing catheter ablation. clinicaltrials.gov/ct2/show/NCT01006876 (first received 3 November 2009). '>Di Biase 2014</a>; <a href="./references#CD013504-bbs2-0007" title="TabishH , ShahzadK . Anticoagulation safety window among elderly Chinese patients with atrial fibrillation catheter ablation. Journal of the Saudi Heart Association2010;22(2):99-100. [DOI: 10.1016/j.jsha.2010.02.325]">Tabish 2010</a>; <a href="./references#CD013504-bbs2-0010" title="YohM , TakagiM , YoshioT , TakahashiH , ShiojimaI . AP19-00329. Safety and efficacy of uninterrupted and interrupted periprocedural direct oral anticoagulants in patients undergoing radiofrequency catheter ablation for atrial fibrillation. Journal of Arrhythmia2019;35(S1):134. [DOI: 10.1002/joa3.12267]">Yoh 2019</a>). </p> </section> <section id="CD013504-sec-0029"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>Three review authors (AAA, NOB, AMA) independently assessed the risk of bias for each study using the criteria outlined in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD013504-bbs2-0093" title="HigginsJP , AltmanDG , SterneJA . Chapter 8: Assessing risk of bias in included studies. In: Higgins JP, Churchill R, Chandler J, Cumpston MS, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.2.0 (updated June 2017). Cochrane, 2017. Available from training.cochrane.org/handbook/archive/v5.2.">Higgins 2017</a>). We resolved any disagreements by discussion or by involving a third review author (GAB or HAK). We assessed the risk of bias according to the following domains. </p> <p> <ul id="CD013504-list-0006"> <li> <p>Random sequence generation.</p> </li> <li> <p>Allocation concealment.</p> </li> <li> <p>Blinding of participants and personnel.</p> </li> <li> <p>Blinding of outcome assessment.</p> </li> <li> <p>Incomplete outcome data.</p> </li> <li> <p>Selective outcome reporting.</p> </li> </ul> </p> <p>For each of the domains, we rated each study at high, low, or unclear risk of bias. We provided a quote from the study report, together with a justification for our judgement, in the risk of bias table. We summarised the risk of bias judgements across different studies for each of the domains listed. Where information on the risk of bias related to unpublished data or correspondence with a study author, we noted this in the risk of bias table. When considering treatment effects, we took into account the risk of bias for the studies that contributed to that outcome. We did not encounter any cluster‐RCT, however, for any potential future updates, we will use recommendations from the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD013504-bbs2-0093" title="HigginsJP , AltmanDG , SterneJA . Chapter 8: Assessing risk of bias in included studies. In: Higgins JP, Churchill R, Chandler J, Cumpston MS, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.2.0 (updated June 2017). Cochrane, 2017. Available from training.cochrane.org/handbook/archive/v5.2.">Higgins 2017</a>). We will consider additional bias arising from the following: randomisation taking place at the cluster level; recruitment of participants after cluster‐level treatment allocation is known, and missing cluster‐level outcome data (<a href="./references#CD013504-bbs2-0094" title="HigginsJP , EldridgeS , Li T (editors). Chapter 4: Searching for and selecting studies. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.0 (updated July 2019). Cochrane, 2019. Available from training.cochrane.org/handbook/archive/v6.">Higgins 2019</a>). </p> </section> <section id="CD013504-sec-0030"> <h4 class="title">Measures of treatment effect</h4> <p>We presented dichotomous outcomes as risk ratios (RRs) with 95% CIs. We used intention‐to‐treat (ITT) analysis to assess study outcomes. However, in cases where the method of analysis was not specified or followed per‐protocol analysis, we used the number randomised as the denominator (for dichotomous outcomes) according to the ITT analysis. We planned to extract continuous data using mean difference (MD) with standard deviation from each trial to calculate the average MD with 95% CIs. In cases where studies used different scales to measure the same continuous outcome, we planned to use the standardises mean difference (SMD) with 95% CI.  However, we did not encounter studies with continuous outcomes. </p> </section> <section id="CD013504-sec-0031"> <h4 class="title">Unit of analysis issues</h4> <p>We did not encounter a unit of analysis issues in the included studies. We planned for cluster‐RCTs to use the recommendation from the <i>Cochrane Handbook</i> and ensure that the adequate sample size is calculated using the intra‐cluster correlation coefficient (<a href="./references#CD013504-bbs2-0094" title="HigginsJP , EldridgeS , Li T (editors). Chapter 4: Searching for and selecting studies. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.0 (updated July 2019). Cochrane, 2019. Available from training.cochrane.org/handbook/archive/v6.">Higgins 2019</a>). However, we did not identify any cluster‐RCTs. We did include one study (<a href="./references#CD013504-bbs2-0010" title="YohM , TakagiM , YoshioT , TakahashiH , ShiojimaI . AP19-00329. Safety and efficacy of uninterrupted and interrupted periprocedural direct oral anticoagulants in patients undergoing radiofrequency catheter ablation for atrial fibrillation. Journal of Arrhythmia2019;35(S1):134. [DOI: 10.1002/joa3.12267]">Yoh 2019</a>) that had two arms which we combined as a single comparison for the main analysis. None of the included studies had multiple time points; hence all data were considered for the follow‐up period specified in each trial. To investigate the effect of combining the multiple arms or using only the longest follow‐up period, we planned to conduct a subgroup analysis; but we did not have an adequate number of studies (at least 10 studies) to perform such analysis (<a href="./references#CD013504-bbs2-0074" title="DeeksJJ , HigginsJP , AltmanDG . Chapter 10: Analysing data and undertaking meta-analyses. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.2 (updated February 2021). Cochrane, 2021. Available from training.cochrane.org/handbook.">Deeks 2021</a>).  </p> </section> <section id="CD013504-sec-0032"> <h4 class="title">Dealing with missing data</h4> <p>We contacted the lead authors for three studies for further clarification on outcomes and definitions as these trials were published as abstract only (<a href="./references#CD013504-bbs2-0002" title='Di BiaseL , BurkhardtJD , SantangeliP , MohantyP , SanchezJ , BaiR , et al. Periprocedural strokes and anticoagulation management during AF ablation: results from the "Compare" randomized multicenter trial. Circulation2013;128:A14307. Di BiaseL , BurkhardtJD , SantangeliP , MohantyP , SanchezJ , BaiR , et al. Silent thromboembolic lesions following catheter ablation for atrial fibrillation using radiofrequency energy: results from a sub-study of the "compare" randomized trial. Circulation2013;128(22 Suppl 1):A14293. Di BiaseL , BurkhardtJD , SantangeliP , MohantyP , SanchezJ , HortonR , et al. Periprocedural stroke and bleeding complications in patients undergoing catheter ablation of atrial fibrillation with different anticoagulation management: results from the "compare" randomized trial. Heart Rhythm2013;10(9):1411. Di BiaseL , BurkhardtJD , SantangeliP , MohantyP , SanchezJE , HortonR , et al. Periprocedural stroke and bleeding complications in patients undergoing catheter ablation of atrial fibrillation with different anticoagulation management: results from the role of coumadin in preventing thromboembolism in atrial fibrillation (AF) patients undergoing catheter ablation (COMPARE) randomized trial. Circulation2014;129(25):2638-44. [DOI: 10.1161/circulationaha.113.006426]NCT01006876. Role of coumadin in preventing thromboembolism in atrial fibrillation (AF) patients undergoing catheter ablation. clinicaltrials.gov/ct2/show/NCT01006876 (first received 3 November 2009). '>Di Biase 2014</a>; <a href="./references#CD013504-bbs2-0007" title="TabishH , ShahzadK . Anticoagulation safety window among elderly Chinese patients with atrial fibrillation catheter ablation. Journal of the Saudi Heart Association2010;22(2):99-100. [DOI: 10.1016/j.jsha.2010.02.325]">Tabish 2010</a>; <a href="./references#CD013504-bbs2-0010" title="YohM , TakagiM , YoshioT , TakahashiH , ShiojimaI . AP19-00329. Safety and efficacy of uninterrupted and interrupted periprocedural direct oral anticoagulants in patients undergoing radiofrequency catheter ablation for atrial fibrillation. Journal of Arrhythmia2019;35(S1):134. [DOI: 10.1002/joa3.12267]">Yoh 2019</a>). </p> </section> <section id="CD013504-sec-0033"> <h4 class="title">Assessment of heterogeneity</h4> <p>We visually inspected forest plots for the direction and magnitude of effects and the degree of overlap between CIs. We also used the P value from the Chi<sup>2</sup> test and measured the heterogeneity using the I<sup>2</sup> statistic (percentage of total variation across studies due to heterogeneity). </p> <p>We used the following guidelines for interpreting the I<sup>2</sup> value (<a href="./references#CD013504-bbs2-0073" title="DeeksJJ , HigginsJP , AltmanDG . Chapter 9: Analysing data and undertaking meta-analyses. In: Higgins JP, Churchill R, Chandler J, Cumpston MS, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.2.0 (updated June 2017). Cochrane, 2017. Available from training.cochrane.org/handbook/archive/v5.2.">Deeks 2017</a>). </p> <p> <ul id="CD013504-list-0007"> <li> <p>0% to 40%: might not be important.</p> </li> <li> <p>30% to 60%: may indicate moderate heterogeneity.</p> </li> <li> <p>50% to 90%: may indicate substantial heterogeneity.</p> </li> <li> <p>75% to 100%: indicates considerable heterogeneity.</p> </li> </ul> </p> <p>When we identified substantial or considerable heterogeneity (I<sup>2</sup> greater than 50%), we reported and explored possible causes by prespecified subgroup analysis. </p> </section> <section id="CD013504-sec-0034"> <h4 class="title">Assessment of reporting biases</h4> <p>Our meta‐analysis included fewer than 10 trials in each specified outcome and a funnel plot was not reported. </p> </section> <section id="CD013504-sec-0035"> <h4 class="title">Data synthesis</h4> <p>We undertook meta‐analyses by pooling the appropriate data using Review Manager 5 (<a href="./references#CD013504-bbs2-0122" title="Nordic Cochrane Centre, The Cochrane CollaborationReview Manager (RevMan). Version 5.3. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2014.">Review Manager 2014</a>). We used a random‐effects model to combine data as we expected some heterogeneity in the interventions and outcome definitions. We repeated the analysis using a fixed‐effect model as a sensitivity analysis. </p> </section> <section id="CD013504-sec-0036"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>We explored heterogeneity using subgroup analyses (when there were enough studies) according to the following parameters. </p> <p> <ul id="CD013504-list-0008"> <li> <p>Gender. Gender differences may influence outcomes.</p> </li> <li> <p>Age (less than 75 years, 75 years or more). Older people (aged 75 years or more) have a higher risk of bleeding and this outcome is pertinent to our review. </p> </li> <li> <p>Anticoagulation type (VKAs, DOAC). Different anticoagulants have differences in bleeding risk. </p> </li> <li> <p>Baseline risk of stroke using CHA2DS2‐VASc or CHADS2 (high risk greater than 2, low‐to‐moderate risk less than 2). The baseline risk of stroke (reported as CHA2DS2‐VASc or CHADS2) is very relevant to the review scope as a higher baseline risk population may have different outcomes during interruption of anticoagulant therapy prior to the procedure. </p> </li> <li> <p>The ablation surgical type (e.g. cryoablation, and radiofrequency hot balloon ablation or radiofrequency ablation). Ablation surgical strategies may have different stroke risks (<a href="./references#CD013504-bbs2-0080" title="Di BiaseL , KirchhofP , RomeroJ . Safety and efficacy of uninterrupted vs. minimally interrupted periprocedural direct oral anticoagulants for catheter ablation of atrial fibrillation: two sides of the same coin?Europace2019;21(2):181-3.">Di Biase 2019</a>), with radiofrequency CA being associated with endothelial denudation compared to cryoablation ablation and radiofrequency hot balloon. </p> </li> <li> <p>Interruption strategy (complete interruption versus minimal interruption, interruption with heparin versus no heparin). The strategy used in the interrupted arm may also influence the outcomes we were interested in (complete interruption versus minimal interruption); also, the use of heparin as bridge therapy during the interruption period may be associated with a higher risk of bleeding, which is relevant to the review objectives. </p> </li> </ul> </p> <p>We assessed subgroup differences using interaction tests available  in Review Manager 5 (<a href="./references#CD013504-bbs2-0122" title="Nordic Cochrane Centre, The Cochrane CollaborationReview Manager (RevMan). Version 5.3. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2014.">Review Manager 2014</a>). We reported the results of subgroup analyses quoting the Chi<sup>2</sup> statistic and P value.  In addition to the outcome major bleeding (10 studies), we decided to conduct a subgroup analysis for the outcome of thromboembolism despite the fact that only 6/12 studies reported events. We thought that such subgroup analysis may provide additional meaningful insights and may explain the heterogeneity identified in this outcome, hence better use of evidence in the clinical practice.  </p> </section> <section id="CD013504-sec-0037"> <h4 class="title">Sensitivity analysis</h4> <p>Depending on the studies obtained from the systematic search, we conducted the following sensitivity analyses for the primary outcomes. </p> <p> <ul id="CD013504-list-0009"> <li> <p>Excluding studies with a high risk of bias (this constitutes studies with low risk of bias for randomisation method, which is not at high risk of bias for any other domain). </p> </li> <li> <p>Only including studies where there were no conflicts of interest, for example regarding the funding source of trials. </p> </li> <li> <p>Testing the robustness of the results by repeating the analyses using different statistical models (fixed‐effect and random‐effects models). </p> </li> <li> <p>Restricting the analyses to published trials.</p> </li> <li> <p>Repeating the analysis excluding cluster‐RCTs.</p> </li> <li> <p>Repeating the analysis excluding studies in which not all included participants meet the review inclusion criteria. </p> </li> <li> <p>Repeating the analysis excluding studies with missing data that were thought to introduce serious bias. This included studies with an attrition rate of over 30%, or where differences in attrition between groups exceed 10%, or both. </p> </li> </ul> </p> <p>We were unable to perform sensitivity analysis based on excluding studies with a high risk of bias because all such studies were judged at high risk in one other domain. We did not encounter cluster‐RCTs, studies with participants not meeting the inclusion criteria nor studies with missing data. </p> </section> <section id="CD013504-sec-0038"> <h4 class="title">Summary of findings and assessment of the certainty of the evidence</h4> <p>We created <a href="./full#CD013504-tbl-0001">summary of findings Table 1</a> using the primary outcomes and the main secondary outcomes. We used the five GRADE considerations (study limitations, consistency of effect, imprecision, indirectness, and publication bias) to assess the certainty of the body of evidence as it related to the studies that contributed data to the meta‐analyses. We used methods and recommendations described in Chapter 12 of the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD013504-bbs2-0125" title="SchünemannHJ , OxmanAD , VistGE , HigginsJP , DeeksJJ , GlasziouP , et al. Chapter 12: Interpreting results and drawing conclusions. In: Higgins JP, Churchill R, Chandler J, Cumpston MS, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.2.0 (updated June 2017). Cochrane, 2017. Available from training.cochrane.org/handbook/archive/v5.2.">Schünemann 2017</a>), using GRADEpro GDT software (<a href="./references#CD013504-bbs2-0090" title="McMaster University (developed by Evidence Prime)GRADEpro GDT. Version accessed 3 December 2019. Hamilton (ON): McMaster University (developed by Evidence Prime), 2019. Available at gradepro.org.">GRADEpro GDT</a>). We justified all decisions to downgrade the certainty of the evidence using footnotes, and made comments to aid the reader's understanding of the review where necessary. Three review authors (AAA, NOB, AMA) independently judged the certainty of the evidence, with disagreements resolved by discussion or involving a fourth review author (GAB). Judgements were justified, documented, and incorporated into reporting of results for each outcome. We planned to extract study data, format our comparisons in data tables and prepared a summary of findings table before writing the results and conclusions of our review. When meta‐analysis was not possible, we presented the results as a narrative summary of findings table. </p> <p>The following is a list of outcomes included in the summary of findings tables.</p> <p>Primary outcomes.</p> <p> <ul id="CD013504-list-0010"> <li> <p>Thromboembolic events.</p> </li> <li> <p>Major bleeding.</p> </li> </ul> </p> <p>Secondary outcomes.</p> <p> <ul id="CD013504-list-0011"> <li> <p>Composite endpoint of thromboembolic events (stroke or systemic embolism), major bleeding events, and all‐cause mortality. </p> </li> <li> <p>Minor bleeding.</p> </li> <li> <p>All‐cause mortality.</p> </li> <li> <p>Asymptomatic thromboembolic events.</p> </li> </ul> </p> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD013504-sec-0039" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD013504-sec-0039"></div> <section id="CD013504-sec-0040"> <h3 class="title">Description of studies</h3> <p>We identified 12 RCTs (<a href="./references#CD013504-bbs2-0001" title="AndoM , IndenY , YoshidaY , SairakuA , YanagisawaS , SuzukiH , et al. Differences in prothrombotic response between the uninterrupted and interrupted apixaban therapies in patients undergoing cryoballoon ablation for paroxysmal atrial fibrillation: a randomized controlled study. Heart Vessels2019;34(9):1533-41. [DOI: 10.1007/s00380-019-01370-9]">Ando 2019</a>; <a href="./references#CD013504-bbs2-0002" title='Di BiaseL , BurkhardtJD , SantangeliP , MohantyP , SanchezJ , BaiR , et al. Periprocedural strokes and anticoagulation management during AF ablation: results from the "Compare" randomized multicenter trial. Circulation2013;128:A14307. Di BiaseL , BurkhardtJD , SantangeliP , MohantyP , SanchezJ , BaiR , et al. Silent thromboembolic lesions following catheter ablation for atrial fibrillation using radiofrequency energy: results from a sub-study of the "compare" randomized trial. Circulation2013;128(22 Suppl 1):A14293. Di BiaseL , BurkhardtJD , SantangeliP , MohantyP , SanchezJ , HortonR , et al. Periprocedural stroke and bleeding complications in patients undergoing catheter ablation of atrial fibrillation with different anticoagulation management: results from the "compare" randomized trial. Heart Rhythm2013;10(9):1411. Di BiaseL , BurkhardtJD , SantangeliP , MohantyP , SanchezJE , HortonR , et al. Periprocedural stroke and bleeding complications in patients undergoing catheter ablation of atrial fibrillation with different anticoagulation management: results from the role of coumadin in preventing thromboembolism in atrial fibrillation (AF) patients undergoing catheter ablation (COMPARE) randomized trial. Circulation2014;129(25):2638-44. [DOI: 10.1161/circulationaha.113.006426]NCT01006876. Role of coumadin in preventing thromboembolism in atrial fibrillation (AF) patients undergoing catheter ablation. clinicaltrials.gov/ct2/show/NCT01006876 (first received 3 November 2009). '>Di Biase 2014</a>; <a href="./references#CD013504-bbs2-0003" title="NagaoT , SuzukiH , MatsunagaS , NishikawaY , HaradaK , MamiyaK . Impact of periprocedural anticoagulation therapy on the incidence of silent stroke after atrial fibrillation ablation in patients receiving direct oral anticoagulants: uninterrupted vs. interrupted by one dose strategy. Europace2019;21(4):590-7. [DOI: 10.1093/europace/euy224]">Nagao 2019</a>; <a href="./references#CD013504-bbs2-0004" title="Nakamura K, Naito S, Sasaki T, Take Y, Minami K, Kitagawa Y, et al. Uninterrupted vs. interrupted periprocedural direct oral anticoagulants for catheter ablation of atrial fibrillation: a prospective randomized single-centre study on post-ablation thrombo-embolic and haemorrhagic events. Europace2019;21(2):259-67. [DOI: 10.1093/europace/euy148]NakamuraK , SasakiT , TakeY , FunabashiN , NaitoS . Uninterrupted vs. interrupted periprocedural direct oral anticoagulants for catheter ablation of atrial fibrillation: a prospective randomized study on post-ablation thromboembolic and hemorrhagic events. Circulation2018;138:2. ">Nakamura 2019</a>; <a href="./references#CD013504-bbs2-0005" title="AonumaK . A prospective, multi-center, parallel-group comparison study to evaluate safety and efficacy of dabigatran during the perioperative period in patients with non-valvular atrial fibrillation who undergo the catheter ablation compared to warfarin. upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000015311 (first received 14 February 2014. GoyaM , NogamiA , HiraoK , AonumaK . Ablation perioperative dabigatran in use envisioning in Japan: the ABRIDGE-J study design. Journal of Cardiology2016;68(3):236-40. [DOI: 10.1016/j.jjcc.2015.10.003]]NogamiA , HaradaT , Sekiguchi Y, Otani R, YoshidaY , Yoshida K, et al. Safety and efficacy of minimally interrupted dabigatran vs uninterrupted warfarin therapy in adults undergoing atrial fibrillation catheter ablation: a randomized clinical trial. JAMA Network Open2019;2(4):15. [DOI: 10.1001/jamanetworkopen.2019.1994]NogamiA , HaradaT , YoshidaY , NakanoY , GoyaM , OrigasaH , et al. Clinical benefit of minimally-interrupted dabigatran versus uninterrupted warfarin for catheter ablation of atrial fibrillation: a prospective randomized multicenter trial. Circulation2017;136:e450. NogamiA , HaradaT , YoshidaY , NakanoY , GoyaM , OrigasaH , et al. Clinical benefit of minimally-interrupted dabigatran versus uninterrupted warfarin for catheter ablation of atrial fibrillation: a prospective randomized multicenter trial. Circulation2017;136(24):E450. [DOI: 10.1161/CIR.0000000000000546]UMIN000013129. A prospective, multi-center, parallel-group comparison study to evaluate safety and efficacy of dabigatran during the perioperative period in patients with non-valvular atrial fibrillation who undergo the catheter ablation compared to warfarin. www.who.int/trialsearch/Trial2.aspx?TrialID=JPRN-UMIN000013129 (first received 1 March 2014). ">Nogami 2019</a>; <a href="./references#CD013504-bbs2-0006" title="ReynoldsMR , AllisonJS , NataleA , WeisbergIL , EllenbogenKA , RichardsM , et al. Apixaban evaluation of interrupted or uninterrupted anticoagulation for ablation of atrial fibrillation. clinicaltrials.gov/show/NCT02608099 (first received 18 November 2015). ReynoldsMR , AllisonJS , NataleA , WeisbergIL , EllenbogenKA , RichardsM , et al. A prospective randomized trial of apixaban dosing during atrial fibrillation ablation: the AEIOU trial. JACC Clinical Electrophysiology2018;4(5):580-8. [DOI: 10.1016/j.jacep.2017.11.005]">Reynolds 2018</a>; <a href="./references#CD013504-bbs2-0007" title="TabishH , ShahzadK . Anticoagulation safety window among elderly Chinese patients with atrial fibrillation catheter ablation. Journal of the Saudi Heart Association2010;22(2):99-100. [DOI: 10.1016/j.jsha.2010.02.325]">Tabish 2010</a>; <a href="./references#CD013504-bbs2-0008" title="XingY , XuB , XuC , PengF , YangB , QiuY , et al. Efficacy and safety of uninterrupted low-intensity warfarin for radiofrequency catheter ablation of atrial fibrillation in the elderly. Annals of Pharmacotherapy2017;51(9):735-42. [DOI: 10.1177/1060028017712532]">Xing 2017</a>; <a href="./references#CD013504-bbs2-0009" title="YamajiH , MurakamiT , HinaK , HigashiyaS , KawamuraH , MurakamiM , et al. Activated clotting time on the day of atrial fibrillation ablation for minimally interrupted and uninterrupted direct oral anticoagulation therapy: sequential changes, differences among direct oral anticoagulants, and ablation safety outcomes. Journal of Cardiovascular Electrophysiology2019;30(12):2823-33. [DOI: 10.1111/jce.14260]">Yamaji 2019</a>; <a href="./references#CD013504-bbs2-0010" title="YohM , TakagiM , YoshioT , TakahashiH , ShiojimaI . AP19-00329. Safety and efficacy of uninterrupted and interrupted periprocedural direct oral anticoagulants in patients undergoing radiofrequency catheter ablation for atrial fibrillation. Journal of Arrhythmia2019;35(S1):134. [DOI: 10.1002/joa3.12267]">Yoh 2019</a>; <a href="./references#CD013504-bbs2-0011" title="IrikiY , IchikiH , OketaniN , YoshimuraA , OkuiH , MaenosonoR , et al. Evaluation of safety and efficacy of perioperative use of rivaroxaban and apixaban in catheter ablation for atrial fibrillation. European Heart Journal2015;36:687. [DOI: 10.1093/eurheartj/ehv400]YoshimuraA , IrikiY , IchikiH , OketaniN , OkuiH , MaenosonoR , et al. Evaluation of safety and efficacy of periprocedural use of rivaroxaban and apixaban in catheter ablation for atrial fibrillation. Journal of Cardiology2017;69(1):228-35. [DOI: 10.1016/j.jjcc.2016.03.014]">Yoshimura 2017</a>; <a href="./references#CD013504-bbs2-0012" title="YuHT , ShimJ , ParkJ , KimTH , UhmJS , KimJY , et al. When is it appropriate to stop non-vitamin K antagonist oral anticoagulants before catheter ablation of atrial fibrillation? A multi-center prospective randomized study. Europace2019;21:ii804. YuHT , ShimJ , ParkJ , KimTH , UhmJS , KimJY , et al. When is it appropriate to stop non-vitamin K antagonist oral anticoagulants before catheter ablation of atrial fibrillation? A multicentre prospective randomized study. European Heart Journal2019;40(19):1531-7. [DOI: 10.1093/eurheartj/ehy870]">Yu 2019</a>). Two studies were in abstract format (<a href="./references#CD013504-bbs2-0007" title="TabishH , ShahzadK . Anticoagulation safety window among elderly Chinese patients with atrial fibrillation catheter ablation. Journal of the Saudi Heart Association2010;22(2):99-100. [DOI: 10.1016/j.jsha.2010.02.325]">Tabish 2010</a>; <a href="./references#CD013504-bbs2-0010" title="YohM , TakagiM , YoshioT , TakahashiH , ShiojimaI . AP19-00329. Safety and efficacy of uninterrupted and interrupted periprocedural direct oral anticoagulants in patients undergoing radiofrequency catheter ablation for atrial fibrillation. Journal of Arrhythmia2019;35(S1):134. [DOI: 10.1002/joa3.12267]">Yoh 2019</a>). See <a href="./references#CD013504-sec-0119" title="">Characteristics of included studies</a> table. </p> <section id="CD013504-sec-0041"> <h4 class="title">Results of the search</h4> <p>The searches yielded 1452 records. After removing duplicates there were 1049 unique records. We excluded 977 irrelevant studies. We retrieved full‐text reports of the remaining eligible 72 records. We excluded 44 references, see <a href="./references#CD013504-sec-0120" title="">Characteristics of excluded studies</a> table. We identified multiple reports of the same studies and determined that 12 studies (from 28 records) met the inclusion criteria. See <a href="#CD013504-fig-0001">Figure 1</a> for a PRISMA diagram documenting our search and decision process. </p> </section> <section id="CD013504-sec-0042"> <h4 class="title">Included studies</h4> <p>The 12 trials compared uninterrupted periprocedural anticoagulation with interrupted anticoagulation in 4714 participants; see the <a href="./references#CD013504-sec-0119" title="">Characteristics of included studies</a> for a detailed description of the included studies. </p> <p>Seven studies included people with a mean age of 65 years or above, three studies enrolled participants with a mean age less than 65 years, and two studies included participants with a mean age less than 60 years. All studies included participants with paroxysmal AF, while seven studies also included other types of AF (persistent and long‐standing persistent). One study included participants with a repeat ablation. </p> <p>The anticoagulant comparators between the studies varied, with three main anticoagulant comparisons. Three studies used VKAs as the periprocedural anticoagulation (<a href="./references#CD013504-bbs2-0002" title='Di BiaseL , BurkhardtJD , SantangeliP , MohantyP , SanchezJ , BaiR , et al. Periprocedural strokes and anticoagulation management during AF ablation: results from the "Compare" randomized multicenter trial. Circulation2013;128:A14307. Di BiaseL , BurkhardtJD , SantangeliP , MohantyP , SanchezJ , BaiR , et al. Silent thromboembolic lesions following catheter ablation for atrial fibrillation using radiofrequency energy: results from a sub-study of the "compare" randomized trial. Circulation2013;128(22 Suppl 1):A14293. Di BiaseL , BurkhardtJD , SantangeliP , MohantyP , SanchezJ , HortonR , et al. Periprocedural stroke and bleeding complications in patients undergoing catheter ablation of atrial fibrillation with different anticoagulation management: results from the "compare" randomized trial. Heart Rhythm2013;10(9):1411. Di BiaseL , BurkhardtJD , SantangeliP , MohantyP , SanchezJE , HortonR , et al. Periprocedural stroke and bleeding complications in patients undergoing catheter ablation of atrial fibrillation with different anticoagulation management: results from the role of coumadin in preventing thromboembolism in atrial fibrillation (AF) patients undergoing catheter ablation (COMPARE) randomized trial. Circulation2014;129(25):2638-44. [DOI: 10.1161/circulationaha.113.006426]NCT01006876. Role of coumadin in preventing thromboembolism in atrial fibrillation (AF) patients undergoing catheter ablation. clinicaltrials.gov/ct2/show/NCT01006876 (first received 3 November 2009). '>Di Biase 2014</a>; <a href="./references#CD013504-bbs2-0007" title="TabishH , ShahzadK . Anticoagulation safety window among elderly Chinese patients with atrial fibrillation catheter ablation. Journal of the Saudi Heart Association2010;22(2):99-100. [DOI: 10.1016/j.jsha.2010.02.325]">Tabish 2010</a>; <a href="./references#CD013504-bbs2-0008" title="XingY , XuB , XuC , PengF , YangB , QiuY , et al. Efficacy and safety of uninterrupted low-intensity warfarin for radiofrequency catheter ablation of atrial fibrillation in the elderly. Annals of Pharmacotherapy2017;51(9):735-42. [DOI: 10.1177/1060028017712532]">Xing 2017</a>), eight studies used different  DOACs (<a href="./references#CD013504-bbs2-0001" title="AndoM , IndenY , YoshidaY , SairakuA , YanagisawaS , SuzukiH , et al. Differences in prothrombotic response between the uninterrupted and interrupted apixaban therapies in patients undergoing cryoballoon ablation for paroxysmal atrial fibrillation: a randomized controlled study. Heart Vessels2019;34(9):1533-41. [DOI: 10.1007/s00380-019-01370-9]">Ando 2019</a>; <a href="./references#CD013504-bbs2-0003" title="NagaoT , SuzukiH , MatsunagaS , NishikawaY , HaradaK , MamiyaK . Impact of periprocedural anticoagulation therapy on the incidence of silent stroke after atrial fibrillation ablation in patients receiving direct oral anticoagulants: uninterrupted vs. interrupted by one dose strategy. Europace2019;21(4):590-7. [DOI: 10.1093/europace/euy224]">Nagao 2019</a>; <a href="./references#CD013504-bbs2-0004" title="Nakamura K, Naito S, Sasaki T, Take Y, Minami K, Kitagawa Y, et al. Uninterrupted vs. interrupted periprocedural direct oral anticoagulants for catheter ablation of atrial fibrillation: a prospective randomized single-centre study on post-ablation thrombo-embolic and haemorrhagic events. Europace2019;21(2):259-67. [DOI: 10.1093/europace/euy148]NakamuraK , SasakiT , TakeY , FunabashiN , NaitoS . Uninterrupted vs. interrupted periprocedural direct oral anticoagulants for catheter ablation of atrial fibrillation: a prospective randomized study on post-ablation thromboembolic and hemorrhagic events. Circulation2018;138:2. ">Nakamura 2019</a>; <a href="./references#CD013504-bbs2-0005" title="AonumaK . A prospective, multi-center, parallel-group comparison study to evaluate safety and efficacy of dabigatran during the perioperative period in patients with non-valvular atrial fibrillation who undergo the catheter ablation compared to warfarin. upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000015311 (first received 14 February 2014. GoyaM , NogamiA , HiraoK , AonumaK . Ablation perioperative dabigatran in use envisioning in Japan: the ABRIDGE-J study design. Journal of Cardiology2016;68(3):236-40. [DOI: 10.1016/j.jjcc.2015.10.003]]NogamiA , HaradaT , Sekiguchi Y, Otani R, YoshidaY , Yoshida K, et al. Safety and efficacy of minimally interrupted dabigatran vs uninterrupted warfarin therapy in adults undergoing atrial fibrillation catheter ablation: a randomized clinical trial. JAMA Network Open2019;2(4):15. [DOI: 10.1001/jamanetworkopen.2019.1994]NogamiA , HaradaT , YoshidaY , NakanoY , GoyaM , OrigasaH , et al. Clinical benefit of minimally-interrupted dabigatran versus uninterrupted warfarin for catheter ablation of atrial fibrillation: a prospective randomized multicenter trial. Circulation2017;136:e450. NogamiA , HaradaT , YoshidaY , NakanoY , GoyaM , OrigasaH , et al. Clinical benefit of minimally-interrupted dabigatran versus uninterrupted warfarin for catheter ablation of atrial fibrillation: a prospective randomized multicenter trial. Circulation2017;136(24):E450. [DOI: 10.1161/CIR.0000000000000546]UMIN000013129. A prospective, multi-center, parallel-group comparison study to evaluate safety and efficacy of dabigatran during the perioperative period in patients with non-valvular atrial fibrillation who undergo the catheter ablation compared to warfarin. www.who.int/trialsearch/Trial2.aspx?TrialID=JPRN-UMIN000013129 (first received 1 March 2014). ">Nogami 2019</a>; <a href="./references#CD013504-bbs2-0006" title="ReynoldsMR , AllisonJS , NataleA , WeisbergIL , EllenbogenKA , RichardsM , et al. Apixaban evaluation of interrupted or uninterrupted anticoagulation for ablation of atrial fibrillation. clinicaltrials.gov/show/NCT02608099 (first received 18 November 2015). ReynoldsMR , AllisonJS , NataleA , WeisbergIL , EllenbogenKA , RichardsM , et al. A prospective randomized trial of apixaban dosing during atrial fibrillation ablation: the AEIOU trial. JACC Clinical Electrophysiology2018;4(5):580-8. [DOI: 10.1016/j.jacep.2017.11.005]">Reynolds 2018</a>; <a href="./references#CD013504-bbs2-0010" title="YohM , TakagiM , YoshioT , TakahashiH , ShiojimaI . AP19-00329. Safety and efficacy of uninterrupted and interrupted periprocedural direct oral anticoagulants in patients undergoing radiofrequency catheter ablation for atrial fibrillation. Journal of Arrhythmia2019;35(S1):134. [DOI: 10.1002/joa3.12267]">Yoh 2019</a>; <a href="./references#CD013504-bbs2-0011" title="IrikiY , IchikiH , OketaniN , YoshimuraA , OkuiH , MaenosonoR , et al. Evaluation of safety and efficacy of perioperative use of rivaroxaban and apixaban in catheter ablation for atrial fibrillation. European Heart Journal2015;36:687. [DOI: 10.1093/eurheartj/ehv400]YoshimuraA , IrikiY , IchikiH , OketaniN , OkuiH , MaenosonoR , et al. Evaluation of safety and efficacy of periprocedural use of rivaroxaban and apixaban in catheter ablation for atrial fibrillation. Journal of Cardiology2017;69(1):228-35. [DOI: 10.1016/j.jjcc.2016.03.014]">Yoshimura 2017</a>; <a href="./references#CD013504-bbs2-0012" title="YuHT , ShimJ , ParkJ , KimTH , UhmJS , KimJY , et al. When is it appropriate to stop non-vitamin K antagonist oral anticoagulants before catheter ablation of atrial fibrillation? A multi-center prospective randomized study. Europace2019;21:ii804. YuHT , ShimJ , ParkJ , KimTH , UhmJS , KimJY , et al. When is it appropriate to stop non-vitamin K antagonist oral anticoagulants before catheter ablation of atrial fibrillation? A multicentre prospective randomized study. European Heart Journal2019;40(19):1531-7. [DOI: 10.1093/eurheartj/ehy870]">Yu 2019</a>), and one study involved comparison of  VKA and dabigatran (<a href="./references#CD013504-bbs2-0009" title="YamajiH , MurakamiT , HinaK , HigashiyaS , KawamuraH , MurakamiM , et al. Activated clotting time on the day of atrial fibrillation ablation for minimally interrupted and uninterrupted direct oral anticoagulation therapy: sequential changes, differences among direct oral anticoagulants, and ablation safety outcomes. Journal of Cardiovascular Electrophysiology2019;30(12):2823-33. [DOI: 10.1111/jce.14260]">Yamaji 2019</a>). Seven studies described CA using radiofrequency energy, three studies used multiple catheter sources (such as radiofrequency, cryoballoon, radiofrequency hot balloon, linear ablation, and cryoablation cavotricuspid isthmus), and two studies did not report the ablation source.  </p> <p>Seven studies were undertaken in Japan, two in the US, two in China, and one in South Korea. Eight studies were conducted in a single centre. Postablation follow‐up was variable among the included studies, and it encompassed a range of follow‐up periods of 48 hours (one study), seven days (one study), 10 days (one study), 30 days (six studies), three to six months (two studies), and 12 months postablation (one study).  </p> <section id="CD013504-sec-0043"> <h5 class="title">Interruption strategies</h5> <p>Studies used two main interruption modalities; either complete interruption or minimal interruption. Eleven studies described using a minimally interrupted strategy. Nine studies used a strategy of holding one or two doses of DOAC with no heparin bridging (<a href="./references#CD013504-bbs2-0001" title="AndoM , IndenY , YoshidaY , SairakuA , YanagisawaS , SuzukiH , et al. Differences in prothrombotic response between the uninterrupted and interrupted apixaban therapies in patients undergoing cryoballoon ablation for paroxysmal atrial fibrillation: a randomized controlled study. Heart Vessels2019;34(9):1533-41. [DOI: 10.1007/s00380-019-01370-9]">Ando 2019</a>; <a href="./references#CD013504-bbs2-0003" title="NagaoT , SuzukiH , MatsunagaS , NishikawaY , HaradaK , MamiyaK . Impact of periprocedural anticoagulation therapy on the incidence of silent stroke after atrial fibrillation ablation in patients receiving direct oral anticoagulants: uninterrupted vs. interrupted by one dose strategy. Europace2019;21(4):590-7. [DOI: 10.1093/europace/euy224]">Nagao 2019</a>; <a href="./references#CD013504-bbs2-0004" title="Nakamura K, Naito S, Sasaki T, Take Y, Minami K, Kitagawa Y, et al. Uninterrupted vs. interrupted periprocedural direct oral anticoagulants for catheter ablation of atrial fibrillation: a prospective randomized single-centre study on post-ablation thrombo-embolic and haemorrhagic events. Europace2019;21(2):259-67. [DOI: 10.1093/europace/euy148]NakamuraK , SasakiT , TakeY , FunabashiN , NaitoS . Uninterrupted vs. interrupted periprocedural direct oral anticoagulants for catheter ablation of atrial fibrillation: a prospective randomized study on post-ablation thromboembolic and hemorrhagic events. Circulation2018;138:2. ">Nakamura 2019</a>; <a href="./references#CD013504-bbs2-0005" title="AonumaK . A prospective, multi-center, parallel-group comparison study to evaluate safety and efficacy of dabigatran during the perioperative period in patients with non-valvular atrial fibrillation who undergo the catheter ablation compared to warfarin. upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000015311 (first received 14 February 2014. GoyaM , NogamiA , HiraoK , AonumaK . Ablation perioperative dabigatran in use envisioning in Japan: the ABRIDGE-J study design. Journal of Cardiology2016;68(3):236-40. [DOI: 10.1016/j.jjcc.2015.10.003]]NogamiA , HaradaT , Sekiguchi Y, Otani R, YoshidaY , Yoshida K, et al. Safety and efficacy of minimally interrupted dabigatran vs uninterrupted warfarin therapy in adults undergoing atrial fibrillation catheter ablation: a randomized clinical trial. JAMA Network Open2019;2(4):15. [DOI: 10.1001/jamanetworkopen.2019.1994]NogamiA , HaradaT , YoshidaY , NakanoY , GoyaM , OrigasaH , et al. Clinical benefit of minimally-interrupted dabigatran versus uninterrupted warfarin for catheter ablation of atrial fibrillation: a prospective randomized multicenter trial. Circulation2017;136:e450. NogamiA , HaradaT , YoshidaY , NakanoY , GoyaM , OrigasaH , et al. Clinical benefit of minimally-interrupted dabigatran versus uninterrupted warfarin for catheter ablation of atrial fibrillation: a prospective randomized multicenter trial. Circulation2017;136(24):E450. [DOI: 10.1161/CIR.0000000000000546]UMIN000013129. A prospective, multi-center, parallel-group comparison study to evaluate safety and efficacy of dabigatran during the perioperative period in patients with non-valvular atrial fibrillation who undergo the catheter ablation compared to warfarin. www.who.int/trialsearch/Trial2.aspx?TrialID=JPRN-UMIN000013129 (first received 1 March 2014). ">Nogami 2019</a>; <a href="./references#CD013504-bbs2-0006" title="ReynoldsMR , AllisonJS , NataleA , WeisbergIL , EllenbogenKA , RichardsM , et al. Apixaban evaluation of interrupted or uninterrupted anticoagulation for ablation of atrial fibrillation. clinicaltrials.gov/show/NCT02608099 (first received 18 November 2015). ReynoldsMR , AllisonJS , NataleA , WeisbergIL , EllenbogenKA , RichardsM , et al. A prospective randomized trial of apixaban dosing during atrial fibrillation ablation: the AEIOU trial. JACC Clinical Electrophysiology2018;4(5):580-8. [DOI: 10.1016/j.jacep.2017.11.005]">Reynolds 2018</a>; <a href="./references#CD013504-bbs2-0009" title="YamajiH , MurakamiT , HinaK , HigashiyaS , KawamuraH , MurakamiM , et al. Activated clotting time on the day of atrial fibrillation ablation for minimally interrupted and uninterrupted direct oral anticoagulation therapy: sequential changes, differences among direct oral anticoagulants, and ablation safety outcomes. Journal of Cardiovascular Electrophysiology2019;30(12):2823-33. [DOI: 10.1111/jce.14260]">Yamaji 2019</a>; <a href="./references#CD013504-bbs2-0010" title="YohM , TakagiM , YoshioT , TakahashiH , ShiojimaI . AP19-00329. Safety and efficacy of uninterrupted and interrupted periprocedural direct oral anticoagulants in patients undergoing radiofrequency catheter ablation for atrial fibrillation. Journal of Arrhythmia2019;35(S1):134. [DOI: 10.1002/joa3.12267]">Yoh 2019</a>; <a href="./references#CD013504-bbs2-0011" title="IrikiY , IchikiH , OketaniN , YoshimuraA , OkuiH , MaenosonoR , et al. Evaluation of safety and efficacy of perioperative use of rivaroxaban and apixaban in catheter ablation for atrial fibrillation. European Heart Journal2015;36:687. [DOI: 10.1093/eurheartj/ehv400]YoshimuraA , IrikiY , IchikiH , OketaniN , OkuiH , MaenosonoR , et al. Evaluation of safety and efficacy of periprocedural use of rivaroxaban and apixaban in catheter ablation for atrial fibrillation. Journal of Cardiology2017;69(1):228-35. [DOI: 10.1016/j.jjcc.2016.03.014]">Yoshimura 2017</a>; <a href="./references#CD013504-bbs2-0012" title="YuHT , ShimJ , ParkJ , KimTH , UhmJS , KimJY , et al. When is it appropriate to stop non-vitamin K antagonist oral anticoagulants before catheter ablation of atrial fibrillation? A multi-center prospective randomized study. Europace2019;21:ii804. YuHT , ShimJ , ParkJ , KimTH , UhmJS , KimJY , et al. When is it appropriate to stop non-vitamin K antagonist oral anticoagulants before catheter ablation of atrial fibrillation? A multicentre prospective randomized study. European Heart Journal2019;40(19):1531-7. [DOI: 10.1093/eurheartj/ehy870]">Yu 2019</a>). <a href="./references#CD013504-bbs2-0001" title="AndoM , IndenY , YoshidaY , SairakuA , YanagisawaS , SuzukiH , et al. Differences in prothrombotic response between the uninterrupted and interrupted apixaban therapies in patients undergoing cryoballoon ablation for paroxysmal atrial fibrillation: a randomized controlled study. Heart Vessels2019;34(9):1533-41. [DOI: 10.1007/s00380-019-01370-9]">Ando 2019</a>, <a href="./references#CD013504-bbs2-0006" title="ReynoldsMR , AllisonJS , NataleA , WeisbergIL , EllenbogenKA , RichardsM , et al. Apixaban evaluation of interrupted or uninterrupted anticoagulation for ablation of atrial fibrillation. clinicaltrials.gov/show/NCT02608099 (first received 18 November 2015). ReynoldsMR , AllisonJS , NataleA , WeisbergIL , EllenbogenKA , RichardsM , et al. A prospective randomized trial of apixaban dosing during atrial fibrillation ablation: the AEIOU trial. JACC Clinical Electrophysiology2018;4(5):580-8. [DOI: 10.1016/j.jacep.2017.11.005]">Reynolds 2018</a>, and <a href="./references#CD013504-bbs2-0011" title="IrikiY , IchikiH , OketaniN , YoshimuraA , OkuiH , MaenosonoR , et al. Evaluation of safety and efficacy of perioperative use of rivaroxaban and apixaban in catheter ablation for atrial fibrillation. European Heart Journal2015;36:687. [DOI: 10.1093/eurheartj/ehv400]YoshimuraA , IrikiY , IchikiH , OketaniN , OkuiH , MaenosonoR , et al. Evaluation of safety and efficacy of periprocedural use of rivaroxaban and apixaban in catheter ablation for atrial fibrillation. Journal of Cardiology2017;69(1):228-35. [DOI: 10.1016/j.jjcc.2016.03.014]">Yoshimura 2017</a> interrupted apixaban on the morning of the procedure, and gave no heparin bridging. <a href="./references#CD013504-bbs2-0003" title="NagaoT , SuzukiH , MatsunagaS , NishikawaY , HaradaK , MamiyaK . Impact of periprocedural anticoagulation therapy on the incidence of silent stroke after atrial fibrillation ablation in patients receiving direct oral anticoagulants: uninterrupted vs. interrupted by one dose strategy. Europace2019;21(4):590-7. [DOI: 10.1093/europace/euy224]">Nagao 2019</a> and <a href="./references#CD013504-bbs2-0004" title="Nakamura K, Naito S, Sasaki T, Take Y, Minami K, Kitagawa Y, et al. Uninterrupted vs. interrupted periprocedural direct oral anticoagulants for catheter ablation of atrial fibrillation: a prospective randomized single-centre study on post-ablation thrombo-embolic and haemorrhagic events. Europace2019;21(2):259-67. [DOI: 10.1093/europace/euy148]NakamuraK , SasakiT , TakeY , FunabashiN , NaitoS . Uninterrupted vs. interrupted periprocedural direct oral anticoagulants for catheter ablation of atrial fibrillation: a prospective randomized study on post-ablation thromboembolic and hemorrhagic events. Circulation2018;138:2. ">Nakamura 2019</a> interrupted the twice‐daily DOACs by giving the last dose on the evening of the day before the procedure, while for once‐daily DOACs the last dose was given on the morning of the day before the procedure, with no heparin bridging. <a href="./references#CD013504-bbs2-0005" title="AonumaK . A prospective, multi-center, parallel-group comparison study to evaluate safety and efficacy of dabigatran during the perioperative period in patients with non-valvular atrial fibrillation who undergo the catheter ablation compared to warfarin. upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000015311 (first received 14 February 2014. GoyaM , NogamiA , HiraoK , AonumaK . Ablation perioperative dabigatran in use envisioning in Japan: the ABRIDGE-J study design. Journal of Cardiology2016;68(3):236-40. [DOI: 10.1016/j.jjcc.2015.10.003]]NogamiA , HaradaT , Sekiguchi Y, Otani R, YoshidaY , Yoshida K, et al. Safety and efficacy of minimally interrupted dabigatran vs uninterrupted warfarin therapy in adults undergoing atrial fibrillation catheter ablation: a randomized clinical trial. JAMA Network Open2019;2(4):15. [DOI: 10.1001/jamanetworkopen.2019.1994]NogamiA , HaradaT , YoshidaY , NakanoY , GoyaM , OrigasaH , et al. Clinical benefit of minimally-interrupted dabigatran versus uninterrupted warfarin for catheter ablation of atrial fibrillation: a prospective randomized multicenter trial. Circulation2017;136:e450. NogamiA , HaradaT , YoshidaY , NakanoY , GoyaM , OrigasaH , et al. Clinical benefit of minimally-interrupted dabigatran versus uninterrupted warfarin for catheter ablation of atrial fibrillation: a prospective randomized multicenter trial. Circulation2017;136(24):E450. [DOI: 10.1161/CIR.0000000000000546]UMIN000013129. A prospective, multi-center, parallel-group comparison study to evaluate safety and efficacy of dabigatran during the perioperative period in patients with non-valvular atrial fibrillation who undergo the catheter ablation compared to warfarin. www.who.int/trialsearch/Trial2.aspx?TrialID=JPRN-UMIN000013129 (first received 1 March 2014). ">Nogami 2019</a> interrupted dabigatran (D) by withholding one or two doses before ablation (A)(D‐A less than 24 or D‐A 24 hours or greater) before the procedure. It is worth mentioning that D‐A is the interval between the final dose of dabigatran and the transseptal puncture. About 35% of participants (78/220) in the interrupted group were bridged with heparin therapy, of them, 15% (20/137) were in D‐A less than 24 and 70% (58/83) in the D‐A 24 hours or greater. <a href="./references#CD013504-bbs2-0010" title="YohM , TakagiM , YoshioT , TakahashiH , ShiojimaI . AP19-00329. Safety and efficacy of uninterrupted and interrupted periprocedural direct oral anticoagulants in patients undergoing radiofrequency catheter ablation for atrial fibrillation. Journal of Arrhythmia2019;35(S1):134. [DOI: 10.1002/joa3.12267]">Yoh 2019</a> gave the interruption on the morning of the day before the procedure for both of the twice‐daily DOACs (dabigatran and apixaban) and the once‐daily DOACs (rivaroxaban and edoxaban) with no heparin bridging. Interruption in <a href="./references#CD013504-bbs2-0012" title="YuHT , ShimJ , ParkJ , KimTH , UhmJS , KimJY , et al. When is it appropriate to stop non-vitamin K antagonist oral anticoagulants before catheter ablation of atrial fibrillation? A multi-center prospective randomized study. Europace2019;21:ii804. YuHT , ShimJ , ParkJ , KimTH , UhmJS , KimJY , et al. When is it appropriate to stop non-vitamin K antagonist oral anticoagulants before catheter ablation of atrial fibrillation? A multicentre prospective randomized study. European Heart Journal2019;40(19):1531-7. [DOI: 10.1093/eurheartj/ehy870]">Yu 2019</a> was either by single‐dose skip or 24 hours of skip (24S). It was unclear when the last dose of DOAC (rivaroxaban, dabigatran, apixaban) was administered. In addition, people with persistent AF with a CHA2DS2‐VASc score of 2 or greater assigned to the 24S group received enoxaparin 1 mg/kg in the evening the day before the procedure. Two trials used low‐intensity warfarin (INR 1.5 to 2.0) as the minimal interruption strategy with no heparin bridging in older people and compared it to standard intensity warfarin (INR 2.0 to 3.0)  (<a href="./references#CD013504-bbs2-0007" title="TabishH , ShahzadK . Anticoagulation safety window among elderly Chinese patients with atrial fibrillation catheter ablation. Journal of the Saudi Heart Association2010;22(2):99-100. [DOI: 10.1016/j.jsha.2010.02.325]">Tabish 2010</a>; <a href="./references#CD013504-bbs2-0008" title="XingY , XuB , XuC , PengF , YangB , QiuY , et al. Efficacy and safety of uninterrupted low-intensity warfarin for radiofrequency catheter ablation of atrial fibrillation in the elderly. Annals of Pharmacotherapy2017;51(9):735-42. [DOI: 10.1177/1060028017712532]">Xing 2017</a>). Of the 12 included studies,  <a href="./references#CD013504-bbs2-0002" title='Di BiaseL , BurkhardtJD , SantangeliP , MohantyP , SanchezJ , BaiR , et al. Periprocedural strokes and anticoagulation management during AF ablation: results from the "Compare" randomized multicenter trial. Circulation2013;128:A14307. Di BiaseL , BurkhardtJD , SantangeliP , MohantyP , SanchezJ , BaiR , et al. Silent thromboembolic lesions following catheter ablation for atrial fibrillation using radiofrequency energy: results from a sub-study of the "compare" randomized trial. Circulation2013;128(22 Suppl 1):A14293. Di BiaseL , BurkhardtJD , SantangeliP , MohantyP , SanchezJ , HortonR , et al. Periprocedural stroke and bleeding complications in patients undergoing catheter ablation of atrial fibrillation with different anticoagulation management: results from the "compare" randomized trial. Heart Rhythm2013;10(9):1411. Di BiaseL , BurkhardtJD , SantangeliP , MohantyP , SanchezJE , HortonR , et al. Periprocedural stroke and bleeding complications in patients undergoing catheter ablation of atrial fibrillation with different anticoagulation management: results from the role of coumadin in preventing thromboembolism in atrial fibrillation (AF) patients undergoing catheter ablation (COMPARE) randomized trial. Circulation2014;129(25):2638-44. [DOI: 10.1161/circulationaha.113.006426]NCT01006876. Role of coumadin in preventing thromboembolism in atrial fibrillation (AF) patients undergoing catheter ablation. clinicaltrials.gov/ct2/show/NCT01006876 (first received 3 November 2009). '>Di Biase 2014</a> was the only one that used complete interruption of the anticoagulant. Warfarin was held two to three days before the ablation, and heparin bridging given with enoxaparin 1 mg/kg twice daily until the evening before the ablation procedure; see <a href="#CD013504-fig-0002">Figure 2</a> for the schematic presentation of anticoagulant management around the time of the procedure. </p> <div class="figure" id="CD013504-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Graphical representation of strategies used for the periprocedural anticoagulation around the ablation procedure.  A: uninterrupted activation clotting time; B: minimally interrupted using one‐dose skipped strategy; C: minimally interrupted using low‐intensity INR strategy; D: minimally interrupted using two‐dose skipped strategy; E: completely interrupted activation clotting time. DOAC: direct oral anticoagulants; H: heparin bridging; R: resumption of the drug; S: skipped dose; VKA: vitamin K antagonist; w/o: without. Included studies: 1: Ando 2019; 2: Di Biase 2014; 3: Nagao 2019; 4: Nakamura 2019; 5: Nogami 2019; 6: Reynolds 2018; 7: Tabish 2010; 8: Xing 2017; 9: Yamaji 2019; 10: Yoh 2019; 11: Yoshimura 2017; 12: Yu 2019." data-id="CD013504-fig-0002" src="/cdsr/doi/10.1002/14651858.CD013504.pub2/media/CDSR/CD013504/image_n/nCD013504-FIG-02.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p><b>Graphical representation of strategies used for the periprocedural anticoagulation around the ablation procedure. </b> <br/><b>A:</b> uninterrupted activation clotting time; <b>B:</b> minimally interrupted using one‐dose skipped strategy; <b>C:</b> minimally interrupted using low‐intensity INR strategy; <b>D:</b> minimally interrupted using two‐dose skipped strategy; <b>E:</b> completely interrupted activation clotting time. <b>DOAC:</b> direct oral anticoagulants; <b>H:</b> heparin bridging; <b>R:</b> resumption of the drug; <b>S:</b> skipped dose; <b>VKA:</b> vitamin K antagonist; <b>w/o:</b> without. <b>Included studies:</b> 1: <a href="./references#CD013504-bbs2-0001" title="AndoM , IndenY , YoshidaY , SairakuA , YanagisawaS , SuzukiH , et al. Differences in prothrombotic response between the uninterrupted and interrupted apixaban therapies in patients undergoing cryoballoon ablation for paroxysmal atrial fibrillation: a randomized controlled study. Heart Vessels2019;34(9):1533-41. [DOI: 10.1007/s00380-019-01370-9]">Ando 2019</a>; 2: <a href="./references#CD013504-bbs2-0002" title='Di BiaseL , BurkhardtJD , SantangeliP , MohantyP , SanchezJ , BaiR , et al. Periprocedural strokes and anticoagulation management during AF ablation: results from the "Compare" randomized multicenter trial. Circulation2013;128:A14307. Di BiaseL , BurkhardtJD , SantangeliP , MohantyP , SanchezJ , BaiR , et al. Silent thromboembolic lesions following catheter ablation for atrial fibrillation using radiofrequency energy: results from a sub-study of the "compare" randomized trial. Circulation2013;128(22 Suppl 1):A14293. Di BiaseL , BurkhardtJD , SantangeliP , MohantyP , SanchezJ , HortonR , et al. Periprocedural stroke and bleeding complications in patients undergoing catheter ablation of atrial fibrillation with different anticoagulation management: results from the "compare" randomized trial. Heart Rhythm2013;10(9):1411. Di BiaseL , BurkhardtJD , SantangeliP , MohantyP , SanchezJE , HortonR , et al. Periprocedural stroke and bleeding complications in patients undergoing catheter ablation of atrial fibrillation with different anticoagulation management: results from the role of coumadin in preventing thromboembolism in atrial fibrillation (AF) patients undergoing catheter ablation (COMPARE) randomized trial. Circulation2014;129(25):2638-44. [DOI: 10.1161/circulationaha.113.006426]NCT01006876. Role of coumadin in preventing thromboembolism in atrial fibrillation (AF) patients undergoing catheter ablation. clinicaltrials.gov/ct2/show/NCT01006876 (first received 3 November 2009). '>Di Biase 2014</a>; 3: <a href="./references#CD013504-bbs2-0003" title="NagaoT , SuzukiH , MatsunagaS , NishikawaY , HaradaK , MamiyaK . Impact of periprocedural anticoagulation therapy on the incidence of silent stroke after atrial fibrillation ablation in patients receiving direct oral anticoagulants: uninterrupted vs. interrupted by one dose strategy. Europace2019;21(4):590-7. [DOI: 10.1093/europace/euy224]">Nagao 2019</a>; 4: <a href="./references#CD013504-bbs2-0004" title="Nakamura K, Naito S, Sasaki T, Take Y, Minami K, Kitagawa Y, et al. Uninterrupted vs. interrupted periprocedural direct oral anticoagulants for catheter ablation of atrial fibrillation: a prospective randomized single-centre study on post-ablation thrombo-embolic and haemorrhagic events. Europace2019;21(2):259-67. [DOI: 10.1093/europace/euy148]NakamuraK , SasakiT , TakeY , FunabashiN , NaitoS . Uninterrupted vs. interrupted periprocedural direct oral anticoagulants for catheter ablation of atrial fibrillation: a prospective randomized study on post-ablation thromboembolic and hemorrhagic events. Circulation2018;138:2. ">Nakamura 2019</a>; 5: <a href="./references#CD013504-bbs2-0005" title="AonumaK . A prospective, multi-center, parallel-group comparison study to evaluate safety and efficacy of dabigatran during the perioperative period in patients with non-valvular atrial fibrillation who undergo the catheter ablation compared to warfarin. upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000015311 (first received 14 February 2014. GoyaM , NogamiA , HiraoK , AonumaK . Ablation perioperative dabigatran in use envisioning in Japan: the ABRIDGE-J study design. Journal of Cardiology2016;68(3):236-40. [DOI: 10.1016/j.jjcc.2015.10.003]]NogamiA , HaradaT , Sekiguchi Y, Otani R, YoshidaY , Yoshida K, et al. Safety and efficacy of minimally interrupted dabigatran vs uninterrupted warfarin therapy in adults undergoing atrial fibrillation catheter ablation: a randomized clinical trial. JAMA Network Open2019;2(4):15. [DOI: 10.1001/jamanetworkopen.2019.1994]NogamiA , HaradaT , YoshidaY , NakanoY , GoyaM , OrigasaH , et al. Clinical benefit of minimally-interrupted dabigatran versus uninterrupted warfarin for catheter ablation of atrial fibrillation: a prospective randomized multicenter trial. Circulation2017;136:e450. NogamiA , HaradaT , YoshidaY , NakanoY , GoyaM , OrigasaH , et al. Clinical benefit of minimally-interrupted dabigatran versus uninterrupted warfarin for catheter ablation of atrial fibrillation: a prospective randomized multicenter trial. Circulation2017;136(24):E450. [DOI: 10.1161/CIR.0000000000000546]UMIN000013129. A prospective, multi-center, parallel-group comparison study to evaluate safety and efficacy of dabigatran during the perioperative period in patients with non-valvular atrial fibrillation who undergo the catheter ablation compared to warfarin. www.who.int/trialsearch/Trial2.aspx?TrialID=JPRN-UMIN000013129 (first received 1 March 2014). ">Nogami 2019</a>; 6: <a href="./references#CD013504-bbs2-0006" title="ReynoldsMR , AllisonJS , NataleA , WeisbergIL , EllenbogenKA , RichardsM , et al. Apixaban evaluation of interrupted or uninterrupted anticoagulation for ablation of atrial fibrillation. clinicaltrials.gov/show/NCT02608099 (first received 18 November 2015). ReynoldsMR , AllisonJS , NataleA , WeisbergIL , EllenbogenKA , RichardsM , et al. A prospective randomized trial of apixaban dosing during atrial fibrillation ablation: the AEIOU trial. JACC Clinical Electrophysiology2018;4(5):580-8. [DOI: 10.1016/j.jacep.2017.11.005]">Reynolds 2018</a>; 7: <a href="./references#CD013504-bbs2-0007" title="TabishH , ShahzadK . Anticoagulation safety window among elderly Chinese patients with atrial fibrillation catheter ablation. Journal of the Saudi Heart Association2010;22(2):99-100. [DOI: 10.1016/j.jsha.2010.02.325]">Tabish 2010</a>; 8: <a href="./references#CD013504-bbs2-0008" title="XingY , XuB , XuC , PengF , YangB , QiuY , et al. Efficacy and safety of uninterrupted low-intensity warfarin for radiofrequency catheter ablation of atrial fibrillation in the elderly. Annals of Pharmacotherapy2017;51(9):735-42. [DOI: 10.1177/1060028017712532]">Xing 2017</a>; 9: <a href="./references#CD013504-bbs2-0009" title="YamajiH , MurakamiT , HinaK , HigashiyaS , KawamuraH , MurakamiM , et al. Activated clotting time on the day of atrial fibrillation ablation for minimally interrupted and uninterrupted direct oral anticoagulation therapy: sequential changes, differences among direct oral anticoagulants, and ablation safety outcomes. Journal of Cardiovascular Electrophysiology2019;30(12):2823-33. [DOI: 10.1111/jce.14260]">Yamaji 2019</a>; 10: <a href="./references#CD013504-bbs2-0010" title="YohM , TakagiM , YoshioT , TakahashiH , ShiojimaI . AP19-00329. Safety and efficacy of uninterrupted and interrupted periprocedural direct oral anticoagulants in patients undergoing radiofrequency catheter ablation for atrial fibrillation. Journal of Arrhythmia2019;35(S1):134. [DOI: 10.1002/joa3.12267]">Yoh 2019</a>; 11: <a href="./references#CD013504-bbs2-0011" title="IrikiY , IchikiH , OketaniN , YoshimuraA , OkuiH , MaenosonoR , et al. Evaluation of safety and efficacy of perioperative use of rivaroxaban and apixaban in catheter ablation for atrial fibrillation. European Heart Journal2015;36:687. [DOI: 10.1093/eurheartj/ehv400]YoshimuraA , IrikiY , IchikiH , OketaniN , OkuiH , MaenosonoR , et al. Evaluation of safety and efficacy of periprocedural use of rivaroxaban and apixaban in catheter ablation for atrial fibrillation. Journal of Cardiology2017;69(1):228-35. [DOI: 10.1016/j.jjcc.2016.03.014]">Yoshimura 2017</a>; 12: <a href="./references#CD013504-bbs2-0012" title="YuHT , ShimJ , ParkJ , KimTH , UhmJS , KimJY , et al. When is it appropriate to stop non-vitamin K antagonist oral anticoagulants before catheter ablation of atrial fibrillation? A multi-center prospective randomized study. Europace2019;21:ii804. YuHT , ShimJ , ParkJ , KimTH , UhmJS , KimJY , et al. When is it appropriate to stop non-vitamin K antagonist oral anticoagulants before catheter ablation of atrial fibrillation? A multicentre prospective randomized study. European Heart Journal2019;40(19):1531-7. [DOI: 10.1093/eurheartj/ehy870]">Yu 2019</a>. </p> </div> </div> </div> <p>Other procedure‐related protocols were fairly similar between the trials. Anticoagulants were administered for at least four weeks before ablation, transoesophageal echocardiography (TOE) was performed on the day of the procedure, and intraprocedural use of heparin and activation clotting time (ACT) target was similar between trials. Resumption of anticoagulant therapy after the ablation varied depending on the frequency of use of the anticoagulant. Studies using DOAC resumed therapy on the evening of the procedure for a twice‐daily DOAC or in the morning after the procedure for a once‐daily DOAC with or without heparin bridging  (<a href="./references#CD013504-bbs2-0001" title="AndoM , IndenY , YoshidaY , SairakuA , YanagisawaS , SuzukiH , et al. Differences in prothrombotic response between the uninterrupted and interrupted apixaban therapies in patients undergoing cryoballoon ablation for paroxysmal atrial fibrillation: a randomized controlled study. Heart Vessels2019;34(9):1533-41. [DOI: 10.1007/s00380-019-01370-9]">Ando 2019</a>; <a href="./references#CD013504-bbs2-0003" title="NagaoT , SuzukiH , MatsunagaS , NishikawaY , HaradaK , MamiyaK . Impact of periprocedural anticoagulation therapy on the incidence of silent stroke after atrial fibrillation ablation in patients receiving direct oral anticoagulants: uninterrupted vs. interrupted by one dose strategy. Europace2019;21(4):590-7. [DOI: 10.1093/europace/euy224]">Nagao 2019</a>; <a href="./references#CD013504-bbs2-0004" title="Nakamura K, Naito S, Sasaki T, Take Y, Minami K, Kitagawa Y, et al. Uninterrupted vs. interrupted periprocedural direct oral anticoagulants for catheter ablation of atrial fibrillation: a prospective randomized single-centre study on post-ablation thrombo-embolic and haemorrhagic events. Europace2019;21(2):259-67. [DOI: 10.1093/europace/euy148]NakamuraK , SasakiT , TakeY , FunabashiN , NaitoS . Uninterrupted vs. interrupted periprocedural direct oral anticoagulants for catheter ablation of atrial fibrillation: a prospective randomized study on post-ablation thromboembolic and hemorrhagic events. Circulation2018;138:2. ">Nakamura 2019</a>; <a href="./references#CD013504-bbs2-0005" title="AonumaK . A prospective, multi-center, parallel-group comparison study to evaluate safety and efficacy of dabigatran during the perioperative period in patients with non-valvular atrial fibrillation who undergo the catheter ablation compared to warfarin. upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000015311 (first received 14 February 2014. GoyaM , NogamiA , HiraoK , AonumaK . Ablation perioperative dabigatran in use envisioning in Japan: the ABRIDGE-J study design. Journal of Cardiology2016;68(3):236-40. [DOI: 10.1016/j.jjcc.2015.10.003]]NogamiA , HaradaT , Sekiguchi Y, Otani R, YoshidaY , Yoshida K, et al. Safety and efficacy of minimally interrupted dabigatran vs uninterrupted warfarin therapy in adults undergoing atrial fibrillation catheter ablation: a randomized clinical trial. JAMA Network Open2019;2(4):15. [DOI: 10.1001/jamanetworkopen.2019.1994]NogamiA , HaradaT , YoshidaY , NakanoY , GoyaM , OrigasaH , et al. Clinical benefit of minimally-interrupted dabigatran versus uninterrupted warfarin for catheter ablation of atrial fibrillation: a prospective randomized multicenter trial. Circulation2017;136:e450. NogamiA , HaradaT , YoshidaY , NakanoY , GoyaM , OrigasaH , et al. Clinical benefit of minimally-interrupted dabigatran versus uninterrupted warfarin for catheter ablation of atrial fibrillation: a prospective randomized multicenter trial. Circulation2017;136(24):E450. [DOI: 10.1161/CIR.0000000000000546]UMIN000013129. A prospective, multi-center, parallel-group comparison study to evaluate safety and efficacy of dabigatran during the perioperative period in patients with non-valvular atrial fibrillation who undergo the catheter ablation compared to warfarin. www.who.int/trialsearch/Trial2.aspx?TrialID=JPRN-UMIN000013129 (first received 1 March 2014). ">Nogami 2019</a>; <a href="./references#CD013504-bbs2-0006" title="ReynoldsMR , AllisonJS , NataleA , WeisbergIL , EllenbogenKA , RichardsM , et al. Apixaban evaluation of interrupted or uninterrupted anticoagulation for ablation of atrial fibrillation. clinicaltrials.gov/show/NCT02608099 (first received 18 November 2015). ReynoldsMR , AllisonJS , NataleA , WeisbergIL , EllenbogenKA , RichardsM , et al. A prospective randomized trial of apixaban dosing during atrial fibrillation ablation: the AEIOU trial. JACC Clinical Electrophysiology2018;4(5):580-8. [DOI: 10.1016/j.jacep.2017.11.005]">Reynolds 2018</a>; <a href="./references#CD013504-bbs2-0009" title="YamajiH , MurakamiT , HinaK , HigashiyaS , KawamuraH , MurakamiM , et al. Activated clotting time on the day of atrial fibrillation ablation for minimally interrupted and uninterrupted direct oral anticoagulation therapy: sequential changes, differences among direct oral anticoagulants, and ablation safety outcomes. Journal of Cardiovascular Electrophysiology2019;30(12):2823-33. [DOI: 10.1111/jce.14260]">Yamaji 2019</a>; <a href="./references#CD013504-bbs2-0010" title="YohM , TakagiM , YoshioT , TakahashiH , ShiojimaI . AP19-00329. Safety and efficacy of uninterrupted and interrupted periprocedural direct oral anticoagulants in patients undergoing radiofrequency catheter ablation for atrial fibrillation. Journal of Arrhythmia2019;35(S1):134. [DOI: 10.1002/joa3.12267]">Yoh 2019</a>; <a href="./references#CD013504-bbs2-0011" title="IrikiY , IchikiH , OketaniN , YoshimuraA , OkuiH , MaenosonoR , et al. Evaluation of safety and efficacy of perioperative use of rivaroxaban and apixaban in catheter ablation for atrial fibrillation. European Heart Journal2015;36:687. [DOI: 10.1093/eurheartj/ehv400]YoshimuraA , IrikiY , IchikiH , OketaniN , OkuiH , MaenosonoR , et al. Evaluation of safety and efficacy of periprocedural use of rivaroxaban and apixaban in catheter ablation for atrial fibrillation. Journal of Cardiology2017;69(1):228-35. [DOI: 10.1016/j.jjcc.2016.03.014]">Yoshimura 2017</a>; <a href="./references#CD013504-bbs2-0012" title="YuHT , ShimJ , ParkJ , KimTH , UhmJS , KimJY , et al. When is it appropriate to stop non-vitamin K antagonist oral anticoagulants before catheter ablation of atrial fibrillation? A multi-center prospective randomized study. Europace2019;21:ii804. YuHT , ShimJ , ParkJ , KimTH , UhmJS , KimJY , et al. When is it appropriate to stop non-vitamin K antagonist oral anticoagulants before catheter ablation of atrial fibrillation? A multicentre prospective randomized study. European Heart Journal2019;40(19):1531-7. [DOI: 10.1093/eurheartj/ehy870]">Yu 2019</a>). For VKA anticoagulant, one study resumed VKA on the evening of the procedure with heparin bridging (<a href="./references#CD013504-bbs2-0002" title='Di BiaseL , BurkhardtJD , SantangeliP , MohantyP , SanchezJ , BaiR , et al. Periprocedural strokes and anticoagulation management during AF ablation: results from the "Compare" randomized multicenter trial. Circulation2013;128:A14307. Di BiaseL , BurkhardtJD , SantangeliP , MohantyP , SanchezJ , BaiR , et al. Silent thromboembolic lesions following catheter ablation for atrial fibrillation using radiofrequency energy: results from a sub-study of the "compare" randomized trial. Circulation2013;128(22 Suppl 1):A14293. Di BiaseL , BurkhardtJD , SantangeliP , MohantyP , SanchezJ , HortonR , et al. Periprocedural stroke and bleeding complications in patients undergoing catheter ablation of atrial fibrillation with different anticoagulation management: results from the "compare" randomized trial. Heart Rhythm2013;10(9):1411. Di BiaseL , BurkhardtJD , SantangeliP , MohantyP , SanchezJE , HortonR , et al. Periprocedural stroke and bleeding complications in patients undergoing catheter ablation of atrial fibrillation with different anticoagulation management: results from the role of coumadin in preventing thromboembolism in atrial fibrillation (AF) patients undergoing catheter ablation (COMPARE) randomized trial. Circulation2014;129(25):2638-44. [DOI: 10.1161/circulationaha.113.006426]NCT01006876. Role of coumadin in preventing thromboembolism in atrial fibrillation (AF) patients undergoing catheter ablation. clinicaltrials.gov/ct2/show/NCT01006876 (first received 3 November 2009). '>Di Biase 2014</a>), and two studies used lower‐intensity INR throughout and after the procedure (<a href="./references#CD013504-bbs2-0007" title="TabishH , ShahzadK . Anticoagulation safety window among elderly Chinese patients with atrial fibrillation catheter ablation. Journal of the Saudi Heart Association2010;22(2):99-100. [DOI: 10.1016/j.jsha.2010.02.325]">Tabish 2010</a>; <a href="./references#CD013504-bbs2-0008" title="XingY , XuB , XuC , PengF , YangB , QiuY , et al. Efficacy and safety of uninterrupted low-intensity warfarin for radiofrequency catheter ablation of atrial fibrillation in the elderly. Annals of Pharmacotherapy2017;51(9):735-42. [DOI: 10.1177/1060028017712532]">Xing 2017</a>). </p> </section> <section id="CD013504-sec-0044"> <h5 class="title">Outcomes</h5> <p>All 12 studies reported on thromboembolic event outcome (stroke, transient ischaemic attack, or systemic embolism) (<a href="./references#CD013504-bbs2-0001" title="AndoM , IndenY , YoshidaY , SairakuA , YanagisawaS , SuzukiH , et al. Differences in prothrombotic response between the uninterrupted and interrupted apixaban therapies in patients undergoing cryoballoon ablation for paroxysmal atrial fibrillation: a randomized controlled study. Heart Vessels2019;34(9):1533-41. [DOI: 10.1007/s00380-019-01370-9]">Ando 2019</a>; <a href="./references#CD013504-bbs2-0002" title='Di BiaseL , BurkhardtJD , SantangeliP , MohantyP , SanchezJ , BaiR , et al. Periprocedural strokes and anticoagulation management during AF ablation: results from the "Compare" randomized multicenter trial. Circulation2013;128:A14307. Di BiaseL , BurkhardtJD , SantangeliP , MohantyP , SanchezJ , BaiR , et al. Silent thromboembolic lesions following catheter ablation for atrial fibrillation using radiofrequency energy: results from a sub-study of the "compare" randomized trial. Circulation2013;128(22 Suppl 1):A14293. Di BiaseL , BurkhardtJD , SantangeliP , MohantyP , SanchezJ , HortonR , et al. Periprocedural stroke and bleeding complications in patients undergoing catheter ablation of atrial fibrillation with different anticoagulation management: results from the "compare" randomized trial. Heart Rhythm2013;10(9):1411. Di BiaseL , BurkhardtJD , SantangeliP , MohantyP , SanchezJE , HortonR , et al. Periprocedural stroke and bleeding complications in patients undergoing catheter ablation of atrial fibrillation with different anticoagulation management: results from the role of coumadin in preventing thromboembolism in atrial fibrillation (AF) patients undergoing catheter ablation (COMPARE) randomized trial. Circulation2014;129(25):2638-44. [DOI: 10.1161/circulationaha.113.006426]NCT01006876. Role of coumadin in preventing thromboembolism in atrial fibrillation (AF) patients undergoing catheter ablation. clinicaltrials.gov/ct2/show/NCT01006876 (first received 3 November 2009). '>Di Biase 2014</a>; <a href="./references#CD013504-bbs2-0003" title="NagaoT , SuzukiH , MatsunagaS , NishikawaY , HaradaK , MamiyaK . Impact of periprocedural anticoagulation therapy on the incidence of silent stroke after atrial fibrillation ablation in patients receiving direct oral anticoagulants: uninterrupted vs. interrupted by one dose strategy. Europace2019;21(4):590-7. [DOI: 10.1093/europace/euy224]">Nagao 2019</a>; <a href="./references#CD013504-bbs2-0004" title="Nakamura K, Naito S, Sasaki T, Take Y, Minami K, Kitagawa Y, et al. Uninterrupted vs. interrupted periprocedural direct oral anticoagulants for catheter ablation of atrial fibrillation: a prospective randomized single-centre study on post-ablation thrombo-embolic and haemorrhagic events. Europace2019;21(2):259-67. [DOI: 10.1093/europace/euy148]NakamuraK , SasakiT , TakeY , FunabashiN , NaitoS . Uninterrupted vs. interrupted periprocedural direct oral anticoagulants for catheter ablation of atrial fibrillation: a prospective randomized study on post-ablation thromboembolic and hemorrhagic events. Circulation2018;138:2. ">Nakamura 2019</a>; <a href="./references#CD013504-bbs2-0005" title="AonumaK . A prospective, multi-center, parallel-group comparison study to evaluate safety and efficacy of dabigatran during the perioperative period in patients with non-valvular atrial fibrillation who undergo the catheter ablation compared to warfarin. upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000015311 (first received 14 February 2014. GoyaM , NogamiA , HiraoK , AonumaK . Ablation perioperative dabigatran in use envisioning in Japan: the ABRIDGE-J study design. Journal of Cardiology2016;68(3):236-40. [DOI: 10.1016/j.jjcc.2015.10.003]]NogamiA , HaradaT , Sekiguchi Y, Otani R, YoshidaY , Yoshida K, et al. Safety and efficacy of minimally interrupted dabigatran vs uninterrupted warfarin therapy in adults undergoing atrial fibrillation catheter ablation: a randomized clinical trial. JAMA Network Open2019;2(4):15. [DOI: 10.1001/jamanetworkopen.2019.1994]NogamiA , HaradaT , YoshidaY , NakanoY , GoyaM , OrigasaH , et al. Clinical benefit of minimally-interrupted dabigatran versus uninterrupted warfarin for catheter ablation of atrial fibrillation: a prospective randomized multicenter trial. Circulation2017;136:e450. NogamiA , HaradaT , YoshidaY , NakanoY , GoyaM , OrigasaH , et al. Clinical benefit of minimally-interrupted dabigatran versus uninterrupted warfarin for catheter ablation of atrial fibrillation: a prospective randomized multicenter trial. Circulation2017;136(24):E450. [DOI: 10.1161/CIR.0000000000000546]UMIN000013129. A prospective, multi-center, parallel-group comparison study to evaluate safety and efficacy of dabigatran during the perioperative period in patients with non-valvular atrial fibrillation who undergo the catheter ablation compared to warfarin. www.who.int/trialsearch/Trial2.aspx?TrialID=JPRN-UMIN000013129 (first received 1 March 2014). ">Nogami 2019</a>; <a href="./references#CD013504-bbs2-0006" title="ReynoldsMR , AllisonJS , NataleA , WeisbergIL , EllenbogenKA , RichardsM , et al. Apixaban evaluation of interrupted or uninterrupted anticoagulation for ablation of atrial fibrillation. clinicaltrials.gov/show/NCT02608099 (first received 18 November 2015). ReynoldsMR , AllisonJS , NataleA , WeisbergIL , EllenbogenKA , RichardsM , et al. A prospective randomized trial of apixaban dosing during atrial fibrillation ablation: the AEIOU trial. JACC Clinical Electrophysiology2018;4(5):580-8. [DOI: 10.1016/j.jacep.2017.11.005]">Reynolds 2018</a>; <a href="./references#CD013504-bbs2-0007" title="TabishH , ShahzadK . Anticoagulation safety window among elderly Chinese patients with atrial fibrillation catheter ablation. Journal of the Saudi Heart Association2010;22(2):99-100. [DOI: 10.1016/j.jsha.2010.02.325]">Tabish 2010</a>; <a href="./references#CD013504-bbs2-0008" title="XingY , XuB , XuC , PengF , YangB , QiuY , et al. Efficacy and safety of uninterrupted low-intensity warfarin for radiofrequency catheter ablation of atrial fibrillation in the elderly. Annals of Pharmacotherapy2017;51(9):735-42. [DOI: 10.1177/1060028017712532]">Xing 2017</a>; <a href="./references#CD013504-bbs2-0009" title="YamajiH , MurakamiT , HinaK , HigashiyaS , KawamuraH , MurakamiM , et al. Activated clotting time on the day of atrial fibrillation ablation for minimally interrupted and uninterrupted direct oral anticoagulation therapy: sequential changes, differences among direct oral anticoagulants, and ablation safety outcomes. Journal of Cardiovascular Electrophysiology2019;30(12):2823-33. [DOI: 10.1111/jce.14260]">Yamaji 2019</a>; <a href="./references#CD013504-bbs2-0010" title="YohM , TakagiM , YoshioT , TakahashiH , ShiojimaI . AP19-00329. Safety and efficacy of uninterrupted and interrupted periprocedural direct oral anticoagulants in patients undergoing radiofrequency catheter ablation for atrial fibrillation. Journal of Arrhythmia2019;35(S1):134. [DOI: 10.1002/joa3.12267]">Yoh 2019</a>; <a href="./references#CD013504-bbs2-0011" title="IrikiY , IchikiH , OketaniN , YoshimuraA , OkuiH , MaenosonoR , et al. Evaluation of safety and efficacy of perioperative use of rivaroxaban and apixaban in catheter ablation for atrial fibrillation. European Heart Journal2015;36:687. [DOI: 10.1093/eurheartj/ehv400]YoshimuraA , IrikiY , IchikiH , OketaniN , OkuiH , MaenosonoR , et al. Evaluation of safety and efficacy of periprocedural use of rivaroxaban and apixaban in catheter ablation for atrial fibrillation. Journal of Cardiology2017;69(1):228-35. [DOI: 10.1016/j.jjcc.2016.03.014]">Yoshimura 2017</a>; <a href="./references#CD013504-bbs2-0012" title="YuHT , ShimJ , ParkJ , KimTH , UhmJS , KimJY , et al. When is it appropriate to stop non-vitamin K antagonist oral anticoagulants before catheter ablation of atrial fibrillation? A multi-center prospective randomized study. Europace2019;21:ii804. YuHT , ShimJ , ParkJ , KimTH , UhmJS , KimJY , et al. When is it appropriate to stop non-vitamin K antagonist oral anticoagulants before catheter ablation of atrial fibrillation? A multicentre prospective randomized study. European Heart Journal2019;40(19):1531-7. [DOI: 10.1093/eurheartj/ehy870]">Yu 2019</a>). Six studies reported no events. </p> <p>Eleven studies reported major bleeding (<a href="./references#CD013504-bbs2-0001" title="AndoM , IndenY , YoshidaY , SairakuA , YanagisawaS , SuzukiH , et al. Differences in prothrombotic response between the uninterrupted and interrupted apixaban therapies in patients undergoing cryoballoon ablation for paroxysmal atrial fibrillation: a randomized controlled study. Heart Vessels2019;34(9):1533-41. [DOI: 10.1007/s00380-019-01370-9]">Ando 2019</a>; <a href="./references#CD013504-bbs2-0002" title='Di BiaseL , BurkhardtJD , SantangeliP , MohantyP , SanchezJ , BaiR , et al. Periprocedural strokes and anticoagulation management during AF ablation: results from the "Compare" randomized multicenter trial. Circulation2013;128:A14307. Di BiaseL , BurkhardtJD , SantangeliP , MohantyP , SanchezJ , BaiR , et al. Silent thromboembolic lesions following catheter ablation for atrial fibrillation using radiofrequency energy: results from a sub-study of the "compare" randomized trial. Circulation2013;128(22 Suppl 1):A14293. Di BiaseL , BurkhardtJD , SantangeliP , MohantyP , SanchezJ , HortonR , et al. Periprocedural stroke and bleeding complications in patients undergoing catheter ablation of atrial fibrillation with different anticoagulation management: results from the "compare" randomized trial. Heart Rhythm2013;10(9):1411. Di BiaseL , BurkhardtJD , SantangeliP , MohantyP , SanchezJE , HortonR , et al. Periprocedural stroke and bleeding complications in patients undergoing catheter ablation of atrial fibrillation with different anticoagulation management: results from the role of coumadin in preventing thromboembolism in atrial fibrillation (AF) patients undergoing catheter ablation (COMPARE) randomized trial. Circulation2014;129(25):2638-44. [DOI: 10.1161/circulationaha.113.006426]NCT01006876. Role of coumadin in preventing thromboembolism in atrial fibrillation (AF) patients undergoing catheter ablation. clinicaltrials.gov/ct2/show/NCT01006876 (first received 3 November 2009). '>Di Biase 2014</a>; <a href="./references#CD013504-bbs2-0003" title="NagaoT , SuzukiH , MatsunagaS , NishikawaY , HaradaK , MamiyaK . Impact of periprocedural anticoagulation therapy on the incidence of silent stroke after atrial fibrillation ablation in patients receiving direct oral anticoagulants: uninterrupted vs. interrupted by one dose strategy. Europace2019;21(4):590-7. [DOI: 10.1093/europace/euy224]">Nagao 2019</a>; <a href="./references#CD013504-bbs2-0004" title="Nakamura K, Naito S, Sasaki T, Take Y, Minami K, Kitagawa Y, et al. Uninterrupted vs. interrupted periprocedural direct oral anticoagulants for catheter ablation of atrial fibrillation: a prospective randomized single-centre study on post-ablation thrombo-embolic and haemorrhagic events. Europace2019;21(2):259-67. [DOI: 10.1093/europace/euy148]NakamuraK , SasakiT , TakeY , FunabashiN , NaitoS . Uninterrupted vs. interrupted periprocedural direct oral anticoagulants for catheter ablation of atrial fibrillation: a prospective randomized study on post-ablation thromboembolic and hemorrhagic events. Circulation2018;138:2. ">Nakamura 2019</a>; <a href="./references#CD013504-bbs2-0005" title="AonumaK . A prospective, multi-center, parallel-group comparison study to evaluate safety and efficacy of dabigatran during the perioperative period in patients with non-valvular atrial fibrillation who undergo the catheter ablation compared to warfarin. upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000015311 (first received 14 February 2014. GoyaM , NogamiA , HiraoK , AonumaK . Ablation perioperative dabigatran in use envisioning in Japan: the ABRIDGE-J study design. Journal of Cardiology2016;68(3):236-40. [DOI: 10.1016/j.jjcc.2015.10.003]]NogamiA , HaradaT , Sekiguchi Y, Otani R, YoshidaY , Yoshida K, et al. Safety and efficacy of minimally interrupted dabigatran vs uninterrupted warfarin therapy in adults undergoing atrial fibrillation catheter ablation: a randomized clinical trial. JAMA Network Open2019;2(4):15. [DOI: 10.1001/jamanetworkopen.2019.1994]NogamiA , HaradaT , YoshidaY , NakanoY , GoyaM , OrigasaH , et al. Clinical benefit of minimally-interrupted dabigatran versus uninterrupted warfarin for catheter ablation of atrial fibrillation: a prospective randomized multicenter trial. Circulation2017;136:e450. NogamiA , HaradaT , YoshidaY , NakanoY , GoyaM , OrigasaH , et al. Clinical benefit of minimally-interrupted dabigatran versus uninterrupted warfarin for catheter ablation of atrial fibrillation: a prospective randomized multicenter trial. Circulation2017;136(24):E450. [DOI: 10.1161/CIR.0000000000000546]UMIN000013129. A prospective, multi-center, parallel-group comparison study to evaluate safety and efficacy of dabigatran during the perioperative period in patients with non-valvular atrial fibrillation who undergo the catheter ablation compared to warfarin. www.who.int/trialsearch/Trial2.aspx?TrialID=JPRN-UMIN000013129 (first received 1 March 2014). ">Nogami 2019</a>; <a href="./references#CD013504-bbs2-0006" title="ReynoldsMR , AllisonJS , NataleA , WeisbergIL , EllenbogenKA , RichardsM , et al. Apixaban evaluation of interrupted or uninterrupted anticoagulation for ablation of atrial fibrillation. clinicaltrials.gov/show/NCT02608099 (first received 18 November 2015). ReynoldsMR , AllisonJS , NataleA , WeisbergIL , EllenbogenKA , RichardsM , et al. A prospective randomized trial of apixaban dosing during atrial fibrillation ablation: the AEIOU trial. JACC Clinical Electrophysiology2018;4(5):580-8. [DOI: 10.1016/j.jacep.2017.11.005]">Reynolds 2018</a>; <a href="./references#CD013504-bbs2-0008" title="XingY , XuB , XuC , PengF , YangB , QiuY , et al. Efficacy and safety of uninterrupted low-intensity warfarin for radiofrequency catheter ablation of atrial fibrillation in the elderly. Annals of Pharmacotherapy2017;51(9):735-42. [DOI: 10.1177/1060028017712532]">Xing 2017</a>; <a href="./references#CD013504-bbs2-0009" title="YamajiH , MurakamiT , HinaK , HigashiyaS , KawamuraH , MurakamiM , et al. Activated clotting time on the day of atrial fibrillation ablation for minimally interrupted and uninterrupted direct oral anticoagulation therapy: sequential changes, differences among direct oral anticoagulants, and ablation safety outcomes. Journal of Cardiovascular Electrophysiology2019;30(12):2823-33. [DOI: 10.1111/jce.14260]">Yamaji 2019</a>; <a href="./references#CD013504-bbs2-0010" title="YohM , TakagiM , YoshioT , TakahashiH , ShiojimaI . AP19-00329. Safety and efficacy of uninterrupted and interrupted periprocedural direct oral anticoagulants in patients undergoing radiofrequency catheter ablation for atrial fibrillation. Journal of Arrhythmia2019;35(S1):134. [DOI: 10.1002/joa3.12267]">Yoh 2019</a>; <a href="./references#CD013504-bbs2-0011" title="IrikiY , IchikiH , OketaniN , YoshimuraA , OkuiH , MaenosonoR , et al. Evaluation of safety and efficacy of perioperative use of rivaroxaban and apixaban in catheter ablation for atrial fibrillation. European Heart Journal2015;36:687. [DOI: 10.1093/eurheartj/ehv400]YoshimuraA , IrikiY , IchikiH , OketaniN , OkuiH , MaenosonoR , et al. Evaluation of safety and efficacy of periprocedural use of rivaroxaban and apixaban in catheter ablation for atrial fibrillation. Journal of Cardiology2017;69(1):228-35. [DOI: 10.1016/j.jjcc.2016.03.014]">Yoshimura 2017</a>; <a href="./references#CD013504-bbs2-0012" title="YuHT , ShimJ , ParkJ , KimTH , UhmJS , KimJY , et al. When is it appropriate to stop non-vitamin K antagonist oral anticoagulants before catheter ablation of atrial fibrillation? A multi-center prospective randomized study. Europace2019;21:ii804. YuHT , ShimJ , ParkJ , KimTH , UhmJS , KimJY , et al. When is it appropriate to stop non-vitamin K antagonist oral anticoagulants before catheter ablation of atrial fibrillation? A multicentre prospective randomized study. European Heart Journal2019;40(19):1531-7. [DOI: 10.1093/eurheartj/ehy870]">Yu 2019</a>). Major bleeding definitions used across studies were International Society of Thrombosis and Hemostasis (ISTH) criteria (<a href="./references#CD013504-bbs2-0001" title="AndoM , IndenY , YoshidaY , SairakuA , YanagisawaS , SuzukiH , et al. Differences in prothrombotic response between the uninterrupted and interrupted apixaban therapies in patients undergoing cryoballoon ablation for paroxysmal atrial fibrillation: a randomized controlled study. Heart Vessels2019;34(9):1533-41. [DOI: 10.1007/s00380-019-01370-9]">Ando 2019</a>; <a href="./references#CD013504-bbs2-0005" title="AonumaK . A prospective, multi-center, parallel-group comparison study to evaluate safety and efficacy of dabigatran during the perioperative period in patients with non-valvular atrial fibrillation who undergo the catheter ablation compared to warfarin. upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000015311 (first received 14 February 2014. GoyaM , NogamiA , HiraoK , AonumaK . Ablation perioperative dabigatran in use envisioning in Japan: the ABRIDGE-J study design. Journal of Cardiology2016;68(3):236-40. [DOI: 10.1016/j.jjcc.2015.10.003]]NogamiA , HaradaT , Sekiguchi Y, Otani R, YoshidaY , Yoshida K, et al. Safety and efficacy of minimally interrupted dabigatran vs uninterrupted warfarin therapy in adults undergoing atrial fibrillation catheter ablation: a randomized clinical trial. JAMA Network Open2019;2(4):15. [DOI: 10.1001/jamanetworkopen.2019.1994]NogamiA , HaradaT , YoshidaY , NakanoY , GoyaM , OrigasaH , et al. Clinical benefit of minimally-interrupted dabigatran versus uninterrupted warfarin for catheter ablation of atrial fibrillation: a prospective randomized multicenter trial. Circulation2017;136:e450. NogamiA , HaradaT , YoshidaY , NakanoY , GoyaM , OrigasaH , et al. Clinical benefit of minimally-interrupted dabigatran versus uninterrupted warfarin for catheter ablation of atrial fibrillation: a prospective randomized multicenter trial. Circulation2017;136(24):E450. [DOI: 10.1161/CIR.0000000000000546]UMIN000013129. A prospective, multi-center, parallel-group comparison study to evaluate safety and efficacy of dabigatran during the perioperative period in patients with non-valvular atrial fibrillation who undergo the catheter ablation compared to warfarin. www.who.int/trialsearch/Trial2.aspx?TrialID=JPRN-UMIN000013129 (first received 1 March 2014). ">Nogami 2019</a>; <a href="./references#CD013504-bbs2-0012" title="YuHT , ShimJ , ParkJ , KimTH , UhmJS , KimJY , et al. When is it appropriate to stop non-vitamin K antagonist oral anticoagulants before catheter ablation of atrial fibrillation? A multi-center prospective randomized study. Europace2019;21:ii804. YuHT , ShimJ , ParkJ , KimTH , UhmJS , KimJY , et al. When is it appropriate to stop non-vitamin K antagonist oral anticoagulants before catheter ablation of atrial fibrillation? A multicentre prospective randomized study. European Heart Journal2019;40(19):1531-7. [DOI: 10.1093/eurheartj/ehy870]">Yu 2019</a>), Bleeding Academic Research Consortium (BARC) 3 or greater (<a href="./references#CD013504-bbs2-0006" title="ReynoldsMR , AllisonJS , NataleA , WeisbergIL , EllenbogenKA , RichardsM , et al. Apixaban evaluation of interrupted or uninterrupted anticoagulation for ablation of atrial fibrillation. clinicaltrials.gov/show/NCT02608099 (first received 18 November 2015). ReynoldsMR , AllisonJS , NataleA , WeisbergIL , EllenbogenKA , RichardsM , et al. A prospective randomized trial of apixaban dosing during atrial fibrillation ablation: the AEIOU trial. JACC Clinical Electrophysiology2018;4(5):580-8. [DOI: 10.1016/j.jacep.2017.11.005]">Reynolds 2018</a>), bleeding into a critical anatomical site (<a href="./references#CD013504-bbs2-0010" title="YohM , TakagiM , YoshioT , TakahashiH , ShiojimaI . AP19-00329. Safety and efficacy of uninterrupted and interrupted periprocedural direct oral anticoagulants in patients undergoing radiofrequency catheter ablation for atrial fibrillation. Journal of Arrhythmia2019;35(S1):134. [DOI: 10.1002/joa3.12267]">Yoh 2019</a>), or bleeding requiring intervention in remaining studies. </p> <p>Six studies reported minor bleeding (<a href="./references#CD013504-bbs2-0002" title='Di BiaseL , BurkhardtJD , SantangeliP , MohantyP , SanchezJ , BaiR , et al. Periprocedural strokes and anticoagulation management during AF ablation: results from the "Compare" randomized multicenter trial. Circulation2013;128:A14307. Di BiaseL , BurkhardtJD , SantangeliP , MohantyP , SanchezJ , BaiR , et al. Silent thromboembolic lesions following catheter ablation for atrial fibrillation using radiofrequency energy: results from a sub-study of the "compare" randomized trial. Circulation2013;128(22 Suppl 1):A14293. Di BiaseL , BurkhardtJD , SantangeliP , MohantyP , SanchezJ , HortonR , et al. Periprocedural stroke and bleeding complications in patients undergoing catheter ablation of atrial fibrillation with different anticoagulation management: results from the "compare" randomized trial. Heart Rhythm2013;10(9):1411. Di BiaseL , BurkhardtJD , SantangeliP , MohantyP , SanchezJE , HortonR , et al. Periprocedural stroke and bleeding complications in patients undergoing catheter ablation of atrial fibrillation with different anticoagulation management: results from the role of coumadin in preventing thromboembolism in atrial fibrillation (AF) patients undergoing catheter ablation (COMPARE) randomized trial. Circulation2014;129(25):2638-44. [DOI: 10.1161/circulationaha.113.006426]NCT01006876. Role of coumadin in preventing thromboembolism in atrial fibrillation (AF) patients undergoing catheter ablation. clinicaltrials.gov/ct2/show/NCT01006876 (first received 3 November 2009). '>Di Biase 2014</a>; <a href="./references#CD013504-bbs2-0003" title="NagaoT , SuzukiH , MatsunagaS , NishikawaY , HaradaK , MamiyaK . Impact of periprocedural anticoagulation therapy on the incidence of silent stroke after atrial fibrillation ablation in patients receiving direct oral anticoagulants: uninterrupted vs. interrupted by one dose strategy. Europace2019;21(4):590-7. [DOI: 10.1093/europace/euy224]">Nagao 2019</a>; <a href="./references#CD013504-bbs2-0004" title="Nakamura K, Naito S, Sasaki T, Take Y, Minami K, Kitagawa Y, et al. Uninterrupted vs. interrupted periprocedural direct oral anticoagulants for catheter ablation of atrial fibrillation: a prospective randomized single-centre study on post-ablation thrombo-embolic and haemorrhagic events. Europace2019;21(2):259-67. [DOI: 10.1093/europace/euy148]NakamuraK , SasakiT , TakeY , FunabashiN , NaitoS . Uninterrupted vs. interrupted periprocedural direct oral anticoagulants for catheter ablation of atrial fibrillation: a prospective randomized study on post-ablation thromboembolic and hemorrhagic events. Circulation2018;138:2. ">Nakamura 2019</a>; <a href="./references#CD013504-bbs2-0008" title="XingY , XuB , XuC , PengF , YangB , QiuY , et al. Efficacy and safety of uninterrupted low-intensity warfarin for radiofrequency catheter ablation of atrial fibrillation in the elderly. Annals of Pharmacotherapy2017;51(9):735-42. [DOI: 10.1177/1060028017712532]">Xing 2017</a>; <a href="./references#CD013504-bbs2-0010" title="YohM , TakagiM , YoshioT , TakahashiH , ShiojimaI . AP19-00329. Safety and efficacy of uninterrupted and interrupted periprocedural direct oral anticoagulants in patients undergoing radiofrequency catheter ablation for atrial fibrillation. Journal of Arrhythmia2019;35(S1):134. [DOI: 10.1002/joa3.12267]">Yoh 2019</a>; <a href="./references#CD013504-bbs2-0012" title="YuHT , ShimJ , ParkJ , KimTH , UhmJS , KimJY , et al. When is it appropriate to stop non-vitamin K antagonist oral anticoagulants before catheter ablation of atrial fibrillation? A multi-center prospective randomized study. Europace2019;21:ii804. YuHT , ShimJ , ParkJ , KimTH , UhmJS , KimJY , et al. When is it appropriate to stop non-vitamin K antagonist oral anticoagulants before catheter ablation of atrial fibrillation? A multicentre prospective randomized study. European Heart Journal2019;40(19):1531-7. [DOI: 10.1093/eurheartj/ehy870]">Yu 2019</a>). <a href="./references#CD013504-bbs2-0005" title="AonumaK . A prospective, multi-center, parallel-group comparison study to evaluate safety and efficacy of dabigatran during the perioperative period in patients with non-valvular atrial fibrillation who undergo the catheter ablation compared to warfarin. upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000015311 (first received 14 February 2014. GoyaM , NogamiA , HiraoK , AonumaK . Ablation perioperative dabigatran in use envisioning in Japan: the ABRIDGE-J study design. Journal of Cardiology2016;68(3):236-40. [DOI: 10.1016/j.jjcc.2015.10.003]]NogamiA , HaradaT , Sekiguchi Y, Otani R, YoshidaY , Yoshida K, et al. Safety and efficacy of minimally interrupted dabigatran vs uninterrupted warfarin therapy in adults undergoing atrial fibrillation catheter ablation: a randomized clinical trial. JAMA Network Open2019;2(4):15. [DOI: 10.1001/jamanetworkopen.2019.1994]NogamiA , HaradaT , YoshidaY , NakanoY , GoyaM , OrigasaH , et al. Clinical benefit of minimally-interrupted dabigatran versus uninterrupted warfarin for catheter ablation of atrial fibrillation: a prospective randomized multicenter trial. Circulation2017;136:e450. NogamiA , HaradaT , YoshidaY , NakanoY , GoyaM , OrigasaH , et al. Clinical benefit of minimally-interrupted dabigatran versus uninterrupted warfarin for catheter ablation of atrial fibrillation: a prospective randomized multicenter trial. Circulation2017;136(24):E450. [DOI: 10.1161/CIR.0000000000000546]UMIN000013129. A prospective, multi-center, parallel-group comparison study to evaluate safety and efficacy of dabigatran during the perioperative period in patients with non-valvular atrial fibrillation who undergo the catheter ablation compared to warfarin. www.who.int/trialsearch/Trial2.aspx?TrialID=JPRN-UMIN000013129 (first received 1 March 2014). ">Nogami 2019</a> reported on minor bleeding within a composite endpoint but not separately. </p> <p>Two studies reported all cause‐mortality (<a href="./references#CD013504-bbs2-0005" title="AonumaK . A prospective, multi-center, parallel-group comparison study to evaluate safety and efficacy of dabigatran during the perioperative period in patients with non-valvular atrial fibrillation who undergo the catheter ablation compared to warfarin. upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000015311 (first received 14 February 2014. GoyaM , NogamiA , HiraoK , AonumaK . Ablation perioperative dabigatran in use envisioning in Japan: the ABRIDGE-J study design. Journal of Cardiology2016;68(3):236-40. [DOI: 10.1016/j.jjcc.2015.10.003]]NogamiA , HaradaT , Sekiguchi Y, Otani R, YoshidaY , Yoshida K, et al. Safety and efficacy of minimally interrupted dabigatran vs uninterrupted warfarin therapy in adults undergoing atrial fibrillation catheter ablation: a randomized clinical trial. JAMA Network Open2019;2(4):15. [DOI: 10.1001/jamanetworkopen.2019.1994]NogamiA , HaradaT , YoshidaY , NakanoY , GoyaM , OrigasaH , et al. Clinical benefit of minimally-interrupted dabigatran versus uninterrupted warfarin for catheter ablation of atrial fibrillation: a prospective randomized multicenter trial. Circulation2017;136:e450. NogamiA , HaradaT , YoshidaY , NakanoY , GoyaM , OrigasaH , et al. Clinical benefit of minimally-interrupted dabigatran versus uninterrupted warfarin for catheter ablation of atrial fibrillation: a prospective randomized multicenter trial. Circulation2017;136(24):E450. [DOI: 10.1161/CIR.0000000000000546]UMIN000013129. A prospective, multi-center, parallel-group comparison study to evaluate safety and efficacy of dabigatran during the perioperative period in patients with non-valvular atrial fibrillation who undergo the catheter ablation compared to warfarin. www.who.int/trialsearch/Trial2.aspx?TrialID=JPRN-UMIN000013129 (first received 1 March 2014). ">Nogami 2019</a>; <a href="./references#CD013504-bbs2-0006" title="ReynoldsMR , AllisonJS , NataleA , WeisbergIL , EllenbogenKA , RichardsM , et al. Apixaban evaluation of interrupted or uninterrupted anticoagulation for ablation of atrial fibrillation. clinicaltrials.gov/show/NCT02608099 (first received 18 November 2015). ReynoldsMR , AllisonJS , NataleA , WeisbergIL , EllenbogenKA , RichardsM , et al. A prospective randomized trial of apixaban dosing during atrial fibrillation ablation: the AEIOU trial. JACC Clinical Electrophysiology2018;4(5):580-8. [DOI: 10.1016/j.jacep.2017.11.005]">Reynolds 2018</a>); <a href="./references#CD013504-bbs2-0006" title="ReynoldsMR , AllisonJS , NataleA , WeisbergIL , EllenbogenKA , RichardsM , et al. Apixaban evaluation of interrupted or uninterrupted anticoagulation for ablation of atrial fibrillation. clinicaltrials.gov/show/NCT02608099 (first received 18 November 2015). ReynoldsMR , AllisonJS , NataleA , WeisbergIL , EllenbogenKA , RichardsM , et al. A prospective randomized trial of apixaban dosing during atrial fibrillation ablation: the AEIOU trial. JACC Clinical Electrophysiology2018;4(5):580-8. [DOI: 10.1016/j.jacep.2017.11.005]">Reynolds 2018</a> reported zero events.  </p> <p>Six studies reported asymptomatic thromboembolic events (<a href="./references#CD013504-bbs2-0002" title='Di BiaseL , BurkhardtJD , SantangeliP , MohantyP , SanchezJ , BaiR , et al. Periprocedural strokes and anticoagulation management during AF ablation: results from the "Compare" randomized multicenter trial. Circulation2013;128:A14307. Di BiaseL , BurkhardtJD , SantangeliP , MohantyP , SanchezJ , BaiR , et al. Silent thromboembolic lesions following catheter ablation for atrial fibrillation using radiofrequency energy: results from a sub-study of the "compare" randomized trial. Circulation2013;128(22 Suppl 1):A14293. Di BiaseL , BurkhardtJD , SantangeliP , MohantyP , SanchezJ , HortonR , et al. Periprocedural stroke and bleeding complications in patients undergoing catheter ablation of atrial fibrillation with different anticoagulation management: results from the "compare" randomized trial. Heart Rhythm2013;10(9):1411. Di BiaseL , BurkhardtJD , SantangeliP , MohantyP , SanchezJE , HortonR , et al. Periprocedural stroke and bleeding complications in patients undergoing catheter ablation of atrial fibrillation with different anticoagulation management: results from the role of coumadin in preventing thromboembolism in atrial fibrillation (AF) patients undergoing catheter ablation (COMPARE) randomized trial. Circulation2014;129(25):2638-44. [DOI: 10.1161/circulationaha.113.006426]NCT01006876. Role of coumadin in preventing thromboembolism in atrial fibrillation (AF) patients undergoing catheter ablation. clinicaltrials.gov/ct2/show/NCT01006876 (first received 3 November 2009). '>Di Biase 2014</a>; <a href="./references#CD013504-bbs2-0003" title="NagaoT , SuzukiH , MatsunagaS , NishikawaY , HaradaK , MamiyaK . Impact of periprocedural anticoagulation therapy on the incidence of silent stroke after atrial fibrillation ablation in patients receiving direct oral anticoagulants: uninterrupted vs. interrupted by one dose strategy. Europace2019;21(4):590-7. [DOI: 10.1093/europace/euy224]">Nagao 2019</a>; <a href="./references#CD013504-bbs2-0004" title="Nakamura K, Naito S, Sasaki T, Take Y, Minami K, Kitagawa Y, et al. Uninterrupted vs. interrupted periprocedural direct oral anticoagulants for catheter ablation of atrial fibrillation: a prospective randomized single-centre study on post-ablation thrombo-embolic and haemorrhagic events. Europace2019;21(2):259-67. [DOI: 10.1093/europace/euy148]NakamuraK , SasakiT , TakeY , FunabashiN , NaitoS . Uninterrupted vs. interrupted periprocedural direct oral anticoagulants for catheter ablation of atrial fibrillation: a prospective randomized study on post-ablation thromboembolic and hemorrhagic events. Circulation2018;138:2. ">Nakamura 2019</a>; <a href="./references#CD013504-bbs2-0008" title="XingY , XuB , XuC , PengF , YangB , QiuY , et al. Efficacy and safety of uninterrupted low-intensity warfarin for radiofrequency catheter ablation of atrial fibrillation in the elderly. Annals of Pharmacotherapy2017;51(9):735-42. [DOI: 10.1177/1060028017712532]">Xing 2017</a>; <a href="./references#CD013504-bbs2-0010" title="YohM , TakagiM , YoshioT , TakahashiH , ShiojimaI . AP19-00329. Safety and efficacy of uninterrupted and interrupted periprocedural direct oral anticoagulants in patients undergoing radiofrequency catheter ablation for atrial fibrillation. Journal of Arrhythmia2019;35(S1):134. [DOI: 10.1002/joa3.12267]">Yoh 2019</a>; <a href="./references#CD013504-bbs2-0011" title="IrikiY , IchikiH , OketaniN , YoshimuraA , OkuiH , MaenosonoR , et al. Evaluation of safety and efficacy of perioperative use of rivaroxaban and apixaban in catheter ablation for atrial fibrillation. European Heart Journal2015;36:687. [DOI: 10.1093/eurheartj/ehv400]YoshimuraA , IrikiY , IchikiH , OketaniN , OkuiH , MaenosonoR , et al. Evaluation of safety and efficacy of periprocedural use of rivaroxaban and apixaban in catheter ablation for atrial fibrillation. Journal of Cardiology2017;69(1):228-35. [DOI: 10.1016/j.jjcc.2016.03.014]">Yoshimura 2017</a>). Although the trials used variable terms for the events, all trials agreed on the lack of neurological symptoms and all used magnetic resonance imaging (MRI) to detect this outcome. <a href="./references#CD013504-bbs2-0078" title="Deneke T,  Jais P,  Scaglione M,  SchmittR ,  Di BiaseL ,  Christopoulos G, et al. Silent cerebral events/lesions related to atrial fibrillation ablation: a clinical review. Journal of Cardiovascular Electrophysiology2015;26:455-63.">Deneke 2015</a> defined the silent cerebral event as "an acute new MRI‐detected brain lesion typical to cerebral ischaemia in a patient without clinically apparent neurological deficit." In that clinical review, the author related silent cerebral events and silent cerebral lesions to cerebral ischaemic infarcts due to embolic "fingerprint" specific to the type of ablation procedure. Therefore, we believed that despite the different terms used they reflected a relatively similar outcome. <a href="./references#CD013504-bbs2-0002" title='Di BiaseL , BurkhardtJD , SantangeliP , MohantyP , SanchezJ , BaiR , et al. Periprocedural strokes and anticoagulation management during AF ablation: results from the "Compare" randomized multicenter trial. Circulation2013;128:A14307. Di BiaseL , BurkhardtJD , SantangeliP , MohantyP , SanchezJ , BaiR , et al. Silent thromboembolic lesions following catheter ablation for atrial fibrillation using radiofrequency energy: results from a sub-study of the "compare" randomized trial. Circulation2013;128(22 Suppl 1):A14293. Di BiaseL , BurkhardtJD , SantangeliP , MohantyP , SanchezJ , HortonR , et al. Periprocedural stroke and bleeding complications in patients undergoing catheter ablation of atrial fibrillation with different anticoagulation management: results from the "compare" randomized trial. Heart Rhythm2013;10(9):1411. Di BiaseL , BurkhardtJD , SantangeliP , MohantyP , SanchezJE , HortonR , et al. Periprocedural stroke and bleeding complications in patients undergoing catheter ablation of atrial fibrillation with different anticoagulation management: results from the role of coumadin in preventing thromboembolism in atrial fibrillation (AF) patients undergoing catheter ablation (COMPARE) randomized trial. Circulation2014;129(25):2638-44. [DOI: 10.1161/circulationaha.113.006426]NCT01006876. Role of coumadin in preventing thromboembolism in atrial fibrillation (AF) patients undergoing catheter ablation. clinicaltrials.gov/ct2/show/NCT01006876 (first received 3 November 2009). '>Di Biase 2014</a> used the term silent thromboembolic lesion (STL), detected symptoms using diffusion magnetic resonance imaging (dMRI) and not resulting in clinical symptoms. <a href="./references#CD013504-bbs2-0003" title="NagaoT , SuzukiH , MatsunagaS , NishikawaY , HaradaK , MamiyaK . Impact of periprocedural anticoagulation therapy on the incidence of silent stroke after atrial fibrillation ablation in patients receiving direct oral anticoagulants: uninterrupted vs. interrupted by one dose strategy. Europace2019;21(4):590-7. [DOI: 10.1093/europace/euy224]">Nagao 2019</a> used the term silent stroke and was defined as a focal hyperintense region on the diffusion‐weighted (DW) image (DWI) despite the absence of corresponding clinical symptoms detected on MRI on the day after ablation. <a href="./references#CD013504-bbs2-0004" title="Nakamura K, Naito S, Sasaki T, Take Y, Minami K, Kitagawa Y, et al. Uninterrupted vs. interrupted periprocedural direct oral anticoagulants for catheter ablation of atrial fibrillation: a prospective randomized single-centre study on post-ablation thrombo-embolic and haemorrhagic events. Europace2019;21(2):259-67. [DOI: 10.1093/europace/euy148]NakamuraK , SasakiT , TakeY , FunabashiN , NaitoS . Uninterrupted vs. interrupted periprocedural direct oral anticoagulants for catheter ablation of atrial fibrillation: a prospective randomized study on post-ablation thromboembolic and hemorrhagic events. Circulation2018;138:2. ">Nakamura 2019</a> used the term silent cerebral ischaemic lesions (silent thromboembolism) defined as hyperintense lesions on magnetic resonance DWI, corresponding to a reduced apparent diffusion coefficient map detected on the day after ablation. The study also described detailed characteristics of DWI and the lesion size. <a href="./references#CD013504-bbs2-0008" title="XingY , XuB , XuC , PengF , YangB , QiuY , et al. Efficacy and safety of uninterrupted low-intensity warfarin for radiofrequency catheter ablation of atrial fibrillation in the elderly. Annals of Pharmacotherapy2017;51(9):735-42. [DOI: 10.1177/1060028017712532]">Xing 2017</a> used the term asymptomatic cerebral emboli (ACE) defined as focal hyperintense areas detected by the DW sequence without any symptoms detected by MRI seven days postablation. <a href="./references#CD013504-bbs2-0010" title="YohM , TakagiM , YoshioT , TakahashiH , ShiojimaI . AP19-00329. Safety and efficacy of uninterrupted and interrupted periprocedural direct oral anticoagulants in patients undergoing radiofrequency catheter ablation for atrial fibrillation. Journal of Arrhythmia2019;35(S1):134. [DOI: 10.1002/joa3.12267]">Yoh 2019</a> used the term silent cerebral ischaemia defined as a lesion detected by brain MRI after the procedure, without any symptoms. <a href="./references#CD013504-bbs2-0011" title="IrikiY , IchikiH , OketaniN , YoshimuraA , OkuiH , MaenosonoR , et al. Evaluation of safety and efficacy of perioperative use of rivaroxaban and apixaban in catheter ablation for atrial fibrillation. European Heart Journal2015;36:687. [DOI: 10.1093/eurheartj/ehv400]YoshimuraA , IrikiY , IchikiH , OketaniN , OkuiH , MaenosonoR , et al. Evaluation of safety and efficacy of periprocedural use of rivaroxaban and apixaban in catheter ablation for atrial fibrillation. Journal of Cardiology2017;69(1):228-35. [DOI: 10.1016/j.jjcc.2016.03.014]">Yoshimura 2017</a> used the term asymptomatic cerebral micro‐thromboembolism detected by MRI on the day after the procedure. Except for <a href="./references#CD013504-bbs2-0002" title='Di BiaseL , BurkhardtJD , SantangeliP , MohantyP , SanchezJ , BaiR , et al. Periprocedural strokes and anticoagulation management during AF ablation: results from the "Compare" randomized multicenter trial. Circulation2013;128:A14307. Di BiaseL , BurkhardtJD , SantangeliP , MohantyP , SanchezJ , BaiR , et al. Silent thromboembolic lesions following catheter ablation for atrial fibrillation using radiofrequency energy: results from a sub-study of the "compare" randomized trial. Circulation2013;128(22 Suppl 1):A14293. Di BiaseL , BurkhardtJD , SantangeliP , MohantyP , SanchezJ , HortonR , et al. Periprocedural stroke and bleeding complications in patients undergoing catheter ablation of atrial fibrillation with different anticoagulation management: results from the "compare" randomized trial. Heart Rhythm2013;10(9):1411. Di BiaseL , BurkhardtJD , SantangeliP , MohantyP , SanchezJE , HortonR , et al. Periprocedural stroke and bleeding complications in patients undergoing catheter ablation of atrial fibrillation with different anticoagulation management: results from the role of coumadin in preventing thromboembolism in atrial fibrillation (AF) patients undergoing catheter ablation (COMPARE) randomized trial. Circulation2014;129(25):2638-44. [DOI: 10.1161/circulationaha.113.006426]NCT01006876. Role of coumadin in preventing thromboembolism in atrial fibrillation (AF) patients undergoing catheter ablation. clinicaltrials.gov/ct2/show/NCT01006876 (first received 3 November 2009). '>Di Biase 2014</a>, all other trials performed only postablation MRI. </p> </section> <section id="CD013504-sec-0045"> <h5 class="title">Funding</h5> <p>Three studies reported funding by a non‐industrial entity, of which the source came from a governmental grant (<a href="./references#CD013504-bbs2-0012" title="YuHT , ShimJ , ParkJ , KimTH , UhmJS , KimJY , et al. When is it appropriate to stop non-vitamin K antagonist oral anticoagulants before catheter ablation of atrial fibrillation? A multi-center prospective randomized study. Europace2019;21:ii804. YuHT , ShimJ , ParkJ , KimTH , UhmJS , KimJY , et al. When is it appropriate to stop non-vitamin K antagonist oral anticoagulants before catheter ablation of atrial fibrillation? A multicentre prospective randomized study. European Heart Journal2019;40(19):1531-7. [DOI: 10.1093/eurheartj/ehy870]">Yu 2019</a>) and a grant from a private foundation or scientific society (<a href="./references#CD013504-bbs2-0002" title='Di BiaseL , BurkhardtJD , SantangeliP , MohantyP , SanchezJ , BaiR , et al. Periprocedural strokes and anticoagulation management during AF ablation: results from the "Compare" randomized multicenter trial. Circulation2013;128:A14307. Di BiaseL , BurkhardtJD , SantangeliP , MohantyP , SanchezJ , BaiR , et al. Silent thromboembolic lesions following catheter ablation for atrial fibrillation using radiofrequency energy: results from a sub-study of the "compare" randomized trial. Circulation2013;128(22 Suppl 1):A14293. Di BiaseL , BurkhardtJD , SantangeliP , MohantyP , SanchezJ , HortonR , et al. Periprocedural stroke and bleeding complications in patients undergoing catheter ablation of atrial fibrillation with different anticoagulation management: results from the "compare" randomized trial. Heart Rhythm2013;10(9):1411. Di BiaseL , BurkhardtJD , SantangeliP , MohantyP , SanchezJE , HortonR , et al. Periprocedural stroke and bleeding complications in patients undergoing catheter ablation of atrial fibrillation with different anticoagulation management: results from the role of coumadin in preventing thromboembolism in atrial fibrillation (AF) patients undergoing catheter ablation (COMPARE) randomized trial. Circulation2014;129(25):2638-44. [DOI: 10.1161/circulationaha.113.006426]NCT01006876. Role of coumadin in preventing thromboembolism in atrial fibrillation (AF) patients undergoing catheter ablation. clinicaltrials.gov/ct2/show/NCT01006876 (first received 3 November 2009). '>Di Biase 2014</a>; <a href="./references#CD013504-bbs2-0011" title="IrikiY , IchikiH , OketaniN , YoshimuraA , OkuiH , MaenosonoR , et al. Evaluation of safety and efficacy of perioperative use of rivaroxaban and apixaban in catheter ablation for atrial fibrillation. European Heart Journal2015;36:687. [DOI: 10.1093/eurheartj/ehv400]YoshimuraA , IrikiY , IchikiH , OketaniN , OkuiH , MaenosonoR , et al. Evaluation of safety and efficacy of periprocedural use of rivaroxaban and apixaban in catheter ablation for atrial fibrillation. Journal of Cardiology2017;69(1):228-35. [DOI: 10.1016/j.jjcc.2016.03.014]">Yoshimura 2017</a>), respectively. One study received no funding (<a href="./references#CD013504-bbs2-0008" title="XingY , XuB , XuC , PengF , YangB , QiuY , et al. Efficacy and safety of uninterrupted low-intensity warfarin for radiofrequency catheter ablation of atrial fibrillation in the elderly. Annals of Pharmacotherapy2017;51(9):735-42. [DOI: 10.1177/1060028017712532]">Xing 2017</a>). Two studies declared funding by the pharmaceutical industry (<a href="./references#CD013504-bbs2-0005" title="AonumaK . A prospective, multi-center, parallel-group comparison study to evaluate safety and efficacy of dabigatran during the perioperative period in patients with non-valvular atrial fibrillation who undergo the catheter ablation compared to warfarin. upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000015311 (first received 14 February 2014. GoyaM , NogamiA , HiraoK , AonumaK . Ablation perioperative dabigatran in use envisioning in Japan: the ABRIDGE-J study design. Journal of Cardiology2016;68(3):236-40. [DOI: 10.1016/j.jjcc.2015.10.003]]NogamiA , HaradaT , Sekiguchi Y, Otani R, YoshidaY , Yoshida K, et al. Safety and efficacy of minimally interrupted dabigatran vs uninterrupted warfarin therapy in adults undergoing atrial fibrillation catheter ablation: a randomized clinical trial. JAMA Network Open2019;2(4):15. [DOI: 10.1001/jamanetworkopen.2019.1994]NogamiA , HaradaT , YoshidaY , NakanoY , GoyaM , OrigasaH , et al. Clinical benefit of minimally-interrupted dabigatran versus uninterrupted warfarin for catheter ablation of atrial fibrillation: a prospective randomized multicenter trial. Circulation2017;136:e450. NogamiA , HaradaT , YoshidaY , NakanoY , GoyaM , OrigasaH , et al. Clinical benefit of minimally-interrupted dabigatran versus uninterrupted warfarin for catheter ablation of atrial fibrillation: a prospective randomized multicenter trial. Circulation2017;136(24):E450. [DOI: 10.1161/CIR.0000000000000546]UMIN000013129. A prospective, multi-center, parallel-group comparison study to evaluate safety and efficacy of dabigatran during the perioperative period in patients with non-valvular atrial fibrillation who undergo the catheter ablation compared to warfarin. www.who.int/trialsearch/Trial2.aspx?TrialID=JPRN-UMIN000013129 (first received 1 March 2014). ">Nogami 2019</a>; <a href="./references#CD013504-bbs2-0006" title="ReynoldsMR , AllisonJS , NataleA , WeisbergIL , EllenbogenKA , RichardsM , et al. Apixaban evaluation of interrupted or uninterrupted anticoagulation for ablation of atrial fibrillation. clinicaltrials.gov/show/NCT02608099 (first received 18 November 2015). ReynoldsMR , AllisonJS , NataleA , WeisbergIL , EllenbogenKA , RichardsM , et al. A prospective randomized trial of apixaban dosing during atrial fibrillation ablation: the AEIOU trial. JACC Clinical Electrophysiology2018;4(5):580-8. [DOI: 10.1016/j.jacep.2017.11.005]">Reynolds 2018</a>). <a href="./references#CD013504-bbs2-0005" title="AonumaK . A prospective, multi-center, parallel-group comparison study to evaluate safety and efficacy of dabigatran during the perioperative period in patients with non-valvular atrial fibrillation who undergo the catheter ablation compared to warfarin. upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000015311 (first received 14 February 2014. GoyaM , NogamiA , HiraoK , AonumaK . Ablation perioperative dabigatran in use envisioning in Japan: the ABRIDGE-J study design. Journal of Cardiology2016;68(3):236-40. [DOI: 10.1016/j.jjcc.2015.10.003]]NogamiA , HaradaT , Sekiguchi Y, Otani R, YoshidaY , Yoshida K, et al. Safety and efficacy of minimally interrupted dabigatran vs uninterrupted warfarin therapy in adults undergoing atrial fibrillation catheter ablation: a randomized clinical trial. JAMA Network Open2019;2(4):15. [DOI: 10.1001/jamanetworkopen.2019.1994]NogamiA , HaradaT , YoshidaY , NakanoY , GoyaM , OrigasaH , et al. Clinical benefit of minimally-interrupted dabigatran versus uninterrupted warfarin for catheter ablation of atrial fibrillation: a prospective randomized multicenter trial. Circulation2017;136:e450. NogamiA , HaradaT , YoshidaY , NakanoY , GoyaM , OrigasaH , et al. Clinical benefit of minimally-interrupted dabigatran versus uninterrupted warfarin for catheter ablation of atrial fibrillation: a prospective randomized multicenter trial. Circulation2017;136(24):E450. [DOI: 10.1161/CIR.0000000000000546]UMIN000013129. A prospective, multi-center, parallel-group comparison study to evaluate safety and efficacy of dabigatran during the perioperative period in patients with non-valvular atrial fibrillation who undergo the catheter ablation compared to warfarin. www.who.int/trialsearch/Trial2.aspx?TrialID=JPRN-UMIN000013129 (first received 1 March 2014). ">Nogami 2019</a> declared that the funding source had no role in any aspect of the study conduct and publication, whereas <a href="./references#CD013504-bbs2-0006" title="ReynoldsMR , AllisonJS , NataleA , WeisbergIL , EllenbogenKA , RichardsM , et al. Apixaban evaluation of interrupted or uninterrupted anticoagulation for ablation of atrial fibrillation. clinicaltrials.gov/show/NCT02608099 (first received 18 November 2015). ReynoldsMR , AllisonJS , NataleA , WeisbergIL , EllenbogenKA , RichardsM , et al. A prospective randomized trial of apixaban dosing during atrial fibrillation ablation: the AEIOU trial. JACC Clinical Electrophysiology2018;4(5):580-8. [DOI: 10.1016/j.jacep.2017.11.005]">Reynolds 2018</a> did not declare the role of the funder. The remaining six studies (<a href="./references#CD013504-bbs2-0001" title="AndoM , IndenY , YoshidaY , SairakuA , YanagisawaS , SuzukiH , et al. Differences in prothrombotic response between the uninterrupted and interrupted apixaban therapies in patients undergoing cryoballoon ablation for paroxysmal atrial fibrillation: a randomized controlled study. Heart Vessels2019;34(9):1533-41. [DOI: 10.1007/s00380-019-01370-9]">Ando 2019</a>; <a href="./references#CD013504-bbs2-0003" title="NagaoT , SuzukiH , MatsunagaS , NishikawaY , HaradaK , MamiyaK . Impact of periprocedural anticoagulation therapy on the incidence of silent stroke after atrial fibrillation ablation in patients receiving direct oral anticoagulants: uninterrupted vs. interrupted by one dose strategy. Europace2019;21(4):590-7. [DOI: 10.1093/europace/euy224]">Nagao 2019</a>; <a href="./references#CD013504-bbs2-0004" title="Nakamura K, Naito S, Sasaki T, Take Y, Minami K, Kitagawa Y, et al. Uninterrupted vs. interrupted periprocedural direct oral anticoagulants for catheter ablation of atrial fibrillation: a prospective randomized single-centre study on post-ablation thrombo-embolic and haemorrhagic events. Europace2019;21(2):259-67. [DOI: 10.1093/europace/euy148]NakamuraK , SasakiT , TakeY , FunabashiN , NaitoS . Uninterrupted vs. interrupted periprocedural direct oral anticoagulants for catheter ablation of atrial fibrillation: a prospective randomized study on post-ablation thromboembolic and hemorrhagic events. Circulation2018;138:2. ">Nakamura 2019</a>; <a href="./references#CD013504-bbs2-0007" title="TabishH , ShahzadK . Anticoagulation safety window among elderly Chinese patients with atrial fibrillation catheter ablation. Journal of the Saudi Heart Association2010;22(2):99-100. [DOI: 10.1016/j.jsha.2010.02.325]">Tabish 2010</a>; <a href="./references#CD013504-bbs2-0009" title="YamajiH , MurakamiT , HinaK , HigashiyaS , KawamuraH , MurakamiM , et al. Activated clotting time on the day of atrial fibrillation ablation for minimally interrupted and uninterrupted direct oral anticoagulation therapy: sequential changes, differences among direct oral anticoagulants, and ablation safety outcomes. Journal of Cardiovascular Electrophysiology2019;30(12):2823-33. [DOI: 10.1111/jce.14260]">Yamaji 2019</a>; <a href="./references#CD013504-bbs2-0010" title="YohM , TakagiM , YoshioT , TakahashiH , ShiojimaI . AP19-00329. Safety and efficacy of uninterrupted and interrupted periprocedural direct oral anticoagulants in patients undergoing radiofrequency catheter ablation for atrial fibrillation. Journal of Arrhythmia2019;35(S1):134. [DOI: 10.1002/joa3.12267]">Yoh 2019</a>) did not report the source of funding . </p> </section> </section> <section id="CD013504-sec-0046"> <h4 class="title">Excluded studies</h4> <p>On inspection of full‐texts, we excluded 44 studies, and details were reported in the <a href="./references#CD013504-sec-0120" title="">Characteristics of excluded studies</a> table. Of those 44 studies, 27 studies were non‐randomised comparisons of anticoagulants (<a href="./references#CD013504-bbs2-0013" title="AbhishekF , HeistEK , BarrettC , DanikS , BlendeaD , CorrentiC , et al. Effectiveness of a strategy to reduce major vascular complications from catheter ablation of atrial fibrillation. Journal of Interventional Cardiac Electrophysiology2011;30(3):211-5. ">Abhishek 2011</a>; <a href="./references#CD013504-bbs2-0014" title='AoyamaD , MiyazakiS , HasegawaK , KasenoK , IshikawaE , MukaiM , et al. Feasibility of uninterrupted direct oral anticoagulants with temporary switching to dabigatran ("Dabigatran Bridge") for catheter ablation of atrial fibrillation. International Heart Journal2019;60(6):1315-20. [DOI: 10.1536/ihj.19-143]'>Aoyama 2019</a>; <a href="./references#CD013504-bbs2-0015" title="BaltogiannisG , ChierchiaGB , ConteG , SieiraJ , Di GiovanniG , CiconteG , et al. The role of novel oral anticoagulants in patients undergoing cryoballoon ablation for atrial fibrillation. HJC Hellenic Journal of Cardiology2016;57(5):331-7. [DOI: 10.1016/j.hjc.2016.11.003]">Baltogiannis 2016</a>; <a href="./references#CD013504-bbs2-0016" title="Brinkmeier-TheofanopoulouM , TzamalisP , Wehrkamp-RichterS , RadzewitzA , MerkelM , SchymikG , et al. Periprocedural anticoagulation during left atrial ablation: interrupted and uninterrupted vitamin K-antagonists or uninterrupted novel anticoagulants. BMC Cardiovascular Disorders2018;18(1):71. [DOI: 10.1186/s12872-018-0804-6]">Brinkmeier 2018</a>; <a href="./references#CD013504-bbs2-0018" title="CavalliG , ChinaP , MarrasE , CorradoA , ThemistoclakisS . Safety and efficacy of oral anticoagulation discontinuation in high thromboembolic risk patients at long term follow-up after successful atrial fibrillation ablation. European Heart Journal2019;40:1777. [DOI: 10.1093/eurheartj/ehz748.1143]">Cavalli 2019</a>; <a href="./references#CD013504-bbs2-0019" title="ChiCTR-OPN-15006584. Rivaroxaban versus warfarin during catheter ablation in patients with atrial fibrillation or atrial flutter. www.who.int/trialsearch/Trial2.aspx?TrialID=ChiCTR-OPN-15006584 (first received 3 June 2015). [DOI: 10.1002/central/CN-01819316/full]">ChiCTR‐OPN‐15006584</a>; <a href="./references#CD013504-bbs2-0020" title="DiCY , WanZ , LinWH . Efficacy and safety of Rivaroxaban anticoagulant therapy in the treatment of atrial fibrillation cryoablation. Chung-Hua i Hsueh Tsa Chih [Chinese Medical Journal]2017;97(33):2591-4. [DOI: 10.3760/cma.j.issn.0376-2491.2017.33.008]">Di 2017</a>; <a href="./references#CD013504-bbs2-0021" title="Di BiaseL , DenekeT , TrivediC , MohantyS , SzollosiA , SchadeA , et al. Uninterrupted rivaroxaban reduces the prevalence of silent cerebral ischemia during radiofrequency ablation of atrial fibrillation. Heart Rhythm2014;11:S138. [DOI: 10.1016/j.hrthm.2014.03.027]">Di Biase 2014a</a>; <a href="./references#CD013504-bbs2-0022" title="Di BiaseL , DenekeT , TrivediC , MohantyS ,  Santangeli S, SzollosiA , et al. Uninterrupted rivaroxaban reduces the prevalence of silent cerebral ischemia during radiofrequency ablation of atrial fibrillation. European Heart Journal2014;35:592. ">Di Biase 2014b</a>; <a href="./references#CD013504-bbs2-0023" title="EfremidisM , VlachosK , LetsasKP , GiannopoulosG , LioniL , GeorgopoulosS , et al. Low dose dabigatran versus uninterrupted acenocoumarol for peri-procedural anticoagulation in atrial fibrillation catheter ablation. Journal of Electrocardiology2015;48(5):840-4. [DOI: 10.1016/j.jelectrocard.2015.06.011]">Efremidis 2015</a>; <a href="./references#CD013504-bbs2-0026" title="FinlayM , SawhneyV , SchillingR , ThomasG , DuncanE , HunterR , et al. Uninterrupted warfarin for periprocedural anticoagulation in catheter ablation of typical atrial flutter: a safe and cost-effective strategy. Journal of Cardiovascular Electrophysiology2010;21(2):150-4. [DOI: 10.1111/j.1540-8167.2009.01603.x]">Finlay 2010</a>; <a href="./references#CD013504-bbs2-0027" title="GunawardeneM , WillemsS , SchafferB , MoserJ , AkbulakRO , JularicM , et al. Influence of periprocedural anticoagulation strategies on complication rate and hospital stay in patients undergoing catheter ablation for persistent atrial fibrillation. Clinical Research in Cardiology2017;106(1):38-48. ">Gunawardene 2017</a>; <a href="./references#CD013504-bbs2-0032" title="KonduruSV , CheemaAA , JonesP , LiY , RamzaB , WimmerAP , et al. Differences in intraprocedural ACTs with standardized heparin dosing during catheter ablation for atrial fibrillation in patients treated with dabigatran vs. patients on uninterrupted warfarin. Journal of Interventional Cardiac Electrophysiology2012;35(3):277-84. ">Konduru 2012</a>; <a href="./references#CD013504-bbs2-0033" title="KuwaharaT , TakahashiA , TakahashiY , KoboriA , MiyazakiS , TakeiA , et al. Prevention of periprocedural ischemic stroke and management of hemorrhagic complications in atrial fibrillation ablation under continuous warfarin administration. Journal of Cardiovascular Electrophysiology2013;24(5):510-5. [DOI: 10.1111/jce.12069]">Kuwahara 2013</a>; <a href="./references#CD013504-bbs2-0034" title="LaneJD , CannieD , VolkovaE , GrahamA , ChowA , EarleyMJ , et al. Anticoagulation and the risk of complications in ventricular tachycardia and premature ventricular complex ablation. Pacing and Clinical Electrophysiology2018;41(11):1454-60. ">Lane 2018</a>; <a href="./references#CD013504-bbs2-0035" title="MullerP , HalbfassP , SzollosiA , DietrichJW , FochlerF , NentwichK , et al. Impact of periprocedural anticoagulation strategy on the incidence of new-onset silent cerebral events after radiofrequency catheter ablation of atrial fibrillation. Journal of Interventional Cardiac Electrophysiology2016;46(3):203-11. ">Muller 2016</a>; <a href="./references#CD013504-bbs2-0040" title="PageSP , SiddiquiMS , FinlayM , HunterRJ , AbramsDJ , DhinojaM , et al. Catheter ablation for atrial fibrillation on uninterrupted warfarin: can it be done without echo guidance?Journal of Cardiovascular Electrophysiology2011;22(3):265-70. [DOI: 10.1111/j.1540-8167.2010.01910.x]">Page 2011</a>; <a href="./references#CD013504-bbs2-0041" title="PageSP , HerringN , HunterRJ , WithycombeE , LovellM , WaliG , et al. Periprocedural stroke risk in patients undergoing catheter ablation for atrial fibrillation on uninterrupted warfarin. Journal of Cardiovascular Electrophysiology2014;25(6):585-90. [DOI: 10.1111/jce.12411]">Page 2014</a>; <a href="./references#CD013504-bbs2-0042" title="SaadEB , CostaIP , CostaRE , InacioLA , SlaterC , CamilettiA , et al. Safety of ablation for atrial fibrillation with therapeutic INR: comparison with transition to low-molecular-weight heparin. Arquivos Brasileiros de Cardiologia 11;97(4):289-96. ">Saad 2011</a>; <a href="./references#CD013504-bbs2-0043" title="SagawaY , NagataY , YamaguchiT , IwaiT , YamaguchiJ , HijikataS , et al. Comparison of direct oral anticoagulants and warfarin regarding midterm adverse events in patients with atrial fibrillation undergoing catheter ablation. Journal of Arrhythmia2018;24(4):428-34. ">Sagawa 2018</a>; <a href="./references#CD013504-bbs2-0045" title="SteffelJ , RuffCT , HamershockRA , MurphySA , SeniorR , RoyD , et al. First experience with edoxaban and atrial fibrillation ablation – insights from the ENGAGE AF-TIMI 48 trial. International Journal of Cardiology2017;244:192-5. [DOI: 10.1016/j.ijcard.2017.05.098]">Steffel 2017</a>; <a href="./references#CD013504-bbs2-0046" title="StepanyanG , BadhwarN , LeeRJ , MarcusGM , LeeBK , TsengZH , et al. Safety of new oral anticoagulants for patients undergoing atrial fibrillation ablation. Journal of Interventional Cardiac Electrophysiology2014;40(1):33-8. [DOI: 10.1007/s10840-014-9888-9]">Stepanyan 2014</a>; <a href="./references#CD013504-bbs2-0047" title="TschollV , LsharafAK , LinT , BellmannB , NagelP , LenzK , et al. Apixaban, rivaroxaban, and dabigatran use in patients undergoing catheter ablation for atrial fibrillation using the second-generation cryoballoon. Clinical Cardiology2017;40(11):1095-9. [DOI: 10.1002/clc.22782]">Tscholl 2017</a>; <a href="./references#CD013504-bbs2-0050" title="UMIN000029693. Multicenter study associated with KYU-shu to evaluate the efficacy and safety of edoxaban in patients with non-valvulaR Atrial fiBriLlation undergoing cathEter ablation. www.who.int/trialsearch/Trial2.aspx?TrialID=JPRN-UMIN000029693 (first received 25 October 2017). ">UMIN000029693</a>; <a href="./references#CD013504-bbs2-0051" title="WakamatsuY , NagashimaK , WatanabeR , AraiM , YokoyamaK , MatsumotoN . Clinical outcomes of off-label underdosing of direct oral anticoagulants after ablation for atrial fibrillation. International Heart Journal2020;61(6):1165-73. [DOI: 10.1536/ihj.20-335]">Wakamatsu 2020</a>; <a href="./references#CD013504-bbs2-0052" title="WazniOM , BeheiryS , FahmyT , BarrettC , HaoS , PatelD , et al. Atrial fibrillation ablation in patients with therapeutic international normalized ratio: comparison of strategies of anticoagulation management in the periprocedural period. Circulation2007;116(22):2531-4. ">Wazni 2007</a>; <a href="./references#CD013504-bbs2-0053" title="XingY , XuB , ShengX , XuC , PengF , SunY , et al. Efficacy and safety of uninterrupted low-intensity warfarin for cryoballoon ablation of atrial fibrillation in the elderly: a pilot study. Journal of Clinical Pharmacy and Therapeutics2018;43(3):401-7. [DOI: 10.1111/jcpt.12671]">Xing 2018</a>; <a href="./references#CD013504-bbs2-0054" title="YamajiH , MurakamiT , HinaK , HigashiyaS , KawamuraH , MurakamiM , et al. Usefulness of dabigatran etexilate as periprocedural anticoagulation therapy for atrial fibrillation ablation. Clinical Drug Investigation2013;33(6):409-18. ">Yamaji 2013</a>). Nine trials were not the intervention of interest (<a href="./references#CD013504-bbs2-0029" title="jRCTs031180249. Stroke secondary prevention with catheter ablation and edoxaban for patients with non-valvular atrial fibrillation. In: www.who.int/trialsearch/Trial2.aspx?TrialID=JPRN-jRCTs031180249. (first received 12 March 2019). ">jRCTs031180249</a>; <a href="./references#CD013504-bbs2-0030" title="KimTS , KimSH , KimBK , KimJY , KimJH , JangSW , et al. Randomized comparison of continuous versus intermittent heparin infusion during catheter ablation of atrial fibrillation. JACC Clinical Electrophysiology2016;2(3):319-26. ">Kim 2016</a>; <a href="./references#CD013504-bbs2-0031" title="KirchhofP , HaeuslerKG , BlankB , De BonoJ , CallansD , ElvanA ,  et al. Apixaban in patients at risk of stroke undergoing atrial fibrillation ablation. European Heart Journal2018;39(32):2942-55. [DOI: 10.1093/eurheartj/ehy176]">Kirchhof 2018</a>; <a href="./references#CD013504-bbs2-0038" title="OhY , KimS , KiT , ShinW , KimJ , JangS , et al. Randomized comparison of continuous and intermittent heparin infusion during catheter ablation of atrial fibrillation; interim results of ongoing COHERE (COntinuous HEparin infusion REferring to ablat: P1168). Eurospace2013;15:ii171–215. [10.1093/europace/eut184]">Oh 2013</a>; <a href="./references#CD013504-bbs2-0039" title="OkumuraK , AonumaK , KumagaiK , HiraoK , InoueK , KimuraM , et al. Efficacy and safety of rivaroxaban and warfarin in the perioperative period of catheter ablation for atrial fibrillation – outcome analysis from a prospective multicenter registry study in Japan. Circulation Journal2016;80(11):2295-301. ">Okumura 2016</a>; <a href="./references#CD013504-bbs2-0044" title="SakamotoY , NishiyamaY , IwasakiYK , DaidaH , ToyodaK , KitagawaK , et al. Design and rationale of the STroke secondary prevention with catheter ABLation and EDoxaban clinical trial in patients with non-valvular atrial fibrillation: the STABLED study. Journal of Cardiology2019;74(6):539-42. ">Sakamoto 2019</a>; <a href="./references#CD013504-bbs2-0049" title="UMIN000028892. Prospective study regarding the safety of a periprocedural anticoagulation regimen with direct oral anticoagulant (DOAC) other than dabigatran in the patients undergoing catheter ablation for paroxysmal or persistent atrial fibrillation. www.who.int/trialsearch/Trial2.aspx?TrialID=JPRN-UMIN000028892 (first received 7 September 2017). ">UMIN000028892</a>; <a href="./references#CD013504-bbs2-0055" title="YamajiH , MurakamiT , HinaK , HigashiyaS , KawamuraH , MurakamiM , et al. Differences in activated clotting time and initial heparin dosage during atrial fibrillation ablation for patients with edoxaban compared with warfarin. Journal of Cardiovascular Electrophysiology2018;29(6):835-43. ">Yamaji 2018</a>). Eight trials were single‐arm with interruption (<a href="./references#CD013504-bbs2-0017" title="CalkinsH , WillemsS , VermaA , SchillingR , HohnloserSH , OkumuraK . Heparin dosing in uninterrupted anticoagulation with dabigatran vs. warfarin in atrial fibrillation ablation: RE-CIRCUIT study. Europace2019;21(6):879-85. [DOI: 10.1093/europace/euz057]">Calkins 2019</a>; <a href="./references#CD013504-bbs2-0024" title="EUCTR2012-001484-79-DE. Safety of rivaroxaban in patients with nonvalvular atrial fibrillation who undergo catheter ablation. www.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2012-001484-79-DE (first received 16 October 2012). ">EUCTR2012‐001484‐79‐DE</a>; <a href="./references#CD013504-bbs2-0025" title="EUCTR2016-003069-25-HU. Edoxaban treatment versus anticoagulant treatment (here vitamin K antagonist) in patients with atrial fibrillation undergoing a catheter ablation. www.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2016-003069-25-HU (first received 10 January 2017). ">EUCTR2016‐003069‐25‐HU</a>; <a href="./references#CD013504-bbs2-0028" title="HohnloserSH , CammJ , CappatoR , DienerHC , HeidbuchelH , MontL , et al. Uninterrupted edoxaban vs. vitamin K antagonists for ablation of atrial fibrillation: the ELIMINATE-AF trial. European Heart Journal2019;40(36):3013-21. [DOI: 10.1093/eurheartj/ehz190]">Hohnloser 2019</a>; <a href="./references#CD013504-bbs2-0036" title="NCT01729871. A study exploring two treatment strategies in patients with atrial fibrillation who undergo catheter ablation therapy. clinicaltrials.gov/ct2/show/NCT01729871 (first received 20 November 2012). ">NCT01729871</a>; <a href="./references#CD013504-bbs2-0037" title="NCT02504177. Clinical trial for optimal novel oral anticoagulant (NOAC) schedule immediate before catheter ablation for atrial fibrillation. clinicaltrials.gov/ct2/show/NCT02504177 (first received 21 July 2015). ">NCT02504177</a>; <a href="./references#CD013504-bbs2-0048" title="UMIN000013341. Exploratory study to evaluate the effect of uninterrupted anticoagulants in catheter ablation procedure for non-valvular atrial fibrillation – comparison between rivaroxaban and warfarin. www.who.int/trialsearch/Trial2.aspx?TrialID=JPRN-UMIN000013341 (first received 5 March 2014). ">UMIN000013341</a>; <a href="./references#CD013504-bbs2-0056" title="YoshimotoI , IrikiY , OketaniN , OkuiH , IchikiH , MaenosonoR . A randomized comparison of two direct oral anticoagulants for patients undergoing cardiac ablation with a contemporary warfarin control arm. Journal of Interventional Cardiac Electrophysiology2020;21:11. [DOI: 10.1007/s10840-020-00732-y]">Yoshimoto 2020</a>). </p> </section> </section> <section id="CD013504-sec-0047"> <h3 class="title">Risk of bias in included studies</h3> <p>We presented the results of risk of bias assessments across all included studies (<a href="#CD013504-fig-0003">Figure 3</a>) and the summary of risk of bias assessment of each individual study (<a href="#CD013504-fig-0004">Figure 4</a>). </p> <div class="figure" id="CD013504-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD013504-fig-0003" src="/cdsr/doi/10.1002/14651858.CD013504.pub2/media/CDSR/CD013504/image_n/nCD013504-FIG-03.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> </div> <div class="figure" id="CD013504-fig-0004"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 4</div> </div> <hr class="top"/><img alt="original image" data-id="CD013504-fig-0004" src="/cdsr/doi/10.1002/14651858.CD013504.pub2/media/CDSR/CD013504/image_n/nCD013504-FIG-04.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"></div> </div> <section id="CD013504-sec-0048"> <h4 class="title">Allocation</h4> <section id="CD013504-sec-0049"> <h5 class="title">Random sequence generation and allocation</h5> <p>Of the 12 included studies, only<b> </b>five described the random sequence generation and were judged at low risk of bias (<a href="./references#CD013504-bbs2-0002" title='Di BiaseL , BurkhardtJD , SantangeliP , MohantyP , SanchezJ , BaiR , et al. Periprocedural strokes and anticoagulation management during AF ablation: results from the "Compare" randomized multicenter trial. Circulation2013;128:A14307. Di BiaseL , BurkhardtJD , SantangeliP , MohantyP , SanchezJ , BaiR , et al. Silent thromboembolic lesions following catheter ablation for atrial fibrillation using radiofrequency energy: results from a sub-study of the "compare" randomized trial. Circulation2013;128(22 Suppl 1):A14293. Di BiaseL , BurkhardtJD , SantangeliP , MohantyP , SanchezJ , HortonR , et al. Periprocedural stroke and bleeding complications in patients undergoing catheter ablation of atrial fibrillation with different anticoagulation management: results from the "compare" randomized trial. Heart Rhythm2013;10(9):1411. Di BiaseL , BurkhardtJD , SantangeliP , MohantyP , SanchezJE , HortonR , et al. Periprocedural stroke and bleeding complications in patients undergoing catheter ablation of atrial fibrillation with different anticoagulation management: results from the role of coumadin in preventing thromboembolism in atrial fibrillation (AF) patients undergoing catheter ablation (COMPARE) randomized trial. Circulation2014;129(25):2638-44. [DOI: 10.1161/circulationaha.113.006426]NCT01006876. Role of coumadin in preventing thromboembolism in atrial fibrillation (AF) patients undergoing catheter ablation. clinicaltrials.gov/ct2/show/NCT01006876 (first received 3 November 2009). '>Di Biase 2014</a>; <a href="./references#CD013504-bbs2-0004" title="Nakamura K, Naito S, Sasaki T, Take Y, Minami K, Kitagawa Y, et al. Uninterrupted vs. interrupted periprocedural direct oral anticoagulants for catheter ablation of atrial fibrillation: a prospective randomized single-centre study on post-ablation thrombo-embolic and haemorrhagic events. Europace2019;21(2):259-67. [DOI: 10.1093/europace/euy148]NakamuraK , SasakiT , TakeY , FunabashiN , NaitoS . Uninterrupted vs. interrupted periprocedural direct oral anticoagulants for catheter ablation of atrial fibrillation: a prospective randomized study on post-ablation thromboembolic and hemorrhagic events. Circulation2018;138:2. ">Nakamura 2019</a>; <a href="./references#CD013504-bbs2-0005" title="AonumaK . A prospective, multi-center, parallel-group comparison study to evaluate safety and efficacy of dabigatran during the perioperative period in patients with non-valvular atrial fibrillation who undergo the catheter ablation compared to warfarin. upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000015311 (first received 14 February 2014. GoyaM , NogamiA , HiraoK , AonumaK . Ablation perioperative dabigatran in use envisioning in Japan: the ABRIDGE-J study design. Journal of Cardiology2016;68(3):236-40. [DOI: 10.1016/j.jjcc.2015.10.003]]NogamiA , HaradaT , Sekiguchi Y, Otani R, YoshidaY , Yoshida K, et al. Safety and efficacy of minimally interrupted dabigatran vs uninterrupted warfarin therapy in adults undergoing atrial fibrillation catheter ablation: a randomized clinical trial. JAMA Network Open2019;2(4):15. [DOI: 10.1001/jamanetworkopen.2019.1994]NogamiA , HaradaT , YoshidaY , NakanoY , GoyaM , OrigasaH , et al. Clinical benefit of minimally-interrupted dabigatran versus uninterrupted warfarin for catheter ablation of atrial fibrillation: a prospective randomized multicenter trial. Circulation2017;136:e450. NogamiA , HaradaT , YoshidaY , NakanoY , GoyaM , OrigasaH , et al. Clinical benefit of minimally-interrupted dabigatran versus uninterrupted warfarin for catheter ablation of atrial fibrillation: a prospective randomized multicenter trial. Circulation2017;136(24):E450. [DOI: 10.1161/CIR.0000000000000546]UMIN000013129. A prospective, multi-center, parallel-group comparison study to evaluate safety and efficacy of dabigatran during the perioperative period in patients with non-valvular atrial fibrillation who undergo the catheter ablation compared to warfarin. www.who.int/trialsearch/Trial2.aspx?TrialID=JPRN-UMIN000013129 (first received 1 March 2014). ">Nogami 2019</a>; <a href="./references#CD013504-bbs2-0011" title="IrikiY , IchikiH , OketaniN , YoshimuraA , OkuiH , MaenosonoR , et al. Evaluation of safety and efficacy of perioperative use of rivaroxaban and apixaban in catheter ablation for atrial fibrillation. European Heart Journal2015;36:687. [DOI: 10.1093/eurheartj/ehv400]YoshimuraA , IrikiY , IchikiH , OketaniN , OkuiH , MaenosonoR , et al. Evaluation of safety and efficacy of periprocedural use of rivaroxaban and apixaban in catheter ablation for atrial fibrillation. Journal of Cardiology2017;69(1):228-35. [DOI: 10.1016/j.jjcc.2016.03.014]">Yoshimura 2017</a>; <a href="./references#CD013504-bbs2-0012" title="YuHT , ShimJ , ParkJ , KimTH , UhmJS , KimJY , et al. When is it appropriate to stop non-vitamin K antagonist oral anticoagulants before catheter ablation of atrial fibrillation? A multi-center prospective randomized study. Europace2019;21:ii804. YuHT , ShimJ , ParkJ , KimTH , UhmJS , KimJY , et al. When is it appropriate to stop non-vitamin K antagonist oral anticoagulants before catheter ablation of atrial fibrillation? A multicentre prospective randomized study. European Heart Journal2019;40(19):1531-7. [DOI: 10.1093/eurheartj/ehy870]">Yu 2019</a>). <a href="./references#CD013504-bbs2-0002" title='Di BiaseL , BurkhardtJD , SantangeliP , MohantyP , SanchezJ , BaiR , et al. Periprocedural strokes and anticoagulation management during AF ablation: results from the "Compare" randomized multicenter trial. Circulation2013;128:A14307. Di BiaseL , BurkhardtJD , SantangeliP , MohantyP , SanchezJ , BaiR , et al. Silent thromboembolic lesions following catheter ablation for atrial fibrillation using radiofrequency energy: results from a sub-study of the "compare" randomized trial. Circulation2013;128(22 Suppl 1):A14293. Di BiaseL , BurkhardtJD , SantangeliP , MohantyP , SanchezJ , HortonR , et al. Periprocedural stroke and bleeding complications in patients undergoing catheter ablation of atrial fibrillation with different anticoagulation management: results from the "compare" randomized trial. Heart Rhythm2013;10(9):1411. Di BiaseL , BurkhardtJD , SantangeliP , MohantyP , SanchezJE , HortonR , et al. Periprocedural stroke and bleeding complications in patients undergoing catheter ablation of atrial fibrillation with different anticoagulation management: results from the role of coumadin in preventing thromboembolism in atrial fibrillation (AF) patients undergoing catheter ablation (COMPARE) randomized trial. Circulation2014;129(25):2638-44. [DOI: 10.1161/circulationaha.113.006426]NCT01006876. Role of coumadin in preventing thromboembolism in atrial fibrillation (AF) patients undergoing catheter ablation. clinicaltrials.gov/ct2/show/NCT01006876 (first received 3 November 2009). '>Di Biase 2014</a> described using block randomisation with the study centre as the blocking variable. Then used a central randomisation algorithm to generate the randomisation code. <a href="./references#CD013504-bbs2-0004" title="Nakamura K, Naito S, Sasaki T, Take Y, Minami K, Kitagawa Y, et al. Uninterrupted vs. interrupted periprocedural direct oral anticoagulants for catheter ablation of atrial fibrillation: a prospective randomized single-centre study on post-ablation thrombo-embolic and haemorrhagic events. Europace2019;21(2):259-67. [DOI: 10.1093/europace/euy148]NakamuraK , SasakiT , TakeY , FunabashiN , NaitoS . Uninterrupted vs. interrupted periprocedural direct oral anticoagulants for catheter ablation of atrial fibrillation: a prospective randomized study on post-ablation thromboembolic and hemorrhagic events. Circulation2018;138:2. ">Nakamura 2019</a> used a computer‐generated list of random numbers. <a href="./references#CD013504-bbs2-0005" title="AonumaK . A prospective, multi-center, parallel-group comparison study to evaluate safety and efficacy of dabigatran during the perioperative period in patients with non-valvular atrial fibrillation who undergo the catheter ablation compared to warfarin. upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000015311 (first received 14 February 2014. GoyaM , NogamiA , HiraoK , AonumaK . Ablation perioperative dabigatran in use envisioning in Japan: the ABRIDGE-J study design. Journal of Cardiology2016;68(3):236-40. [DOI: 10.1016/j.jjcc.2015.10.003]]NogamiA , HaradaT , Sekiguchi Y, Otani R, YoshidaY , Yoshida K, et al. Safety and efficacy of minimally interrupted dabigatran vs uninterrupted warfarin therapy in adults undergoing atrial fibrillation catheter ablation: a randomized clinical trial. JAMA Network Open2019;2(4):15. [DOI: 10.1001/jamanetworkopen.2019.1994]NogamiA , HaradaT , YoshidaY , NakanoY , GoyaM , OrigasaH , et al. Clinical benefit of minimally-interrupted dabigatran versus uninterrupted warfarin for catheter ablation of atrial fibrillation: a prospective randomized multicenter trial. Circulation2017;136:e450. NogamiA , HaradaT , YoshidaY , NakanoY , GoyaM , OrigasaH , et al. Clinical benefit of minimally-interrupted dabigatran versus uninterrupted warfarin for catheter ablation of atrial fibrillation: a prospective randomized multicenter trial. Circulation2017;136(24):E450. [DOI: 10.1161/CIR.0000000000000546]UMIN000013129. A prospective, multi-center, parallel-group comparison study to evaluate safety and efficacy of dabigatran during the perioperative period in patients with non-valvular atrial fibrillation who undergo the catheter ablation compared to warfarin. www.who.int/trialsearch/Trial2.aspx?TrialID=JPRN-UMIN000013129 (first received 1 March 2014). ">Nogami 2019</a> used a randomisation registration system Mebix Inc to conduct a random allocation sequence, participant enrolment, and assignment of participants to the interventions. <a href="./references#CD013504-bbs2-0011" title="IrikiY , IchikiH , OketaniN , YoshimuraA , OkuiH , MaenosonoR , et al. Evaluation of safety and efficacy of perioperative use of rivaroxaban and apixaban in catheter ablation for atrial fibrillation. European Heart Journal2015;36:687. [DOI: 10.1093/eurheartj/ehv400]YoshimuraA , IrikiY , IchikiH , OketaniN , OkuiH , MaenosonoR , et al. Evaluation of safety and efficacy of periprocedural use of rivaroxaban and apixaban in catheter ablation for atrial fibrillation. Journal of Cardiology2017;69(1):228-35. [DOI: 10.1016/j.jjcc.2016.03.014]">Yoshimura 2017</a> stratified participants according to the type of AF and sex, and used the table of random numbers for randomisation. <a href="./references#CD013504-bbs2-0012" title="YuHT , ShimJ , ParkJ , KimTH , UhmJS , KimJY , et al. When is it appropriate to stop non-vitamin K antagonist oral anticoagulants before catheter ablation of atrial fibrillation? A multi-center prospective randomized study. Europace2019;21:ii804. YuHT , ShimJ , ParkJ , KimTH , UhmJS , KimJY , et al. When is it appropriate to stop non-vitamin K antagonist oral anticoagulants before catheter ablation of atrial fibrillation? A multicentre prospective randomized study. European Heart Journal2019;40(19):1531-7. [DOI: 10.1093/eurheartj/ehy870]">Yu 2019</a> described a central randomisation strategy using computer‐generated random permutation sequences. </p> <p>Four studies did not describe methods of randomisation and were judged at unclear risk of bias (<a href="./references#CD013504-bbs2-0001" title="AndoM , IndenY , YoshidaY , SairakuA , YanagisawaS , SuzukiH , et al. Differences in prothrombotic response between the uninterrupted and interrupted apixaban therapies in patients undergoing cryoballoon ablation for paroxysmal atrial fibrillation: a randomized controlled study. Heart Vessels2019;34(9):1533-41. [DOI: 10.1007/s00380-019-01370-9]">Ando 2019</a>; <a href="./references#CD013504-bbs2-0003" title="NagaoT , SuzukiH , MatsunagaS , NishikawaY , HaradaK , MamiyaK . Impact of periprocedural anticoagulation therapy on the incidence of silent stroke after atrial fibrillation ablation in patients receiving direct oral anticoagulants: uninterrupted vs. interrupted by one dose strategy. Europace2019;21(4):590-7. [DOI: 10.1093/europace/euy224]">Nagao 2019</a>; <a href="./references#CD013504-bbs2-0006" title="ReynoldsMR , AllisonJS , NataleA , WeisbergIL , EllenbogenKA , RichardsM , et al. Apixaban evaluation of interrupted or uninterrupted anticoagulation for ablation of atrial fibrillation. clinicaltrials.gov/show/NCT02608099 (first received 18 November 2015). ReynoldsMR , AllisonJS , NataleA , WeisbergIL , EllenbogenKA , RichardsM , et al. A prospective randomized trial of apixaban dosing during atrial fibrillation ablation: the AEIOU trial. JACC Clinical Electrophysiology2018;4(5):580-8. [DOI: 10.1016/j.jacep.2017.11.005]">Reynolds 2018</a>;  <a href="./references#CD013504-bbs2-0008" title="XingY , XuB , XuC , PengF , YangB , QiuY , et al. Efficacy and safety of uninterrupted low-intensity warfarin for radiofrequency catheter ablation of atrial fibrillation in the elderly. Annals of Pharmacotherapy2017;51(9):735-42. [DOI: 10.1177/1060028017712532]">Xing 2017</a>). <a href="./references#CD013504-bbs2-0007" title="TabishH , ShahzadK . Anticoagulation safety window among elderly Chinese patients with atrial fibrillation catheter ablation. Journal of the Saudi Heart Association2010;22(2):99-100. [DOI: 10.1016/j.jsha.2010.02.325]">Tabish 2010</a> and <a href="./references#CD013504-bbs2-0010" title="YohM , TakagiM , YoshioT , TakahashiH , ShiojimaI . AP19-00329. Safety and efficacy of uninterrupted and interrupted periprocedural direct oral anticoagulants in patients undergoing radiofrequency catheter ablation for atrial fibrillation. Journal of Arrhythmia2019;35(S1):134. [DOI: 10.1002/joa3.12267]">Yoh 2019</a> are abstract papers and had insufficient information; both were judged at unclear risk of bias. One study was judged at high risk of bias as they described a non‐random component in the sequence generation process (<a href="./references#CD013504-bbs2-0009" title="YamajiH , MurakamiT , HinaK , HigashiyaS , KawamuraH , MurakamiM , et al. Activated clotting time on the day of atrial fibrillation ablation for minimally interrupted and uninterrupted direct oral anticoagulation therapy: sequential changes, differences among direct oral anticoagulants, and ablation safety outcomes. Journal of Cardiovascular Electrophysiology2019;30(12):2823-33. [DOI: 10.1111/jce.14260]">Yamaji 2019</a>). </p> </section> <section id="CD013504-sec-0050"> <h5 class="title">Allocation concealment</h5> <p>Three studies were judged to have a low risk for allocation concealment using central randomisation to assign participants to the intervention arms (<a href="./references#CD013504-bbs2-0002" title='Di BiaseL , BurkhardtJD , SantangeliP , MohantyP , SanchezJ , BaiR , et al. Periprocedural strokes and anticoagulation management during AF ablation: results from the "Compare" randomized multicenter trial. Circulation2013;128:A14307. Di BiaseL , BurkhardtJD , SantangeliP , MohantyP , SanchezJ , BaiR , et al. Silent thromboembolic lesions following catheter ablation for atrial fibrillation using radiofrequency energy: results from a sub-study of the "compare" randomized trial. Circulation2013;128(22 Suppl 1):A14293. Di BiaseL , BurkhardtJD , SantangeliP , MohantyP , SanchezJ , HortonR , et al. Periprocedural stroke and bleeding complications in patients undergoing catheter ablation of atrial fibrillation with different anticoagulation management: results from the "compare" randomized trial. Heart Rhythm2013;10(9):1411. Di BiaseL , BurkhardtJD , SantangeliP , MohantyP , SanchezJE , HortonR , et al. Periprocedural stroke and bleeding complications in patients undergoing catheter ablation of atrial fibrillation with different anticoagulation management: results from the role of coumadin in preventing thromboembolism in atrial fibrillation (AF) patients undergoing catheter ablation (COMPARE) randomized trial. Circulation2014;129(25):2638-44. [DOI: 10.1161/circulationaha.113.006426]NCT01006876. Role of coumadin in preventing thromboembolism in atrial fibrillation (AF) patients undergoing catheter ablation. clinicaltrials.gov/ct2/show/NCT01006876 (first received 3 November 2009). '>Di Biase 2014</a>; <a href="./references#CD013504-bbs2-0005" title="AonumaK . A prospective, multi-center, parallel-group comparison study to evaluate safety and efficacy of dabigatran during the perioperative period in patients with non-valvular atrial fibrillation who undergo the catheter ablation compared to warfarin. upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000015311 (first received 14 February 2014. GoyaM , NogamiA , HiraoK , AonumaK . Ablation perioperative dabigatran in use envisioning in Japan: the ABRIDGE-J study design. Journal of Cardiology2016;68(3):236-40. [DOI: 10.1016/j.jjcc.2015.10.003]]NogamiA , HaradaT , Sekiguchi Y, Otani R, YoshidaY , Yoshida K, et al. Safety and efficacy of minimally interrupted dabigatran vs uninterrupted warfarin therapy in adults undergoing atrial fibrillation catheter ablation: a randomized clinical trial. JAMA Network Open2019;2(4):15. [DOI: 10.1001/jamanetworkopen.2019.1994]NogamiA , HaradaT , YoshidaY , NakanoY , GoyaM , OrigasaH , et al. Clinical benefit of minimally-interrupted dabigatran versus uninterrupted warfarin for catheter ablation of atrial fibrillation: a prospective randomized multicenter trial. Circulation2017;136:e450. NogamiA , HaradaT , YoshidaY , NakanoY , GoyaM , OrigasaH , et al. Clinical benefit of minimally-interrupted dabigatran versus uninterrupted warfarin for catheter ablation of atrial fibrillation: a prospective randomized multicenter trial. Circulation2017;136(24):E450. [DOI: 10.1161/CIR.0000000000000546]UMIN000013129. A prospective, multi-center, parallel-group comparison study to evaluate safety and efficacy of dabigatran during the perioperative period in patients with non-valvular atrial fibrillation who undergo the catheter ablation compared to warfarin. www.who.int/trialsearch/Trial2.aspx?TrialID=JPRN-UMIN000013129 (first received 1 March 2014). ">Nogami 2019</a>; <a href="./references#CD013504-bbs2-0012" title="YuHT , ShimJ , ParkJ , KimTH , UhmJS , KimJY , et al. When is it appropriate to stop non-vitamin K antagonist oral anticoagulants before catheter ablation of atrial fibrillation? A multi-center prospective randomized study. Europace2019;21:ii804. YuHT , ShimJ , ParkJ , KimTH , UhmJS , KimJY , et al. When is it appropriate to stop non-vitamin K antagonist oral anticoagulants before catheter ablation of atrial fibrillation? A multicentre prospective randomized study. European Heart Journal2019;40(19):1531-7. [DOI: 10.1093/eurheartj/ehy870]">Yu 2019</a>). Seven studies did not describe how randomised interventions were assigned to participants  (<a href="./references#CD013504-bbs2-0001" title="AndoM , IndenY , YoshidaY , SairakuA , YanagisawaS , SuzukiH , et al. Differences in prothrombotic response between the uninterrupted and interrupted apixaban therapies in patients undergoing cryoballoon ablation for paroxysmal atrial fibrillation: a randomized controlled study. Heart Vessels2019;34(9):1533-41. [DOI: 10.1007/s00380-019-01370-9]">Ando 2019</a>; <a href="./references#CD013504-bbs2-0003" title="NagaoT , SuzukiH , MatsunagaS , NishikawaY , HaradaK , MamiyaK . Impact of periprocedural anticoagulation therapy on the incidence of silent stroke after atrial fibrillation ablation in patients receiving direct oral anticoagulants: uninterrupted vs. interrupted by one dose strategy. Europace2019;21(4):590-7. [DOI: 10.1093/europace/euy224]">Nagao 2019</a>; <a href="./references#CD013504-bbs2-0004" title="Nakamura K, Naito S, Sasaki T, Take Y, Minami K, Kitagawa Y, et al. Uninterrupted vs. interrupted periprocedural direct oral anticoagulants for catheter ablation of atrial fibrillation: a prospective randomized single-centre study on post-ablation thrombo-embolic and haemorrhagic events. Europace2019;21(2):259-67. [DOI: 10.1093/europace/euy148]NakamuraK , SasakiT , TakeY , FunabashiN , NaitoS . Uninterrupted vs. interrupted periprocedural direct oral anticoagulants for catheter ablation of atrial fibrillation: a prospective randomized study on post-ablation thromboembolic and hemorrhagic events. Circulation2018;138:2. ">Nakamura 2019</a>; <a href="./references#CD013504-bbs2-0006" title="ReynoldsMR , AllisonJS , NataleA , WeisbergIL , EllenbogenKA , RichardsM , et al. Apixaban evaluation of interrupted or uninterrupted anticoagulation for ablation of atrial fibrillation. clinicaltrials.gov/show/NCT02608099 (first received 18 November 2015). ReynoldsMR , AllisonJS , NataleA , WeisbergIL , EllenbogenKA , RichardsM , et al. A prospective randomized trial of apixaban dosing during atrial fibrillation ablation: the AEIOU trial. JACC Clinical Electrophysiology2018;4(5):580-8. [DOI: 10.1016/j.jacep.2017.11.005]">Reynolds 2018</a>; <a href="./references#CD013504-bbs2-0008" title="XingY , XuB , XuC , PengF , YangB , QiuY , et al. Efficacy and safety of uninterrupted low-intensity warfarin for radiofrequency catheter ablation of atrial fibrillation in the elderly. Annals of Pharmacotherapy2017;51(9):735-42. [DOI: 10.1177/1060028017712532]">Xing 2017</a>; <a href="./references#CD013504-bbs2-0009" title="YamajiH , MurakamiT , HinaK , HigashiyaS , KawamuraH , MurakamiM , et al. Activated clotting time on the day of atrial fibrillation ablation for minimally interrupted and uninterrupted direct oral anticoagulation therapy: sequential changes, differences among direct oral anticoagulants, and ablation safety outcomes. Journal of Cardiovascular Electrophysiology2019;30(12):2823-33. [DOI: 10.1111/jce.14260]">Yamaji 2019</a>; <a href="./references#CD013504-bbs2-0011" title="IrikiY , IchikiH , OketaniN , YoshimuraA , OkuiH , MaenosonoR , et al. Evaluation of safety and efficacy of perioperative use of rivaroxaban and apixaban in catheter ablation for atrial fibrillation. European Heart Journal2015;36:687. [DOI: 10.1093/eurheartj/ehv400]YoshimuraA , IrikiY , IchikiH , OketaniN , OkuiH , MaenosonoR , et al. Evaluation of safety and efficacy of periprocedural use of rivaroxaban and apixaban in catheter ablation for atrial fibrillation. Journal of Cardiology2017;69(1):228-35. [DOI: 10.1016/j.jjcc.2016.03.014]">Yoshimura 2017</a>), and two studies were abstract papers and had insufficient information (<a href="./references#CD013504-bbs2-0007" title="TabishH , ShahzadK . Anticoagulation safety window among elderly Chinese patients with atrial fibrillation catheter ablation. Journal of the Saudi Heart Association2010;22(2):99-100. [DOI: 10.1016/j.jsha.2010.02.325]">Tabish 2010</a>; <a href="./references#CD013504-bbs2-0010" title="YohM , TakagiM , YoshioT , TakahashiH , ShiojimaI . AP19-00329. Safety and efficacy of uninterrupted and interrupted periprocedural direct oral anticoagulants in patients undergoing radiofrequency catheter ablation for atrial fibrillation. Journal of Arrhythmia2019;35(S1):134. [DOI: 10.1002/joa3.12267]">Yoh 2019</a>); all were judged at unclear risk of bias.  </p> </section> </section> <section id="CD013504-sec-0051"> <h4 class="title">Blinding</h4> <section id="CD013504-sec-0052"> <h5 class="title">Blinding of participants and personnel</h5> <p>There was a high risk of performance bias in eight studies since they were open‐label (<a href="./references#CD013504-bbs2-0001" title="AndoM , IndenY , YoshidaY , SairakuA , YanagisawaS , SuzukiH , et al. Differences in prothrombotic response between the uninterrupted and interrupted apixaban therapies in patients undergoing cryoballoon ablation for paroxysmal atrial fibrillation: a randomized controlled study. Heart Vessels2019;34(9):1533-41. [DOI: 10.1007/s00380-019-01370-9]">Ando 2019</a>; <a href="./references#CD013504-bbs2-0002" title='Di BiaseL , BurkhardtJD , SantangeliP , MohantyP , SanchezJ , BaiR , et al. Periprocedural strokes and anticoagulation management during AF ablation: results from the "Compare" randomized multicenter trial. Circulation2013;128:A14307. Di BiaseL , BurkhardtJD , SantangeliP , MohantyP , SanchezJ , BaiR , et al. Silent thromboembolic lesions following catheter ablation for atrial fibrillation using radiofrequency energy: results from a sub-study of the "compare" randomized trial. Circulation2013;128(22 Suppl 1):A14293. Di BiaseL , BurkhardtJD , SantangeliP , MohantyP , SanchezJ , HortonR , et al. Periprocedural stroke and bleeding complications in patients undergoing catheter ablation of atrial fibrillation with different anticoagulation management: results from the "compare" randomized trial. Heart Rhythm2013;10(9):1411. Di BiaseL , BurkhardtJD , SantangeliP , MohantyP , SanchezJE , HortonR , et al. Periprocedural stroke and bleeding complications in patients undergoing catheter ablation of atrial fibrillation with different anticoagulation management: results from the role of coumadin in preventing thromboembolism in atrial fibrillation (AF) patients undergoing catheter ablation (COMPARE) randomized trial. Circulation2014;129(25):2638-44. [DOI: 10.1161/circulationaha.113.006426]NCT01006876. Role of coumadin in preventing thromboembolism in atrial fibrillation (AF) patients undergoing catheter ablation. clinicaltrials.gov/ct2/show/NCT01006876 (first received 3 November 2009). '>Di Biase 2014</a>; <a href="./references#CD013504-bbs2-0004" title="Nakamura K, Naito S, Sasaki T, Take Y, Minami K, Kitagawa Y, et al. Uninterrupted vs. interrupted periprocedural direct oral anticoagulants for catheter ablation of atrial fibrillation: a prospective randomized single-centre study on post-ablation thrombo-embolic and haemorrhagic events. Europace2019;21(2):259-67. [DOI: 10.1093/europace/euy148]NakamuraK , SasakiT , TakeY , FunabashiN , NaitoS . Uninterrupted vs. interrupted periprocedural direct oral anticoagulants for catheter ablation of atrial fibrillation: a prospective randomized study on post-ablation thromboembolic and hemorrhagic events. Circulation2018;138:2. ">Nakamura 2019</a>; <a href="./references#CD013504-bbs2-0005" title="AonumaK . A prospective, multi-center, parallel-group comparison study to evaluate safety and efficacy of dabigatran during the perioperative period in patients with non-valvular atrial fibrillation who undergo the catheter ablation compared to warfarin. upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000015311 (first received 14 February 2014. GoyaM , NogamiA , HiraoK , AonumaK . Ablation perioperative dabigatran in use envisioning in Japan: the ABRIDGE-J study design. Journal of Cardiology2016;68(3):236-40. [DOI: 10.1016/j.jjcc.2015.10.003]]NogamiA , HaradaT , Sekiguchi Y, Otani R, YoshidaY , Yoshida K, et al. Safety and efficacy of minimally interrupted dabigatran vs uninterrupted warfarin therapy in adults undergoing atrial fibrillation catheter ablation: a randomized clinical trial. JAMA Network Open2019;2(4):15. [DOI: 10.1001/jamanetworkopen.2019.1994]NogamiA , HaradaT , YoshidaY , NakanoY , GoyaM , OrigasaH , et al. Clinical benefit of minimally-interrupted dabigatran versus uninterrupted warfarin for catheter ablation of atrial fibrillation: a prospective randomized multicenter trial. Circulation2017;136:e450. NogamiA , HaradaT , YoshidaY , NakanoY , GoyaM , OrigasaH , et al. Clinical benefit of minimally-interrupted dabigatran versus uninterrupted warfarin for catheter ablation of atrial fibrillation: a prospective randomized multicenter trial. Circulation2017;136(24):E450. [DOI: 10.1161/CIR.0000000000000546]UMIN000013129. A prospective, multi-center, parallel-group comparison study to evaluate safety and efficacy of dabigatran during the perioperative period in patients with non-valvular atrial fibrillation who undergo the catheter ablation compared to warfarin. www.who.int/trialsearch/Trial2.aspx?TrialID=JPRN-UMIN000013129 (first received 1 March 2014). ">Nogami 2019</a>; <a href="./references#CD013504-bbs2-0006" title="ReynoldsMR , AllisonJS , NataleA , WeisbergIL , EllenbogenKA , RichardsM , et al. Apixaban evaluation of interrupted or uninterrupted anticoagulation for ablation of atrial fibrillation. clinicaltrials.gov/show/NCT02608099 (first received 18 November 2015). ReynoldsMR , AllisonJS , NataleA , WeisbergIL , EllenbogenKA , RichardsM , et al. A prospective randomized trial of apixaban dosing during atrial fibrillation ablation: the AEIOU trial. JACC Clinical Electrophysiology2018;4(5):580-8. [DOI: 10.1016/j.jacep.2017.11.005]">Reynolds 2018</a>; <a href="./references#CD013504-bbs2-0008" title="XingY , XuB , XuC , PengF , YangB , QiuY , et al. Efficacy and safety of uninterrupted low-intensity warfarin for radiofrequency catheter ablation of atrial fibrillation in the elderly. Annals of Pharmacotherapy2017;51(9):735-42. [DOI: 10.1177/1060028017712532]">Xing 2017</a>; <a href="./references#CD013504-bbs2-0011" title="IrikiY , IchikiH , OketaniN , YoshimuraA , OkuiH , MaenosonoR , et al. Evaluation of safety and efficacy of perioperative use of rivaroxaban and apixaban in catheter ablation for atrial fibrillation. European Heart Journal2015;36:687. [DOI: 10.1093/eurheartj/ehv400]YoshimuraA , IrikiY , IchikiH , OketaniN , OkuiH , MaenosonoR , et al. Evaluation of safety and efficacy of periprocedural use of rivaroxaban and apixaban in catheter ablation for atrial fibrillation. Journal of Cardiology2017;69(1):228-35. [DOI: 10.1016/j.jjcc.2016.03.014]">Yoshimura 2017</a>; <a href="./references#CD013504-bbs2-0012" title="YuHT , ShimJ , ParkJ , KimTH , UhmJS , KimJY , et al. When is it appropriate to stop non-vitamin K antagonist oral anticoagulants before catheter ablation of atrial fibrillation? A multi-center prospective randomized study. Europace2019;21:ii804. YuHT , ShimJ , ParkJ , KimTH , UhmJS , KimJY , et al. When is it appropriate to stop non-vitamin K antagonist oral anticoagulants before catheter ablation of atrial fibrillation? A multicentre prospective randomized study. European Heart Journal2019;40(19):1531-7. [DOI: 10.1093/eurheartj/ehy870]">Yu 2019</a>). We judged two studies at unclear risk of bias since they did not report the blinding of participants and personnel (<a href="./references#CD013504-bbs2-0003" title="NagaoT , SuzukiH , MatsunagaS , NishikawaY , HaradaK , MamiyaK . Impact of periprocedural anticoagulation therapy on the incidence of silent stroke after atrial fibrillation ablation in patients receiving direct oral anticoagulants: uninterrupted vs. interrupted by one dose strategy. Europace2019;21(4):590-7. [DOI: 10.1093/europace/euy224]">Nagao 2019</a>; <a href="./references#CD013504-bbs2-0009" title="YamajiH , MurakamiT , HinaK , HigashiyaS , KawamuraH , MurakamiM , et al. Activated clotting time on the day of atrial fibrillation ablation for minimally interrupted and uninterrupted direct oral anticoagulation therapy: sequential changes, differences among direct oral anticoagulants, and ablation safety outcomes. Journal of Cardiovascular Electrophysiology2019;30(12):2823-33. [DOI: 10.1111/jce.14260]">Yamaji 2019</a>). <a href="./references#CD013504-bbs2-0007" title="TabishH , ShahzadK . Anticoagulation safety window among elderly Chinese patients with atrial fibrillation catheter ablation. Journal of the Saudi Heart Association2010;22(2):99-100. [DOI: 10.1016/j.jsha.2010.02.325]">Tabish 2010</a> and <a href="./references#CD013504-bbs2-0010" title="YohM , TakagiM , YoshioT , TakahashiH , ShiojimaI . AP19-00329. Safety and efficacy of uninterrupted and interrupted periprocedural direct oral anticoagulants in patients undergoing radiofrequency catheter ablation for atrial fibrillation. Journal of Arrhythmia2019;35(S1):134. [DOI: 10.1002/joa3.12267]">Yoh 2019</a> are abstract papers and had insufficient information; both were judged at unclear risk of bias. </p> </section> <section id="CD013504-sec-0053"> <h5 class="title">Blinding of outcome assessment</h5> <p>Seven studies were at low risk of bias since an independent committee of physicians adjudicated outcomes in a blinded manner (<a href="./references#CD013504-bbs2-0002" title='Di BiaseL , BurkhardtJD , SantangeliP , MohantyP , SanchezJ , BaiR , et al. Periprocedural strokes and anticoagulation management during AF ablation: results from the "Compare" randomized multicenter trial. Circulation2013;128:A14307. Di BiaseL , BurkhardtJD , SantangeliP , MohantyP , SanchezJ , BaiR , et al. Silent thromboembolic lesions following catheter ablation for atrial fibrillation using radiofrequency energy: results from a sub-study of the "compare" randomized trial. Circulation2013;128(22 Suppl 1):A14293. Di BiaseL , BurkhardtJD , SantangeliP , MohantyP , SanchezJ , HortonR , et al. Periprocedural stroke and bleeding complications in patients undergoing catheter ablation of atrial fibrillation with different anticoagulation management: results from the "compare" randomized trial. Heart Rhythm2013;10(9):1411. Di BiaseL , BurkhardtJD , SantangeliP , MohantyP , SanchezJE , HortonR , et al. Periprocedural stroke and bleeding complications in patients undergoing catheter ablation of atrial fibrillation with different anticoagulation management: results from the role of coumadin in preventing thromboembolism in atrial fibrillation (AF) patients undergoing catheter ablation (COMPARE) randomized trial. Circulation2014;129(25):2638-44. [DOI: 10.1161/circulationaha.113.006426]NCT01006876. Role of coumadin in preventing thromboembolism in atrial fibrillation (AF) patients undergoing catheter ablation. clinicaltrials.gov/ct2/show/NCT01006876 (first received 3 November 2009). '>Di Biase 2014</a>; <a href="./references#CD013504-bbs2-0003" title="NagaoT , SuzukiH , MatsunagaS , NishikawaY , HaradaK , MamiyaK . Impact of periprocedural anticoagulation therapy on the incidence of silent stroke after atrial fibrillation ablation in patients receiving direct oral anticoagulants: uninterrupted vs. interrupted by one dose strategy. Europace2019;21(4):590-7. [DOI: 10.1093/europace/euy224]">Nagao 2019</a>; <a href="./references#CD013504-bbs2-0004" title="Nakamura K, Naito S, Sasaki T, Take Y, Minami K, Kitagawa Y, et al. Uninterrupted vs. interrupted periprocedural direct oral anticoagulants for catheter ablation of atrial fibrillation: a prospective randomized single-centre study on post-ablation thrombo-embolic and haemorrhagic events. Europace2019;21(2):259-67. [DOI: 10.1093/europace/euy148]NakamuraK , SasakiT , TakeY , FunabashiN , NaitoS . Uninterrupted vs. interrupted periprocedural direct oral anticoagulants for catheter ablation of atrial fibrillation: a prospective randomized study on post-ablation thromboembolic and hemorrhagic events. Circulation2018;138:2. ">Nakamura 2019</a>; <a href="./references#CD013504-bbs2-0005" title="AonumaK . A prospective, multi-center, parallel-group comparison study to evaluate safety and efficacy of dabigatran during the perioperative period in patients with non-valvular atrial fibrillation who undergo the catheter ablation compared to warfarin. upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000015311 (first received 14 February 2014. GoyaM , NogamiA , HiraoK , AonumaK . Ablation perioperative dabigatran in use envisioning in Japan: the ABRIDGE-J study design. Journal of Cardiology2016;68(3):236-40. [DOI: 10.1016/j.jjcc.2015.10.003]]NogamiA , HaradaT , Sekiguchi Y, Otani R, YoshidaY , Yoshida K, et al. Safety and efficacy of minimally interrupted dabigatran vs uninterrupted warfarin therapy in adults undergoing atrial fibrillation catheter ablation: a randomized clinical trial. JAMA Network Open2019;2(4):15. [DOI: 10.1001/jamanetworkopen.2019.1994]NogamiA , HaradaT , YoshidaY , NakanoY , GoyaM , OrigasaH , et al. Clinical benefit of minimally-interrupted dabigatran versus uninterrupted warfarin for catheter ablation of atrial fibrillation: a prospective randomized multicenter trial. Circulation2017;136:e450. NogamiA , HaradaT , YoshidaY , NakanoY , GoyaM , OrigasaH , et al. Clinical benefit of minimally-interrupted dabigatran versus uninterrupted warfarin for catheter ablation of atrial fibrillation: a prospective randomized multicenter trial. Circulation2017;136(24):E450. [DOI: 10.1161/CIR.0000000000000546]UMIN000013129. A prospective, multi-center, parallel-group comparison study to evaluate safety and efficacy of dabigatran during the perioperative period in patients with non-valvular atrial fibrillation who undergo the catheter ablation compared to warfarin. www.who.int/trialsearch/Trial2.aspx?TrialID=JPRN-UMIN000013129 (first received 1 March 2014). ">Nogami 2019</a>; <a href="./references#CD013504-bbs2-0006" title="ReynoldsMR , AllisonJS , NataleA , WeisbergIL , EllenbogenKA , RichardsM , et al. Apixaban evaluation of interrupted or uninterrupted anticoagulation for ablation of atrial fibrillation. clinicaltrials.gov/show/NCT02608099 (first received 18 November 2015). ReynoldsMR , AllisonJS , NataleA , WeisbergIL , EllenbogenKA , RichardsM , et al. A prospective randomized trial of apixaban dosing during atrial fibrillation ablation: the AEIOU trial. JACC Clinical Electrophysiology2018;4(5):580-8. [DOI: 10.1016/j.jacep.2017.11.005]">Reynolds 2018</a>; <a href="./references#CD013504-bbs2-0011" title="IrikiY , IchikiH , OketaniN , YoshimuraA , OkuiH , MaenosonoR , et al. Evaluation of safety and efficacy of perioperative use of rivaroxaban and apixaban in catheter ablation for atrial fibrillation. European Heart Journal2015;36:687. [DOI: 10.1093/eurheartj/ehv400]YoshimuraA , IrikiY , IchikiH , OketaniN , OkuiH , MaenosonoR , et al. Evaluation of safety and efficacy of periprocedural use of rivaroxaban and apixaban in catheter ablation for atrial fibrillation. Journal of Cardiology2017;69(1):228-35. [DOI: 10.1016/j.jjcc.2016.03.014]">Yoshimura 2017</a>; <a href="./references#CD013504-bbs2-0012" title="YuHT , ShimJ , ParkJ , KimTH , UhmJS , KimJY , et al. When is it appropriate to stop non-vitamin K antagonist oral anticoagulants before catheter ablation of atrial fibrillation? A multi-center prospective randomized study. Europace2019;21:ii804. YuHT , ShimJ , ParkJ , KimTH , UhmJS , KimJY , et al. When is it appropriate to stop non-vitamin K antagonist oral anticoagulants before catheter ablation of atrial fibrillation? A multicentre prospective randomized study. European Heart Journal2019;40(19):1531-7. [DOI: 10.1093/eurheartj/ehy870]">Yu 2019</a>). <a href="./references#CD013504-bbs2-0002" title='Di BiaseL , BurkhardtJD , SantangeliP , MohantyP , SanchezJ , BaiR , et al. Periprocedural strokes and anticoagulation management during AF ablation: results from the "Compare" randomized multicenter trial. Circulation2013;128:A14307. Di BiaseL , BurkhardtJD , SantangeliP , MohantyP , SanchezJ , BaiR , et al. Silent thromboembolic lesions following catheter ablation for atrial fibrillation using radiofrequency energy: results from a sub-study of the "compare" randomized trial. Circulation2013;128(22 Suppl 1):A14293. Di BiaseL , BurkhardtJD , SantangeliP , MohantyP , SanchezJ , HortonR , et al. Periprocedural stroke and bleeding complications in patients undergoing catheter ablation of atrial fibrillation with different anticoagulation management: results from the "compare" randomized trial. Heart Rhythm2013;10(9):1411. Di BiaseL , BurkhardtJD , SantangeliP , MohantyP , SanchezJE , HortonR , et al. Periprocedural stroke and bleeding complications in patients undergoing catheter ablation of atrial fibrillation with different anticoagulation management: results from the role of coumadin in preventing thromboembolism in atrial fibrillation (AF) patients undergoing catheter ablation (COMPARE) randomized trial. Circulation2014;129(25):2638-44. [DOI: 10.1161/circulationaha.113.006426]NCT01006876. Role of coumadin in preventing thromboembolism in atrial fibrillation (AF) patients undergoing catheter ablation. clinicaltrials.gov/ct2/show/NCT01006876 (first received 3 November 2009). '>Di Biase 2014</a> reported that "stroke and TIA [transient ischaemic attack] diagnoses were performed by a neurologist who was blinded to the patient's group assignment as well as diagnoses of peripheral embolic events or deep venous thrombosis were performed by other physicians blinded to the group assignment." <a href="./references#CD013504-bbs2-0003" title="NagaoT , SuzukiH , MatsunagaS , NishikawaY , HaradaK , MamiyaK . Impact of periprocedural anticoagulation therapy on the incidence of silent stroke after atrial fibrillation ablation in patients receiving direct oral anticoagulants: uninterrupted vs. interrupted by one dose strategy. Europace2019;21(4):590-7. [DOI: 10.1093/europace/euy224]">Nagao 2019</a> mentioned that MRI images were analysed by an independent radiologist using blinded methods. <a href="./references#CD013504-bbs2-0004" title="Nakamura K, Naito S, Sasaki T, Take Y, Minami K, Kitagawa Y, et al. Uninterrupted vs. interrupted periprocedural direct oral anticoagulants for catheter ablation of atrial fibrillation: a prospective randomized single-centre study on post-ablation thrombo-embolic and haemorrhagic events. Europace2019;21(2):259-67. [DOI: 10.1093/europace/euy148]NakamuraK , SasakiT , TakeY , FunabashiN , NaitoS . Uninterrupted vs. interrupted periprocedural direct oral anticoagulants for catheter ablation of atrial fibrillation: a prospective randomized study on post-ablation thromboembolic and hemorrhagic events. Circulation2018;138:2. ">Nakamura 2019</a>, <a href="./references#CD013504-bbs2-0005" title="AonumaK . A prospective, multi-center, parallel-group comparison study to evaluate safety and efficacy of dabigatran during the perioperative period in patients with non-valvular atrial fibrillation who undergo the catheter ablation compared to warfarin. upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000015311 (first received 14 February 2014. GoyaM , NogamiA , HiraoK , AonumaK . Ablation perioperative dabigatran in use envisioning in Japan: the ABRIDGE-J study design. Journal of Cardiology2016;68(3):236-40. [DOI: 10.1016/j.jjcc.2015.10.003]]NogamiA , HaradaT , Sekiguchi Y, Otani R, YoshidaY , Yoshida K, et al. Safety and efficacy of minimally interrupted dabigatran vs uninterrupted warfarin therapy in adults undergoing atrial fibrillation catheter ablation: a randomized clinical trial. JAMA Network Open2019;2(4):15. [DOI: 10.1001/jamanetworkopen.2019.1994]NogamiA , HaradaT , YoshidaY , NakanoY , GoyaM , OrigasaH , et al. Clinical benefit of minimally-interrupted dabigatran versus uninterrupted warfarin for catheter ablation of atrial fibrillation: a prospective randomized multicenter trial. Circulation2017;136:e450. NogamiA , HaradaT , YoshidaY , NakanoY , GoyaM , OrigasaH , et al. Clinical benefit of minimally-interrupted dabigatran versus uninterrupted warfarin for catheter ablation of atrial fibrillation: a prospective randomized multicenter trial. Circulation2017;136(24):E450. [DOI: 10.1161/CIR.0000000000000546]UMIN000013129. A prospective, multi-center, parallel-group comparison study to evaluate safety and efficacy of dabigatran during the perioperative period in patients with non-valvular atrial fibrillation who undergo the catheter ablation compared to warfarin. www.who.int/trialsearch/Trial2.aspx?TrialID=JPRN-UMIN000013129 (first received 1 March 2014). ">Nogami 2019</a>, and  <a href="./references#CD013504-bbs2-0012" title="YuHT , ShimJ , ParkJ , KimTH , UhmJS , KimJY , et al. When is it appropriate to stop non-vitamin K antagonist oral anticoagulants before catheter ablation of atrial fibrillation? A multi-center prospective randomized study. Europace2019;21:ii804. YuHT , ShimJ , ParkJ , KimTH , UhmJS , KimJY , et al. When is it appropriate to stop non-vitamin K antagonist oral anticoagulants before catheter ablation of atrial fibrillation? A multicentre prospective randomized study. European Heart Journal2019;40(19):1531-7. [DOI: 10.1093/eurheartj/ehy870]">Yu 2019</a> mentioned that a panel of experts adjudicated all endpoints in a blinded manner. <a href="./references#CD013504-bbs2-0006" title="ReynoldsMR , AllisonJS , NataleA , WeisbergIL , EllenbogenKA , RichardsM , et al. Apixaban evaluation of interrupted or uninterrupted anticoagulation for ablation of atrial fibrillation. clinicaltrials.gov/show/NCT02608099 (first received 18 November 2015). ReynoldsMR , AllisonJS , NataleA , WeisbergIL , EllenbogenKA , RichardsM , et al. A prospective randomized trial of apixaban dosing during atrial fibrillation ablation: the AEIOU trial. JACC Clinical Electrophysiology2018;4(5):580-8. [DOI: 10.1016/j.jacep.2017.11.005]">Reynolds 2018</a> reported that an independent endpoints committee reviewed and adjudicated all potential endpoints. A safety officer of the study sponsor and the principal investigator reviewed other procedure‐attributable adverse events not meeting endpoint criteria. <a href="./references#CD013504-bbs2-0011" title="IrikiY , IchikiH , OketaniN , YoshimuraA , OkuiH , MaenosonoR , et al. Evaluation of safety and efficacy of perioperative use of rivaroxaban and apixaban in catheter ablation for atrial fibrillation. European Heart Journal2015;36:687. [DOI: 10.1093/eurheartj/ehv400]YoshimuraA , IrikiY , IchikiH , OketaniN , OkuiH , MaenosonoR , et al. Evaluation of safety and efficacy of periprocedural use of rivaroxaban and apixaban in catheter ablation for atrial fibrillation. Journal of Cardiology2017;69(1):228-35. [DOI: 10.1016/j.jjcc.2016.03.014]">Yoshimura 2017</a> reported that blinded radiologists diagnosed cerebral MRI including DW‐ and T2W‐MRI with or without new or old thromboembolism.  </p> <p>Three studies provided no information about the blinding of outcome assessors, hence were judged at unclear risk of bias (<a href="./references#CD013504-bbs2-0001" title="AndoM , IndenY , YoshidaY , SairakuA , YanagisawaS , SuzukiH , et al. Differences in prothrombotic response between the uninterrupted and interrupted apixaban therapies in patients undergoing cryoballoon ablation for paroxysmal atrial fibrillation: a randomized controlled study. Heart Vessels2019;34(9):1533-41. [DOI: 10.1007/s00380-019-01370-9]">Ando 2019</a>; <a href="./references#CD013504-bbs2-0008" title="XingY , XuB , XuC , PengF , YangB , QiuY , et al. Efficacy and safety of uninterrupted low-intensity warfarin for radiofrequency catheter ablation of atrial fibrillation in the elderly. Annals of Pharmacotherapy2017;51(9):735-42. [DOI: 10.1177/1060028017712532]">Xing 2017</a>; <a href="./references#CD013504-bbs2-0009" title="YamajiH , MurakamiT , HinaK , HigashiyaS , KawamuraH , MurakamiM , et al. Activated clotting time on the day of atrial fibrillation ablation for minimally interrupted and uninterrupted direct oral anticoagulation therapy: sequential changes, differences among direct oral anticoagulants, and ablation safety outcomes. Journal of Cardiovascular Electrophysiology2019;30(12):2823-33. [DOI: 10.1111/jce.14260]">Yamaji 2019</a>). <a href="./references#CD013504-bbs2-0007" title="TabishH , ShahzadK . Anticoagulation safety window among elderly Chinese patients with atrial fibrillation catheter ablation. Journal of the Saudi Heart Association2010;22(2):99-100. [DOI: 10.1016/j.jsha.2010.02.325]">Tabish 2010</a> and <a href="./references#CD013504-bbs2-0010" title="YohM , TakagiM , YoshioT , TakahashiH , ShiojimaI . AP19-00329. Safety and efficacy of uninterrupted and interrupted periprocedural direct oral anticoagulants in patients undergoing radiofrequency catheter ablation for atrial fibrillation. Journal of Arrhythmia2019;35(S1):134. [DOI: 10.1002/joa3.12267]">Yoh 2019</a> are abstract papers and had insufficient information; both were judged at unclear risk of bias. </p> </section> </section> <section id="CD013504-sec-0054"> <h4 class="title">Incomplete outcome data</h4> <p>We evaluated seven studies at low risk of attrition bias since they had clear participants flow charts and sufficient details about the analysis of participants where all receiving the ablation were analysed (<a href="./references#CD013504-bbs2-0001" title="AndoM , IndenY , YoshidaY , SairakuA , YanagisawaS , SuzukiH , et al. Differences in prothrombotic response between the uninterrupted and interrupted apixaban therapies in patients undergoing cryoballoon ablation for paroxysmal atrial fibrillation: a randomized controlled study. Heart Vessels2019;34(9):1533-41. [DOI: 10.1007/s00380-019-01370-9]">Ando 2019</a>; <a href="./references#CD013504-bbs2-0002" title='Di BiaseL , BurkhardtJD , SantangeliP , MohantyP , SanchezJ , BaiR , et al. Periprocedural strokes and anticoagulation management during AF ablation: results from the "Compare" randomized multicenter trial. Circulation2013;128:A14307. Di BiaseL , BurkhardtJD , SantangeliP , MohantyP , SanchezJ , BaiR , et al. Silent thromboembolic lesions following catheter ablation for atrial fibrillation using radiofrequency energy: results from a sub-study of the "compare" randomized trial. Circulation2013;128(22 Suppl 1):A14293. Di BiaseL , BurkhardtJD , SantangeliP , MohantyP , SanchezJ , HortonR , et al. Periprocedural stroke and bleeding complications in patients undergoing catheter ablation of atrial fibrillation with different anticoagulation management: results from the "compare" randomized trial. Heart Rhythm2013;10(9):1411. Di BiaseL , BurkhardtJD , SantangeliP , MohantyP , SanchezJE , HortonR , et al. Periprocedural stroke and bleeding complications in patients undergoing catheter ablation of atrial fibrillation with different anticoagulation management: results from the role of coumadin in preventing thromboembolism in atrial fibrillation (AF) patients undergoing catheter ablation (COMPARE) randomized trial. Circulation2014;129(25):2638-44. [DOI: 10.1161/circulationaha.113.006426]NCT01006876. Role of coumadin in preventing thromboembolism in atrial fibrillation (AF) patients undergoing catheter ablation. clinicaltrials.gov/ct2/show/NCT01006876 (first received 3 November 2009). '>Di Biase 2014</a>; <a href="./references#CD013504-bbs2-0004" title="Nakamura K, Naito S, Sasaki T, Take Y, Minami K, Kitagawa Y, et al. Uninterrupted vs. interrupted periprocedural direct oral anticoagulants for catheter ablation of atrial fibrillation: a prospective randomized single-centre study on post-ablation thrombo-embolic and haemorrhagic events. Europace2019;21(2):259-67. [DOI: 10.1093/europace/euy148]NakamuraK , SasakiT , TakeY , FunabashiN , NaitoS . Uninterrupted vs. interrupted periprocedural direct oral anticoagulants for catheter ablation of atrial fibrillation: a prospective randomized study on post-ablation thromboembolic and hemorrhagic events. Circulation2018;138:2. ">Nakamura 2019</a>; <a href="./references#CD013504-bbs2-0005" title="AonumaK . A prospective, multi-center, parallel-group comparison study to evaluate safety and efficacy of dabigatran during the perioperative period in patients with non-valvular atrial fibrillation who undergo the catheter ablation compared to warfarin. upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000015311 (first received 14 February 2014. GoyaM , NogamiA , HiraoK , AonumaK . Ablation perioperative dabigatran in use envisioning in Japan: the ABRIDGE-J study design. Journal of Cardiology2016;68(3):236-40. [DOI: 10.1016/j.jjcc.2015.10.003]]NogamiA , HaradaT , Sekiguchi Y, Otani R, YoshidaY , Yoshida K, et al. Safety and efficacy of minimally interrupted dabigatran vs uninterrupted warfarin therapy in adults undergoing atrial fibrillation catheter ablation: a randomized clinical trial. JAMA Network Open2019;2(4):15. [DOI: 10.1001/jamanetworkopen.2019.1994]NogamiA , HaradaT , YoshidaY , NakanoY , GoyaM , OrigasaH , et al. Clinical benefit of minimally-interrupted dabigatran versus uninterrupted warfarin for catheter ablation of atrial fibrillation: a prospective randomized multicenter trial. Circulation2017;136:e450. NogamiA , HaradaT , YoshidaY , NakanoY , GoyaM , OrigasaH , et al. Clinical benefit of minimally-interrupted dabigatran versus uninterrupted warfarin for catheter ablation of atrial fibrillation: a prospective randomized multicenter trial. Circulation2017;136(24):E450. [DOI: 10.1161/CIR.0000000000000546]UMIN000013129. A prospective, multi-center, parallel-group comparison study to evaluate safety and efficacy of dabigatran during the perioperative period in patients with non-valvular atrial fibrillation who undergo the catheter ablation compared to warfarin. www.who.int/trialsearch/Trial2.aspx?TrialID=JPRN-UMIN000013129 (first received 1 March 2014). ">Nogami 2019</a>; <a href="./references#CD013504-bbs2-0006" title="ReynoldsMR , AllisonJS , NataleA , WeisbergIL , EllenbogenKA , RichardsM , et al. Apixaban evaluation of interrupted or uninterrupted anticoagulation for ablation of atrial fibrillation. clinicaltrials.gov/show/NCT02608099 (first received 18 November 2015). ReynoldsMR , AllisonJS , NataleA , WeisbergIL , EllenbogenKA , RichardsM , et al. A prospective randomized trial of apixaban dosing during atrial fibrillation ablation: the AEIOU trial. JACC Clinical Electrophysiology2018;4(5):580-8. [DOI: 10.1016/j.jacep.2017.11.005]">Reynolds 2018</a>; <a href="./references#CD013504-bbs2-0011" title="IrikiY , IchikiH , OketaniN , YoshimuraA , OkuiH , MaenosonoR , et al. Evaluation of safety and efficacy of perioperative use of rivaroxaban and apixaban in catheter ablation for atrial fibrillation. European Heart Journal2015;36:687. [DOI: 10.1093/eurheartj/ehv400]YoshimuraA , IrikiY , IchikiH , OketaniN , OkuiH , MaenosonoR , et al. Evaluation of safety and efficacy of periprocedural use of rivaroxaban and apixaban in catheter ablation for atrial fibrillation. Journal of Cardiology2017;69(1):228-35. [DOI: 10.1016/j.jjcc.2016.03.014]">Yoshimura 2017</a>; <a href="./references#CD013504-bbs2-0012" title="YuHT , ShimJ , ParkJ , KimTH , UhmJS , KimJY , et al. When is it appropriate to stop non-vitamin K antagonist oral anticoagulants before catheter ablation of atrial fibrillation? A multi-center prospective randomized study. Europace2019;21:ii804. YuHT , ShimJ , ParkJ , KimTH , UhmJS , KimJY , et al. When is it appropriate to stop non-vitamin K antagonist oral anticoagulants before catheter ablation of atrial fibrillation? A multicentre prospective randomized study. European Heart Journal2019;40(19):1531-7. [DOI: 10.1093/eurheartj/ehy870]">Yu 2019</a>). The remaining studies provided no participants flow charts to make a judgement  and are at unclear risk of attrition bias (<a href="./references#CD013504-bbs2-0003" title="NagaoT , SuzukiH , MatsunagaS , NishikawaY , HaradaK , MamiyaK . Impact of periprocedural anticoagulation therapy on the incidence of silent stroke after atrial fibrillation ablation in patients receiving direct oral anticoagulants: uninterrupted vs. interrupted by one dose strategy. Europace2019;21(4):590-7. [DOI: 10.1093/europace/euy224]">Nagao 2019</a>; <a href="./references#CD013504-bbs2-0007" title="TabishH , ShahzadK . Anticoagulation safety window among elderly Chinese patients with atrial fibrillation catheter ablation. Journal of the Saudi Heart Association2010;22(2):99-100. [DOI: 10.1016/j.jsha.2010.02.325]">Tabish 2010</a>; <a href="./references#CD013504-bbs2-0008" title="XingY , XuB , XuC , PengF , YangB , QiuY , et al. Efficacy and safety of uninterrupted low-intensity warfarin for radiofrequency catheter ablation of atrial fibrillation in the elderly. Annals of Pharmacotherapy2017;51(9):735-42. [DOI: 10.1177/1060028017712532]">Xing 2017</a>; <a href="./references#CD013504-bbs2-0009" title="YamajiH , MurakamiT , HinaK , HigashiyaS , KawamuraH , MurakamiM , et al. Activated clotting time on the day of atrial fibrillation ablation for minimally interrupted and uninterrupted direct oral anticoagulation therapy: sequential changes, differences among direct oral anticoagulants, and ablation safety outcomes. Journal of Cardiovascular Electrophysiology2019;30(12):2823-33. [DOI: 10.1111/jce.14260]">Yamaji 2019</a>; <a href="./references#CD013504-bbs2-0010" title="YohM , TakagiM , YoshioT , TakahashiH , ShiojimaI . AP19-00329. Safety and efficacy of uninterrupted and interrupted periprocedural direct oral anticoagulants in patients undergoing radiofrequency catheter ablation for atrial fibrillation. Journal of Arrhythmia2019;35(S1):134. [DOI: 10.1002/joa3.12267]">Yoh 2019</a>).   </p> </section> <section id="CD013504-sec-0055"> <h4 class="title">Selective reporting</h4> <p>To judge a study at low risk of reporting bias, we required that the trial was registered, or a protocol was published, where those prespecified outcomes were reported. Four studies were at low risk of reporting bias (<a href="./references#CD013504-bbs2-0002" title='Di BiaseL , BurkhardtJD , SantangeliP , MohantyP , SanchezJ , BaiR , et al. Periprocedural strokes and anticoagulation management during AF ablation: results from the "Compare" randomized multicenter trial. Circulation2013;128:A14307. Di BiaseL , BurkhardtJD , SantangeliP , MohantyP , SanchezJ , BaiR , et al. Silent thromboembolic lesions following catheter ablation for atrial fibrillation using radiofrequency energy: results from a sub-study of the "compare" randomized trial. Circulation2013;128(22 Suppl 1):A14293. Di BiaseL , BurkhardtJD , SantangeliP , MohantyP , SanchezJ , HortonR , et al. Periprocedural stroke and bleeding complications in patients undergoing catheter ablation of atrial fibrillation with different anticoagulation management: results from the "compare" randomized trial. Heart Rhythm2013;10(9):1411. Di BiaseL , BurkhardtJD , SantangeliP , MohantyP , SanchezJE , HortonR , et al. Periprocedural stroke and bleeding complications in patients undergoing catheter ablation of atrial fibrillation with different anticoagulation management: results from the role of coumadin in preventing thromboembolism in atrial fibrillation (AF) patients undergoing catheter ablation (COMPARE) randomized trial. Circulation2014;129(25):2638-44. [DOI: 10.1161/circulationaha.113.006426]NCT01006876. Role of coumadin in preventing thromboembolism in atrial fibrillation (AF) patients undergoing catheter ablation. clinicaltrials.gov/ct2/show/NCT01006876 (first received 3 November 2009). '>Di Biase 2014</a>; <a href="./references#CD013504-bbs2-0005" title="AonumaK . A prospective, multi-center, parallel-group comparison study to evaluate safety and efficacy of dabigatran during the perioperative period in patients with non-valvular atrial fibrillation who undergo the catheter ablation compared to warfarin. upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000015311 (first received 14 February 2014. GoyaM , NogamiA , HiraoK , AonumaK . Ablation perioperative dabigatran in use envisioning in Japan: the ABRIDGE-J study design. Journal of Cardiology2016;68(3):236-40. [DOI: 10.1016/j.jjcc.2015.10.003]]NogamiA , HaradaT , Sekiguchi Y, Otani R, YoshidaY , Yoshida K, et al. Safety and efficacy of minimally interrupted dabigatran vs uninterrupted warfarin therapy in adults undergoing atrial fibrillation catheter ablation: a randomized clinical trial. JAMA Network Open2019;2(4):15. [DOI: 10.1001/jamanetworkopen.2019.1994]NogamiA , HaradaT , YoshidaY , NakanoY , GoyaM , OrigasaH , et al. Clinical benefit of minimally-interrupted dabigatran versus uninterrupted warfarin for catheter ablation of atrial fibrillation: a prospective randomized multicenter trial. Circulation2017;136:e450. NogamiA , HaradaT , YoshidaY , NakanoY , GoyaM , OrigasaH , et al. Clinical benefit of minimally-interrupted dabigatran versus uninterrupted warfarin for catheter ablation of atrial fibrillation: a prospective randomized multicenter trial. Circulation2017;136(24):E450. [DOI: 10.1161/CIR.0000000000000546]UMIN000013129. A prospective, multi-center, parallel-group comparison study to evaluate safety and efficacy of dabigatran during the perioperative period in patients with non-valvular atrial fibrillation who undergo the catheter ablation compared to warfarin. www.who.int/trialsearch/Trial2.aspx?TrialID=JPRN-UMIN000013129 (first received 1 March 2014). ">Nogami 2019</a>; <a href="./references#CD013504-bbs2-0006" title="ReynoldsMR , AllisonJS , NataleA , WeisbergIL , EllenbogenKA , RichardsM , et al. Apixaban evaluation of interrupted or uninterrupted anticoagulation for ablation of atrial fibrillation. clinicaltrials.gov/show/NCT02608099 (first received 18 November 2015). ReynoldsMR , AllisonJS , NataleA , WeisbergIL , EllenbogenKA , RichardsM , et al. A prospective randomized trial of apixaban dosing during atrial fibrillation ablation: the AEIOU trial. JACC Clinical Electrophysiology2018;4(5):580-8. [DOI: 10.1016/j.jacep.2017.11.005]">Reynolds 2018</a>; <a href="./references#CD013504-bbs2-0012" title="YuHT , ShimJ , ParkJ , KimTH , UhmJS , KimJY , et al. When is it appropriate to stop non-vitamin K antagonist oral anticoagulants before catheter ablation of atrial fibrillation? A multi-center prospective randomized study. Europace2019;21:ii804. YuHT , ShimJ , ParkJ , KimTH , UhmJS , KimJY , et al. When is it appropriate to stop non-vitamin K antagonist oral anticoagulants before catheter ablation of atrial fibrillation? A multicentre prospective randomized study. European Heart Journal2019;40(19):1531-7. [DOI: 10.1093/eurheartj/ehy870]">Yu 2019</a>). In <a href="./references#CD013504-bbs2-0002" title='Di BiaseL , BurkhardtJD , SantangeliP , MohantyP , SanchezJ , BaiR , et al. Periprocedural strokes and anticoagulation management during AF ablation: results from the "Compare" randomized multicenter trial. Circulation2013;128:A14307. Di BiaseL , BurkhardtJD , SantangeliP , MohantyP , SanchezJ , BaiR , et al. Silent thromboembolic lesions following catheter ablation for atrial fibrillation using radiofrequency energy: results from a sub-study of the "compare" randomized trial. Circulation2013;128(22 Suppl 1):A14293. Di BiaseL , BurkhardtJD , SantangeliP , MohantyP , SanchezJ , HortonR , et al. Periprocedural stroke and bleeding complications in patients undergoing catheter ablation of atrial fibrillation with different anticoagulation management: results from the "compare" randomized trial. Heart Rhythm2013;10(9):1411. Di BiaseL , BurkhardtJD , SantangeliP , MohantyP , SanchezJE , HortonR , et al. Periprocedural stroke and bleeding complications in patients undergoing catheter ablation of atrial fibrillation with different anticoagulation management: results from the role of coumadin in preventing thromboembolism in atrial fibrillation (AF) patients undergoing catheter ablation (COMPARE) randomized trial. Circulation2014;129(25):2638-44. [DOI: 10.1161/circulationaha.113.006426]NCT01006876. Role of coumadin in preventing thromboembolism in atrial fibrillation (AF) patients undergoing catheter ablation. clinicaltrials.gov/ct2/show/NCT01006876 (first received 3 November 2009). '>Di Biase 2014</a>, although no prespecified plan was reported for STLs outcome, we did not consider this a major bias as the primary outcomes matched the published protocol for the outcomes of thromboembolic and major bleeding events. <a href="./references#CD013504-bbs2-0005" title="AonumaK . A prospective, multi-center, parallel-group comparison study to evaluate safety and efficacy of dabigatran during the perioperative period in patients with non-valvular atrial fibrillation who undergo the catheter ablation compared to warfarin. upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000015311 (first received 14 February 2014. GoyaM , NogamiA , HiraoK , AonumaK . Ablation perioperative dabigatran in use envisioning in Japan: the ABRIDGE-J study design. Journal of Cardiology2016;68(3):236-40. [DOI: 10.1016/j.jjcc.2015.10.003]]NogamiA , HaradaT , Sekiguchi Y, Otani R, YoshidaY , Yoshida K, et al. Safety and efficacy of minimally interrupted dabigatran vs uninterrupted warfarin therapy in adults undergoing atrial fibrillation catheter ablation: a randomized clinical trial. JAMA Network Open2019;2(4):15. [DOI: 10.1001/jamanetworkopen.2019.1994]NogamiA , HaradaT , YoshidaY , NakanoY , GoyaM , OrigasaH , et al. Clinical benefit of minimally-interrupted dabigatran versus uninterrupted warfarin for catheter ablation of atrial fibrillation: a prospective randomized multicenter trial. Circulation2017;136:e450. NogamiA , HaradaT , YoshidaY , NakanoY , GoyaM , OrigasaH , et al. Clinical benefit of minimally-interrupted dabigatran versus uninterrupted warfarin for catheter ablation of atrial fibrillation: a prospective randomized multicenter trial. Circulation2017;136(24):E450. [DOI: 10.1161/CIR.0000000000000546]UMIN000013129. A prospective, multi-center, parallel-group comparison study to evaluate safety and efficacy of dabigatran during the perioperative period in patients with non-valvular atrial fibrillation who undergo the catheter ablation compared to warfarin. www.who.int/trialsearch/Trial2.aspx?TrialID=JPRN-UMIN000013129 (first received 1 March 2014). ">Nogami 2019</a> reported outcomes as per the published protocol. However, the length of hospital stays (one of the secondary outcomes stated in their protocol) was not mentioned in the results (we did not consider this a major bias). In <a href="./references#CD013504-bbs2-0006" title="ReynoldsMR , AllisonJS , NataleA , WeisbergIL , EllenbogenKA , RichardsM , et al. Apixaban evaluation of interrupted or uninterrupted anticoagulation for ablation of atrial fibrillation. clinicaltrials.gov/show/NCT02608099 (first received 18 November 2015). ReynoldsMR , AllisonJS , NataleA , WeisbergIL , EllenbogenKA , RichardsM , et al. A prospective randomized trial of apixaban dosing during atrial fibrillation ablation: the AEIOU trial. JACC Clinical Electrophysiology2018;4(5):580-8. [DOI: 10.1016/j.jacep.2017.11.005]">Reynolds 2018</a> and <a href="./references#CD013504-bbs2-0012" title="YuHT , ShimJ , ParkJ , KimTH , UhmJS , KimJY , et al. When is it appropriate to stop non-vitamin K antagonist oral anticoagulants before catheter ablation of atrial fibrillation? A multi-center prospective randomized study. Europace2019;21:ii804. YuHT , ShimJ , ParkJ , KimTH , UhmJS , KimJY , et al. When is it appropriate to stop non-vitamin K antagonist oral anticoagulants before catheter ablation of atrial fibrillation? A multicentre prospective randomized study. European Heart Journal2019;40(19):1531-7. [DOI: 10.1093/eurheartj/ehy870]">Yu 2019</a>, outcomes reported matched the published protocols.  </p> <p>We could not judge the risk of reporting bias for the remaining eight studies because we did not identify study protocols (<a href="./references#CD013504-bbs2-0001" title="AndoM , IndenY , YoshidaY , SairakuA , YanagisawaS , SuzukiH , et al. Differences in prothrombotic response between the uninterrupted and interrupted apixaban therapies in patients undergoing cryoballoon ablation for paroxysmal atrial fibrillation: a randomized controlled study. Heart Vessels2019;34(9):1533-41. [DOI: 10.1007/s00380-019-01370-9]">Ando 2019</a>; <a href="./references#CD013504-bbs2-0003" title="NagaoT , SuzukiH , MatsunagaS , NishikawaY , HaradaK , MamiyaK . Impact of periprocedural anticoagulation therapy on the incidence of silent stroke after atrial fibrillation ablation in patients receiving direct oral anticoagulants: uninterrupted vs. interrupted by one dose strategy. Europace2019;21(4):590-7. [DOI: 10.1093/europace/euy224]">Nagao 2019</a>; <a href="./references#CD013504-bbs2-0004" title="Nakamura K, Naito S, Sasaki T, Take Y, Minami K, Kitagawa Y, et al. Uninterrupted vs. interrupted periprocedural direct oral anticoagulants for catheter ablation of atrial fibrillation: a prospective randomized single-centre study on post-ablation thrombo-embolic and haemorrhagic events. Europace2019;21(2):259-67. [DOI: 10.1093/europace/euy148]NakamuraK , SasakiT , TakeY , FunabashiN , NaitoS . Uninterrupted vs. interrupted periprocedural direct oral anticoagulants for catheter ablation of atrial fibrillation: a prospective randomized study on post-ablation thromboembolic and hemorrhagic events. Circulation2018;138:2. ">Nakamura 2019</a>; <a href="./references#CD013504-bbs2-0007" title="TabishH , ShahzadK . Anticoagulation safety window among elderly Chinese patients with atrial fibrillation catheter ablation. Journal of the Saudi Heart Association2010;22(2):99-100. [DOI: 10.1016/j.jsha.2010.02.325]">Tabish 2010</a>; <a href="./references#CD013504-bbs2-0008" title="XingY , XuB , XuC , PengF , YangB , QiuY , et al. Efficacy and safety of uninterrupted low-intensity warfarin for radiofrequency catheter ablation of atrial fibrillation in the elderly. Annals of Pharmacotherapy2017;51(9):735-42. [DOI: 10.1177/1060028017712532]">Xing 2017</a>; <a href="./references#CD013504-bbs2-0009" title="YamajiH , MurakamiT , HinaK , HigashiyaS , KawamuraH , MurakamiM , et al. Activated clotting time on the day of atrial fibrillation ablation for minimally interrupted and uninterrupted direct oral anticoagulation therapy: sequential changes, differences among direct oral anticoagulants, and ablation safety outcomes. Journal of Cardiovascular Electrophysiology2019;30(12):2823-33. [DOI: 10.1111/jce.14260]">Yamaji 2019</a>; <a href="./references#CD013504-bbs2-0010" title="YohM , TakagiM , YoshioT , TakahashiH , ShiojimaI . AP19-00329. Safety and efficacy of uninterrupted and interrupted periprocedural direct oral anticoagulants in patients undergoing radiofrequency catheter ablation for atrial fibrillation. Journal of Arrhythmia2019;35(S1):134. [DOI: 10.1002/joa3.12267]">Yoh 2019</a>; <a href="./references#CD013504-bbs2-0011" title="IrikiY , IchikiH , OketaniN , YoshimuraA , OkuiH , MaenosonoR , et al. Evaluation of safety and efficacy of perioperative use of rivaroxaban and apixaban in catheter ablation for atrial fibrillation. European Heart Journal2015;36:687. [DOI: 10.1093/eurheartj/ehv400]YoshimuraA , IrikiY , IchikiH , OketaniN , OkuiH , MaenosonoR , et al. Evaluation of safety and efficacy of periprocedural use of rivaroxaban and apixaban in catheter ablation for atrial fibrillation. Journal of Cardiology2017;69(1):228-35. [DOI: 10.1016/j.jjcc.2016.03.014]">Yoshimura 2017</a>). </p> </section> <section id="CD013504-sec-0056"> <h4 class="title">Other potential sources of bias</h4> <p>We did not identify any other potential sources of bias.</p> </section> </section> <section id="CD013504-sec-0057"> <h3 class="title" id="CD013504-sec-0057">Effects of interventions</h3> <p>See: <a href="./full#CD013504-tbl-0001"><b>Summary of findings 1</b> Interrupted versus uninterrupted anticoagulation therapy for catheter ablation in adults with arrhythmias</a> </p> <p>See <a href="./full#CD013504-tbl-0001">summary of findings Table 1</a>. </p> <section id="CD013504-sec-0058"> <h4 class="title">Primary outcomes</h4> <section id="CD013504-sec-0059"> <h5 class="title">Thromboembolic events</h5> <p>All 12 studies reported on the primary outcome of thromboembolic events; however, six studies reported zero events and, therefore, six studies were included in the meta‐analysis. Overall, events rates were low in both comparison groups. Pooling the data from the six studies found very low certainty evidence for the risk of thromboembolic events in the interrupted or minimally interrupted compared to uninterrupted anticoagulation (RR 1.76, 95% CI 0.33 to 9.46; I<sup>2</sup> = 59%; 6 studies, 3468 participants; <a href="./references#CD013504-fig-0005" title="">Analysis 1.1</a>). We downgraded the certainty of the evidence three levels. First, due to the risk of bias in included studies, specifically in the domains of randomisation and allocation concealment. Second, due to heterogeneity that led to inconsistency of results. Several factors could explain the moderate heterogeneity observed in the analysis such as several included studies were relatively small (i.e. fewer than 200 participants), use of different ablation sources and surgical techniques, use of different types of anticoagulation and strategies of interruption, and the difference in populations studied. Third, because of imprecision around the estimate of the effect that could have been driven by the relatively few participants and few events in most of the included studies. </p> <section id="CD013504-sec-0060"> <h6 class="title">Subgroup analysis</h6> <p>Although we planned to perform subgroup analysis if the outcome is reported in 10 studies, we thought that the heterogeneity between the different anticoagulants used and how the interruption was carried out was worth an inspection due to the distinct nature of each type of anticoagulant. Hence, we conducted selective subgroup analysis based on the anticoagulant used and the type of interruption strategy.  </p> <section id="CD013504-sec-0061"> <p><b>Anticoagulant type</b></p> <p>Of the six studies that reported events, we compared the two studies that used VKA in both the interrupted and uninterrupted arms (<a href="./references#CD013504-bbs2-0002" title='Di BiaseL , BurkhardtJD , SantangeliP , MohantyP , SanchezJ , BaiR , et al. Periprocedural strokes and anticoagulation management during AF ablation: results from the "Compare" randomized multicenter trial. Circulation2013;128:A14307. Di BiaseL , BurkhardtJD , SantangeliP , MohantyP , SanchezJ , BaiR , et al. Silent thromboembolic lesions following catheter ablation for atrial fibrillation using radiofrequency energy: results from a sub-study of the "compare" randomized trial. Circulation2013;128(22 Suppl 1):A14293. Di BiaseL , BurkhardtJD , SantangeliP , MohantyP , SanchezJ , HortonR , et al. Periprocedural stroke and bleeding complications in patients undergoing catheter ablation of atrial fibrillation with different anticoagulation management: results from the "compare" randomized trial. Heart Rhythm2013;10(9):1411. Di BiaseL , BurkhardtJD , SantangeliP , MohantyP , SanchezJE , HortonR , et al. Periprocedural stroke and bleeding complications in patients undergoing catheter ablation of atrial fibrillation with different anticoagulation management: results from the role of coumadin in preventing thromboembolism in atrial fibrillation (AF) patients undergoing catheter ablation (COMPARE) randomized trial. Circulation2014;129(25):2638-44. [DOI: 10.1161/circulationaha.113.006426]NCT01006876. Role of coumadin in preventing thromboembolism in atrial fibrillation (AF) patients undergoing catheter ablation. clinicaltrials.gov/ct2/show/NCT01006876 (first received 3 November 2009). '>Di Biase 2014</a>; <a href="./references#CD013504-bbs2-0008" title="XingY , XuB , XuC , PengF , YangB , QiuY , et al. Efficacy and safety of uninterrupted low-intensity warfarin for radiofrequency catheter ablation of atrial fibrillation in the elderly. Annals of Pharmacotherapy2017;51(9):735-42. [DOI: 10.1177/1060028017712532]">Xing 2017</a>), the three studies that used DOAC in both arms (<a href="./references#CD013504-bbs2-0003" title="NagaoT , SuzukiH , MatsunagaS , NishikawaY , HaradaK , MamiyaK . Impact of periprocedural anticoagulation therapy on the incidence of silent stroke after atrial fibrillation ablation in patients receiving direct oral anticoagulants: uninterrupted vs. interrupted by one dose strategy. Europace2019;21(4):590-7. [DOI: 10.1093/europace/euy224]">Nagao 2019</a>; <a href="./references#CD013504-bbs2-0004" title="Nakamura K, Naito S, Sasaki T, Take Y, Minami K, Kitagawa Y, et al. Uninterrupted vs. interrupted periprocedural direct oral anticoagulants for catheter ablation of atrial fibrillation: a prospective randomized single-centre study on post-ablation thrombo-embolic and haemorrhagic events. Europace2019;21(2):259-67. [DOI: 10.1093/europace/euy148]NakamuraK , SasakiT , TakeY , FunabashiN , NaitoS . Uninterrupted vs. interrupted periprocedural direct oral anticoagulants for catheter ablation of atrial fibrillation: a prospective randomized study on post-ablation thromboembolic and hemorrhagic events. Circulation2018;138:2. ">Nakamura 2019</a>), and the one study that compared VKA in one arm and DOAC in the other arm (<a href="./references#CD013504-bbs2-0005" title="AonumaK . A prospective, multi-center, parallel-group comparison study to evaluate safety and efficacy of dabigatran during the perioperative period in patients with non-valvular atrial fibrillation who undergo the catheter ablation compared to warfarin. upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000015311 (first received 14 February 2014. GoyaM , NogamiA , HiraoK , AonumaK . Ablation perioperative dabigatran in use envisioning in Japan: the ABRIDGE-J study design. Journal of Cardiology2016;68(3):236-40. [DOI: 10.1016/j.jjcc.2015.10.003]]NogamiA , HaradaT , Sekiguchi Y, Otani R, YoshidaY , Yoshida K, et al. Safety and efficacy of minimally interrupted dabigatran vs uninterrupted warfarin therapy in adults undergoing atrial fibrillation catheter ablation: a randomized clinical trial. JAMA Network Open2019;2(4):15. [DOI: 10.1001/jamanetworkopen.2019.1994]NogamiA , HaradaT , YoshidaY , NakanoY , GoyaM , OrigasaH , et al. Clinical benefit of minimally-interrupted dabigatran versus uninterrupted warfarin for catheter ablation of atrial fibrillation: a prospective randomized multicenter trial. Circulation2017;136:e450. NogamiA , HaradaT , YoshidaY , NakanoY , GoyaM , OrigasaH , et al. Clinical benefit of minimally-interrupted dabigatran versus uninterrupted warfarin for catheter ablation of atrial fibrillation: a prospective randomized multicenter trial. Circulation2017;136(24):E450. [DOI: 10.1161/CIR.0000000000000546]UMIN000013129. A prospective, multi-center, parallel-group comparison study to evaluate safety and efficacy of dabigatran during the perioperative period in patients with non-valvular atrial fibrillation who undergo the catheter ablation compared to warfarin. www.who.int/trialsearch/Trial2.aspx?TrialID=JPRN-UMIN000013129 (first received 1 March 2014). ">Nogami 2019</a>). The test for subgroup differences was not significant (Chi² = 0.86; degrees of freedom (df) = 2 (P = 0.65); I² = 0%; <a href="./references#CD013504-fig-0006" title="">Analysis 1.2</a>). </p> </section> <section id="CD013504-sec-0062"> <p><b>Interruption strategy</b></p> <p>We analysed two types of interruption strategies, complete interruption with heparin bridging using VKA in one study (<a href="./references#CD013504-bbs2-0002" title='Di BiaseL , BurkhardtJD , SantangeliP , MohantyP , SanchezJ , BaiR , et al. Periprocedural strokes and anticoagulation management during AF ablation: results from the "Compare" randomized multicenter trial. Circulation2013;128:A14307. Di BiaseL , BurkhardtJD , SantangeliP , MohantyP , SanchezJ , BaiR , et al. Silent thromboembolic lesions following catheter ablation for atrial fibrillation using radiofrequency energy: results from a sub-study of the "compare" randomized trial. Circulation2013;128(22 Suppl 1):A14293. Di BiaseL , BurkhardtJD , SantangeliP , MohantyP , SanchezJ , HortonR , et al. Periprocedural stroke and bleeding complications in patients undergoing catheter ablation of atrial fibrillation with different anticoagulation management: results from the "compare" randomized trial. Heart Rhythm2013;10(9):1411. Di BiaseL , BurkhardtJD , SantangeliP , MohantyP , SanchezJE , HortonR , et al. Periprocedural stroke and bleeding complications in patients undergoing catheter ablation of atrial fibrillation with different anticoagulation management: results from the role of coumadin in preventing thromboembolism in atrial fibrillation (AF) patients undergoing catheter ablation (COMPARE) randomized trial. Circulation2014;129(25):2638-44. [DOI: 10.1161/circulationaha.113.006426]NCT01006876. Role of coumadin in preventing thromboembolism in atrial fibrillation (AF) patients undergoing catheter ablation. clinicaltrials.gov/ct2/show/NCT01006876 (first received 3 November 2009). '>Di Biase 2014</a>), and the other five studies that used minimal interruption strategies (<a href="./references#CD013504-bbs2-0003" title="NagaoT , SuzukiH , MatsunagaS , NishikawaY , HaradaK , MamiyaK . Impact of periprocedural anticoagulation therapy on the incidence of silent stroke after atrial fibrillation ablation in patients receiving direct oral anticoagulants: uninterrupted vs. interrupted by one dose strategy. Europace2019;21(4):590-7. [DOI: 10.1093/europace/euy224]">Nagao 2019</a>; <a href="./references#CD013504-bbs2-0004" title="Nakamura K, Naito S, Sasaki T, Take Y, Minami K, Kitagawa Y, et al. Uninterrupted vs. interrupted periprocedural direct oral anticoagulants for catheter ablation of atrial fibrillation: a prospective randomized single-centre study on post-ablation thrombo-embolic and haemorrhagic events. Europace2019;21(2):259-67. [DOI: 10.1093/europace/euy148]NakamuraK , SasakiT , TakeY , FunabashiN , NaitoS . Uninterrupted vs. interrupted periprocedural direct oral anticoagulants for catheter ablation of atrial fibrillation: a prospective randomized study on post-ablation thromboembolic and hemorrhagic events. Circulation2018;138:2. ">Nakamura 2019</a>; <a href="./references#CD013504-bbs2-0005" title="AonumaK . A prospective, multi-center, parallel-group comparison study to evaluate safety and efficacy of dabigatran during the perioperative period in patients with non-valvular atrial fibrillation who undergo the catheter ablation compared to warfarin. upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000015311 (first received 14 February 2014. GoyaM , NogamiA , HiraoK , AonumaK . Ablation perioperative dabigatran in use envisioning in Japan: the ABRIDGE-J study design. Journal of Cardiology2016;68(3):236-40. [DOI: 10.1016/j.jjcc.2015.10.003]]NogamiA , HaradaT , Sekiguchi Y, Otani R, YoshidaY , Yoshida K, et al. Safety and efficacy of minimally interrupted dabigatran vs uninterrupted warfarin therapy in adults undergoing atrial fibrillation catheter ablation: a randomized clinical trial. JAMA Network Open2019;2(4):15. [DOI: 10.1001/jamanetworkopen.2019.1994]NogamiA , HaradaT , YoshidaY , NakanoY , GoyaM , OrigasaH , et al. Clinical benefit of minimally-interrupted dabigatran versus uninterrupted warfarin for catheter ablation of atrial fibrillation: a prospective randomized multicenter trial. Circulation2017;136:e450. NogamiA , HaradaT , YoshidaY , NakanoY , GoyaM , OrigasaH , et al. Clinical benefit of minimally-interrupted dabigatran versus uninterrupted warfarin for catheter ablation of atrial fibrillation: a prospective randomized multicenter trial. Circulation2017;136(24):E450. [DOI: 10.1161/CIR.0000000000000546]UMIN000013129. A prospective, multi-center, parallel-group comparison study to evaluate safety and efficacy of dabigatran during the perioperative period in patients with non-valvular atrial fibrillation who undergo the catheter ablation compared to warfarin. www.who.int/trialsearch/Trial2.aspx?TrialID=JPRN-UMIN000013129 (first received 1 March 2014). ">Nogami 2019</a>; <a href="./references#CD013504-bbs2-0006" title="ReynoldsMR , AllisonJS , NataleA , WeisbergIL , EllenbogenKA , RichardsM , et al. Apixaban evaluation of interrupted or uninterrupted anticoagulation for ablation of atrial fibrillation. clinicaltrials.gov/show/NCT02608099 (first received 18 November 2015). ReynoldsMR , AllisonJS , NataleA , WeisbergIL , EllenbogenKA , RichardsM , et al. A prospective randomized trial of apixaban dosing during atrial fibrillation ablation: the AEIOU trial. JACC Clinical Electrophysiology2018;4(5):580-8. [DOI: 10.1016/j.jacep.2017.11.005]">Reynolds 2018</a>; <a href="./references#CD013504-bbs2-0008" title="XingY , XuB , XuC , PengF , YangB , QiuY , et al. Efficacy and safety of uninterrupted low-intensity warfarin for radiofrequency catheter ablation of atrial fibrillation in the elderly. Annals of Pharmacotherapy2017;51(9):735-42. [DOI: 10.1177/1060028017712532]">Xing 2017</a>). The test for subgroup differences was significant (Chi² = 10.16; df = 1 (P = 0.001); I² = 90.2%; <a href="./references#CD013504-fig-0007" title="">Analysis 1.3</a>). </p> </section> </section> <section id="CD013504-sec-0063"> <h6 class="title">Sensitivity analysis</h6> <section id="CD013504-sec-0064"> <p><b>Removing studies with industrial funding</b></p> <p>Two studies reported funding from an industrial body (<a href="./references#CD013504-bbs2-0005" title="AonumaK . A prospective, multi-center, parallel-group comparison study to evaluate safety and efficacy of dabigatran during the perioperative period in patients with non-valvular atrial fibrillation who undergo the catheter ablation compared to warfarin. upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000015311 (first received 14 February 2014. GoyaM , NogamiA , HiraoK , AonumaK . Ablation perioperative dabigatran in use envisioning in Japan: the ABRIDGE-J study design. Journal of Cardiology2016;68(3):236-40. [DOI: 10.1016/j.jjcc.2015.10.003]]NogamiA , HaradaT , Sekiguchi Y, Otani R, YoshidaY , Yoshida K, et al. Safety and efficacy of minimally interrupted dabigatran vs uninterrupted warfarin therapy in adults undergoing atrial fibrillation catheter ablation: a randomized clinical trial. JAMA Network Open2019;2(4):15. [DOI: 10.1001/jamanetworkopen.2019.1994]NogamiA , HaradaT , YoshidaY , NakanoY , GoyaM , OrigasaH , et al. Clinical benefit of minimally-interrupted dabigatran versus uninterrupted warfarin for catheter ablation of atrial fibrillation: a prospective randomized multicenter trial. Circulation2017;136:e450. NogamiA , HaradaT , YoshidaY , NakanoY , GoyaM , OrigasaH , et al. Clinical benefit of minimally-interrupted dabigatran versus uninterrupted warfarin for catheter ablation of atrial fibrillation: a prospective randomized multicenter trial. Circulation2017;136(24):E450. [DOI: 10.1161/CIR.0000000000000546]UMIN000013129. A prospective, multi-center, parallel-group comparison study to evaluate safety and efficacy of dabigatran during the perioperative period in patients with non-valvular atrial fibrillation who undergo the catheter ablation compared to warfarin. www.who.int/trialsearch/Trial2.aspx?TrialID=JPRN-UMIN000013129 (first received 1 March 2014). ">Nogami 2019</a>; <a href="./references#CD013504-bbs2-0006" title="ReynoldsMR , AllisonJS , NataleA , WeisbergIL , EllenbogenKA , RichardsM , et al. Apixaban evaluation of interrupted or uninterrupted anticoagulation for ablation of atrial fibrillation. clinicaltrials.gov/show/NCT02608099 (first received 18 November 2015). ReynoldsMR , AllisonJS , NataleA , WeisbergIL , EllenbogenKA , RichardsM , et al. A prospective randomized trial of apixaban dosing during atrial fibrillation ablation: the AEIOU trial. JACC Clinical Electrophysiology2018;4(5):580-8. [DOI: 10.1016/j.jacep.2017.11.005]">Reynolds 2018</a>); excluding these studies did not cause major changes in the results (<a href="./references#CD013504-fig-0008" title="">Analysis 1.4</a>). </p> </section> <section id="CD013504-sec-0065"> <p><b>Analysis using the fixed‐effect model</b></p> <p>Sensitivity analysis using a fixed‐effect model suggested that interruption of anticoagulation therapy increases the risk of thromboembolic events compared to uninterrupted strategy (RR 5.80, 95% CI 2.68 to 12.54; <a href="./references#CD013504-fig-0009" title="">Analysis 1.5</a>). However, due to moderate heterogeneity and the very low certainty of the evidence, there is uncertainty around this finding. Specifically that the study by <a href="./references#CD013504-bbs2-0002" title='Di BiaseL , BurkhardtJD , SantangeliP , MohantyP , SanchezJ , BaiR , et al. Periprocedural strokes and anticoagulation management during AF ablation: results from the "Compare" randomized multicenter trial. Circulation2013;128:A14307. Di BiaseL , BurkhardtJD , SantangeliP , MohantyP , SanchezJ , BaiR , et al. Silent thromboembolic lesions following catheter ablation for atrial fibrillation using radiofrequency energy: results from a sub-study of the "compare" randomized trial. Circulation2013;128(22 Suppl 1):A14293. Di BiaseL , BurkhardtJD , SantangeliP , MohantyP , SanchezJ , HortonR , et al. Periprocedural stroke and bleeding complications in patients undergoing catheter ablation of atrial fibrillation with different anticoagulation management: results from the "compare" randomized trial. Heart Rhythm2013;10(9):1411. Di BiaseL , BurkhardtJD , SantangeliP , MohantyP , SanchezJE , HortonR , et al. Periprocedural stroke and bleeding complications in patients undergoing catheter ablation of atrial fibrillation with different anticoagulation management: results from the role of coumadin in preventing thromboembolism in atrial fibrillation (AF) patients undergoing catheter ablation (COMPARE) randomized trial. Circulation2014;129(25):2638-44. [DOI: 10.1161/circulationaha.113.006426]NCT01006876. Role of coumadin in preventing thromboembolism in atrial fibrillation (AF) patients undergoing catheter ablation. clinicaltrials.gov/ct2/show/NCT01006876 (first received 3 November 2009). '>Di Biase 2014</a> differed greatly in the interruption strategy as it is the only study with complete interruption of the anticoagulant VKA with heparin bridging before and after the procedure. It also contributed more weight to the analysis due to its large sample size and high event rate. </p> </section> </section> </section> <section id="CD013504-sec-0066"> <h5 class="title">Major bleeding</h5> <p>Eleven studies reported major bleeding events (<a href="./references#CD013504-bbs2-0001" title="AndoM , IndenY , YoshidaY , SairakuA , YanagisawaS , SuzukiH , et al. Differences in prothrombotic response between the uninterrupted and interrupted apixaban therapies in patients undergoing cryoballoon ablation for paroxysmal atrial fibrillation: a randomized controlled study. Heart Vessels2019;34(9):1533-41. [DOI: 10.1007/s00380-019-01370-9]">Ando 2019</a>; <a href="./references#CD013504-bbs2-0002" title='Di BiaseL , BurkhardtJD , SantangeliP , MohantyP , SanchezJ , BaiR , et al. Periprocedural strokes and anticoagulation management during AF ablation: results from the "Compare" randomized multicenter trial. Circulation2013;128:A14307. Di BiaseL , BurkhardtJD , SantangeliP , MohantyP , SanchezJ , BaiR , et al. Silent thromboembolic lesions following catheter ablation for atrial fibrillation using radiofrequency energy: results from a sub-study of the "compare" randomized trial. Circulation2013;128(22 Suppl 1):A14293. Di BiaseL , BurkhardtJD , SantangeliP , MohantyP , SanchezJ , HortonR , et al. Periprocedural stroke and bleeding complications in patients undergoing catheter ablation of atrial fibrillation with different anticoagulation management: results from the "compare" randomized trial. Heart Rhythm2013;10(9):1411. Di BiaseL , BurkhardtJD , SantangeliP , MohantyP , SanchezJE , HortonR , et al. Periprocedural stroke and bleeding complications in patients undergoing catheter ablation of atrial fibrillation with different anticoagulation management: results from the role of coumadin in preventing thromboembolism in atrial fibrillation (AF) patients undergoing catheter ablation (COMPARE) randomized trial. Circulation2014;129(25):2638-44. [DOI: 10.1161/circulationaha.113.006426]NCT01006876. Role of coumadin in preventing thromboembolism in atrial fibrillation (AF) patients undergoing catheter ablation. clinicaltrials.gov/ct2/show/NCT01006876 (first received 3 November 2009). '>Di Biase 2014</a>; <a href="./references#CD013504-bbs2-0003" title="NagaoT , SuzukiH , MatsunagaS , NishikawaY , HaradaK , MamiyaK . Impact of periprocedural anticoagulation therapy on the incidence of silent stroke after atrial fibrillation ablation in patients receiving direct oral anticoagulants: uninterrupted vs. interrupted by one dose strategy. Europace2019;21(4):590-7. [DOI: 10.1093/europace/euy224]">Nagao 2019</a>; <a href="./references#CD013504-bbs2-0004" title="Nakamura K, Naito S, Sasaki T, Take Y, Minami K, Kitagawa Y, et al. Uninterrupted vs. interrupted periprocedural direct oral anticoagulants for catheter ablation of atrial fibrillation: a prospective randomized single-centre study on post-ablation thrombo-embolic and haemorrhagic events. Europace2019;21(2):259-67. [DOI: 10.1093/europace/euy148]NakamuraK , SasakiT , TakeY , FunabashiN , NaitoS . Uninterrupted vs. interrupted periprocedural direct oral anticoagulants for catheter ablation of atrial fibrillation: a prospective randomized study on post-ablation thromboembolic and hemorrhagic events. Circulation2018;138:2. ">Nakamura 2019</a>; <a href="./references#CD013504-bbs2-0005" title="AonumaK . A prospective, multi-center, parallel-group comparison study to evaluate safety and efficacy of dabigatran during the perioperative period in patients with non-valvular atrial fibrillation who undergo the catheter ablation compared to warfarin. upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000015311 (first received 14 February 2014. GoyaM , NogamiA , HiraoK , AonumaK . Ablation perioperative dabigatran in use envisioning in Japan: the ABRIDGE-J study design. Journal of Cardiology2016;68(3):236-40. [DOI: 10.1016/j.jjcc.2015.10.003]]NogamiA , HaradaT , Sekiguchi Y, Otani R, YoshidaY , Yoshida K, et al. Safety and efficacy of minimally interrupted dabigatran vs uninterrupted warfarin therapy in adults undergoing atrial fibrillation catheter ablation: a randomized clinical trial. JAMA Network Open2019;2(4):15. [DOI: 10.1001/jamanetworkopen.2019.1994]NogamiA , HaradaT , YoshidaY , NakanoY , GoyaM , OrigasaH , et al. Clinical benefit of minimally-interrupted dabigatran versus uninterrupted warfarin for catheter ablation of atrial fibrillation: a prospective randomized multicenter trial. Circulation2017;136:e450. NogamiA , HaradaT , YoshidaY , NakanoY , GoyaM , OrigasaH , et al. Clinical benefit of minimally-interrupted dabigatran versus uninterrupted warfarin for catheter ablation of atrial fibrillation: a prospective randomized multicenter trial. Circulation2017;136(24):E450. [DOI: 10.1161/CIR.0000000000000546]UMIN000013129. A prospective, multi-center, parallel-group comparison study to evaluate safety and efficacy of dabigatran during the perioperative period in patients with non-valvular atrial fibrillation who undergo the catheter ablation compared to warfarin. www.who.int/trialsearch/Trial2.aspx?TrialID=JPRN-UMIN000013129 (first received 1 March 2014). ">Nogami 2019</a>; <a href="./references#CD013504-bbs2-0006" title="ReynoldsMR , AllisonJS , NataleA , WeisbergIL , EllenbogenKA , RichardsM , et al. Apixaban evaluation of interrupted or uninterrupted anticoagulation for ablation of atrial fibrillation. clinicaltrials.gov/show/NCT02608099 (first received 18 November 2015). ReynoldsMR , AllisonJS , NataleA , WeisbergIL , EllenbogenKA , RichardsM , et al. A prospective randomized trial of apixaban dosing during atrial fibrillation ablation: the AEIOU trial. JACC Clinical Electrophysiology2018;4(5):580-8. [DOI: 10.1016/j.jacep.2017.11.005]">Reynolds 2018</a>;  <a href="./references#CD013504-bbs2-0008" title="XingY , XuB , XuC , PengF , YangB , QiuY , et al. Efficacy and safety of uninterrupted low-intensity warfarin for radiofrequency catheter ablation of atrial fibrillation in the elderly. Annals of Pharmacotherapy2017;51(9):735-42. [DOI: 10.1177/1060028017712532]">Xing 2017</a>; <a href="./references#CD013504-bbs2-0009" title="YamajiH , MurakamiT , HinaK , HigashiyaS , KawamuraH , MurakamiM , et al. Activated clotting time on the day of atrial fibrillation ablation for minimally interrupted and uninterrupted direct oral anticoagulation therapy: sequential changes, differences among direct oral anticoagulants, and ablation safety outcomes. Journal of Cardiovascular Electrophysiology2019;30(12):2823-33. [DOI: 10.1111/jce.14260]">Yamaji 2019</a>; <a href="./references#CD013504-bbs2-0010" title="YohM , TakagiM , YoshioT , TakahashiH , ShiojimaI . AP19-00329. Safety and efficacy of uninterrupted and interrupted periprocedural direct oral anticoagulants in patients undergoing radiofrequency catheter ablation for atrial fibrillation. Journal of Arrhythmia2019;35(S1):134. [DOI: 10.1002/joa3.12267]">Yoh 2019</a>; <a href="./references#CD013504-bbs2-0011" title="IrikiY , IchikiH , OketaniN , YoshimuraA , OkuiH , MaenosonoR , et al. Evaluation of safety and efficacy of perioperative use of rivaroxaban and apixaban in catheter ablation for atrial fibrillation. European Heart Journal2015;36:687. [DOI: 10.1093/eurheartj/ehv400]YoshimuraA , IrikiY , IchikiH , OketaniN , OkuiH , MaenosonoR , et al. Evaluation of safety and efficacy of periprocedural use of rivaroxaban and apixaban in catheter ablation for atrial fibrillation. Journal of Cardiology2017;69(1):228-35. [DOI: 10.1016/j.jjcc.2016.03.014]">Yoshimura 2017</a>; <a href="./references#CD013504-bbs2-0012" title="YuHT , ShimJ , ParkJ , KimTH , UhmJS , KimJY , et al. When is it appropriate to stop non-vitamin K antagonist oral anticoagulants before catheter ablation of atrial fibrillation? A multi-center prospective randomized study. Europace2019;21:ii804. YuHT , ShimJ , ParkJ , KimTH , UhmJS , KimJY , et al. When is it appropriate to stop non-vitamin K antagonist oral anticoagulants before catheter ablation of atrial fibrillation? A multicentre prospective randomized study. European Heart Journal2019;40(19):1531-7. [DOI: 10.1093/eurheartj/ehy870]">Yu 2019</a>). We pooled data from 10 studies as <a href="./references#CD013504-bbs2-0008" title="XingY , XuB , XuC , PengF , YangB , QiuY , et al. Efficacy and safety of uninterrupted low-intensity warfarin for radiofrequency catheter ablation of atrial fibrillation in the elderly. Annals of Pharmacotherapy2017;51(9):735-42. [DOI: 10.1177/1060028017712532]">Xing 2017</a> reported zero events therefore it was not included in the meta‐analysis. There is uncertainty in the evidence for the risk of major bleeding in the interrupted compared to uninterrupted anticoagulation (RR 1.10, 95% CI 0.59 to 2.05; I<sup>2</sup> = 6%; 10 studies, 4584 participants; low‐certainty evidence; <a href="./references#CD013504-fig-0010" title="">Analysis 1.6</a>). We downgraded the certainty of the evidence two levels due to risk of bias, which was observed in the domains of randomisation and allocation concealment in most included studies, and due to imprecision. </p> <section id="CD013504-sec-0067"> <h6 class="title">Subgroup analyses</h6> <section id="CD013504-sec-0068"> <p><b>Anticoagulation type </b></p> <p>Eight of 10 studies used DOAC (<a href="./references#CD013504-bbs2-0001" title="AndoM , IndenY , YoshidaY , SairakuA , YanagisawaS , SuzukiH , et al. Differences in prothrombotic response between the uninterrupted and interrupted apixaban therapies in patients undergoing cryoballoon ablation for paroxysmal atrial fibrillation: a randomized controlled study. Heart Vessels2019;34(9):1533-41. [DOI: 10.1007/s00380-019-01370-9]">Ando 2019</a>; <a href="./references#CD013504-bbs2-0003" title="NagaoT , SuzukiH , MatsunagaS , NishikawaY , HaradaK , MamiyaK . Impact of periprocedural anticoagulation therapy on the incidence of silent stroke after atrial fibrillation ablation in patients receiving direct oral anticoagulants: uninterrupted vs. interrupted by one dose strategy. Europace2019;21(4):590-7. [DOI: 10.1093/europace/euy224]">Nagao 2019</a>; <a href="./references#CD013504-bbs2-0004" title="Nakamura K, Naito S, Sasaki T, Take Y, Minami K, Kitagawa Y, et al. Uninterrupted vs. interrupted periprocedural direct oral anticoagulants for catheter ablation of atrial fibrillation: a prospective randomized single-centre study on post-ablation thrombo-embolic and haemorrhagic events. Europace2019;21(2):259-67. [DOI: 10.1093/europace/euy148]NakamuraK , SasakiT , TakeY , FunabashiN , NaitoS . Uninterrupted vs. interrupted periprocedural direct oral anticoagulants for catheter ablation of atrial fibrillation: a prospective randomized study on post-ablation thromboembolic and hemorrhagic events. Circulation2018;138:2. ">Nakamura 2019</a>; <a href="./references#CD013504-bbs2-0006" title="ReynoldsMR , AllisonJS , NataleA , WeisbergIL , EllenbogenKA , RichardsM , et al. Apixaban evaluation of interrupted or uninterrupted anticoagulation for ablation of atrial fibrillation. clinicaltrials.gov/show/NCT02608099 (first received 18 November 2015). ReynoldsMR , AllisonJS , NataleA , WeisbergIL , EllenbogenKA , RichardsM , et al. A prospective randomized trial of apixaban dosing during atrial fibrillation ablation: the AEIOU trial. JACC Clinical Electrophysiology2018;4(5):580-8. [DOI: 10.1016/j.jacep.2017.11.005]">Reynolds 2018</a>; <a href="./references#CD013504-bbs2-0009" title="YamajiH , MurakamiT , HinaK , HigashiyaS , KawamuraH , MurakamiM , et al. Activated clotting time on the day of atrial fibrillation ablation for minimally interrupted and uninterrupted direct oral anticoagulation therapy: sequential changes, differences among direct oral anticoagulants, and ablation safety outcomes. Journal of Cardiovascular Electrophysiology2019;30(12):2823-33. [DOI: 10.1111/jce.14260]">Yamaji 2019</a>; <a href="./references#CD013504-bbs2-0010" title="YohM , TakagiM , YoshioT , TakahashiH , ShiojimaI . AP19-00329. Safety and efficacy of uninterrupted and interrupted periprocedural direct oral anticoagulants in patients undergoing radiofrequency catheter ablation for atrial fibrillation. Journal of Arrhythmia2019;35(S1):134. [DOI: 10.1002/joa3.12267]">Yoh 2019</a>; <a href="./references#CD013504-bbs2-0011" title="IrikiY , IchikiH , OketaniN , YoshimuraA , OkuiH , MaenosonoR , et al. Evaluation of safety and efficacy of perioperative use of rivaroxaban and apixaban in catheter ablation for atrial fibrillation. European Heart Journal2015;36:687. [DOI: 10.1093/eurheartj/ehv400]YoshimuraA , IrikiY , IchikiH , OketaniN , OkuiH , MaenosonoR , et al. Evaluation of safety and efficacy of periprocedural use of rivaroxaban and apixaban in catheter ablation for atrial fibrillation. Journal of Cardiology2017;69(1):228-35. [DOI: 10.1016/j.jjcc.2016.03.014]">Yoshimura 2017</a>; <a href="./references#CD013504-bbs2-0012" title="YuHT , ShimJ , ParkJ , KimTH , UhmJS , KimJY , et al. When is it appropriate to stop non-vitamin K antagonist oral anticoagulants before catheter ablation of atrial fibrillation? A multi-center prospective randomized study. Europace2019;21:ii804. YuHT , ShimJ , ParkJ , KimTH , UhmJS , KimJY , et al. When is it appropriate to stop non-vitamin K antagonist oral anticoagulants before catheter ablation of atrial fibrillation? A multicentre prospective randomized study. European Heart Journal2019;40(19):1531-7. [DOI: 10.1093/eurheartj/ehy870]">Yu 2019</a>), one study used VKA (<a href="./references#CD013504-bbs2-0002" title='Di BiaseL , BurkhardtJD , SantangeliP , MohantyP , SanchezJ , BaiR , et al. Periprocedural strokes and anticoagulation management during AF ablation: results from the "Compare" randomized multicenter trial. Circulation2013;128:A14307. Di BiaseL , BurkhardtJD , SantangeliP , MohantyP , SanchezJ , BaiR , et al. Silent thromboembolic lesions following catheter ablation for atrial fibrillation using radiofrequency energy: results from a sub-study of the "compare" randomized trial. Circulation2013;128(22 Suppl 1):A14293. Di BiaseL , BurkhardtJD , SantangeliP , MohantyP , SanchezJ , HortonR , et al. Periprocedural stroke and bleeding complications in patients undergoing catheter ablation of atrial fibrillation with different anticoagulation management: results from the "compare" randomized trial. Heart Rhythm2013;10(9):1411. Di BiaseL , BurkhardtJD , SantangeliP , MohantyP , SanchezJE , HortonR , et al. Periprocedural stroke and bleeding complications in patients undergoing catheter ablation of atrial fibrillation with different anticoagulation management: results from the role of coumadin in preventing thromboembolism in atrial fibrillation (AF) patients undergoing catheter ablation (COMPARE) randomized trial. Circulation2014;129(25):2638-44. [DOI: 10.1161/circulationaha.113.006426]NCT01006876. Role of coumadin in preventing thromboembolism in atrial fibrillation (AF) patients undergoing catheter ablation. clinicaltrials.gov/ct2/show/NCT01006876 (first received 3 November 2009). '>Di Biase 2014</a>), and one study included both DOAC and VKA (<a href="./references#CD013504-bbs2-0005" title="AonumaK . A prospective, multi-center, parallel-group comparison study to evaluate safety and efficacy of dabigatran during the perioperative period in patients with non-valvular atrial fibrillation who undergo the catheter ablation compared to warfarin. upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000015311 (first received 14 February 2014. GoyaM , NogamiA , HiraoK , AonumaK . Ablation perioperative dabigatran in use envisioning in Japan: the ABRIDGE-J study design. Journal of Cardiology2016;68(3):236-40. [DOI: 10.1016/j.jjcc.2015.10.003]]NogamiA , HaradaT , Sekiguchi Y, Otani R, YoshidaY , Yoshida K, et al. Safety and efficacy of minimally interrupted dabigatran vs uninterrupted warfarin therapy in adults undergoing atrial fibrillation catheter ablation: a randomized clinical trial. JAMA Network Open2019;2(4):15. [DOI: 10.1001/jamanetworkopen.2019.1994]NogamiA , HaradaT , YoshidaY , NakanoY , GoyaM , OrigasaH , et al. Clinical benefit of minimally-interrupted dabigatran versus uninterrupted warfarin for catheter ablation of atrial fibrillation: a prospective randomized multicenter trial. Circulation2017;136:e450. NogamiA , HaradaT , YoshidaY , NakanoY , GoyaM , OrigasaH , et al. Clinical benefit of minimally-interrupted dabigatran versus uninterrupted warfarin for catheter ablation of atrial fibrillation: a prospective randomized multicenter trial. Circulation2017;136(24):E450. [DOI: 10.1161/CIR.0000000000000546]UMIN000013129. A prospective, multi-center, parallel-group comparison study to evaluate safety and efficacy of dabigatran during the perioperative period in patients with non-valvular atrial fibrillation who undergo the catheter ablation compared to warfarin. www.who.int/trialsearch/Trial2.aspx?TrialID=JPRN-UMIN000013129 (first received 1 March 2014). ">Nogami 2019</a>). The test for subgroup differences was significant (Chi² = 6.61, df = 2 (P = 0.04); I² = 69.7%; <a href="./references#CD013504-fig-0009" title="">Analysis 1.5</a>). </p> </section> <section id="CD013504-sec-0069"> <p><b>Baseline risk of stroke using CHADS‐VASc or CHADS2</b></p> <p>Only the study by <a href="./references#CD013504-bbs2-0005" title="AonumaK . A prospective, multi-center, parallel-group comparison study to evaluate safety and efficacy of dabigatran during the perioperative period in patients with non-valvular atrial fibrillation who undergo the catheter ablation compared to warfarin. upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000015311 (first received 14 February 2014. GoyaM , NogamiA , HiraoK , AonumaK . Ablation perioperative dabigatran in use envisioning in Japan: the ABRIDGE-J study design. Journal of Cardiology2016;68(3):236-40. [DOI: 10.1016/j.jjcc.2015.10.003]]NogamiA , HaradaT , Sekiguchi Y, Otani R, YoshidaY , Yoshida K, et al. Safety and efficacy of minimally interrupted dabigatran vs uninterrupted warfarin therapy in adults undergoing atrial fibrillation catheter ablation: a randomized clinical trial. JAMA Network Open2019;2(4):15. [DOI: 10.1001/jamanetworkopen.2019.1994]NogamiA , HaradaT , YoshidaY , NakanoY , GoyaM , OrigasaH , et al. Clinical benefit of minimally-interrupted dabigatran versus uninterrupted warfarin for catheter ablation of atrial fibrillation: a prospective randomized multicenter trial. Circulation2017;136:e450. NogamiA , HaradaT , YoshidaY , NakanoY , GoyaM , OrigasaH , et al. Clinical benefit of minimally-interrupted dabigatran versus uninterrupted warfarin for catheter ablation of atrial fibrillation: a prospective randomized multicenter trial. Circulation2017;136(24):E450. [DOI: 10.1161/CIR.0000000000000546]UMIN000013129. A prospective, multi-center, parallel-group comparison study to evaluate safety and efficacy of dabigatran during the perioperative period in patients with non-valvular atrial fibrillation who undergo the catheter ablation compared to warfarin. www.who.int/trialsearch/Trial2.aspx?TrialID=JPRN-UMIN000013129 (first received 1 March 2014). ">Nogami 2019</a> reported the outcome of major bleeding using the CHADS‐VASc or CHADS2. In participants with CHADS‐VASc or CHADS2 score of 2 or higher, there were three major bleeding events in the interrupted and uninterrupted arms. For those with CHA2DS2‐VASc or CHADS<sub>2</sub> less than 2, there were eight major bleeding events in the uninterrupted arm and no events in the interrupted arm. </p> </section> <section id="CD013504-sec-0070"> <p><b>Ablation source of energy, and ablation surgical type</b></p> <p>The outcome of major bleeding events in each subgroup, and the tests for subgroup differences were not significant (<a href="./references#CD013504-fig-0012" title="">Analysis 1.8</a>; <a href="./references#CD013504-fig-0013" title="">Analysis 1.9</a>). </p> </section> <section id="CD013504-sec-0071"> <p><b>Interruption strategy </b></p> <p>The outcome of major bleeding events and the test of subgroup differences by interruption strategy were not significant (<a href="./references#CD013504-fig-0014" title="">Analysis 1.10</a>). </p> </section> <section id="CD013504-sec-0072"> <p><b>Use of heparin bridging</b></p> <p>The outcome of major bleeding events and the test of subgroup differences by use of heparin bridging were not significant (<a href="./references#CD013504-fig-0015" title="">Analysis 1.11</a>). </p> </section> </section> <section id="CD013504-sec-0073"> <h6 class="title">Sensitivity analysis</h6> <section id="CD013504-sec-0074"> <p><b>Removing studies with industrial funding</b></p> <p>Excluding industry‐funded studies resulted in no major changes in the results of major bleeding (<a href="./references#CD013504-fig-0016" title="">Analysis 1.12</a>). </p> </section> <section id="CD013504-sec-0075"> <p><b>Analysis using the fixed‐effect model</b></p> <p>There were no changes in major bleeding events using the fixed‐effect model (RR 1.08, 95% CI 0.63 to 1.85; <a href="./references#CD013504-fig-0017" title="">Analysis 1.13</a>). </p> </section> <section id="CD013504-sec-0076"> <p><b>Removing unpublished studies</b></p> <p> We excluded one study that was published as an abstract (<a href="./references#CD013504-bbs2-0012" title="YuHT , ShimJ , ParkJ , KimTH , UhmJS , KimJY , et al. When is it appropriate to stop non-vitamin K antagonist oral anticoagulants before catheter ablation of atrial fibrillation? A multi-center prospective randomized study. Europace2019;21:ii804. YuHT , ShimJ , ParkJ , KimTH , UhmJS , KimJY , et al. When is it appropriate to stop non-vitamin K antagonist oral anticoagulants before catheter ablation of atrial fibrillation? A multicentre prospective randomized study. European Heart Journal2019;40(19):1531-7. [DOI: 10.1093/eurheartj/ehy870]">Yu 2019</a>). Removing the study did not change the results (<a href="./references#CD013504-fig-0018" title="">Analysis 1.14</a>). </p> </section> </section> </section> </section> <section id="CD013504-sec-0077"> <h4 class="title">Secondary outcomes</h4> <section id="CD013504-sec-0078"> <h5 class="title">Composite endpoint of thromboembolic events, major bleeding, and all‐cause mortality</h5> <p>One study reported on the composite endpoint of interest, therefore meta‐analysis was not performed for this outcome (<a href="./references#CD013504-bbs2-0005" title="AonumaK . A prospective, multi-center, parallel-group comparison study to evaluate safety and efficacy of dabigatran during the perioperative period in patients with non-valvular atrial fibrillation who undergo the catheter ablation compared to warfarin. upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000015311 (first received 14 February 2014. GoyaM , NogamiA , HiraoK , AonumaK . Ablation perioperative dabigatran in use envisioning in Japan: the ABRIDGE-J study design. Journal of Cardiology2016;68(3):236-40. [DOI: 10.1016/j.jjcc.2015.10.003]]NogamiA , HaradaT , Sekiguchi Y, Otani R, YoshidaY , Yoshida K, et al. Safety and efficacy of minimally interrupted dabigatran vs uninterrupted warfarin therapy in adults undergoing atrial fibrillation catheter ablation: a randomized clinical trial. JAMA Network Open2019;2(4):15. [DOI: 10.1001/jamanetworkopen.2019.1994]NogamiA , HaradaT , YoshidaY , NakanoY , GoyaM , OrigasaH , et al. Clinical benefit of minimally-interrupted dabigatran versus uninterrupted warfarin for catheter ablation of atrial fibrillation: a prospective randomized multicenter trial. Circulation2017;136:e450. NogamiA , HaradaT , YoshidaY , NakanoY , GoyaM , OrigasaH , et al. Clinical benefit of minimally-interrupted dabigatran versus uninterrupted warfarin for catheter ablation of atrial fibrillation: a prospective randomized multicenter trial. Circulation2017;136(24):E450. [DOI: 10.1161/CIR.0000000000000546]UMIN000013129. A prospective, multi-center, parallel-group comparison study to evaluate safety and efficacy of dabigatran during the perioperative period in patients with non-valvular atrial fibrillation who undergo the catheter ablation compared to warfarin. www.who.int/trialsearch/Trial2.aspx?TrialID=JPRN-UMIN000013129 (first received 1 March 2014). ">Nogami 2019</a>). Three participants in the interrupted arm developed the composite endpoint versus 13 participants in the uninterrupted arm. The analysis demonstrated a lower risk of the composite endpoint in the interrupted compared to uninterrupted arm (RR 0.23, 95% CI 0.07 to 0.81; 1 study, 442 participants; low‐certainty evidence; <a href="./references#CD013504-fig-0019" title="">Analysis 1.15</a>). We downgraded the certainty of the evidence due to imprecision probably caused by the low event rate. </p> </section> <section id="CD013504-sec-0079"> <h5 class="title">Minor bleeding</h5> <p>Ten studies reported minor bleeding events (<a href="./references#CD013504-bbs2-0001" title="AndoM , IndenY , YoshidaY , SairakuA , YanagisawaS , SuzukiH , et al. Differences in prothrombotic response between the uninterrupted and interrupted apixaban therapies in patients undergoing cryoballoon ablation for paroxysmal atrial fibrillation: a randomized controlled study. Heart Vessels2019;34(9):1533-41. [DOI: 10.1007/s00380-019-01370-9]">Ando 2019</a>; <a href="./references#CD013504-bbs2-0002" title='Di BiaseL , BurkhardtJD , SantangeliP , MohantyP , SanchezJ , BaiR , et al. Periprocedural strokes and anticoagulation management during AF ablation: results from the "Compare" randomized multicenter trial. Circulation2013;128:A14307. Di BiaseL , BurkhardtJD , SantangeliP , MohantyP , SanchezJ , BaiR , et al. Silent thromboembolic lesions following catheter ablation for atrial fibrillation using radiofrequency energy: results from a sub-study of the "compare" randomized trial. Circulation2013;128(22 Suppl 1):A14293. Di BiaseL , BurkhardtJD , SantangeliP , MohantyP , SanchezJ , HortonR , et al. Periprocedural stroke and bleeding complications in patients undergoing catheter ablation of atrial fibrillation with different anticoagulation management: results from the "compare" randomized trial. Heart Rhythm2013;10(9):1411. Di BiaseL , BurkhardtJD , SantangeliP , MohantyP , SanchezJE , HortonR , et al. Periprocedural stroke and bleeding complications in patients undergoing catheter ablation of atrial fibrillation with different anticoagulation management: results from the role of coumadin in preventing thromboembolism in atrial fibrillation (AF) patients undergoing catheter ablation (COMPARE) randomized trial. Circulation2014;129(25):2638-44. [DOI: 10.1161/circulationaha.113.006426]NCT01006876. Role of coumadin in preventing thromboembolism in atrial fibrillation (AF) patients undergoing catheter ablation. clinicaltrials.gov/ct2/show/NCT01006876 (first received 3 November 2009). '>Di Biase 2014</a>; <a href="./references#CD013504-bbs2-0003" title="NagaoT , SuzukiH , MatsunagaS , NishikawaY , HaradaK , MamiyaK . Impact of periprocedural anticoagulation therapy on the incidence of silent stroke after atrial fibrillation ablation in patients receiving direct oral anticoagulants: uninterrupted vs. interrupted by one dose strategy. Europace2019;21(4):590-7. [DOI: 10.1093/europace/euy224]">Nagao 2019</a>; <a href="./references#CD013504-bbs2-0004" title="Nakamura K, Naito S, Sasaki T, Take Y, Minami K, Kitagawa Y, et al. Uninterrupted vs. interrupted periprocedural direct oral anticoagulants for catheter ablation of atrial fibrillation: a prospective randomized single-centre study on post-ablation thrombo-embolic and haemorrhagic events. Europace2019;21(2):259-67. [DOI: 10.1093/europace/euy148]NakamuraK , SasakiT , TakeY , FunabashiN , NaitoS . Uninterrupted vs. interrupted periprocedural direct oral anticoagulants for catheter ablation of atrial fibrillation: a prospective randomized study on post-ablation thromboembolic and hemorrhagic events. Circulation2018;138:2. ">Nakamura 2019</a>; <a href="./references#CD013504-bbs2-0005" title="AonumaK . A prospective, multi-center, parallel-group comparison study to evaluate safety and efficacy of dabigatran during the perioperative period in patients with non-valvular atrial fibrillation who undergo the catheter ablation compared to warfarin. upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000015311 (first received 14 February 2014. GoyaM , NogamiA , HiraoK , AonumaK . Ablation perioperative dabigatran in use envisioning in Japan: the ABRIDGE-J study design. Journal of Cardiology2016;68(3):236-40. [DOI: 10.1016/j.jjcc.2015.10.003]]NogamiA , HaradaT , Sekiguchi Y, Otani R, YoshidaY , Yoshida K, et al. Safety and efficacy of minimally interrupted dabigatran vs uninterrupted warfarin therapy in adults undergoing atrial fibrillation catheter ablation: a randomized clinical trial. JAMA Network Open2019;2(4):15. [DOI: 10.1001/jamanetworkopen.2019.1994]NogamiA , HaradaT , YoshidaY , NakanoY , GoyaM , OrigasaH , et al. Clinical benefit of minimally-interrupted dabigatran versus uninterrupted warfarin for catheter ablation of atrial fibrillation: a prospective randomized multicenter trial. Circulation2017;136:e450. NogamiA , HaradaT , YoshidaY , NakanoY , GoyaM , OrigasaH , et al. Clinical benefit of minimally-interrupted dabigatran versus uninterrupted warfarin for catheter ablation of atrial fibrillation: a prospective randomized multicenter trial. Circulation2017;136(24):E450. [DOI: 10.1161/CIR.0000000000000546]UMIN000013129. A prospective, multi-center, parallel-group comparison study to evaluate safety and efficacy of dabigatran during the perioperative period in patients with non-valvular atrial fibrillation who undergo the catheter ablation compared to warfarin. www.who.int/trialsearch/Trial2.aspx?TrialID=JPRN-UMIN000013129 (first received 1 March 2014). ">Nogami 2019</a>; <a href="./references#CD013504-bbs2-0006" title="ReynoldsMR , AllisonJS , NataleA , WeisbergIL , EllenbogenKA , RichardsM , et al. Apixaban evaluation of interrupted or uninterrupted anticoagulation for ablation of atrial fibrillation. clinicaltrials.gov/show/NCT02608099 (first received 18 November 2015). ReynoldsMR , AllisonJS , NataleA , WeisbergIL , EllenbogenKA , RichardsM , et al. A prospective randomized trial of apixaban dosing during atrial fibrillation ablation: the AEIOU trial. JACC Clinical Electrophysiology2018;4(5):580-8. [DOI: 10.1016/j.jacep.2017.11.005]">Reynolds 2018</a>; <a href="./references#CD013504-bbs2-0007" title="TabishH , ShahzadK . Anticoagulation safety window among elderly Chinese patients with atrial fibrillation catheter ablation. Journal of the Saudi Heart Association2010;22(2):99-100. [DOI: 10.1016/j.jsha.2010.02.325]">Tabish 2010</a>; <a href="./references#CD013504-bbs2-0008" title="XingY , XuB , XuC , PengF , YangB , QiuY , et al. Efficacy and safety of uninterrupted low-intensity warfarin for radiofrequency catheter ablation of atrial fibrillation in the elderly. Annals of Pharmacotherapy2017;51(9):735-42. [DOI: 10.1177/1060028017712532]">Xing 2017</a>; <a href="./references#CD013504-bbs2-0009" title="YamajiH , MurakamiT , HinaK , HigashiyaS , KawamuraH , MurakamiM , et al. Activated clotting time on the day of atrial fibrillation ablation for minimally interrupted and uninterrupted direct oral anticoagulation therapy: sequential changes, differences among direct oral anticoagulants, and ablation safety outcomes. Journal of Cardiovascular Electrophysiology2019;30(12):2823-33. [DOI: 10.1111/jce.14260]">Yamaji 2019</a>; <a href="./references#CD013504-bbs2-0010" title="YohM , TakagiM , YoshioT , TakahashiH , ShiojimaI . AP19-00329. Safety and efficacy of uninterrupted and interrupted periprocedural direct oral anticoagulants in patients undergoing radiofrequency catheter ablation for atrial fibrillation. Journal of Arrhythmia2019;35(S1):134. [DOI: 10.1002/joa3.12267]">Yoh 2019</a>); however, <a href="./references#CD013504-bbs2-0005" title="AonumaK . A prospective, multi-center, parallel-group comparison study to evaluate safety and efficacy of dabigatran during the perioperative period in patients with non-valvular atrial fibrillation who undergo the catheter ablation compared to warfarin. upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000015311 (first received 14 February 2014. GoyaM , NogamiA , HiraoK , AonumaK . Ablation perioperative dabigatran in use envisioning in Japan: the ABRIDGE-J study design. Journal of Cardiology2016;68(3):236-40. [DOI: 10.1016/j.jjcc.2015.10.003]]NogamiA , HaradaT , Sekiguchi Y, Otani R, YoshidaY , Yoshida K, et al. Safety and efficacy of minimally interrupted dabigatran vs uninterrupted warfarin therapy in adults undergoing atrial fibrillation catheter ablation: a randomized clinical trial. JAMA Network Open2019;2(4):15. [DOI: 10.1001/jamanetworkopen.2019.1994]NogamiA , HaradaT , YoshidaY , NakanoY , GoyaM , OrigasaH , et al. Clinical benefit of minimally-interrupted dabigatran versus uninterrupted warfarin for catheter ablation of atrial fibrillation: a prospective randomized multicenter trial. Circulation2017;136:e450. NogamiA , HaradaT , YoshidaY , NakanoY , GoyaM , OrigasaH , et al. Clinical benefit of minimally-interrupted dabigatran versus uninterrupted warfarin for catheter ablation of atrial fibrillation: a prospective randomized multicenter trial. Circulation2017;136(24):E450. [DOI: 10.1161/CIR.0000000000000546]UMIN000013129. A prospective, multi-center, parallel-group comparison study to evaluate safety and efficacy of dabigatran during the perioperative period in patients with non-valvular atrial fibrillation who undergo the catheter ablation compared to warfarin. www.who.int/trialsearch/Trial2.aspx?TrialID=JPRN-UMIN000013129 (first received 1 March 2014). ">Nogami 2019</a> did not report minor bleeding as a separate outcome but within a composite endpoint. The analysis suggested that there is uncertainty around the risk of minor bleeding in the interrupted compared to uninterrupted anticoagulation (RR 1.01, 95% CI 0.46 to 2.22; I<sup>2</sup> = 87%; 9 studies, 3843 participants; very low‐certainty evidence; <a href="./references#CD013504-fig-0020" title="">Analysis 1.16</a>). We downgraded the certainty of the evidence due to the risk of bias, imprecision, and high heterogeneity of the included studies, especially as <a href="./references#CD013504-bbs2-0002" title='Di BiaseL , BurkhardtJD , SantangeliP , MohantyP , SanchezJ , BaiR , et al. Periprocedural strokes and anticoagulation management during AF ablation: results from the "Compare" randomized multicenter trial. Circulation2013;128:A14307. Di BiaseL , BurkhardtJD , SantangeliP , MohantyP , SanchezJ , BaiR , et al. Silent thromboembolic lesions following catheter ablation for atrial fibrillation using radiofrequency energy: results from a sub-study of the "compare" randomized trial. Circulation2013;128(22 Suppl 1):A14293. Di BiaseL , BurkhardtJD , SantangeliP , MohantyP , SanchezJ , HortonR , et al. Periprocedural stroke and bleeding complications in patients undergoing catheter ablation of atrial fibrillation with different anticoagulation management: results from the "compare" randomized trial. Heart Rhythm2013;10(9):1411. Di BiaseL , BurkhardtJD , SantangeliP , MohantyP , SanchezJE , HortonR , et al. Periprocedural stroke and bleeding complications in patients undergoing catheter ablation of atrial fibrillation with different anticoagulation management: results from the role of coumadin in preventing thromboembolism in atrial fibrillation (AF) patients undergoing catheter ablation (COMPARE) randomized trial. Circulation2014;129(25):2638-44. [DOI: 10.1161/circulationaha.113.006426]NCT01006876. Role of coumadin in preventing thromboembolism in atrial fibrillation (AF) patients undergoing catheter ablation. clinicaltrials.gov/ct2/show/NCT01006876 (first received 3 November 2009). '>Di Biase 2014</a> was the only one of the nine studies that used heparin bridging in the interrupted arm. Also, the different ablation surgical techniques, different types of anticoagulation used, and the different populations studied could explain the high heterogeneity observed in the analysis. Due to the low number of studies that reported the outcome of minor bleeding, subgroup analyses were not performed. </p> </section> <section id="CD013504-sec-0080"> <h5 class="title">Cardiovascular mortality</h5> <p>None of the included studies reported participant cardiovascular mortality.</p> </section> <section id="CD013504-sec-0081"> <h5 class="title">All‐cause mortality</h5> <p>Two studies reported all‐cause mortality (<a href="./references#CD013504-bbs2-0005" title="AonumaK . A prospective, multi-center, parallel-group comparison study to evaluate safety and efficacy of dabigatran during the perioperative period in patients with non-valvular atrial fibrillation who undergo the catheter ablation compared to warfarin. upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000015311 (first received 14 February 2014. GoyaM , NogamiA , HiraoK , AonumaK . Ablation perioperative dabigatran in use envisioning in Japan: the ABRIDGE-J study design. Journal of Cardiology2016;68(3):236-40. [DOI: 10.1016/j.jjcc.2015.10.003]]NogamiA , HaradaT , Sekiguchi Y, Otani R, YoshidaY , Yoshida K, et al. Safety and efficacy of minimally interrupted dabigatran vs uninterrupted warfarin therapy in adults undergoing atrial fibrillation catheter ablation: a randomized clinical trial. JAMA Network Open2019;2(4):15. [DOI: 10.1001/jamanetworkopen.2019.1994]NogamiA , HaradaT , YoshidaY , NakanoY , GoyaM , OrigasaH , et al. Clinical benefit of minimally-interrupted dabigatran versus uninterrupted warfarin for catheter ablation of atrial fibrillation: a prospective randomized multicenter trial. Circulation2017;136:e450. NogamiA , HaradaT , YoshidaY , NakanoY , GoyaM , OrigasaH , et al. Clinical benefit of minimally-interrupted dabigatran versus uninterrupted warfarin for catheter ablation of atrial fibrillation: a prospective randomized multicenter trial. Circulation2017;136(24):E450. [DOI: 10.1161/CIR.0000000000000546]UMIN000013129. A prospective, multi-center, parallel-group comparison study to evaluate safety and efficacy of dabigatran during the perioperative period in patients with non-valvular atrial fibrillation who undergo the catheter ablation compared to warfarin. www.who.int/trialsearch/Trial2.aspx?TrialID=JPRN-UMIN000013129 (first received 1 March 2014). ">Nogami 2019</a>; <a href="./references#CD013504-bbs2-0006" title="ReynoldsMR , AllisonJS , NataleA , WeisbergIL , EllenbogenKA , RichardsM , et al. Apixaban evaluation of interrupted or uninterrupted anticoagulation for ablation of atrial fibrillation. clinicaltrials.gov/show/NCT02608099 (first received 18 November 2015). ReynoldsMR , AllisonJS , NataleA , WeisbergIL , EllenbogenKA , RichardsM , et al. A prospective randomized trial of apixaban dosing during atrial fibrillation ablation: the AEIOU trial. JACC Clinical Electrophysiology2018;4(5):580-8. [DOI: 10.1016/j.jacep.2017.11.005]">Reynolds 2018</a>). None of the participants in either treatment arm died in <a href="./references#CD013504-bbs2-0006" title="ReynoldsMR , AllisonJS , NataleA , WeisbergIL , EllenbogenKA , RichardsM , et al. Apixaban evaluation of interrupted or uninterrupted anticoagulation for ablation of atrial fibrillation. clinicaltrials.gov/show/NCT02608099 (first received 18 November 2015). ReynoldsMR , AllisonJS , NataleA , WeisbergIL , EllenbogenKA , RichardsM , et al. A prospective randomized trial of apixaban dosing during atrial fibrillation ablation: the AEIOU trial. JACC Clinical Electrophysiology2018;4(5):580-8. [DOI: 10.1016/j.jacep.2017.11.005]">Reynolds 2018</a>. Only one participant in the uninterrupted arm in <a href="./references#CD013504-bbs2-0005" title="AonumaK . A prospective, multi-center, parallel-group comparison study to evaluate safety and efficacy of dabigatran during the perioperative period in patients with non-valvular atrial fibrillation who undergo the catheter ablation compared to warfarin. upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000015311 (first received 14 February 2014. GoyaM , NogamiA , HiraoK , AonumaK . Ablation perioperative dabigatran in use envisioning in Japan: the ABRIDGE-J study design. Journal of Cardiology2016;68(3):236-40. [DOI: 10.1016/j.jjcc.2015.10.003]]NogamiA , HaradaT , Sekiguchi Y, Otani R, YoshidaY , Yoshida K, et al. Safety and efficacy of minimally interrupted dabigatran vs uninterrupted warfarin therapy in adults undergoing atrial fibrillation catheter ablation: a randomized clinical trial. JAMA Network Open2019;2(4):15. [DOI: 10.1001/jamanetworkopen.2019.1994]NogamiA , HaradaT , YoshidaY , NakanoY , GoyaM , OrigasaH , et al. Clinical benefit of minimally-interrupted dabigatran versus uninterrupted warfarin for catheter ablation of atrial fibrillation: a prospective randomized multicenter trial. Circulation2017;136:e450. NogamiA , HaradaT , YoshidaY , NakanoY , GoyaM , OrigasaH , et al. Clinical benefit of minimally-interrupted dabigatran versus uninterrupted warfarin for catheter ablation of atrial fibrillation: a prospective randomized multicenter trial. Circulation2017;136(24):E450. [DOI: 10.1161/CIR.0000000000000546]UMIN000013129. A prospective, multi-center, parallel-group comparison study to evaluate safety and efficacy of dabigatran during the perioperative period in patients with non-valvular atrial fibrillation who undergo the catheter ablation compared to warfarin. www.who.int/trialsearch/Trial2.aspx?TrialID=JPRN-UMIN000013129 (first received 1 March 2014). ">Nogami 2019</a> died, and there were no deaths in the interrupted arm (RR 0.34, 95% CI 0.01 to 8.21; 1 study, 442 participants; low‐certainty evidence; <a href="./references#CD013504-fig-0021" title="">Analysis 1.17</a>). We downgraded the evidence due to imprecision caused by the low event rate and the wide CIs.  No subgroup or sensitivity analyses were performed for this outcome, as only one study reported on the all‐cause mortality endpoint. </p> </section> <section id="CD013504-sec-0082"> <h5 class="title">Asymptomatic thromboembolic events</h5> <p>Six studies reported asymptomatic thromboembolic events (<a href="./references#CD013504-bbs2-0002" title='Di BiaseL , BurkhardtJD , SantangeliP , MohantyP , SanchezJ , BaiR , et al. Periprocedural strokes and anticoagulation management during AF ablation: results from the "Compare" randomized multicenter trial. Circulation2013;128:A14307. Di BiaseL , BurkhardtJD , SantangeliP , MohantyP , SanchezJ , BaiR , et al. Silent thromboembolic lesions following catheter ablation for atrial fibrillation using radiofrequency energy: results from a sub-study of the "compare" randomized trial. Circulation2013;128(22 Suppl 1):A14293. Di BiaseL , BurkhardtJD , SantangeliP , MohantyP , SanchezJ , HortonR , et al. Periprocedural stroke and bleeding complications in patients undergoing catheter ablation of atrial fibrillation with different anticoagulation management: results from the "compare" randomized trial. Heart Rhythm2013;10(9):1411. Di BiaseL , BurkhardtJD , SantangeliP , MohantyP , SanchezJE , HortonR , et al. Periprocedural stroke and bleeding complications in patients undergoing catheter ablation of atrial fibrillation with different anticoagulation management: results from the role of coumadin in preventing thromboembolism in atrial fibrillation (AF) patients undergoing catheter ablation (COMPARE) randomized trial. Circulation2014;129(25):2638-44. [DOI: 10.1161/circulationaha.113.006426]NCT01006876. Role of coumadin in preventing thromboembolism in atrial fibrillation (AF) patients undergoing catheter ablation. clinicaltrials.gov/ct2/show/NCT01006876 (first received 3 November 2009). '>Di Biase 2014</a>; <a href="./references#CD013504-bbs2-0003" title="NagaoT , SuzukiH , MatsunagaS , NishikawaY , HaradaK , MamiyaK . Impact of periprocedural anticoagulation therapy on the incidence of silent stroke after atrial fibrillation ablation in patients receiving direct oral anticoagulants: uninterrupted vs. interrupted by one dose strategy. Europace2019;21(4):590-7. [DOI: 10.1093/europace/euy224]">Nagao 2019</a>; <a href="./references#CD013504-bbs2-0004" title="Nakamura K, Naito S, Sasaki T, Take Y, Minami K, Kitagawa Y, et al. Uninterrupted vs. interrupted periprocedural direct oral anticoagulants for catheter ablation of atrial fibrillation: a prospective randomized single-centre study on post-ablation thrombo-embolic and haemorrhagic events. Europace2019;21(2):259-67. [DOI: 10.1093/europace/euy148]NakamuraK , SasakiT , TakeY , FunabashiN , NaitoS . Uninterrupted vs. interrupted periprocedural direct oral anticoagulants for catheter ablation of atrial fibrillation: a prospective randomized study on post-ablation thromboembolic and hemorrhagic events. Circulation2018;138:2. ">Nakamura 2019</a>; <a href="./references#CD013504-bbs2-0008" title="XingY , XuB , XuC , PengF , YangB , QiuY , et al. Efficacy and safety of uninterrupted low-intensity warfarin for radiofrequency catheter ablation of atrial fibrillation in the elderly. Annals of Pharmacotherapy2017;51(9):735-42. [DOI: 10.1177/1060028017712532]">Xing 2017</a>; <a href="./references#CD013504-bbs2-0010" title="YohM , TakagiM , YoshioT , TakahashiH , ShiojimaI . AP19-00329. Safety and efficacy of uninterrupted and interrupted periprocedural direct oral anticoagulants in patients undergoing radiofrequency catheter ablation for atrial fibrillation. Journal of Arrhythmia2019;35(S1):134. [DOI: 10.1002/joa3.12267]">Yoh 2019</a>; <a href="./references#CD013504-bbs2-0011" title="IrikiY , IchikiH , OketaniN , YoshimuraA , OkuiH , MaenosonoR , et al. Evaluation of safety and efficacy of perioperative use of rivaroxaban and apixaban in catheter ablation for atrial fibrillation. European Heart Journal2015;36:687. [DOI: 10.1093/eurheartj/ehv400]YoshimuraA , IrikiY , IchikiH , OketaniN , OkuiH , MaenosonoR , et al. Evaluation of safety and efficacy of periprocedural use of rivaroxaban and apixaban in catheter ablation for atrial fibrillation. Journal of Cardiology2017;69(1):228-35. [DOI: 10.1016/j.jjcc.2016.03.014]">Yoshimura 2017</a>). Pooling the data showed that there is uncertainty around the risk of asymptomatic thromboembolism in the interrupted compared to uninterrupted arm (RR 1.45, 95% CI 0.85 to 2.47; I<sup>2</sup> = 56%; 6 studies, 1268 participants; very low‐certainty evidence; <a href="./references#CD013504-fig-0022" title="">Analysis 1.18</a>). We downgraded the certainty of the evidence by three levels. First due to the risk of bias in included studies, specifically in the domains of randomisation and allocation concealment. Second due to inconsistency owing to a moderate level of statistical heterogeneity. Third due to imprecision due to a wide CI in the effect estimate, which could be explained by the variability in assessing this outcome in the included study. Due to the low number of studies that reported on the outcome of minor bleeding, subgroup analyses were not performed. </p> </section> <section id="CD013504-sec-0083"> <h5 class="title">Patient quality of life</h5> <p>None of the included studies reported on patient QoL.</p> </section> <section id="CD013504-sec-0084"> <h5 class="title">Economic costs</h5> <p>None of the included studies reported on economic costs.</p> </section> <section id="CD013504-sec-0085"> <h5 class="title">Length of hospital stay</h5> <p>None of the included studies reported on length of hospital stay.</p> </section> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD013504-sec-0086" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD013504-sec-0086"></div> <section id="CD013504-sec-0087"> <h3 class="title" id="CD013504-sec-0087">Summary of main results</h3> <p>The current systematic review and meta‐analysis included 12 studies with 4714 participants. The meta‐analysis showed that there is uncertainty in the evidence on the effect of interrupted and uninterrupted anticoagulation therapy for CA in adults with arrhythmias, for the outcomes of thromboembolic events (stroke, systemic embolism), major and minor bleeding, and asymptomatic thromboembolism. There was also uncertainty in the evidence on all‐cause mortality and composite endpoint (thromboembolic events, major bleeding, and all‐cause mortality). However, not all studies reported on all the review outcomes, therefore the number of participants varied across different analyses; furthermore, for most outcomes event rates were small. Overall, the certainty of the evidence for the major outcomes assessed by GRADE ranged from very low to low, mainly due to the risk of bias in included studies, heterogeneity that led to inconsistency of results, and due to imprecision around the estimate of effect (<a href="./full#CD013504-tbl-0001">summary of findings Table 1</a>).  </p> </section> <section id="CD013504-sec-0088"> <h3 class="title" id="CD013504-sec-0088">Overall completeness and applicability of evidence</h3> <p>Several features in the included studies need to be carefully considered before drawing any generalisation. Across all studies, participants with a high risk of stroke or bleeding (or both) were not well‐represented (less than 10%). Ten studies were conducted in the East‐Asian population: Japanese (seven studies), Chinese (two studies), and South Korean (one study). The interethnic variabilities of drug action and the potential risk of bleeding are highly likely. In addition, manufacture recommended doses as well as local guidelines of dose adjustment of DOAC in Asian populations further limit the generalisability of the results. Paroxysmal AF was the most represented type of AF in the studies. Females made up less than a third of any population in the included studies. Representation of various comorbidities was similar between studies, but there was a low number of participants with prior stroke and almost or no representation of participants with renal impairment. </p> <p><a href="./references#CD013504-bbs2-0002" title='Di BiaseL , BurkhardtJD , SantangeliP , MohantyP , SanchezJ , BaiR , et al. Periprocedural strokes and anticoagulation management during AF ablation: results from the "Compare" randomized multicenter trial. Circulation2013;128:A14307. Di BiaseL , BurkhardtJD , SantangeliP , MohantyP , SanchezJ , BaiR , et al. Silent thromboembolic lesions following catheter ablation for atrial fibrillation using radiofrequency energy: results from a sub-study of the "compare" randomized trial. Circulation2013;128(22 Suppl 1):A14293. Di BiaseL , BurkhardtJD , SantangeliP , MohantyP , SanchezJ , HortonR , et al. Periprocedural stroke and bleeding complications in patients undergoing catheter ablation of atrial fibrillation with different anticoagulation management: results from the "compare" randomized trial. Heart Rhythm2013;10(9):1411. Di BiaseL , BurkhardtJD , SantangeliP , MohantyP , SanchezJE , HortonR , et al. Periprocedural stroke and bleeding complications in patients undergoing catheter ablation of atrial fibrillation with different anticoagulation management: results from the role of coumadin in preventing thromboembolism in atrial fibrillation (AF) patients undergoing catheter ablation (COMPARE) randomized trial. Circulation2014;129(25):2638-44. [DOI: 10.1161/circulationaha.113.006426]NCT01006876. Role of coumadin in preventing thromboembolism in atrial fibrillation (AF) patients undergoing catheter ablation. clinicaltrials.gov/ct2/show/NCT01006876 (first received 3 November 2009). '>Di Biase 2014</a> was the only trial that used complete interruption (warfarin held two or three days before ablation and bridging with heparin), whereas the rest of the studies implemented minimal interruption by skipping one or two doses of DOAC with or without heparin bridging or used low‐intensity warfarin (INR 1.5 to 2.0) (surrogate to minimal interruption). It is also the largest study with most events, while the remaining studies reported no or few events. </p> <p>The protocol of periprocedural management was fairly similar in all studies. All studies prescribed anticoagulant for at least four weeks before the procedure, and eight studies performed TOE prior to ablation. Two studies gave heparin bridging during the interruption of DOAC. This applied to participants with persistent AF (<a href="./references#CD013504-bbs2-0012" title="YuHT , ShimJ , ParkJ , KimTH , UhmJS , KimJY , et al. When is it appropriate to stop non-vitamin K antagonist oral anticoagulants before catheter ablation of atrial fibrillation? A multi-center prospective randomized study. Europace2019;21:ii804. YuHT , ShimJ , ParkJ , KimTH , UhmJS , KimJY , et al. When is it appropriate to stop non-vitamin K antagonist oral anticoagulants before catheter ablation of atrial fibrillation? A multicentre prospective randomized study. European Heart Journal2019;40(19):1531-7. [DOI: 10.1093/eurheartj/ehy870]">Yu 2019</a>), and in those who had their dabigatran therapy discontinued at least 24 hours before the ablation (<a href="./references#CD013504-bbs2-0005" title="AonumaK . A prospective, multi-center, parallel-group comparison study to evaluate safety and efficacy of dabigatran during the perioperative period in patients with non-valvular atrial fibrillation who undergo the catheter ablation compared to warfarin. upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000015311 (first received 14 February 2014. GoyaM , NogamiA , HiraoK , AonumaK . Ablation perioperative dabigatran in use envisioning in Japan: the ABRIDGE-J study design. Journal of Cardiology2016;68(3):236-40. [DOI: 10.1016/j.jjcc.2015.10.003]]NogamiA , HaradaT , Sekiguchi Y, Otani R, YoshidaY , Yoshida K, et al. Safety and efficacy of minimally interrupted dabigatran vs uninterrupted warfarin therapy in adults undergoing atrial fibrillation catheter ablation: a randomized clinical trial. JAMA Network Open2019;2(4):15. [DOI: 10.1001/jamanetworkopen.2019.1994]NogamiA , HaradaT , YoshidaY , NakanoY , GoyaM , OrigasaH , et al. Clinical benefit of minimally-interrupted dabigatran versus uninterrupted warfarin for catheter ablation of atrial fibrillation: a prospective randomized multicenter trial. Circulation2017;136:e450. NogamiA , HaradaT , YoshidaY , NakanoY , GoyaM , OrigasaH , et al. Clinical benefit of minimally-interrupted dabigatran versus uninterrupted warfarin for catheter ablation of atrial fibrillation: a prospective randomized multicenter trial. Circulation2017;136(24):E450. [DOI: 10.1161/CIR.0000000000000546]UMIN000013129. A prospective, multi-center, parallel-group comparison study to evaluate safety and efficacy of dabigatran during the perioperative period in patients with non-valvular atrial fibrillation who undergo the catheter ablation compared to warfarin. www.who.int/trialsearch/Trial2.aspx?TrialID=JPRN-UMIN000013129 (first received 1 March 2014). ">Nogami 2019</a>). One study only implemented postprocedural heparin bridging until DOAC was initiated the next morning (<a href="./references#CD013504-bbs2-0004" title="Nakamura K, Naito S, Sasaki T, Take Y, Minami K, Kitagawa Y, et al. Uninterrupted vs. interrupted periprocedural direct oral anticoagulants for catheter ablation of atrial fibrillation: a prospective randomized single-centre study on post-ablation thrombo-embolic and haemorrhagic events. Europace2019;21(2):259-67. [DOI: 10.1093/europace/euy148]NakamuraK , SasakiT , TakeY , FunabashiN , NaitoS . Uninterrupted vs. interrupted periprocedural direct oral anticoagulants for catheter ablation of atrial fibrillation: a prospective randomized study on post-ablation thromboembolic and hemorrhagic events. Circulation2018;138:2. ">Nakamura 2019</a>). </p> <p>The intra‐procedural use of heparin was reasonably similar between studies, but studies used mixed ablation procedures and diverse sources of ablation energy. Most studies that used mixed DOAC randomised participants based on the interruption strategy rather than the DOAC type. One study included participants who had received radiofrequency (<a href="./references#CD013504-bbs2-0011" title="IrikiY , IchikiH , OketaniN , YoshimuraA , OkuiH , MaenosonoR , et al. Evaluation of safety and efficacy of perioperative use of rivaroxaban and apixaban in catheter ablation for atrial fibrillation. European Heart Journal2015;36:687. [DOI: 10.1093/eurheartj/ehv400]YoshimuraA , IrikiY , IchikiH , OketaniN , OkuiH , MaenosonoR , et al. Evaluation of safety and efficacy of periprocedural use of rivaroxaban and apixaban in catheter ablation for atrial fibrillation. Journal of Cardiology2017;69(1):228-35. [DOI: 10.1016/j.jjcc.2016.03.014]">Yoshimura 2017</a>). One study assessed compliance with preprocedural DOAC anticoagulant by self‐reporting (<a href="./references#CD013504-bbs2-0006" title="ReynoldsMR , AllisonJS , NataleA , WeisbergIL , EllenbogenKA , RichardsM , et al. Apixaban evaluation of interrupted or uninterrupted anticoagulation for ablation of atrial fibrillation. clinicaltrials.gov/show/NCT02608099 (first received 18 November 2015). ReynoldsMR , AllisonJS , NataleA , WeisbergIL , EllenbogenKA , RichardsM , et al. A prospective randomized trial of apixaban dosing during atrial fibrillation ablation: the AEIOU trial. JACC Clinical Electrophysiology2018;4(5):580-8. [DOI: 10.1016/j.jacep.2017.11.005]">Reynolds 2018</a>). Studies that used VKAs tested the INR of participants prior to the procedure. In <a href="./references#CD013504-bbs2-0008" title="XingY , XuB , XuC , PengF , YangB , QiuY , et al. Efficacy and safety of uninterrupted low-intensity warfarin for radiofrequency catheter ablation of atrial fibrillation in the elderly. Annals of Pharmacotherapy2017;51(9):735-42. [DOI: 10.1177/1060028017712532]">Xing 2017</a>, the mean INR in the low‐intensity (INR 1.5 to 2.0), minimally interrupted arm was 1.80 (SD 0.12) on the morning of the procedure. </p> <p>The heterogeneity observed in some of the study outcomes could have limited the review findings. We performed several subgroup analyses when possible to explore this heterogeneity where the stratification by interruption strategy, the type of anticoagulant, and the use of heparin bridging yielded different results for several of the study outcomes. However, these results need to be interpreted with caution, due to the observational nature of this analysis and the availability of too few studies in each subgroup arm. <a href="./references#CD013504-bbs2-0002" title='Di BiaseL , BurkhardtJD , SantangeliP , MohantyP , SanchezJ , BaiR , et al. Periprocedural strokes and anticoagulation management during AF ablation: results from the "Compare" randomized multicenter trial. Circulation2013;128:A14307. Di BiaseL , BurkhardtJD , SantangeliP , MohantyP , SanchezJ , BaiR , et al. Silent thromboembolic lesions following catheter ablation for atrial fibrillation using radiofrequency energy: results from a sub-study of the "compare" randomized trial. Circulation2013;128(22 Suppl 1):A14293. Di BiaseL , BurkhardtJD , SantangeliP , MohantyP , SanchezJ , HortonR , et al. Periprocedural stroke and bleeding complications in patients undergoing catheter ablation of atrial fibrillation with different anticoagulation management: results from the "compare" randomized trial. Heart Rhythm2013;10(9):1411. Di BiaseL , BurkhardtJD , SantangeliP , MohantyP , SanchezJE , HortonR , et al. Periprocedural stroke and bleeding complications in patients undergoing catheter ablation of atrial fibrillation with different anticoagulation management: results from the role of coumadin in preventing thromboembolism in atrial fibrillation (AF) patients undergoing catheter ablation (COMPARE) randomized trial. Circulation2014;129(25):2638-44. [DOI: 10.1161/circulationaha.113.006426]NCT01006876. Role of coumadin in preventing thromboembolism in atrial fibrillation (AF) patients undergoing catheter ablation. clinicaltrials.gov/ct2/show/NCT01006876 (first received 3 November 2009). '>Di Biase 2014</a> was the only study that was sufficiently powered to show a difference between the two strategies, and it is currently is the only high‐quality study that showed the safety of uninterrupted VKA compared to the interrupted strategy with heparin bridging. </p> <p>Eight studies were conducted in single centres; however, these centres were described as experienced with CA procedures. Most studies had underpowered study design limitations. The lack of blindness across all the trials raises the concern of ascertainment bias. However, seven studies used blinded assessment of the outcome (<a href="./references#CD013504-bbs2-0002" title='Di BiaseL , BurkhardtJD , SantangeliP , MohantyP , SanchezJ , BaiR , et al. Periprocedural strokes and anticoagulation management during AF ablation: results from the "Compare" randomized multicenter trial. Circulation2013;128:A14307. Di BiaseL , BurkhardtJD , SantangeliP , MohantyP , SanchezJ , BaiR , et al. Silent thromboembolic lesions following catheter ablation for atrial fibrillation using radiofrequency energy: results from a sub-study of the "compare" randomized trial. Circulation2013;128(22 Suppl 1):A14293. Di BiaseL , BurkhardtJD , SantangeliP , MohantyP , SanchezJ , HortonR , et al. Periprocedural stroke and bleeding complications in patients undergoing catheter ablation of atrial fibrillation with different anticoagulation management: results from the "compare" randomized trial. Heart Rhythm2013;10(9):1411. Di BiaseL , BurkhardtJD , SantangeliP , MohantyP , SanchezJE , HortonR , et al. Periprocedural stroke and bleeding complications in patients undergoing catheter ablation of atrial fibrillation with different anticoagulation management: results from the role of coumadin in preventing thromboembolism in atrial fibrillation (AF) patients undergoing catheter ablation (COMPARE) randomized trial. Circulation2014;129(25):2638-44. [DOI: 10.1161/circulationaha.113.006426]NCT01006876. Role of coumadin in preventing thromboembolism in atrial fibrillation (AF) patients undergoing catheter ablation. clinicaltrials.gov/ct2/show/NCT01006876 (first received 3 November 2009). '>Di Biase 2014</a>; <a href="./references#CD013504-bbs2-0003" title="NagaoT , SuzukiH , MatsunagaS , NishikawaY , HaradaK , MamiyaK . Impact of periprocedural anticoagulation therapy on the incidence of silent stroke after atrial fibrillation ablation in patients receiving direct oral anticoagulants: uninterrupted vs. interrupted by one dose strategy. Europace2019;21(4):590-7. [DOI: 10.1093/europace/euy224]">Nagao 2019</a>; <a href="./references#CD013504-bbs2-0004" title="Nakamura K, Naito S, Sasaki T, Take Y, Minami K, Kitagawa Y, et al. Uninterrupted vs. interrupted periprocedural direct oral anticoagulants for catheter ablation of atrial fibrillation: a prospective randomized single-centre study on post-ablation thrombo-embolic and haemorrhagic events. Europace2019;21(2):259-67. [DOI: 10.1093/europace/euy148]NakamuraK , SasakiT , TakeY , FunabashiN , NaitoS . Uninterrupted vs. interrupted periprocedural direct oral anticoagulants for catheter ablation of atrial fibrillation: a prospective randomized study on post-ablation thromboembolic and hemorrhagic events. Circulation2018;138:2. ">Nakamura 2019</a>; <a href="./references#CD013504-bbs2-0005" title="AonumaK . A prospective, multi-center, parallel-group comparison study to evaluate safety and efficacy of dabigatran during the perioperative period in patients with non-valvular atrial fibrillation who undergo the catheter ablation compared to warfarin. upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000015311 (first received 14 February 2014. GoyaM , NogamiA , HiraoK , AonumaK . Ablation perioperative dabigatran in use envisioning in Japan: the ABRIDGE-J study design. Journal of Cardiology2016;68(3):236-40. [DOI: 10.1016/j.jjcc.2015.10.003]]NogamiA , HaradaT , Sekiguchi Y, Otani R, YoshidaY , Yoshida K, et al. Safety and efficacy of minimally interrupted dabigatran vs uninterrupted warfarin therapy in adults undergoing atrial fibrillation catheter ablation: a randomized clinical trial. JAMA Network Open2019;2(4):15. [DOI: 10.1001/jamanetworkopen.2019.1994]NogamiA , HaradaT , YoshidaY , NakanoY , GoyaM , OrigasaH , et al. Clinical benefit of minimally-interrupted dabigatran versus uninterrupted warfarin for catheter ablation of atrial fibrillation: a prospective randomized multicenter trial. Circulation2017;136:e450. NogamiA , HaradaT , YoshidaY , NakanoY , GoyaM , OrigasaH , et al. Clinical benefit of minimally-interrupted dabigatran versus uninterrupted warfarin for catheter ablation of atrial fibrillation: a prospective randomized multicenter trial. Circulation2017;136(24):E450. [DOI: 10.1161/CIR.0000000000000546]UMIN000013129. A prospective, multi-center, parallel-group comparison study to evaluate safety and efficacy of dabigatran during the perioperative period in patients with non-valvular atrial fibrillation who undergo the catheter ablation compared to warfarin. www.who.int/trialsearch/Trial2.aspx?TrialID=JPRN-UMIN000013129 (first received 1 March 2014). ">Nogami 2019</a>; <a href="./references#CD013504-bbs2-0006" title="ReynoldsMR , AllisonJS , NataleA , WeisbergIL , EllenbogenKA , RichardsM , et al. Apixaban evaluation of interrupted or uninterrupted anticoagulation for ablation of atrial fibrillation. clinicaltrials.gov/show/NCT02608099 (first received 18 November 2015). ReynoldsMR , AllisonJS , NataleA , WeisbergIL , EllenbogenKA , RichardsM , et al. A prospective randomized trial of apixaban dosing during atrial fibrillation ablation: the AEIOU trial. JACC Clinical Electrophysiology2018;4(5):580-8. [DOI: 10.1016/j.jacep.2017.11.005]">Reynolds 2018</a>; <a href="./references#CD013504-bbs2-0011" title="IrikiY , IchikiH , OketaniN , YoshimuraA , OkuiH , MaenosonoR , et al. Evaluation of safety and efficacy of perioperative use of rivaroxaban and apixaban in catheter ablation for atrial fibrillation. European Heart Journal2015;36:687. [DOI: 10.1093/eurheartj/ehv400]YoshimuraA , IrikiY , IchikiH , OketaniN , OkuiH , MaenosonoR , et al. Evaluation of safety and efficacy of periprocedural use of rivaroxaban and apixaban in catheter ablation for atrial fibrillation. Journal of Cardiology2017;69(1):228-35. [DOI: 10.1016/j.jjcc.2016.03.014]">Yoshimura 2017</a>; <a href="./references#CD013504-bbs2-0012" title="YuHT , ShimJ , ParkJ , KimTH , UhmJS , KimJY , et al. When is it appropriate to stop non-vitamin K antagonist oral anticoagulants before catheter ablation of atrial fibrillation? A multi-center prospective randomized study. Europace2019;21:ii804. YuHT , ShimJ , ParkJ , KimTH , UhmJS , KimJY , et al. When is it appropriate to stop non-vitamin K antagonist oral anticoagulants before catheter ablation of atrial fibrillation? A multicentre prospective randomized study. European Heart Journal2019;40(19):1531-7. [DOI: 10.1093/eurheartj/ehy870]">Yu 2019</a>). None of the studies had loss to follow‐up, but there was considerable variability in the period of follow‐up, which varied from one hour to 12 months postablation.  </p> </section> <section id="CD013504-sec-0089"> <h3 class="title" id="CD013504-sec-0089">Quality of the evidence</h3> <p>Overall risk of bias across trials can be interpreted as plausible bias with 8/12 included trials having a high or unclear risk of bias in several domains (open‐label design, unclear allocation concealment, and lack of published protocol in eight trials). Studies used different anticoagulant  drugs with a potential difference in their clinical effects. Patients' baseline characteristics regarding risks of stroke, bleeding risk, and study duration varied between trials, and 8/12 trials were conducted in single centres and 10/12 trials described interventions in Asian populations. </p> <section id="CD013504-sec-0090"> <h4 class="title">Limitations in study design or execution (risk of bias)</h4> <p>For all the outcomes, we downgraded the certainty of evidence by one level due to the risk of bias in included studies, specifically in the domains of randomisation, allocation concealment, and blinding. </p> </section> <section id="CD013504-sec-0091"> <h4 class="title">Inconsistency of results</h4> <p>We downgraded the certainty of the evidence for thromboembolic events by one level for the inconsistency of results (I<sup>2</sup> = 59%). We also downgraded the certainty of the evidence for minor bleeding by one level for inconsistency, because of the very high unexplained heterogeneity (I<sup>2</sup> = 87%). Subgroup analyses were not performed for these outcomes due to the small number of studies reporting them. Although such analyses (e.g. comparing the effect of outcomes by different types of anticoagulation) might have explained the high heterogeneity observed. </p> </section> <section id="CD013504-sec-0092"> <h4 class="title">Imprecision</h4> <p>We downgraded the certainty of evidence one level for all outcomes due to the width of the CIs that did not exclude potential benefit and harm, and due to the low event rate in general.  </p> </section> <section id="CD013504-sec-0093"> <h4 class="title">Publication bias</h4> <p>For all outcomes, we did not downgrade the certainty of the evidence for publication bias, as we did not detect it, although the small number of included studies may have prevented this detection. </p> </section> </section> <section id="CD013504-sec-0094"> <h3 class="title" id="CD013504-sec-0094">Potential biases in the review process</h3> <p>We included only randomised trials. Most of these studies described the limitation of sample size, were open‐label, and had unclear allocation concealment. The population studied, the mix of comparators anticoagulants, and ablation procedures were different among studies. We did not conduct a funnel plot to assess publication bias as the number was fewer than 10 trials in each outcome; however, we believe that unpublished data is a potential bias given the small sample size and the non‐significant findings of most of the included studies.  </p> </section> <section id="CD013504-sec-0095"> <h3 class="title" id="CD013504-sec-0095">Agreements and disagreements with other studies or reviews</h3> <p>There are several other systematic reviews with meta‐analyses of various comparisons of interrupted, minimally interrupted, and completely interrupted DOAC and VKA (<a href="./references#CD013504-bbs2-0064" title="Basu-RayI , KhanraD , KupóP , BunchJ , TheusSA , MukherjeeA , et al. Outcomes of uninterrupted vs interrupted periprocedural direct oral anticoagulants in atrial fibrillation ablation: a meta-analysis. Journal of Arrhythmia2021;37(2):384-93.">Basu‐Ray 2020</a>; <a href="./references#CD013504-bbs2-0089" title="GorlaR , DentaliF , CrippaM , MarazzatoJ , Di MinnoMN , GrandiAM , et al. Perioperative safety and efficacy of different anticoagulation strategies with direct oral anticoagulants in pulmonary vein isolation: a meta-analysis. JACC Clinical Electrophysiology2018;4(6):794-806.">Gorla 2018</a>; <a href="./references#CD013504-bbs2-0091" title="HaFJ , BarraS , BrownAJ , BegleyDA , GraceAA , AgarwalS . Continuous and minimally-interrupted direct oral anticoagulant are both safe compared with vitamin K antagonist for atrial fibrillation ablation: an updated meta-analysis. International Journal of Cardiology2018;262:51-6.">Ha 2018</a>; <a href="./references#CD013504-bbs2-0115" title="OttóﬀyM , MátraiP , FarkasN , HegyiP , CzopfL , MártaK , et al. Uninterrupted or minimally interrupted direct oral anticoagulant therapy is a safe alternative to vitamin K antagonists in patients undergoing catheter ablation for atrial fibrillation: an updated meta-analysis. Journal of Clinical Medicine2020;9(3073):2-13. [DOI: 10.3390/jcm9103073]">Ottóﬀy 2020</a>; <a href="./references#CD013504-bbs2-0124" title="SantarpiaG , De RosaS , PolimeniA , GiampaS , MicieliM , CurcioA , et al. Efficacy and safety of non-vitamin K antagonist oral anticoagulants versus vitamin K antagonist oral anticoagulants in patients undergoing radiofrequency catheter ablation of atrial fibrillation: a meta-analysis. PloS One2015;10(5):e0126512.">Santarpia 2015</a>; <a href="./references#CD013504-bbs2-0137" title="YangP , WangC , YeY , HuangT , YangS , ShenW , et al. Interrupted or uninterrupted oral anticoagulants in patients undergoing atrial fibrillation ablation. Cardiovascular Drugs and Therapy2020;34(3):371-81.">Yang 2020</a>; <a href="./references#CD013504-bbs2-0138" title="ZhaoY , YangY , TangX , YuX , ZhangL , XiaoH , et al. New oral anticoagulants compared to warfarin for perioperative anticoagulation in patients undergoing atrial fibrillation catheter ablation: a meta-analysis of continuous or interrupted new oral anticoagulants during ablation compared to interrupted or continuous warfarin. Journal of Interventional Cardica Electrophysiology2017;48(3):267-82.">Zhao 2017</a>). However, the relevance of the findings from these meta‐analyses is not directly relevant to our review because they included both RCTs and observational studies and there was no pooling of data from RCTs that matched our inclusion criteria.  Although <a href="./references#CD013504-bbs2-0115" title="OttóﬀyM , MátraiP , FarkasN , HegyiP , CzopfL , MártaK , et al. Uninterrupted or minimally interrupted direct oral anticoagulant therapy is a safe alternative to vitamin K antagonists in patients undergoing catheter ablation for atrial fibrillation: an updated meta-analysis. Journal of Clinical Medicine2020;9(3073):2-13. [DOI: 10.3390/jcm9103073]">Ottóﬀy 2020</a> described pooled analysis from RCTs and showed no difference between interrupted and uninterrupted strategies in thromboembolic events (Peto odds ratio (OR) 0.66, 95% CI 0.17 to 2.64), and lower risk of major bleeding events (Peto OR 0.36, 95% CI 0.21 to 0.62) in the uninterrupted and minimally interrupted DOAC. However, this meta‐analysis included single strategy studies, which we excluded in our review. </p> <p><a href="./references#CD013504-bbs2-0107" title="MaoYJ , WangH , HuangPF . Peri-procedural novel oral anticoagulants dosing strategy during atrial fibrillation ablation: a meta-analysis. Pacing and Clinical Electrophysiology2020:1-11.">Mao 2020</a> conducted a meta‐analysis on observational studies and six RCTs (all RCTs are included in our review) evaluating the safety and efficacy of minimally interrupted and uninterrupted DOAC. Pooling data from the six RCTs showed no significant difference on outcomes of major bleeding  (OR 0.74, 95% CI 0.32 to 1.70; P = 0.47; I<sup>2</sup> = 0%) and minor bleeding (OR 1.06, 95% CI 0.70 to 1.60; P = 0.80; I<sup>2</sup> = 0%). The meta‐analysis did not include <a href="./references#CD013504-bbs2-0005" title="AonumaK . A prospective, multi-center, parallel-group comparison study to evaluate safety and efficacy of dabigatran during the perioperative period in patients with non-valvular atrial fibrillation who undergo the catheter ablation compared to warfarin. upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000015311 (first received 14 February 2014. GoyaM , NogamiA , HiraoK , AonumaK . Ablation perioperative dabigatran in use envisioning in Japan: the ABRIDGE-J study design. Journal of Cardiology2016;68(3):236-40. [DOI: 10.1016/j.jjcc.2015.10.003]]NogamiA , HaradaT , Sekiguchi Y, Otani R, YoshidaY , Yoshida K, et al. Safety and efficacy of minimally interrupted dabigatran vs uninterrupted warfarin therapy in adults undergoing atrial fibrillation catheter ablation: a randomized clinical trial. JAMA Network Open2019;2(4):15. [DOI: 10.1001/jamanetworkopen.2019.1994]NogamiA , HaradaT , YoshidaY , NakanoY , GoyaM , OrigasaH , et al. Clinical benefit of minimally-interrupted dabigatran versus uninterrupted warfarin for catheter ablation of atrial fibrillation: a prospective randomized multicenter trial. Circulation2017;136:e450. NogamiA , HaradaT , YoshidaY , NakanoY , GoyaM , OrigasaH , et al. Clinical benefit of minimally-interrupted dabigatran versus uninterrupted warfarin for catheter ablation of atrial fibrillation: a prospective randomized multicenter trial. Circulation2017;136(24):E450. [DOI: 10.1161/CIR.0000000000000546]UMIN000013129. A prospective, multi-center, parallel-group comparison study to evaluate safety and efficacy of dabigatran during the perioperative period in patients with non-valvular atrial fibrillation who undergo the catheter ablation compared to warfarin. www.who.int/trialsearch/Trial2.aspx?TrialID=JPRN-UMIN000013129 (first received 1 March 2014). ">Nogami 2019</a> or <a href="./references#CD013504-bbs2-0009" title="YamajiH , MurakamiT , HinaK , HigashiyaS , KawamuraH , MurakamiM , et al. Activated clotting time on the day of atrial fibrillation ablation for minimally interrupted and uninterrupted direct oral anticoagulation therapy: sequential changes, differences among direct oral anticoagulants, and ablation safety outcomes. Journal of Cardiovascular Electrophysiology2019;30(12):2823-33. [DOI: 10.1111/jce.14260]">Yamaji 2019</a>, both are randomised and evaluated minimally interrupted versus interrupted DOAC. A second meta‐analysis by <a href="./references#CD013504-bbs2-0108" title="MaoYJ , WangH , HuangPF . Meta-analysis of the safety and efficacy of using minimally interrupted novel oral anticoagulants in patients undergoing catheter ablation for atrial fibrillation. Journal of Interventional Cardiac Electrophysiology2021;60(3):407-17.">Mao 2021</a> included observational studies, six RCTs, and one randomised registry (all are included in our review). Data from pooled RCTs produced similar findings on major bleeding with no significant difference between the two strategies (OR 1.41, 95% CI 0.73 to 2.73; P = 0.30; I<sup>2</sup> = 0%). Although the author concluded that uninterrupted DOAC or VKA had fewer SCI compared to minimally interrupted, there was no pooled effect from RCTs only. Moreover, the meta‐analysis also did not include <a href="./references#CD013504-bbs2-0009" title="YamajiH , MurakamiT , HinaK , HigashiyaS , KawamuraH , MurakamiM , et al. Activated clotting time on the day of atrial fibrillation ablation for minimally interrupted and uninterrupted direct oral anticoagulation therapy: sequential changes, differences among direct oral anticoagulants, and ablation safety outcomes. Journal of Cardiovascular Electrophysiology2019;30(12):2823-33. [DOI: 10.1111/jce.14260]">Yamaji 2019</a>. </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD013504-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013504.pub2/media/CDSR/CD013504/urn:x-wiley:14651858:media:CD013504:CD013504-FIG-01" target="_blank"><b></b></a></p> </div><img alt="original image" data-id="CD013504-fig-0001" src="/cdsr/doi/10.1002/14651858.CD013504.pub2/media/CDSR/CD013504/image_n/nCD013504-FIG-01.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013504.pub2/media/CDSR/CD013504/image_t/tCD013504-FIG-01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013504.pub2/full#CD013504-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013504.pub2/media/CDSR/CD013504/image_n/nCD013504-FIG-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013504-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013504.pub2/media/CDSR/CD013504/urn:x-wiley:14651858:media:CD013504:CD013504-FIG-02" target="_blank"><b></b></a></p> </div><img alt="Graphical representation of strategies used for the periprocedural anticoagulation around the ablation procedure.  A: uninterrupted activation clotting time; B: minimally interrupted using one‐dose skipped strategy; C: minimally interrupted using low‐intensity INR strategy; D: minimally interrupted using two‐dose skipped strategy; E: completely interrupted activation clotting time. DOAC: direct oral anticoagulants; H: heparin bridging; R: resumption of the drug; S: skipped dose; VKA: vitamin K antagonist; w/o: without. Included studies: 1: Ando 2019; 2: Di Biase 2014; 3: Nagao 2019; 4: Nakamura 2019; 5: Nogami 2019; 6: Reynolds 2018; 7: Tabish 2010; 8: Xing 2017; 9: Yamaji 2019; 10: Yoh 2019; 11: Yoshimura 2017; 12: Yu 2019." data-id="CD013504-fig-0002" src="/cdsr/doi/10.1002/14651858.CD013504.pub2/media/CDSR/CD013504/image_n/nCD013504-FIG-02.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013504.pub2/media/CDSR/CD013504/image_t/tCD013504-FIG-02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p><b>Graphical representation of strategies used for the periprocedural anticoagulation around the ablation procedure. </b> <br/><b>A:</b> uninterrupted activation clotting time; <b>B:</b> minimally interrupted using one‐dose skipped strategy; <b>C:</b> minimally interrupted using low‐intensity INR strategy; <b>D:</b> minimally interrupted using two‐dose skipped strategy; <b>E:</b> completely interrupted activation clotting time. <b>DOAC:</b> direct oral anticoagulants; <b>H:</b> heparin bridging; <b>R:</b> resumption of the drug; <b>S:</b> skipped dose; <b>VKA:</b> vitamin K antagonist; <b>w/o:</b> without. <b>Included studies:</b> 1: <a href="./references#CD013504-bbs2-0001" title="AndoM , IndenY , YoshidaY , SairakuA , YanagisawaS , SuzukiH , et al. Differences in prothrombotic response between the uninterrupted and interrupted apixaban therapies in patients undergoing cryoballoon ablation for paroxysmal atrial fibrillation: a randomized controlled study. Heart Vessels2019;34(9):1533-41. [DOI: 10.1007/s00380-019-01370-9]">Ando 2019</a>; 2: <a href="./references#CD013504-bbs2-0002" title='Di BiaseL , BurkhardtJD , SantangeliP , MohantyP , SanchezJ , BaiR , et al. Periprocedural strokes and anticoagulation management during AF ablation: results from the "Compare" randomized multicenter trial. Circulation2013;128:A14307. Di BiaseL , BurkhardtJD , SantangeliP , MohantyP , SanchezJ , BaiR , et al. Silent thromboembolic lesions following catheter ablation for atrial fibrillation using radiofrequency energy: results from a sub-study of the "compare" randomized trial. Circulation2013;128(22 Suppl 1):A14293. Di BiaseL , BurkhardtJD , SantangeliP , MohantyP , SanchezJ , HortonR , et al. Periprocedural stroke and bleeding complications in patients undergoing catheter ablation of atrial fibrillation with different anticoagulation management: results from the "compare" randomized trial. Heart Rhythm2013;10(9):1411. Di BiaseL , BurkhardtJD , SantangeliP , MohantyP , SanchezJE , HortonR , et al. Periprocedural stroke and bleeding complications in patients undergoing catheter ablation of atrial fibrillation with different anticoagulation management: results from the role of coumadin in preventing thromboembolism in atrial fibrillation (AF) patients undergoing catheter ablation (COMPARE) randomized trial. Circulation2014;129(25):2638-44. [DOI: 10.1161/circulationaha.113.006426]NCT01006876. Role of coumadin in preventing thromboembolism in atrial fibrillation (AF) patients undergoing catheter ablation. clinicaltrials.gov/ct2/show/NCT01006876 (first received 3 November 2009). '>Di Biase 2014</a>; 3: <a href="./references#CD013504-bbs2-0003" title="NagaoT , SuzukiH , MatsunagaS , NishikawaY , HaradaK , MamiyaK . Impact of periprocedural anticoagulation therapy on the incidence of silent stroke after atrial fibrillation ablation in patients receiving direct oral anticoagulants: uninterrupted vs. interrupted by one dose strategy. Europace2019;21(4):590-7. [DOI: 10.1093/europace/euy224]">Nagao 2019</a>; 4: <a href="./references#CD013504-bbs2-0004" title="Nakamura K, Naito S, Sasaki T, Take Y, Minami K, Kitagawa Y, et al. Uninterrupted vs. interrupted periprocedural direct oral anticoagulants for catheter ablation of atrial fibrillation: a prospective randomized single-centre study on post-ablation thrombo-embolic and haemorrhagic events. Europace2019;21(2):259-67. [DOI: 10.1093/europace/euy148]NakamuraK , SasakiT , TakeY , FunabashiN , NaitoS . Uninterrupted vs. interrupted periprocedural direct oral anticoagulants for catheter ablation of atrial fibrillation: a prospective randomized study on post-ablation thromboembolic and hemorrhagic events. Circulation2018;138:2. ">Nakamura 2019</a>; 5: <a href="./references#CD013504-bbs2-0005" title="AonumaK . A prospective, multi-center, parallel-group comparison study to evaluate safety and efficacy of dabigatran during the perioperative period in patients with non-valvular atrial fibrillation who undergo the catheter ablation compared to warfarin. upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000015311 (first received 14 February 2014. GoyaM , NogamiA , HiraoK , AonumaK . Ablation perioperative dabigatran in use envisioning in Japan: the ABRIDGE-J study design. Journal of Cardiology2016;68(3):236-40. [DOI: 10.1016/j.jjcc.2015.10.003]]NogamiA , HaradaT , Sekiguchi Y, Otani R, YoshidaY , Yoshida K, et al. Safety and efficacy of minimally interrupted dabigatran vs uninterrupted warfarin therapy in adults undergoing atrial fibrillation catheter ablation: a randomized clinical trial. JAMA Network Open2019;2(4):15. [DOI: 10.1001/jamanetworkopen.2019.1994]NogamiA , HaradaT , YoshidaY , NakanoY , GoyaM , OrigasaH , et al. Clinical benefit of minimally-interrupted dabigatran versus uninterrupted warfarin for catheter ablation of atrial fibrillation: a prospective randomized multicenter trial. Circulation2017;136:e450. NogamiA , HaradaT , YoshidaY , NakanoY , GoyaM , OrigasaH , et al. Clinical benefit of minimally-interrupted dabigatran versus uninterrupted warfarin for catheter ablation of atrial fibrillation: a prospective randomized multicenter trial. Circulation2017;136(24):E450. [DOI: 10.1161/CIR.0000000000000546]UMIN000013129. A prospective, multi-center, parallel-group comparison study to evaluate safety and efficacy of dabigatran during the perioperative period in patients with non-valvular atrial fibrillation who undergo the catheter ablation compared to warfarin. www.who.int/trialsearch/Trial2.aspx?TrialID=JPRN-UMIN000013129 (first received 1 March 2014). ">Nogami 2019</a>; 6: <a href="./references#CD013504-bbs2-0006" title="ReynoldsMR , AllisonJS , NataleA , WeisbergIL , EllenbogenKA , RichardsM , et al. Apixaban evaluation of interrupted or uninterrupted anticoagulation for ablation of atrial fibrillation. clinicaltrials.gov/show/NCT02608099 (first received 18 November 2015). ReynoldsMR , AllisonJS , NataleA , WeisbergIL , EllenbogenKA , RichardsM , et al. A prospective randomized trial of apixaban dosing during atrial fibrillation ablation: the AEIOU trial. JACC Clinical Electrophysiology2018;4(5):580-8. [DOI: 10.1016/j.jacep.2017.11.005]">Reynolds 2018</a>; 7: <a href="./references#CD013504-bbs2-0007" title="TabishH , ShahzadK . Anticoagulation safety window among elderly Chinese patients with atrial fibrillation catheter ablation. Journal of the Saudi Heart Association2010;22(2):99-100. [DOI: 10.1016/j.jsha.2010.02.325]">Tabish 2010</a>; 8: <a href="./references#CD013504-bbs2-0008" title="XingY , XuB , XuC , PengF , YangB , QiuY , et al. Efficacy and safety of uninterrupted low-intensity warfarin for radiofrequency catheter ablation of atrial fibrillation in the elderly. Annals of Pharmacotherapy2017;51(9):735-42. [DOI: 10.1177/1060028017712532]">Xing 2017</a>; 9: <a href="./references#CD013504-bbs2-0009" title="YamajiH , MurakamiT , HinaK , HigashiyaS , KawamuraH , MurakamiM , et al. Activated clotting time on the day of atrial fibrillation ablation for minimally interrupted and uninterrupted direct oral anticoagulation therapy: sequential changes, differences among direct oral anticoagulants, and ablation safety outcomes. Journal of Cardiovascular Electrophysiology2019;30(12):2823-33. [DOI: 10.1111/jce.14260]">Yamaji 2019</a>; 10: <a href="./references#CD013504-bbs2-0010" title="YohM , TakagiM , YoshioT , TakahashiH , ShiojimaI . AP19-00329. Safety and efficacy of uninterrupted and interrupted periprocedural direct oral anticoagulants in patients undergoing radiofrequency catheter ablation for atrial fibrillation. Journal of Arrhythmia2019;35(S1):134. [DOI: 10.1002/joa3.12267]">Yoh 2019</a>; 11: <a href="./references#CD013504-bbs2-0011" title="IrikiY , IchikiH , OketaniN , YoshimuraA , OkuiH , MaenosonoR , et al. Evaluation of safety and efficacy of perioperative use of rivaroxaban and apixaban in catheter ablation for atrial fibrillation. European Heart Journal2015;36:687. [DOI: 10.1093/eurheartj/ehv400]YoshimuraA , IrikiY , IchikiH , OketaniN , OkuiH , MaenosonoR , et al. Evaluation of safety and efficacy of periprocedural use of rivaroxaban and apixaban in catheter ablation for atrial fibrillation. Journal of Cardiology2017;69(1):228-35. [DOI: 10.1016/j.jjcc.2016.03.014]">Yoshimura 2017</a>; 12: <a href="./references#CD013504-bbs2-0012" title="YuHT , ShimJ , ParkJ , KimTH , UhmJS , KimJY , et al. When is it appropriate to stop non-vitamin K antagonist oral anticoagulants before catheter ablation of atrial fibrillation? A multi-center prospective randomized study. Europace2019;21:ii804. YuHT , ShimJ , ParkJ , KimTH , UhmJS , KimJY , et al. When is it appropriate to stop non-vitamin K antagonist oral anticoagulants before catheter ablation of atrial fibrillation? A multicentre prospective randomized study. European Heart Journal2019;40(19):1531-7. [DOI: 10.1093/eurheartj/ehy870]">Yu 2019</a>. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013504.pub2/full#CD013504-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013504.pub2/media/CDSR/CD013504/image_n/nCD013504-FIG-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013504-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013504.pub2/media/CDSR/CD013504/urn:x-wiley:14651858:media:CD013504:CD013504-FIG-03" target="_blank"><b></b></a></p> </div><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD013504-fig-0003" src="/cdsr/doi/10.1002/14651858.CD013504.pub2/media/CDSR/CD013504/image_n/nCD013504-FIG-03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013504.pub2/media/CDSR/CD013504/image_t/tCD013504-FIG-03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013504.pub2/full#CD013504-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013504.pub2/media/CDSR/CD013504/image_n/nCD013504-FIG-03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013504-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013504.pub2/media/CDSR/CD013504/urn:x-wiley:14651858:media:CD013504:CD013504-FIG-04" target="_blank"><b></b></a></p> </div><img alt="original image" data-id="CD013504-fig-0004" src="/cdsr/doi/10.1002/14651858.CD013504.pub2/media/CDSR/CD013504/image_n/nCD013504-FIG-04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013504.pub2/media/CDSR/CD013504/image_t/tCD013504-FIG-04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 4</div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013504.pub2/full#CD013504-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013504.pub2/media/CDSR/CD013504/image_n/nCD013504-FIG-04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013504-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013504.pub2/media/CDSR/CD013504/urn:x-wiley:14651858:media:CD013504:CD013504-CMP-001.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Interrupted versus uninterrupted anticoagulation, Outcome 1: Thromboembolic events" data-id="CD013504-fig-0005" src="/cdsr/doi/10.1002/14651858.CD013504.pub2/media/CDSR/CD013504/image_n/nCD013504-CMP-001.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013504.pub2/media/CDSR/CD013504/image_t/tCD013504-CMP-001.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1: Interrupted versus uninterrupted anticoagulation, Outcome 1: Thromboembolic events </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013504.pub2/references#CD013504-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013504.pub2/media/CDSR/CD013504/image_n/nCD013504-CMP-001.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013504-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013504.pub2/media/CDSR/CD013504/urn:x-wiley:14651858:media:CD013504:CD013504-CMP-001.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Interrupted versus uninterrupted anticoagulation, Outcome 2: Thromboembolic events (subgroup analysis: anticoagulant type)" data-id="CD013504-fig-0006" src="/cdsr/doi/10.1002/14651858.CD013504.pub2/media/CDSR/CD013504/image_n/nCD013504-CMP-001.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013504.pub2/media/CDSR/CD013504/image_t/tCD013504-CMP-001.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1: Interrupted versus uninterrupted anticoagulation, Outcome 2: Thromboembolic events (subgroup analysis: anticoagulant type) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013504.pub2/references#CD013504-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013504.pub2/media/CDSR/CD013504/image_n/nCD013504-CMP-001.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013504-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013504.pub2/media/CDSR/CD013504/urn:x-wiley:14651858:media:CD013504:CD013504-CMP-001.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Interrupted versus uninterrupted anticoagulation, Outcome 3: Thromboembolic events (subgroup analysis: interruption strategy)" data-id="CD013504-fig-0007" src="/cdsr/doi/10.1002/14651858.CD013504.pub2/media/CDSR/CD013504/image_n/nCD013504-CMP-001.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013504.pub2/media/CDSR/CD013504/image_t/tCD013504-CMP-001.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1: Interrupted versus uninterrupted anticoagulation, Outcome 3: Thromboembolic events (subgroup analysis: interruption strategy) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013504.pub2/references#CD013504-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013504.pub2/media/CDSR/CD013504/image_n/nCD013504-CMP-001.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013504-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013504.pub2/media/CDSR/CD013504/urn:x-wiley:14651858:media:CD013504:CD013504-CMP-001.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Interrupted versus uninterrupted anticoagulation, Outcome 4: Thromboembolic events (sensitivity analysis: non‐industrial  funded studies only)" data-id="CD013504-fig-0008" src="/cdsr/doi/10.1002/14651858.CD013504.pub2/media/CDSR/CD013504/image_n/nCD013504-CMP-001.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013504.pub2/media/CDSR/CD013504/image_t/tCD013504-CMP-001.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1: Interrupted versus uninterrupted anticoagulation, Outcome 4: Thromboembolic events (sensitivity analysis: non‐industrial  funded studies only) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013504.pub2/references#CD013504-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013504.pub2/media/CDSR/CD013504/image_n/nCD013504-CMP-001.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013504-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013504.pub2/media/CDSR/CD013504/urn:x-wiley:14651858:media:CD013504:CD013504-CMP-001.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Interrupted versus uninterrupted anticoagulation, Outcome 5: Thromboembolic events (sensitivity analysis: fixed‐effect model)" data-id="CD013504-fig-0009" src="/cdsr/doi/10.1002/14651858.CD013504.pub2/media/CDSR/CD013504/image_n/nCD013504-CMP-001.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013504.pub2/media/CDSR/CD013504/image_t/tCD013504-CMP-001.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1: Interrupted versus uninterrupted anticoagulation, Outcome 5: Thromboembolic events (sensitivity analysis: fixed‐effect model) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013504.pub2/references#CD013504-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013504.pub2/media/CDSR/CD013504/image_n/nCD013504-CMP-001.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013504-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013504.pub2/media/CDSR/CD013504/urn:x-wiley:14651858:media:CD013504:CD013504-CMP-001.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Interrupted versus uninterrupted anticoagulation, Outcome 6: Major bleeding" data-id="CD013504-fig-0010" src="/cdsr/doi/10.1002/14651858.CD013504.pub2/media/CDSR/CD013504/image_n/nCD013504-CMP-001.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013504.pub2/media/CDSR/CD013504/image_t/tCD013504-CMP-001.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.6</div> <div class="figure-caption"> <p>Comparison 1: Interrupted versus uninterrupted anticoagulation, Outcome 6: Major bleeding</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013504.pub2/references#CD013504-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013504.pub2/media/CDSR/CD013504/image_n/nCD013504-CMP-001.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013504-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013504.pub2/media/CDSR/CD013504/urn:x-wiley:14651858:media:CD013504:CD013504-CMP-001.07" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Interrupted versus uninterrupted anticoagulation, Outcome 7: Major bleeding (subgroup analysis: anticoagulation type (direct oral anticoagulant vs vitamin K antagonist))" data-id="CD013504-fig-0011" src="/cdsr/doi/10.1002/14651858.CD013504.pub2/media/CDSR/CD013504/image_n/nCD013504-CMP-001.07.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013504.pub2/media/CDSR/CD013504/image_t/tCD013504-CMP-001.07.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.7</div> <div class="figure-caption"> <p>Comparison 1: Interrupted versus uninterrupted anticoagulation, Outcome 7: Major bleeding (subgroup analysis: anticoagulation type (direct oral anticoagulant vs vitamin K antagonist)) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013504.pub2/references#CD013504-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013504.pub2/media/CDSR/CD013504/image_n/nCD013504-CMP-001.07.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013504-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013504.pub2/media/CDSR/CD013504/urn:x-wiley:14651858:media:CD013504:CD013504-CMP-001.08" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Interrupted versus uninterrupted anticoagulation, Outcome 8: Major bleeding (subgroup analysis: ablation source of energy (radiofrequency ablation vs cryoablation))" data-id="CD013504-fig-0012" src="/cdsr/doi/10.1002/14651858.CD013504.pub2/media/CDSR/CD013504/image_n/nCD013504-CMP-001.08.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013504.pub2/media/CDSR/CD013504/image_t/tCD013504-CMP-001.08.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.8</div> <div class="figure-caption"> <p>Comparison 1: Interrupted versus uninterrupted anticoagulation, Outcome 8: Major bleeding (subgroup analysis: ablation source of energy (radiofrequency ablation vs cryoablation)) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013504.pub2/references#CD013504-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013504.pub2/media/CDSR/CD013504/image_n/nCD013504-CMP-001.08.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013504-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013504.pub2/media/CDSR/CD013504/urn:x-wiley:14651858:media:CD013504:CD013504-CMP-001.09" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Interrupted versus uninterrupted anticoagulation, Outcome 9: Major bleeding (subgroup analysis: ablation surgical type (pulmonary vein isolation vs mixed types))" data-id="CD013504-fig-0013" src="/cdsr/doi/10.1002/14651858.CD013504.pub2/media/CDSR/CD013504/image_n/nCD013504-CMP-001.09.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013504.pub2/media/CDSR/CD013504/image_t/tCD013504-CMP-001.09.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.9</div> <div class="figure-caption"> <p>Comparison 1: Interrupted versus uninterrupted anticoagulation, Outcome 9: Major bleeding (subgroup analysis: ablation surgical type (pulmonary vein isolation vs mixed types)) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013504.pub2/references#CD013504-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013504.pub2/media/CDSR/CD013504/image_n/nCD013504-CMP-001.09.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013504-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013504.pub2/media/CDSR/CD013504/urn:x-wiley:14651858:media:CD013504:CD013504-CMP-001.10" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Interrupted versus uninterrupted anticoagulation, Outcome 10: Major bleeding (subgroup analysis: interruption strategy (complete interruption vs minimal interruption))" data-id="CD013504-fig-0014" src="/cdsr/doi/10.1002/14651858.CD013504.pub2/media/CDSR/CD013504/image_n/nCD013504-CMP-001.10.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013504.pub2/media/CDSR/CD013504/image_t/tCD013504-CMP-001.10.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.10</div> <div class="figure-caption"> <p>Comparison 1: Interrupted versus uninterrupted anticoagulation, Outcome 10: Major bleeding (subgroup analysis: interruption strategy (complete interruption vs minimal interruption)) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013504.pub2/references#CD013504-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013504.pub2/media/CDSR/CD013504/image_n/nCD013504-CMP-001.10.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013504-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013504.pub2/media/CDSR/CD013504/urn:x-wiley:14651858:media:CD013504:CD013504-CMP-001.11" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Interrupted versus uninterrupted anticoagulation, Outcome 11: Major bleeding (subgroup analysis: interruption strategy (interruption with heparin bridging vs interruption without heparin bridging))" data-id="CD013504-fig-0015" src="/cdsr/doi/10.1002/14651858.CD013504.pub2/media/CDSR/CD013504/image_n/nCD013504-CMP-001.11.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013504.pub2/media/CDSR/CD013504/image_t/tCD013504-CMP-001.11.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.11</div> <div class="figure-caption"> <p>Comparison 1: Interrupted versus uninterrupted anticoagulation, Outcome 11: Major bleeding (subgroup analysis: interruption strategy (interruption with heparin bridging vs interruption without heparin bridging)) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013504.pub2/references#CD013504-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013504.pub2/media/CDSR/CD013504/image_n/nCD013504-CMP-001.11.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013504-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013504.pub2/media/CDSR/CD013504/urn:x-wiley:14651858:media:CD013504:CD013504-CMP-001.12" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Interrupted versus uninterrupted anticoagulation, Outcome 12: Major bleeding (sensitivity analysis: non‐industrial funded studies only)" data-id="CD013504-fig-0016" src="/cdsr/doi/10.1002/14651858.CD013504.pub2/media/CDSR/CD013504/image_n/nCD013504-CMP-001.12.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013504.pub2/media/CDSR/CD013504/image_t/tCD013504-CMP-001.12.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.12</div> <div class="figure-caption"> <p>Comparison 1: Interrupted versus uninterrupted anticoagulation, Outcome 12: Major bleeding (sensitivity analysis: non‐industrial funded studies only) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013504.pub2/references#CD013504-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013504.pub2/media/CDSR/CD013504/image_n/nCD013504-CMP-001.12.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013504-fig-0017"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013504.pub2/media/CDSR/CD013504/urn:x-wiley:14651858:media:CD013504:CD013504-CMP-001.13" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Interrupted versus uninterrupted anticoagulation, Outcome 13: Major bleeding (sensitivity analysis: fixed‐effect model)" data-id="CD013504-fig-0017" src="/cdsr/doi/10.1002/14651858.CD013504.pub2/media/CDSR/CD013504/image_n/nCD013504-CMP-001.13.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013504.pub2/media/CDSR/CD013504/image_t/tCD013504-CMP-001.13.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.13</div> <div class="figure-caption"> <p>Comparison 1: Interrupted versus uninterrupted anticoagulation, Outcome 13: Major bleeding (sensitivity analysis: fixed‐effect model) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013504.pub2/references#CD013504-fig-0017">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013504.pub2/media/CDSR/CD013504/image_n/nCD013504-CMP-001.13.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013504-fig-0018"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013504.pub2/media/CDSR/CD013504/urn:x-wiley:14651858:media:CD013504:CD013504-CMP-001.14" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Interrupted versus uninterrupted anticoagulation, Outcome 14: Major bleeding (sensitivity analysis: published studies only)" data-id="CD013504-fig-0018" src="/cdsr/doi/10.1002/14651858.CD013504.pub2/media/CDSR/CD013504/image_n/nCD013504-CMP-001.14.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013504.pub2/media/CDSR/CD013504/image_t/tCD013504-CMP-001.14.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.14</div> <div class="figure-caption"> <p>Comparison 1: Interrupted versus uninterrupted anticoagulation, Outcome 14: Major bleeding (sensitivity analysis: published studies only) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013504.pub2/references#CD013504-fig-0018">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013504.pub2/media/CDSR/CD013504/image_n/nCD013504-CMP-001.14.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013504-fig-0019"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013504.pub2/media/CDSR/CD013504/urn:x-wiley:14651858:media:CD013504:CD013504-CMP-001.15" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Interrupted versus uninterrupted anticoagulation, Outcome 15: Composite endpoint of thromboembolic events, major bleeding, and all‐cause mortality" data-id="CD013504-fig-0019" src="/cdsr/doi/10.1002/14651858.CD013504.pub2/media/CDSR/CD013504/image_n/nCD013504-CMP-001.15.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013504.pub2/media/CDSR/CD013504/image_t/tCD013504-CMP-001.15.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.15</div> <div class="figure-caption"> <p>Comparison 1: Interrupted versus uninterrupted anticoagulation, Outcome 15: Composite endpoint of thromboembolic events, major bleeding, and all‐cause mortality </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013504.pub2/references#CD013504-fig-0019">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013504.pub2/media/CDSR/CD013504/image_n/nCD013504-CMP-001.15.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013504-fig-0020"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013504.pub2/media/CDSR/CD013504/urn:x-wiley:14651858:media:CD013504:CD013504-CMP-001.16" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Interrupted versus uninterrupted anticoagulation, Outcome 16: Minor bleeding" data-id="CD013504-fig-0020" src="/cdsr/doi/10.1002/14651858.CD013504.pub2/media/CDSR/CD013504/image_n/nCD013504-CMP-001.16.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013504.pub2/media/CDSR/CD013504/image_t/tCD013504-CMP-001.16.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.16</div> <div class="figure-caption"> <p>Comparison 1: Interrupted versus uninterrupted anticoagulation, Outcome 16: Minor bleeding </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013504.pub2/references#CD013504-fig-0020">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013504.pub2/media/CDSR/CD013504/image_n/nCD013504-CMP-001.16.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013504-fig-0021"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013504.pub2/media/CDSR/CD013504/urn:x-wiley:14651858:media:CD013504:CD013504-CMP-001.17" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Interrupted versus uninterrupted anticoagulation, Outcome 17: All‐cause mortality" data-id="CD013504-fig-0021" src="/cdsr/doi/10.1002/14651858.CD013504.pub2/media/CDSR/CD013504/image_n/nCD013504-CMP-001.17.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013504.pub2/media/CDSR/CD013504/image_t/tCD013504-CMP-001.17.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.17</div> <div class="figure-caption"> <p>Comparison 1: Interrupted versus uninterrupted anticoagulation, Outcome 17: All‐cause mortality </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013504.pub2/references#CD013504-fig-0021">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013504.pub2/media/CDSR/CD013504/image_n/nCD013504-CMP-001.17.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013504-fig-0022"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013504.pub2/media/CDSR/CD013504/urn:x-wiley:14651858:media:CD013504:CD013504-CMP-001.18" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Interrupted versus uninterrupted anticoagulation, Outcome 18: Asymptomatic thromboembolic events" data-id="CD013504-fig-0022" src="/cdsr/doi/10.1002/14651858.CD013504.pub2/media/CDSR/CD013504/image_n/nCD013504-CMP-001.18.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013504.pub2/media/CDSR/CD013504/image_t/tCD013504-CMP-001.18.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.18</div> <div class="figure-caption"> <p>Comparison 1: Interrupted versus uninterrupted anticoagulation, Outcome 18: Asymptomatic thromboembolic events </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013504.pub2/references#CD013504-fig-0022">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013504.pub2/media/CDSR/CD013504/image_n/nCD013504-CMP-001.18.svg" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD013504-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Interrupted versus uninterrupted anticoagulation therapy for catheter ablation in adults with arrhythmias</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Interrupted versus uninterrupted anticoagulation therapy for catheter ablation in adults with arrhythmias</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> adults with arrhythmias undergoing catheter ablation </p> <p><b>Setting:</b> hospital </p> <p><b>Intervention:</b> interrupted anticoagulation </p> <p><b>Comparison:</b> uninterrupted anticoagulation </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> <p><b>and follow‐up</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> </b> (95% CI)<b> </b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect</b> <b>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>№ of participants (studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Certainty of the evidence (GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with uninterrupted anticoagulation</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with interrupted</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Thromboembolic events</b> </p> <p>Follow‐up: 48 hours to 1 year</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>3 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>6 per 1000<br/>(1 to 33) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.76</b> </p> <p>(0.33 to 9.46) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3468 (6 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>㊉◯◯◯</p> <p><b>Very low</b><sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>In addition, 6 studies reported no thromboembolic events occurred in either the interrupted or uninterrupted arms. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Major bleeding</b> </p> <p>Follow‐up: 1 month to 1 year</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>10 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>12 per 1000 (6 to 21)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.10</b> </p> <p>(0.59 to 2.05)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4584 (10 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>㊉㊉◯◯</p> <p><b>Low</b><sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>In addition, 1 study reported no major bleeding events occurred in either arm (<a href="./references#CD013504-bbs2-0008" title="XingY , XuB , XuC , PengF , YangB , QiuY , et al. Efficacy and safety of uninterrupted low-intensity warfarin for radiofrequency catheter ablation of atrial fibrillation in the elderly. Annals of Pharmacotherapy2017;51(9):735-42. [DOI: 10.1177/1060028017712532]">Xing 2017</a>). <a href="./references#CD013504-bbs2-0007" title="TabishH , ShahzadK . Anticoagulation safety window among elderly Chinese patients with atrial fibrillation catheter ablation. Journal of the Saudi Heart Association2010;22(2):99-100. [DOI: 10.1016/j.jsha.2010.02.325]">Tabish 2010</a> did not report on this outcome. </p> <p>Follow‐up was unclear for <a href="./references#CD013504-bbs2-0002" title='Di BiaseL , BurkhardtJD , SantangeliP , MohantyP , SanchezJ , BaiR , et al. Periprocedural strokes and anticoagulation management during AF ablation: results from the "Compare" randomized multicenter trial. Circulation2013;128:A14307. Di BiaseL , BurkhardtJD , SantangeliP , MohantyP , SanchezJ , BaiR , et al. Silent thromboembolic lesions following catheter ablation for atrial fibrillation using radiofrequency energy: results from a sub-study of the "compare" randomized trial. Circulation2013;128(22 Suppl 1):A14293. Di BiaseL , BurkhardtJD , SantangeliP , MohantyP , SanchezJ , HortonR , et al. Periprocedural stroke and bleeding complications in patients undergoing catheter ablation of atrial fibrillation with different anticoagulation management: results from the "compare" randomized trial. Heart Rhythm2013;10(9):1411. Di BiaseL , BurkhardtJD , SantangeliP , MohantyP , SanchezJE , HortonR , et al. Periprocedural stroke and bleeding complications in patients undergoing catheter ablation of atrial fibrillation with different anticoagulation management: results from the role of coumadin in preventing thromboembolism in atrial fibrillation (AF) patients undergoing catheter ablation (COMPARE) randomized trial. Circulation2014;129(25):2638-44. [DOI: 10.1161/circulationaha.113.006426]NCT01006876. Role of coumadin in preventing thromboembolism in atrial fibrillation (AF) patients undergoing catheter ablation. clinicaltrials.gov/ct2/show/NCT01006876 (first received 3 November 2009). '>Di Biase 2014</a> and  <a href="./references#CD013504-bbs2-0011" title="IrikiY , IchikiH , OketaniN , YoshimuraA , OkuiH , MaenosonoR , et al. Evaluation of safety and efficacy of perioperative use of rivaroxaban and apixaban in catheter ablation for atrial fibrillation. European Heart Journal2015;36:687. [DOI: 10.1093/eurheartj/ehv400]YoshimuraA , IrikiY , IchikiH , OketaniN , OkuiH , MaenosonoR , et al. Evaluation of safety and efficacy of periprocedural use of rivaroxaban and apixaban in catheter ablation for atrial fibrillation. Journal of Cardiology2017;69(1):228-35. [DOI: 10.1016/j.jjcc.2016.03.014]">Yoshimura 2017</a> for this outcome. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Composite endpoint of thromboembolic events (stroke or systemic embolism), major bleeding events, and all‐cause mortality</b> </p> <p>Follow‐up: 3 months</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>59 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>13 per 1000</p> <p>(4 to 47)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.23</b> </p> <p>(0.07 to 0.81)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>442 (1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>㊉㊉◯◯</p> <p><b>Low</b><sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Minor bleeding</b> </p> <p>Follow‐up: 1 month to 6 months</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>56 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>57 per 1000<br/>(26 to 125) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.01</b> </p> <p>(0.46 to 2.22)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3843 (9 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>㊉◯◯◯</p> <p><b>Very low</b><sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013504-bbs2-0005" title="AonumaK . A prospective, multi-center, parallel-group comparison study to evaluate safety and efficacy of dabigatran during the perioperative period in patients with non-valvular atrial fibrillation who undergo the catheter ablation compared to warfarin. upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000015311 (first received 14 February 2014. GoyaM , NogamiA , HiraoK , AonumaK . Ablation perioperative dabigatran in use envisioning in Japan: the ABRIDGE-J study design. Journal of Cardiology2016;68(3):236-40. [DOI: 10.1016/j.jjcc.2015.10.003]]NogamiA , HaradaT , Sekiguchi Y, Otani R, YoshidaY , Yoshida K, et al. Safety and efficacy of minimally interrupted dabigatran vs uninterrupted warfarin therapy in adults undergoing atrial fibrillation catheter ablation: a randomized clinical trial. JAMA Network Open2019;2(4):15. [DOI: 10.1001/jamanetworkopen.2019.1994]NogamiA , HaradaT , YoshidaY , NakanoY , GoyaM , OrigasaH , et al. Clinical benefit of minimally-interrupted dabigatran versus uninterrupted warfarin for catheter ablation of atrial fibrillation: a prospective randomized multicenter trial. Circulation2017;136:e450. NogamiA , HaradaT , YoshidaY , NakanoY , GoyaM , OrigasaH , et al. Clinical benefit of minimally-interrupted dabigatran versus uninterrupted warfarin for catheter ablation of atrial fibrillation: a prospective randomized multicenter trial. Circulation2017;136(24):E450. [DOI: 10.1161/CIR.0000000000000546]UMIN000013129. A prospective, multi-center, parallel-group comparison study to evaluate safety and efficacy of dabigatran during the perioperative period in patients with non-valvular atrial fibrillation who undergo the catheter ablation compared to warfarin. www.who.int/trialsearch/Trial2.aspx?TrialID=JPRN-UMIN000013129 (first received 1 March 2014). ">Nogami 2019</a> did not report minor bleeding as a separate outcome but within a composite endpoint. </p> <p>Follow‐up was unclear for <a href="./references#CD013504-bbs2-0002" title='Di BiaseL , BurkhardtJD , SantangeliP , MohantyP , SanchezJ , BaiR , et al. Periprocedural strokes and anticoagulation management during AF ablation: results from the "Compare" randomized multicenter trial. Circulation2013;128:A14307. Di BiaseL , BurkhardtJD , SantangeliP , MohantyP , SanchezJ , BaiR , et al. Silent thromboembolic lesions following catheter ablation for atrial fibrillation using radiofrequency energy: results from a sub-study of the "compare" randomized trial. Circulation2013;128(22 Suppl 1):A14293. Di BiaseL , BurkhardtJD , SantangeliP , MohantyP , SanchezJ , HortonR , et al. Periprocedural stroke and bleeding complications in patients undergoing catheter ablation of atrial fibrillation with different anticoagulation management: results from the "compare" randomized trial. Heart Rhythm2013;10(9):1411. Di BiaseL , BurkhardtJD , SantangeliP , MohantyP , SanchezJE , HortonR , et al. Periprocedural stroke and bleeding complications in patients undergoing catheter ablation of atrial fibrillation with different anticoagulation management: results from the role of coumadin in preventing thromboembolism in atrial fibrillation (AF) patients undergoing catheter ablation (COMPARE) randomized trial. Circulation2014;129(25):2638-44. [DOI: 10.1161/circulationaha.113.006426]NCT01006876. Role of coumadin in preventing thromboembolism in atrial fibrillation (AF) patients undergoing catheter ablation. clinicaltrials.gov/ct2/show/NCT01006876 (first received 3 November 2009). '>Di Biase 2014</a>. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>All‐cause mortality</b> </p> <p>Follow‐up: 3 months</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>0/220 in the interrupted group vs 1/222 in the uninterrupted group died from any cause</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.34</b><br/>(0.01 to 8.21) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>442 (1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>㊉㊉◯◯</p> <p><b>Low</b><sup>d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>There was only 1 death in the uninterrupted arm in <a href="./references#CD013504-bbs2-0005" title="AonumaK . A prospective, multi-center, parallel-group comparison study to evaluate safety and efficacy of dabigatran during the perioperative period in patients with non-valvular atrial fibrillation who undergo the catheter ablation compared to warfarin. upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000015311 (first received 14 February 2014. GoyaM , NogamiA , HiraoK , AonumaK . Ablation perioperative dabigatran in use envisioning in Japan: the ABRIDGE-J study design. Journal of Cardiology2016;68(3):236-40. [DOI: 10.1016/j.jjcc.2015.10.003]]NogamiA , HaradaT , Sekiguchi Y, Otani R, YoshidaY , Yoshida K, et al. Safety and efficacy of minimally interrupted dabigatran vs uninterrupted warfarin therapy in adults undergoing atrial fibrillation catheter ablation: a randomized clinical trial. JAMA Network Open2019;2(4):15. [DOI: 10.1001/jamanetworkopen.2019.1994]NogamiA , HaradaT , YoshidaY , NakanoY , GoyaM , OrigasaH , et al. Clinical benefit of minimally-interrupted dabigatran versus uninterrupted warfarin for catheter ablation of atrial fibrillation: a prospective randomized multicenter trial. Circulation2017;136:e450. NogamiA , HaradaT , YoshidaY , NakanoY , GoyaM , OrigasaH , et al. Clinical benefit of minimally-interrupted dabigatran versus uninterrupted warfarin for catheter ablation of atrial fibrillation: a prospective randomized multicenter trial. Circulation2017;136(24):E450. [DOI: 10.1161/CIR.0000000000000546]UMIN000013129. A prospective, multi-center, parallel-group comparison study to evaluate safety and efficacy of dabigatran during the perioperative period in patients with non-valvular atrial fibrillation who undergo the catheter ablation compared to warfarin. www.who.int/trialsearch/Trial2.aspx?TrialID=JPRN-UMIN000013129 (first received 1 March 2014). ">Nogami 2019</a>, and this was used to calculate the RR. In addition, <a href="./references#CD013504-bbs2-0006" title="ReynoldsMR , AllisonJS , NataleA , WeisbergIL , EllenbogenKA , RichardsM , et al. Apixaban evaluation of interrupted or uninterrupted anticoagulation for ablation of atrial fibrillation. clinicaltrials.gov/show/NCT02608099 (first received 18 November 2015). ReynoldsMR , AllisonJS , NataleA , WeisbergIL , EllenbogenKA , RichardsM , et al. A prospective randomized trial of apixaban dosing during atrial fibrillation ablation: the AEIOU trial. JACC Clinical Electrophysiology2018;4(5):580-8. [DOI: 10.1016/j.jacep.2017.11.005]">Reynolds 2018</a> reported that there were 0 mortality events in either arm. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Asymptomatic thromboembolic events</b> </p> <p>Follow‐up: 1 hour to 1 month</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>148 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>215 per 1000<br/>(126 to 366) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.45</b> </p> <p>(0.85 to 2.47)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1268 (6 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>㊉◯◯◯</p> <p><b>Very low</b><sup>e</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Follow‐up was unclear for <a href="./references#CD013504-bbs2-0002" title='Di BiaseL , BurkhardtJD , SantangeliP , MohantyP , SanchezJ , BaiR , et al. Periprocedural strokes and anticoagulation management during AF ablation: results from the "Compare" randomized multicenter trial. Circulation2013;128:A14307. Di BiaseL , BurkhardtJD , SantangeliP , MohantyP , SanchezJ , BaiR , et al. Silent thromboembolic lesions following catheter ablation for atrial fibrillation using radiofrequency energy: results from a sub-study of the "compare" randomized trial. Circulation2013;128(22 Suppl 1):A14293. Di BiaseL , BurkhardtJD , SantangeliP , MohantyP , SanchezJ , HortonR , et al. Periprocedural stroke and bleeding complications in patients undergoing catheter ablation of atrial fibrillation with different anticoagulation management: results from the "compare" randomized trial. Heart Rhythm2013;10(9):1411. Di BiaseL , BurkhardtJD , SantangeliP , MohantyP , SanchezJE , HortonR , et al. Periprocedural stroke and bleeding complications in patients undergoing catheter ablation of atrial fibrillation with different anticoagulation management: results from the role of coumadin in preventing thromboembolism in atrial fibrillation (AF) patients undergoing catheter ablation (COMPARE) randomized trial. Circulation2014;129(25):2638-44. [DOI: 10.1161/circulationaha.113.006426]NCT01006876. Role of coumadin in preventing thromboembolism in atrial fibrillation (AF) patients undergoing catheter ablation. clinicaltrials.gov/ct2/show/NCT01006876 (first received 3 November 2009). '>Di Biase 2014</a> and <a href="./references#CD013504-bbs2-0008" title="XingY , XuB , XuC , PengF , YangB , QiuY , et al. Efficacy and safety of uninterrupted low-intensity warfarin for radiofrequency catheter ablation of atrial fibrillation in the elderly. Annals of Pharmacotherapy2017;51(9):735-42. [DOI: 10.1177/1060028017712532]">Xing 2017</a>. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI). </p> <p><b>CI:</b> confidence interval; <b>RR:</b> risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> </p> <p><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect. </p> <p><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different. </p> <p><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect. </p> <p><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded three levels. Once for risk of bias in included studies, specifically in the domains of randomisation and allocation concealment; once level for inconsistency owing to a moderate level of statistical heterogeneity, and once for imprecision due to wide confidence intervals in the effect estimate that could be explained by the low event rates in included trials.<br/><sup>b</sup>Downgraded two levels. Once for risk of bias in included studies, specifically in the domains of randomisation and allocation concealment; and once for imprecision due to wide confidence intervals in the effect estimate that could be explained by the low event rates in included trials.<br/><sup>c</sup>Downgraded two levels. Once for risk of bias in the included study, specifically in the domains of blinding; and once for imprecision as only one study with a low event rate reported this outcome.<br/><sup>d</sup>Downgraded two levels. Once for risk of bias in the included study, specifically in the domains of blinding; and once for imprecision caused by low event rate and wide confidence interval.<br/><sup>e</sup>Downgraded three levels. Once for risk of bias in included studies, specifically in the domains of randomisation and allocation concealment; once for inconsistency owing to a moderate level of statistical heterogeneity; and once for imprecision due to wide confidence intervals in the effect estimate that could be explained by the variability in assessing this outcome in the included study. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Interrupted versus uninterrupted anticoagulation therapy for catheter ablation in adults with arrhythmias</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013504.pub2/full#CD013504-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD013504-tbl-0002"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Interrupted versus uninterrupted anticoagulation</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.1 Thromboembolic events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3468</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.76 [0.33, 9.46]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.2 Thromboembolic events (subgroup analysis: anticoagulant type) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3468</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.76 [0.33, 9.46]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2.1 Vitamin K antagonist vs vitamin K antagonist</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1685</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.20 [0.06, 180.32]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2.2 Direct oral anticoagulant vs direct oral anticoagulant</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1341</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.36 [0.26, 7.23]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2.3 Vitamin K antagonist vs direct oral anticoagulant</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>442</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.34 [0.01, 8.21]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.3 Thromboembolic events (subgroup analysis: interruption strategy) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3468</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.76 [0.33, 9.46]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3.1 Completely interrupted</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1584</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>19.60 [4.75, 80.89]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3.2 Minimally interrupted </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1884</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.82 [0.22, 3.14]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.4 Thromboembolic events (sensitivity analysis: non‐industrial  funded studies only) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2731</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.74 [0.34, 22.11]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.5 Thromboembolic events (sensitivity analysis: fixed‐effect model) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3468</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>5.80 [2.68, 12.54]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.6 Major bleeding <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4584</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.10 [0.59, 2.05]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.7 Major bleeding (subgroup analysis: anticoagulation type (direct oral anticoagulant vs vitamin K antagonist)) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4584</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.10 [0.59, 2.05]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.7.1 Direct oral anticoagulant</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2558</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.34 [0.61, 2.95]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.7.2 Vitamin K antagonist</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1584</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.68 [0.71, 10.07]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.7.3 Direct oral anticoagulant and vitamin K antagonist</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>442</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.28 [0.08, 0.97]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.8 Major bleeding (subgroup analysis: ablation source of energy (radiofrequency ablation vs cryoablation)) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4584</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.10 [0.59, 2.05]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.8.1 Radiofrequency ablation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1784</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.72 [0.80, 9.25]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.8.2 Cryoablation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>97</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.49 [0.03, 7.62]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.8.3 Mixed ablation sources </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2703</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.88 [0.41, 1.85]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.9 Major bleeding (subgroup analysis: ablation surgical type (pulmonary vein isolation vs mixed types)) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4584</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.10 [0.59, 2.05]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.9.1 Pulmonary vein isolation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2822</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.86 [0.79, 4.36]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.9.2 Mixed</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1762</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.69 [0.29, 1.68]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.10 Major bleeding (subgroup analysis: interruption strategy (complete interruption vs minimal interruption)) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4584</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.10 [0.59, 2.05]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.10.1 Complete interruption</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1584</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.68 [0.71, 10.07]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.10.2 Minimal interruption</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2674</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.91 [0.43, 1.91]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.10.3 Mixed</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>326</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.72 [0.12, 4.26]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.11 Major bleeding (subgroup analysis: interruption strategy (interruption with heparin bridging vs interruption without heparin bridging)) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4584</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.10 [0.59, 2.05]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.11.1 Interruption with heparin bridging</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1584</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.68 [0.71, 10.07]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.11.2 Interruption without heparin bridging</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2232</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.57 [0.65, 3.77]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.11.3 Interruption with heparin bridging in subset of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>768</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.38 [0.14, 1.07]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.12 Major bleeding (sensitivity analysis: non‐industrial funded studies only) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3847</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.62 [0.78, 3.37]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.13 Major bleeding (sensitivity analysis: fixed‐effect model) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4584</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.08 [0.63, 1.85]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.14 Major bleeding (sensitivity analysis: published studies only) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4479</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.06 [0.55, 2.05]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.15 Composite endpoint of thromboembolic events, major bleeding, and all‐cause mortality <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.16 Minor bleeding <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3843</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.01 [0.46, 2.22]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.17 All‐cause mortality <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.18 Asymptomatic thromboembolic events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1268</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.45 [0.85, 2.47]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Interrupted versus uninterrupted anticoagulation</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013504.pub2/references#CD013504-tbl-0002">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD013504.pub2&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="de#CD013504-note-0004">Deutsch</a> </li> <li class="section-language"> <a class="" href="es#CD013504-note-0010">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD013504-note-0008">فارسی</a> </li> <li class="section-language"> <a class="" href="fr#CD013504-note-0009">Français</a> </li> <li class="section-language"> <a class="" href="hr#CD013504-note-0007">Hrvatski</a> </li> <li class="section-language"> <a class="" href="ms#CD013504-note-0006">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="zh_HANS#CD013504-note-0003">简体中文</a> </li> <li class="section-language"> <a class="" href="zh_HANT#CD013504-note-0005">繁體中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734739000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734739000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773542000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773471000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013504\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD013504\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013504\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD013504\x2epub2"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013504\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD013504\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013504\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD013504\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013504\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD013504\x2epub2"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013504\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD013504\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013504\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD013504\x2epub2"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013504\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD013504\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013504\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD013504\x2epub2"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=0TJL4CWK&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD013504.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD013504.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD013504.pub2/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD013504.pub2/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD013504.pub2%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740718195021"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD013504.pub2/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740718195025"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD013504.pub2/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918dca627baef3fd',t:'MTc0MDcxODE5NS4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 